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CHAPTER 1.1 
IMMUNOBIOLOGY OF ACUTE LYMPHOBLASTIC LEUKEMIA* 
Jacques J.M. van Dongen 1, Tomasz Szczepariski1•2, and Henk J. Adriaansen3 
1 Department of Immunology. Erasmus MC, University Medical Center Rotterdam, 
Rotterdam, The Netherlands 
2Department of Pediatric Hematology and Chemotherapy, Silesian Medical Academy, Zabrze, Poland 
3Qepartment of Clinical, Chemical and Hematological Laboratory, Gefre Hospital, Ape/doom, The 
Netherlands 
IMMUNOPHENOTYPE OF ACUTE LYMPHOBLASTIC lEUKEMIA 
The cells in acute lymphoblastic leukemias (ALL) are generally regarded as 
malignant counterparts of immature lymphoid cells.1·5 lmmunophenotyping enables 
the determination of the differentiation stage of normal and abnormal populations 
and subpopulations. Therefore, it allows identification and classification of ALL.6.? 
Using immunophenotyping it is possible to discriminate at least seven different ALL 
subtypes2 ·4·7 ·8 As has been drawn in Figure 1, these concern four types of B-line-
age ALL and at least three types of T-ALL. 
lmmunophenotypic characteristics of precursor-B-ALL 
The immunophenotypes of B-lineage ALL are summarized in Table 1. All four 
forms of precursor-B-ALL (pro-B-ALL, common ALL, pre-B-ALL and transitional pre-
B-ALL) are positive for terminal deoxynucleotidyl transferase (TdT). The B-lineage 
ALL types are positive for HLA-DR, CD19, CyCD79, and for CD22. CD79 is com-
pletely B-cell specific. 9.1 o Except for a small part of the pre-B-ALL, expression of the 
CD79-antigen in precursor-B-ALL is restricted to the cytoplasm9-10 CD1 0, pre-S 
Cylg/-1, and Smlg!-1 are important markers for discrimination between the four sub-
types of B-lineage ALL (see Table 1 and Figure 1 ). An example of fiow cytometric 
immunophenotyping of a common ALL is given in Figure 2. For the diagnosis of pre-
B-ALL, expression of pre-S Cylg!-1 is a prerequisite: at least 10% to 20% of the ALL 
cells should express this marker.7-11 -12 1n about 5% of pre-B-ALL, faint expression of 
the lg!-l-CD79 complex without normal lg light chains is seen on the surface mem-
brane (pre-S complex).13 These ALL have been defined as transitional pre-B-ALL.13 
The distribution of the immunophenotypic subgroups in ALL is age-related. 
"Adapted from Chapter 6 'fmmunobiology of Leukemia' in Henderson E.S., Lister T.A. 
and Greaves M.F. {eds.) Leukemia, 7th edition, Philadelphia, WB Saunders Company, 
2002; 85-129 
13 
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Figure 3 summarizes the ALL subgroups in childhood.14 In infants, pro-B-ALL pre-
dominates, whereas in young children (one to six years old), high frequencies of 
CD1 o+ precursor-B-ALL (i.e., common ALL and pre-B-ALL) are found. Figure 3 illus-
trates that the relatively high incidence of ALL during early childhood mainly con-
cerns CD1 o+ precursor-B-ALL. It has been proposed that altered patterns of infec-
tion due to an improved socioeconomic situation and hygiene may partly explain this 
high incidence in the developed countries.15 
Figure 1. 
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Hypothetical scheme of lymphoid differentiation. The expression of relevant immunologic markers is indi-
cated for each differentiation stage; markers in parentheses are not always expressed. The bars repre-
sent the various types of leukemias and non-Hodgkin lymphomas (NHL) and indicate where these malig-
nancies can be located according to their maturation arrest. Abbreviations used: AITL = angioim-
munob!astic T-cell lymphoma. ALCL =anaplastic large eel! lymphoma (ofT-cell type), ALL= acute lym-
phoblastic leukemia,ATLL =adult T-ee!! leukemia lymphoma,AUL-= acute undifferentiated leukemia, CLL 
= chronic lymphocytic leukemia, CTCL = cutaneous T-cell lymphoma, CTLL = cutaneous T-cellleukemia 
lymphoma (mycosis fungoides/SE:zary syndrome), DLBCL = diffuse large B-ee!! lymphoma, ETTL -
enteropathy-type T-celllymphoma, HCL = hairy ce!l leukemia. HTLV = human T-cellleukemia virus, LGL 
= large granular lymphocyte, MALT= mucosa associated tissue lymphoma, NHL = non-Hodgkin's lym-
phoma, PLL = prolymphocytic leukemia (see reference4). 
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Table 1. lmmunophenotypic characteristics of precursor&B~ALL. 
Markers pro-B-ALL common ALL pre-B-ALL transitional-pre-B-ALL a 
TdT ++ ++ ++ ++ 
CD10 ++ ++ ++ 
CD19 ++ ++ ++ ++ 
CD20 + + + 
CD22 ++ ++ ++ ++ 
CyCD79 ++ ++ ++ ++ 
Pre-B Cylg~ ++ ++ 
SmVpre-B/1.5 ++ 
Smlg-CD79 ++ 
CD34 + + + + 
HLA-DR ++ ++ ++ ++ 
a. approximately 5% of pre-B-ALL patients have a 'transitional pre-B-ALL', defined by both pre-B CylgJ.L 
and surface membrane expression of the pre-B-ee!! complex (pre-8 SmlgJ.L-C079) without expression 
of mature K or A.lg light chains_13 
-, <10% of the leukemias is positive;+, 25-75% of the leukemias is positive;++, >75% of the leukemias 
is positive. 
lmmunophenotypic characteristics of T-ALL 
Virtually all T-ALL are positive for TdT, C02, CD7, and CyCD3.2.4,16 Markers, 
which can be used for additional characterization, concern CD1, surface membrane 
CD3 (SmCD3), CD4, CD5, and CD8.4 ·7·8,17 In fact, using only CD1 and SmCD3 at 
least three types of T-ALL can be recognized, i.e. immature T-ALL (CD1-/SmCD3-), 
common thymocytic (cortical) T-ALL (CD1+/SmCD3- or+), and mature T-ALL (CD1-
common 
Figure 2. 
Flow cytometric immunophenotyping of mononuclear blood ce!!s from a precursor-B-ALL patient at diag-
nosis. The CD19/CD34, C010/TdT and CylgllfSmlgJ.L double immunofluorescence stainings were ana-
lyzed within the indicated FSC/SSC gated cell population. The precursor-B-ALL cells expressed CD19, 
CD1 0, CD34 on the cell surface and TdT intracellularly but they did not produce lgJ.L protein. Such 
immunophenotype is typical for common ALL. 
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~:;. pro-B-ALL 
• common ALL 
o pre-S..ALL 
v T-All 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 
age at diagnosis (years) 
Age-related distribution of immunophenotypic subgroups in childhood ALL in the Netherlands (1986-
1991 ), according to the Dutch Childhood Leukemia Study Group. {Adapted from. Coebergh JWW et a1.).14 
Table 2. lmmunophenotypic characteristics of T-ALL. 
Markers 
TdT 
CD1 
CD2 
CyCD3 
SmCD3 
C04-/COS-
C04•fcos-
C04-/C08• 
co4+Jcoa+ 
CD5 
CD7 
TCRa~ 
TCRyo 
HLA-DR 
immature T-ALL 
prothymocytic 
(pre-T-ALL) 
++ 
+ 
++ 
++ 
++ 
+ 
immature 
thymocytic 
++ 
++ 
++ 
+ 
± 
± 
++ 
++ 
common thymocytic T-ALL 
SmCD3-
++ ++ 
++ ++ 
++ ++ 
++ ++ 
++ 
± ± 
± ± 
+ + 
++ ++ 
++ ++ 
mature T-ALL 
++ 
++ 
++ 
++ 
+ 
± 
± 
++ 
++ 
60%-70% 
30%40% 
-. <10% of the leukemias is positive;±, 10-25% of the leukemias is positive;+, 25-75% of the leukemias 
is positive;++, >75% of the leukemias is positive. 
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/SmCD3+) (Table 2; see Figure 1 )4 ·7 The immature T-ALLs either concern the rarely 
occurring prothymocy1ic T-ALL (pro-T-ALL) or the immature thymocy1ic T-ALL (pre-
T-ALL)4·18 The common thymocy1ic T-ALL can be divided further in SmCD3- and 
SmCD3+ types (Table 2). The distinction between SmCD3- T-ALL and SmCD3+ T-
ALL is used widely; SmCD3 expression is found in approximately 35% of all T-ALL.19 
The CD3 antigen on the cell surface membrane is associated with TCR molecules. 
Approximately 65% of T-ALL is SmCD3-, approximately 20% is TCRa~+, and 
approximately 15% is TCRy8+.19 SmCD3+ T-ALL could be further characterized with 
the monoclonal antibodies specific to particular V~, Vy, or Vo gene segments.2D,21 
lmmunophenotypic classification of T-ALL gives significant prognostic information. 
The most immature T-ALL (CD1-JSmCD3-) is associated with unfavorable outcome, 
while CD1+ (and/or CD4+/CD8+) cortical T-ALL is a distinct subgroup with an excel-
lent prognosis under intensive high-risk treatment.8.22-24 Within SmCD3+ T-ALL, 
event-free survival is significantly better in TCRyo+ T-ALL when compared to 
TCRa~+ T-ALL.25 
Burkitt's Leukemia/Lymphoma (B-ALL) 
French-American-British classification of ALL includes morphological type L3, 
which corresponds immunophenotypically to B-ALL. Only rare cases of ALL-L3 have 
immunophenotype of T-ALL.26 B-ALL is characterized by bright surface expression 
of lgM and negativityforTdTand CD34. Many cases are also CD10 positive. B-ALL 
comprises 2% to 3% of pediatric and adult ALL.27 Based on its similar morphology, 
the presence of characteristic chromosomal aberrations involving C-MYC gene and 
clinical behavior, B-ALL is currently perceived as leukemic form of Burkitt's lym-
phoma. 
Cross-lineage marker expression in All 
The expression of myeloid markers in ALL cells has been defined as cross-line-
age marker expression28,29 This mainly concerns expression of CD13, CD14, 
CD15, CD33 and/or CD65 antigens in up to one third of precursor-B-ALL and T-ALL 
patients28-3D Such observations have been interpreted as lineage infidelity or line-
age promiscuity. Terms such as hybrid acute leukemia, mixed lineage leukemia, 
biphenotypic acute leukemia, and biclonal acute leukemia have been used to 
describe acute leukemia with cross-lineage marker expression.31 It has been sug-
gested that these leukemias exhibit aberrant gene expression, but coexpression of 
lymphoid and myeloid genes may also occur in normal immature cells.31 There are 
only a few lineage-specific antigens, i.e. CD79 and lg molecules in B-cells, CD3 and 
TCR molecules in T-cells and MPO in myeloid cells.9,1D.17,32 
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Applications of lmmunophenotyping of ALL 
lmmunophenotyping is useful for discrimination among ALL, acute myeloid 
leukemia, and acute undifferentiated leukemia, which is the most important step for 
initial selection of the effective treatment strategy.2.4 Furthermore, immunopheno-
typic subclassification of ALL is clinically relevant, particularly the distinction between 
precursor-B-ALL and T-ALL. T-lineage immunophenotype of ALL is more frequently 
associated with several high-risk features when compared with precursor-B-ALL. 
Inclusion of T-ALL patients into more intensive treatment protocols or even estab-
lishment of T-ALL phenotype-specific treatment regimens has been associated with 
significantly improved long-term survival.33 
Detailed immunophenotyping can also be used for identification of ALL sub-
groups with poor prognosis, such as pro-B ALL and immature (CD1-/CD3-) 
T-ALL.8,22 Myeloid marker expression in adult ALL was traditionally associated with 
poor prognosis8.28 In childhood ALL this correlation was not clear, because of con-
flicting data that were attributed to differences in treatment protocols.S.28,29 With the 
current intensive treatment protocols, myeloid antigen expression lacks prognostic 
significance both in adult and pediatric ALL.30.34-36 
Several studies indicate that particular chromosome aberrations are associated 
with specific immunophenotypes. The t(4;11) is seen in pro-B-ALL with cross-lineage 
expression of the myeloid markers CD15 and CD65 and ectopic expression of the 
NG2 antigen , i.e., human homologue of the rat chondroitin sulfate proteoglycan.37-
39 Hyperdiploidy especially occurs in CD10+ precursor-B-ALL 40, and t(1 ;19) seems 
to be restricted to CD10+/CD19+/CD34- precursor-B-ALL, especially pre-B-ALL41.42 
The t(12;21) occurring in more than 25% of pediatric precursor-B-ALL is character-
istically CD66c negative, CD9 negative or partly positive, CD20 negative or partly 
positive, and frequently positive for myeloid antigens CD13, CD33, or both.43-45 The 
most frequent aberration in adult ALL, i.e., t(9;22), is significantly linked with CD25 
and CD66c positivity46.47 
Finally, immunologic marker analysis can be used in ALL patients to study the 
effectiveness of treatment by monitoring bone marrow and blood samples for the 
occurrence of 'minimal residual disease' (see Chapter 1.2). 
IMMUNOGENOTYPIC CHARACTERISTICS OF ALL 
Lymphopoiesis results in the continuous production of mature B lymphocytes 
and T lymphocytes, which together form the antigen-specific immune system48-50 
Both types of lymphocytes express unique receptors on their cell membrane that 
allow the specific recognition of antigens4 9.50 The antigen-specific receptors are dif-
ferent on each lymphocyte, but each single lymphocyte or lymphocyte clone 
expresses thousands (approximately 1 05) of receptors with the same antigen speci-
fmmunobiofogy of ALL 19 
ficity. Surface membrane-bound lg molecules (Smlg) represent the antigen-specific 
receptors of B-lymphocytes. whereas TCR molecules exhibit this function in T-lym-
phocytes.S0.51 
Rearrangement and expression of lg and TCR genes 
The immune system encounters millions of different antigens and antigenic epi-
topes. The ability to recognize specifically these antigens is based on the enormous 
diversity (at least 1 09) of antigen-specific receptors. If the entire repertoire of Jg and 
TCR molecules were to be encoded by separate genes. they would occupy a large 
part of the human genome. Instead, a limited number of gene segments is able to 
code for the receptor diversity owing to the fact that combinations of gene segments 
are made, which are different in each lymphocyte or lymphocyte clone48,49.52 
Immunoglobulin molecules and their encoding genes 
lg molecules consist of two lg heavy (lgH) chains and two lg light chains, held 
together by disulfide bonds. The lg class or subclass is determined by the isotype of 
the involved lgH chain and is independent of the lg light chain. Each B-lymphocyte 
or B-lymphocyte clone expresses only one type of lg light chain (lgK or lgA.), where-
as multiple lgH chains can be expressed .so The majority of B-lymphocytes in periph-
eral blood express lgM and lgD on the cell membrane, whereas a minority express-
es lgG or lgA. In lymph nodes and other lymphoid tissues, higher frequencies of lgG-
and/or lgA-bearing lymphocytes are present. Smlg molecules are closely associated 
with a disulfide-linked heterodimer, which consists of the CD79a protein chain (pre-
TCRa TCR~ 
Figure 4. 
Schematic diagram of Smlg and TCR molecules on the surface membrane of a B lymphocyte and T lym-
phocyte, respectively. Smlg molecules are closely associated with disulfide-linked C079 protein chains, 
whereas TCR molecules are associated with CD3 protein chains. V and C: variable and constant domains 
of lg or TCR chains. 
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Figure 5. 
Schematic diagram of the human lg gene complexes. The IGH gene complex consists of at least 40 func-
tional VH gene segments, 27 DH gene segments, 6 functional JH gene segments, and several CH gene 
segments, which together encode the various JgH class and subclass constant domains. Most CH gene 
segments are preceded by a switch gene{s), which plays a role in lgH (sub)class switch. The JGK gene 
complex consists of approximately 35 functional Vx gene segments, five JK gene segments, and a single 
CK gene segment. The Kde {kappa-deleting element) plays a role in the deletion of the JK-CK or CK gene 
regions in B-cells, which rearrange their IGL genes. The !GL gene complex consists of approximately 30 
VA gene segments and four functional CA genes, all of which are preceded by a JA gene segment. 
Pseudogenes (\j/) are indicated as open symbols. 
viously mb1 or lgo.) and the CD79b chain (previously 829 or lg~). In the Smlg-CD79 
complex, the CD79 protein chains mediate the transmembrane signal transduction 
(Figure 4).51 
The lg protein chains are composed of one variable domain, which is involved in 
antigen recognition, and one constant domain in case of lg light chains or three to 
four constant domains in case of lgH chains (Figure 4). Each domain of an lg chain 
is encoded by a separate exon (Figure 5). The variable domain of an lgH chain is 
encoded by an exon, which consists of a combination of a V (variable), aD (diversi-
ty) and a J Uoining) gene segment. A combination of a V and a J gene segment 
encodes the variable domain of an lg light chain.19.50 During 8-cell differentiation, 
combinations of the available V, D, and J gene segments are made through a 
process of gene rearrangement.52.53 The constant domains of the lg chains are 
encoded by C (constant) gene segments, depending on the isotype of the lg chain 
(Figure 5).54-57 
T-cell receptor molecules and their encoding genes 
TCR molecules consist of two chains, which are generally disulfide-linked. Two 
types of TCR have been recognized: the 'classical' TCR, which consists of a TCRo. 
lmmunobiology of ALL 21 
and a TCR0 chain (TCRa0) and the 'alternative' TCR, which is composed of a TCRy 
and a TCR8 chain (TCRy8).19,49 The majority of mature T-lymphocy1es (85 to 98%) 
in peripheral blood and most lymphoid tissues express TCRa~; a minority (2% to 
15%) expresses TCRy8.19 Both types ofTCR molecules are closely associated with 
the CD3 protein chains, which together form the TCR-CD3 complex (Figure 4). After 
antigen recognition by the TCR molecule, transmembrane signal transduction is 
mediated via the CD3 protein chains.S1 
Each TCR chain consists of two domains: a variable domain and a constant 
domain. Analogous to the lg chains, the variable domain of a TCR chain is encoded 
by a combination of the available V and J gene segments in case of TCRa and TCRy 
chains, or by a combination of the available V, D, and J gene segments in case of 
TCR~ and TCR8 chains.19,49 The constant domains of the TCR chains are encoded 
by C gene segments: one C gene segment for the constant domain of the TCRa 
chain and one for the TCR8 chain, and two C gene segments are available for the 
constant domains of the TCR0 and TCRy chains (Figure 6).57-60 
Gene rearrangement: V-(D-)J joining 
During early 8- and T-cell differentiation, the germline V, (D,) and J gene seg-
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Figure 6. 
Schematic diagram of the four human TCR genes. The TCRA gene complex consists of >50 Va gene seg-
ments. a remarkably long stretch of 61 functional Ja gene segments. and one Ca gene segment The 
major part of the TCRD gene complex is located between the Va and Ja gene segments and consists of 
eight VO, three DO, and four JO gene segments and one CO gene segment The OREC and \lfJa gene seg-
ments play a role in TCRD gene deletions, which precede TCRA gene rearrangements in developing T-
cells. The TCRB gene complex consists of 65 V~ gene segments and two C~ gene segments. both of 
which are preceded by one D~ and six or seven Jf) gene segments. The TCRG gene complex consists of 
a restricted number of Vy gene segments (six functional Vy gene segments and nine pseudogene seg-
ments) and two Cy gene segments. each preceded by two Jy1 or three Jy2 gene segments. Pseudogenes 
(\jf) are indicated with open symbols. 
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ments of the lg and TCR gene complexes rearrange, and each lymphocyte thereby 
obtains a specific combination of V-(0-)J segments4 8,49,S2 An example of an IGH 
gene rearrangement is illustrated in Figure 7: one of the J gene segments is joined 
to one of the 0 gene segments, and subsequently a V to 0-J joining occurs, thereby 
deleting all intervening sequences. After the process of rearrangement, the gene is 
transcribed into a precursor mRNA, which is transformed into mature mRNA by splic-
ing and eliminating all noncoding intervening sequences. Comparable rearrange-
ment and transcription processes occur in the other lg and TCR gene complexes. 
The gene rearrangement processes are mediated by a recombinase enzyme 
system, which probably contains several components, including the protein products 
of the so-called recombinase activating genes (RAG-1 and RAG-2).61 -62 The recom-
binase complex recognizes specific recombination signal sequences (RSS), which 
are well conserved during evolution and consist of a palindromic heptamer and non-
amer sequence, separated by spacer regions of 12 or 23 base pairs.63 Complete 
RSS, starting with the heptamer, border the 3' side of V gene segments, both sides 
of D gene segments and the s· side of J gene segments.63 A gene rearrangement 
first involves a back-to-back fusion of the heptamer-nonamer RSS. This is followed 
by deletion of these RSS and all intervening sequences in the form of a circular exci-
sion product and by joining of the two gene segments (Figure 8).63 
germnne IGH genes 
2 
Figure 7. 
VH 
4 
precursor IGH mRNA 
DH JH s 
D- Jjoining 
V - D~J joining 
.t transcription 
~
-!- RNA splicing 
mature IGH mRNA Ill '--'.ll---~ 
VDJ C~ 
Schematic diagram of human IGH gene rearrangement In this example DH3 is first joined to JH4, followed 
by VH4 to DH3-JH4 joining, thereby deleting a!! intervening sequences. The rearranged gene complex can 
be transcribed into precursor mRNA, which will be transformed into mature mRNA by splicing out all non-
coding intervening sequences. 
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Schematic diagram of the role of heptamer-nonamer recombination signal sequences (RSS) during gene 
rearrangement. The downstream RSS of DH3 and upstream RSS of JH4 fuse back to back. followed by 
DH3-JH4 joining and deletion of the intervening sequences in the form of a circular excision product. The 
presented RSS are not the exact RSS of the DH3 and JH4 gene segments, but represent the consensus 
heptamer-nonamer RSS, which are well conserved in lg and TCR genes. 
Secondary gene rearrangements 
lg and TCR gene rearrangements are complex processes in which the joining of 
the gene segments is imprecise49 Because of the triplet reading frame of DNA 
sequences, approximately two out of three joinings will be out-of-frame; that is, an 
mRNA is produced that cannot be transcribed into a complete protein49 The high 
frequency of out-of-frame rearrangements and the generation of stop codons at the 
joining sites may explain why most B-cells have rearranged both IGH alleles and why 
most T-cells have biallelic rearrangements of their TCRB and TCRG genes.52,64 
In addition to the biallelic rearrangements, secondary gene rearrangements 
appear to occur that are assumed to rescue precursor B- and T-cells with nonpro-
ductive lg or TCR genes. Three types of secondary rearrangements can occur, 
dependent on the involved lg or TCR gene complex and the type of preexisting 
rearrangement (Table 3). DH-JH replacements in B-cells replace preexisting DH-JH 
complexes by joining an upstream DH gene segment to a downstream JH gene seg-
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Table 3. Occurrence of secondary rearrangements in lg and TCR genes. 
lg genes TCR genes 
!GH IGK IGL TCRA TCRB TCRG 
O-J replacement + (+) 
V-J replacement + (+) + + 
V replacement + + (+) 
+, replacement reported to occur; (+),replacement can potentially occur, but not (yet) reported; 
-, replacement not likely to occur. 
TCRD 
(+) 
ment (Figure 9).65 0-J replacements can also potentially occur in TCRB and TCRD 
genes. In a comparable way, V-J replacements replace a preexisting V-J complex in 
TCRA, TCRG, and lg light chain genes_66 Both types of replacements can occur 
repeatedly on the same lg or TCR allele as long as germline V, (0,) and J gene seg-
ments are available (Table 3). 
The third type of secondary rearrangement concerns V replacement in complete 
V(D)J complexes_67,68 The V gene segment of the V(D)J complex is replaced by a 
new upstream V gene segment (Figure 9). This process is mediated via an internal 
heptamer RSS in the 3' part of the V gene segments in JGH, TCRB, and TCRG 
genes, but this heptamer RSS is not present in V gene segments of lg light chain, 
TCRA, and TCRD genes_67-69 So far, V replacements have especially been 
observed in JGH genes and have also been reported to occur in TCRB genes (Table 
3). 
Secondary rearrangements have been found to replace not only preexisting non-
productive rearrangements but also productive rearrangements, such as productive 
Va-Ja rearrangements. This suggests that secondary rearrangements not only res-
cue precursor-S- and T-cells from nonproductive rearrangements but are also 
involved in selection processes, such as thymic selection of the T-cell repertoire6 6 
Repertoire of lg and TCR molecules 
The enormous diversity of antigen-specific receptors of lymphocytes is mediated 
by the described rearrangements of the gene segments that code for the variable 
domains of lg and TCR molecules. The extent of the potential primary repertoire of 
antigen-specific receptors is based on the combinatorial diversity (i.e. the number of 
possible V-0-J combinations) and the junctional diversity (i.e. diversity due to impre-
cise joining of the V, D, and J gene segments)48,49 
The so-called combinatorial diversity can be calculated from the possible combi-
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DH-JH replacement 
VH replacement 
Figure 9. 
Examples of secondary gene rearrangements in IGH genes. 
{A) OH-JH replacement: an upstream DH gene segment rearranges to a downstream JH gene segment. 
thereby replacing the preexisting OH-JH rearrangement. 
(B) VH replacement: the VH gene segment in a complete V-0-JH rearrangement is replaced by an 
upstream VH gene segment via a rearrangement process. which is mediated via heptamer RSS (indicat-
ed as: 7) within the VH gene segments. 
nations of the available V, D. and J gene segments per gene complex and the pair-
ing of two different protein chains per antigen-receptor molecule, i.e. lgH with lgK or 
lgA., TCRa with TCR~. and TCRy with TCR84 8.49 For example, the !GH gene com-
plex contains at least 40 functional VH gene segments, 25 functional DH gene seg-
ments, and 6 functional JH gene segments, resulting in at least 6000 possible VH-DH-
JH combinations7 0-?2 Together with the V-J combinations of the IGK and IGL genes, 
a potential combinatorial diversity of more than 2 x 106 can be obtained. A compa-
rable diversity can be obtained for the TCRa~ molecules (Table 4). However, the 
combinatorial diversity of TCRy8 molecules is less extensive due to the limited num-
ber of V,(D,) and J gene segments in the encoding gene complexes. Nevertheless, 
because of multiple 08 gene usage, a combinatorial repertoire of potentially more 
than 5000 TCRyo molecules can be produced. 
The calculations in Table 4 are based on the assumption that the available func-
tional V, D, and J gene segments are used randomly. This is not always the case. 
For instance, fetal B-cells use a restricted set of VH gene segments, related to JH 
proximity.73·74 TCRa~+ cells tend to use J~2 gene segments more frequently than 
J[)1 gene segments.75 Peripheral TCRyi5+ T-lymphocytes exhibit preferential usage 
of Vy9-Jy1.2 and V82-J81 gene segments_76,?? However, it might well be that the 
whole potential combinatorial repertoire is present but that particular receptor speci-
ficities dominate due to clonal selection and expansionn 
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Table 4. Estimation of the potential primary repertoire of human lg and TCR molecules.<~ 
lg molecules TCRaf) molecules TCRyO molecules 
lgH IQK lgl. TCRa TCRP TCRy TCRS 
Number of functional 
gene segments: 
V gene segments 40-46 34-37 30-33 45 44-47 6 6 
D gene segments 25b 2b 3b 
J gene segments 6 5 4 50 13 5 4 
Combinatorial diversity >2 X 1Q6 >2 X 1Q6 >5000 
Junctional diversity .. ± ± + ++ ++ ++++ 
ESTIMATION OF >1012 >1Q12 >1Q12 
TOTAL REPERTOIRE 
a. Based on the internationai!MGT (lmMunoGenencs) Database. 57 
b. In TCRD gene rearrangements, multiple D segments might be used; this implies that the number of 
junctions can vary from one to four. In IGH and TCRB gene rearrangements, only one D gene segment 
is genera!!y used. 
The junctional diversity of lg and TCR genes is based on deletion of germ line 
nucleotides by trimming the ends of the rearranging gene segments as well as by 
insertion of nucleotides between the joined gene segments. Insertion of nucleotides 
(N region insertion) at the junction sites is mediated by TdT, which is able to add 
nucleotides to 3' ends of DNA breakpoints without need for a template_79,80 The 
junctional regions of lg and TCR genes encode for the so-called third complemen-
tarily determining region (COR3), which contributes considerably to the antigen 
recognition site of the variable protein domains. Therefore N-region insertion drasti-
cally increases the diversity of antigen receptors, especially when multiple junction 
sites occur in a junctional region, such as in /GH, TCRB, and especially TCRD genes 
(Table 4 ). The random insertion and deletion of nucleotides at the junction sites of V, 
(0,) and J gene segments make the junctional regions into 'fingerprint-like' 
sequences, which are most probably different in each lymphocyte (Figure 1 0). 
Absence or decreased TdT activity during lg or TCR gene rearrangements leads 
to the absence of N-region insertion, as is found in fetal thymocytes and B-cell pre-
cursors in fetal liver81 -83 Also rearranged lg light chain genes in mature B-cells vir-
tually lack N-region insertion,48-49,84 suggesting that the lg light chain genes 
rearrange in the absence of TdT activity. This is in contrast to the junctional regions 
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Vyl 
GermHne Vyl sequence junctional region 
GCG 
ACTGTGCCACCTGGGATAGG 
v,s ACTGTGCCACCT CITITA 
V-(2 ACTGTGCCACCTGGGACG CACCTACTC 
ViJ ACTGTGCCACCTGGGACAGG TCCATI 
Vy' ACTGTGCCACCTGGGATG AGGCCCCCCACACCA 
ViJ ACTGTGCCACCTGGG ecce 
VC' ACTGTGCCACCTGGG CGTCCCCTAAAA 
V-(2 ACTGTGCCACCTGGG c 
Vy8 ACTGTGCCACCTGGGA CTCAGGCCCGOG 
Vy8 ACTGTGCCACCTGGGA AAAGAGGCTAACAGOOTTT 
Vy8 ACTGTGCCACCTGGGA cnccGAGT 
Vy8 ACTGTGCCACCTGGGA 
Vy3 ACTGTGCCACCTGGGACG AATGTA 
Vy8 ACTGTGCCACCTGGGATA ecce 
Vc< ACTGTGCCACCTGGGATGGG ACTACAACTA 
Vc< ACTGTGCC TCTGAACAATCCAAACAAOACCACG 
v1a ACTGTGCCACCTGGGAT GGA 
V01 
Germline V01 sequence junctional region 
.QIQIIG.G.G.G.MCI 
junctional 
region 
Jy1.3/2.3 ,. 
----------_, 
Germ line Jy1 .3/2.3 sequence 
GAATTATTATAAGAAACTCT 
T Jy1.3 
TAAGAAACTCT Jy2.3 
ATTATTATAAGAAACTCT Jy2.3 
ATAAGAAACTCT Jy2.3 
GAATTATTATAAGAAACTCT Jy2.3 
TATAAGAAACTCT Jy2.3 
GAATTATTATAAGAAACTCT Jy1.3 
TAAGAAACTCT Jy2.3 
TTATTATAAGAAACTCT Jy2.3 
AATTATTATAAGAAACTCT Jy2.3 
TTATTATAAGAAACTCT Jy2.3 
ATAAGAAACTCT Jy2.3 
ATTATAAGAAACTCT Jy2.3 
ATTATAAGAAACTCT Jy2.3 
GAATTATTATAAGAAACTCT Jy2.3 
AATTATTATAAGAAACTCT Jy2.3 
junctional 
region JOJ 
D:S DO -+-"'"---. 3' 
1111 " 
Germllne J01 sequence 
ACACCGATAAACT 
CTCTTGGGGAA 
CTCTTGGGGAACT 
CTCTTGGGGAACT 
CTCTTGGGGAAC 
CTCTTGGGGA 
CTCTTGGG 
CTCTTGGGGAACT 
ACTTCAACCCGGGGACCGTICATACCAACCACCCTCTACGGGGG 
GAATTCATIGTACGGGGG 
ATTCOGTCCCTACGOATAACTGGGGGATACGTGTGGAGTA 
CTOTOGOTAGOOTCTCGCCCGTACTGGGGGTCTT 
TAAACCTCCCCOOCCAGAGAGCT ACTGGGACGATGGGC 
AACOGCAAOCCTTCCCCAAAATTT ACTGGGGGACCTT 
AAAGAGGGTGGGGGCCCCGT 
CACCGATAAACT 
CGATAAACT 
ACACCGATAAACT 
CACCGATAAACT 
CCGATAAACT 
ACACCGATAAACT 
ACACCGATAAACT 
ACACCGATAAACT 
ACACCGATAAACT 
ACACCGATAAACT 
CTCTTGGGGAACT 
CTCTTGGGGA 
CTCTTGGGGA 
CTCTTGGGGA 
CTCTTGGGGAA 
CTCTTGGGGAA 
CTCTTGGG 
ACGGT 
TCAAGGAGGAAGAACTT AATOOCCGGGGGOGOTATAGTCGGCTGGAA 
GGGATACTTCCCCG 
ccnATCTCTCATACAAACTGGGGGATACGCGGTG 
TGGAGTAGTTTCCCCTTGGCTGGGAAGGOTAAG 
GGAGGTCCGTTACTGGGGGATACTGAGOT 
CCAACCCCTACTGA TGGGGGAGCGT 
AACT 
ACT 
TAAACT 
ACACCGATAAACT 
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(A) Schematic diagram of the Vyl gene segment joined to the Jy1.3/2.3 gene segment via a junctional 
region. PCR-mediated amplification of the joined TCRG gene segments and subsequent sequencing of 
the junctional region in the obtained PCR products can be performed. The presented junctional region 
sequences are derived from T-ALL patients and illustrate the deletion of nucleotides from the germline 
sequences as well as the size and composition of the junctional regions. 
(B) Schematic diagram of the V81 gene segment joined to the J81 gene segment via a junctional region. 
TCRD junctional regions may contain one. two, or three 08 gene segments. The presented TCRD junc-
tional region sequences are derived from the same T-ALL patients as in panel A and illustrate that dele-
tion and insertion of nucleotides are more extensive than in the case of TCRG junctions. DO gene seg-
ments and inserted nucleotides are indicated by capital letters and small capital letters, respectively. 
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of postnatally rearranged TCR genes, all of which contain N regions. This discrep-
ancy in N-region diversity between lg and TCR genes is in line with the fact that 
Smlg+/TdT+ immature B-cells are extremely rare, whereas TCR+/TdT+ T-cells occur 
in a great amount in the thymus.19 Apparently TdTactivity decreases early during B-
cell differentiation (after IGH gene rearrangement), whereas TdT is expressed 
throughout thymic T-cell differentiation. 
Rearrangement and expression of lg and TCR genes during lymphoid 
differentiation 
lg and TCR gene rearrangements start early during lymphoid differentiation and 
occur in a hierarchical order. One of the earliest events during normal B-cell differ-
entiation are incomplete DH-JH rearrangements, which are already found in 
CD34+/CD19-JCD10+ precursor cellsBS.86 Most of the more mature 
CD34+/CD19+/CD10+ B-lineage precursors contain at least one DH-JH rearranged 
allele and frequently also complete VH-(DH-)JH rearrangementsB6,87. JGH gene 
rearrangements are followed by recombination in the JGK locus. If the latter 
rearrangements are nonfunctional, the JGL genes will rearrange4 S.s2 Generally, IGL 
gene rearrangements occur after or coincide with JGK gene deletionsBS.S9 All IGK 
gene deletions are mediated via rearrangement of the so-called kappa deleting ele-
ment (Kde), which is located downstream of the CK gene segment (Figure 5).90.91 
Kde rearranges to a heptamer RSS in the JK-CK intron, thereby deleting the CK gene 
segment, or to a VK gene segment, thereby deleting a large part of the IGK gene, 
including the JK and CK gene segments.90.92 Functional rearrangement of JGH and 
lg light chain genes results in Smlg+ B-lymphocytes. 
During T-cell differentiation, TCRD genes rearrange followed by TCRG gene 
rearrangements, which might result in TCRy8+ T-lymphocytes if the rearrangements 
are functional. TCRaJ3+ T-lymphocytes most probably develop via a separate differ-
entiation lineage with TCRB gene rearrangements prior to TCRA gene rearrange-
ments. 52 TCRA rearrangements are preceded by deletion of the TCRD genes 
because the major part of the TCRD gene complex is located between the Va and 
Ja gene segments59.93-95 and is flanked by the so-called 8REC and \ifJa gene seg-
ments (Figure 6).96.97 TCRD gene deletion is mediated via rearrangement of the 
8REC and \ifJa gene segments.82.96.97 These rearrangement and deletion process-
es in the TCRA!D locus probably play a crucial role in the divergence of the TCRy8 
and TCRaJ3 differentiation pathways.19 It is not yet clear in which differentiation stage 
this divergence occurs, but it is remarkable that virtually all TCRaJ3+ T-lymphocytes 
have rearranged TCRG genes and that most TCRy8+ T-lymphocytes have 
rearranged TCRB genes (Figure 11 ).21 ,52 
The Smlg-CD79 complex (Figure 4) is expressed on B-cells as soon as func-
tional IGH and lg light chain gene rearrangements are completed. However in the 
pre-B-cell differentiation stage, the result of functional IGH gene rearrangement can 
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be seen, i.e. the weak cytoplasmic expression of lgJ.! heavy chain (pre-B-CylgJ-!).11,98 
In a part of the pre-B-cells also, a weak membrane expression of the so-called pre-
B-cell complex (pre-B-Smlg;.c-CD79) can be found.13,51 This pre-B-cell complex con-
sists of CD79 and lgJ.! protein chains and a pseudo lg light chain, which is derived 
from nonrearranging lgic-like gene segments.99 The precise function of this tran-
siently expressed pre-B-cell complex is still unclear, but it is assumed that it plays a 
role in the regulation of early B-cell development. 51 
Surface membrane expression of TCR-CD3 complexes depends on the func-
tional rearrangement of TCRD and TCRG genes or TCRB and TCRA genes. 
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TCRA genes rearranged (in TCRa.~+ cells) I 
Hypothetical diagram of lg and TCR gene rearrangements during lymphoid differentiation. The ordered 
rearrangement of lg and TCR genes is indicated with bars. The expression of nuclear TdT, cytoplasmic 
CD3 (CyCD3), cytoplasmic CD79 (CyCD79), pre-B-Ig molecules (pre-B-Cylgu and pre-B SmlgwCD79), 
pre-T complex, and the mature Smlg-CD79 and TCR-CD3 antigen receptor complexes are indicated per 
differentiation stage. 
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Analogous to the pre-8-cell complex, the so-called pre-T-cell complex is weakly 
expressed on the surface membrane of immature thymocytes of the TCRcxj3 differ-
entiation lineage.100 In addition to CD3 and TCRJ3 protein chains, this pre-T-cell com-
plex contains a second TCR chain.100 
DETECTION OF CLONAL IG AND TCR GENE REARRANGEMENTS 
Rearrangements in lg and TCR genes result in relocation and joining of gene 
segments with simultaneous deletion of the intervening gene segments. In principle, 
these rearrangements are assumed to be identical in all cells of a particular 
leukemia, because leukemias are clonal cell proliferations. The deletion-relocation-
joining processes can be studied by Southern blotting and PCR-based techniques. 
Southern blotting allows detection of deletion and relocation of gene segments 
based on changes in distances between cleavage sites of restriction enzymes in the 
DNA. PCR analysis of lg and TCR gene rearrangements is based on the (selective) 
amplification of junctional regions of rearranged lg or TCR gene segments. Such 
amplification is possible only when the lg or TCR gene segments are juxtaposed 
through rearrangement, as the distance between these gene segments in germline 
configuration is far too large for PCR amplification. It should be noted that clonality 
studies by Southern blotting take advantage of the combinatorial diversity, i.e., the 
relocation of gene segments, whereas clonality studies by PCR-based methods 
employ mainly the junctional diversity of lg and TCR gene rearrangements. 
Southern blotting 
In Southern blot studies the DNA samples are digested with restriction 
enzymes.101 The obtained DNA fragments (restriction fragments) are size-separat-
ed by agar electrophoresis, transferred (blotted) onto a nitrocellulose or nylon mem-
brane, and immobilized.101 This membrane is incubated with a radiolabeled DNA 
probe that hybridizes to complementary sequences of lg and TCR genes.52 
Unbound probe is washed away, and the location of the probe and thereby the size 
of the recognized restriction fragments can be detected by autoradiography or by 
phosphorimaging. If appropriate combinations of restriction enzymes and DNA 
probes are used, the detected restriction fragments of rearranged lg or TCR genes 
will differ from those of germline genes.S2,94.102,103 
Figure 12 illustrates various aspects of Southern blot analysis of IGH genes: the 
germ line restriction map of the JH-Cf.l region with an appropriate JH probe (IGHJ6), 
the separation of restriction fragments in an agarose gel and the autoradiographic 
results of hybridization with the radiolabeled IGHJ6 probe.52.102 
Optimally designed lg/TCR probes recognize sequences just downstream of the 
rearranging gene segments and should be used in combination with at least two dif-
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Figure 12. 
Southern blot analysis of IGH genes. 
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(A) Restriction map of JH-CJl region. The position of the relevant EcoR! (E), Hind Ill (H). BamHI (B). and 
Bg/11 (Bg) restriction sites are indicated. Also the location of the switch region (Sil) is indicated. The solid 
bar represents the JH probe (IGHJ6). 
(B) Ethidium bromide-stained agarose gel with size-separated Bg/!1 restriction fragments of control DNA 
and four different 8-cell chronic lymphocytic leukemia (B-CLL) DNA samples. The two outer lanes contain 
size markers (left: Hindi II digested A DNA; right: EcoRI!Hindlll digested A DNA). The DNA fragments were 
blotted to a nylon filter. 
(C) X-ray film after exposure to the nylon filter, which was hybridized to the 32P-radiolabeled IGHJ6 probe. 
The size of the germline band (G) and the position of the size markers are indicated. The two control lanes 
contain the 3.9 kb germline band, whereas each of the four B-CLL lanes show two clonally rearranged 
bands, due to biallelic IGH gene rearrangements. 
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ferent restriction enzyme digests, which result in germ line restriction fragments that 
are not affected by polymorphisms and which are smaller than or the size of 10 kb. 
The latter is important for prevention of comigration of germline and/or rearranged 
bands.S2.1 03-107 
Because lg and TCR gene rearrangements in ALL are identical, the (identical) 
restriction fragments give rise to a clearly visible rearranged band, which is different 
from the germ line band 5 2 Furthermore, two rearranged bands of comparable densi-
ty will be visible if the clonal cell population has rearranged both lg or TCR alleles 
(Figure 12). In contrast to clonal cell populations, reactive (polyclonal) lymphoid cell 
proliferations contain many different lg and TCR gene rearrangements that are 
detectable as a characteristic background pattern or smear of multiple faint 
rearranged bands. Thus, Southern blot analysis of lg and TCR genes allows dis-
crimination between clonal rearrangements and polyclonal rearrangements.52-64 
Leukemic cell populations can be detected with a sensitivity of approximately 5%, 
whereas the detection limit is 10% to 15% if a clonal cell population has to be iden-
tified within a background of polyclonal, reactive cells. 
PCR analysis 
The PCR technique allows the selective amplification of a particular DNA region 
while it is still incorporated in the total genomic DNA.108.109 Knowledge of the pre-
cise nucleotide sequences, which fiank the target DNA region, is a prerequisite for 
the PCR technique. Based on this information, two synthetic oligonucleotides are 
prepared that can hybridize to the fianking sequences of opposite strands (primer 
annealing), after the DNA has been denatured to single-stranded DNA.108.109 The 
two oligonucleotides serve as primers for the Taq polymerase-mediated DNA syn-
thesis (primer extension), which proceeds across the target DNA region using this 
region as template (Figure 13). The PCR process involves temperature-regulated 
cycles of DNA denaturation (94°C), primer annealing (55-65°C), and primer exten-
sion (72°C). Because the PCR product of one primer can serve as a template for the 
other primer in subsequent cycles, each successive PCR cycle essentially doubles 
the number of PCR products (Figure 13). Continuation of the PCR procedure for 20-
30 cycles theoretically results in 220-230 times amplification of the target DNA 
region. In principle, the PCR technique can amplify target DNA sequences up to 10 
kb, but preferably the PCR target should not be longer than 2 kb in routinely per-
formed PCR analyses.109, 110 The PCR primers for amplification of junctional regions 
are designed at opposite sides of the junctional region, generally within a distance of 
less than 500 bp. 
Because most PCR studies on lg and TCR gene rearrangements in leukemias 
are performed at the DNA level, the primers are complementary to exon and/or intron 
sequences of V, D, and/or J gene segments, depending on the type and complete-
ness of the rearrangement,111-113 Also, mRNA of complete V-(D-)J-C transcripts can 
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be used as target for the PCR technique after the mRNA has been transcribed into 
complementary (c)DNA by use of reverse transcriptase (RT-PCR). Such studies 
generally use V exon primers in combination with a single C exon primer.114-116 It is 
obvious that the choice of primers depends on the type of lg or TCR gene and the 
type of rearranged gene segments. It may be possible to design general or consen-
sus primers, which recognize virtually all V or J gene segments of a particular lg or 
TCR gene complex; family-specific primers, which recognize families of V or J gene 
segments; or even member-specific primers, which recognize individual V or J gene 
segments.111-113, 117 
It should be noted that the lg and TCR genes not only contain functional V, (D), 
and J gene segments but also nonfunctional (pseudo) gene segments. Such seg-
ments can be involved in gene rearrangements, provided they are fianked by a prop-
er RSS. Table 5 summarizes the estimated number of gene segments and families 
of the three lg genes and four TCR genes. 
Complete IGH, TCRG, and TCRD gene rearrangements can be analyzed rela-
tively easily with the PCR technique, because the IGH gene complex contains only 
seven VH families and six functional JH gene segments and because the TCRG and 
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(A) Temperature-regulated PCR cycle in which double-stranded DNA is heat denatured at 94°C, followed 
by pr·1mer annealing at 60°C, and primer extension by Taq polymerase at 72<'C. In the first PCR cycle, syn-
thesis of the new DNA proceeds across the target DNA. resulting in long PCR products. 
(B) In subsequent cycles. the PCR products of the previous cycle(s) can serve as template, resulting in 
short PCR products. Each PCR cycle essentially doubles the number of PCR products. 
(C) Temperature cycle for denaturation, primer annealing, and primer extension. Each cycle takes 5 to 10 
minutes, depending on the size of the PCR product (i.e., the duration of primer extension). 
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Table 5. Estimated number of human V, D, and J gene segments that can be potentially involved 
in lg or TCR gene rearrangements. a 
Gene segment 
V (family) 
D (family) 
J (family) 
!GH 
-70 (7) 
25 (7) 
6 
IGK IGL 
-60 (7) -40 (11) 
5 
TCRA 
-60 (32) 
TCRB 
-65 (30) 
2 
13 
TCRG 
9 (4) 
5 (3) 
TCRD 
7b 
3 
4 
a. The estimated numbers include non-functional {pseudo) gene segments with functional RSS, which 
allow rearrangement; orphan genes are excluded. The calculations are based on the international I MGT 
(ImMunoGeneTics) DatabaseS? and complete genomic sequences of IGH. TCRB, and /GL.56.6D,71 
b. These numbers include the non-functional 5REC gene segment (TCRD locus) and the \j!Ja gene seg-
ment (TCRA locus). 
c. Two of the seven JA. gene segments (J)A and J/5) have never been observed in IGL gene rearrange-
ments, probably because of their inefficient RSS (TUmkaya et al., unpublished results). 
TCRD genes contain a limited number of V and J gene segments (Table 4 and Figure 
6).54.94.118.119 This implies that only a restricted number of oligonucleotide primers is 
needed.120.121 In principle, PCR analysis of IGK, IGL, TCRA and TCRB gene 
rearrangements is also possible, but it requires more primers, especially for the 
many different V and J gene segments in TCRA and TCRB gene complexes (Figure 
6). RT-PCR analysis of TCRA and TCRB V-(D-)J-C transcripts still requires many dif-
ferent Va or V~ primers, although these can be used in combination with a single Ca 
or c~ primer.114-11 6 
One disadvantage of lg or TCR gene analysis by PCR-based techniques, as 
compared with Southern blot analysis, is that the delectability of (clonal) rearrange-
ments is limited by the choice of primers, raising the possibility of false-negative 
results. A more essenf1al drawback is the risk of false-positive results owing to the 
fact that not only clonally rearranged lg and TCR genes but also lg and TCR 
rearrangements from normal, polyclonal cells are amplified. 
Analysis of PCR-amplified lg and TCR gene rearrangement products 
PCR-mediated detection of clonal lg and TCR gene rearrangements is relatively 
easy if the percentage of leukemic cells is high (e.g., greater than 90%). In such cell 
samples, the background of lg and TCR gene rearrangements in normal polyclonal 
cells generally does not hamper the PCR studies of leukemic cells. This is illustrat-
ed in Figure 14, which shows that PCR products of comparable clonal TCRD 
rearrangements in different T-ALLs are clearly different from each other, based on 
differences in the size of their junctional regions (compare with Figure 1 0).112 If many 
normal polyclonal B- or T-cells are present in the cell sample, many polyclonal PCR 
products will also be present. Discrimination between clonal (leukemia-derived) PCR 
Figure 14. 
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V01-J01 PCR products in cases of T-ALL with monoallelic or biallelic V01-J01 rearrangements. The PCR 
products were separated in a polyacrylamide gel, resulting in optimal size separation. The positions of the 
size markers are indicated in the left margin. The differences in size of the PCR products (115-155 bp) 
are due to differences in size of the junctional regions (see Figure 1 OB). 
products and polyclonal (normal) PCR products with standard gel electrophoresis is 
hampered by the fact that the clonal PCR products have to be identified as a domi-
nant band within a background of multiple weaker bands of slightly different sizes, 
representing polyclonal PCR products.11 3 Because junctional regions are 'finger-
print-like' sequences that differ between lymphocytes or lymphocyte clones, it is 
assumed that they represent specific markers for each individual leukemia.111 -117 
Thus, strategies should be followed that employ the junctional regions of amplified 
rearranged lg and TCR genes as PCR targets for discrimination between polyclonal 
and clonal cell populations. Methods that have been successfully applied to solve 
this background problem include direct sequencing of PCR products, 122 single-
strand conformation polymorphism analysis, 123 denaturing gradient gel elec-
trophoresis, 124 heteroduplex analysis (Figure 15), 125 temperature gradient gel elec-
trophoresis, 126 high resolution radioactive fingerprinting, 113 and fiuorescent gene 
scanning analysis.127 
lg and TCR gene rearrangements in B-lineage ALL 
Based on their immunophenotypic characteristics, precursor-B-ALL are general-
ly regarded as clonal malignant counterparts of normal precursor-S-cells. In line with 
this assumption, our studies indicate that more than 95% of precursor-B-ALL have 
IGH gene rearrangements and that most of them contain IGK gene rearrangements 
(30%) or deletions (50%); even 20% of precursor-B-ALL cases have IGL gene 
rearrangements (Table 6).64.103.128 Deletions in the IGK genes are predominantly 
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Figure 15. 
(A) Heteroduplex analysis of V'ti-Jy1.3/2.3 PCR products from several T-ALL and precursor-B-ALL 
patients in a non-denaturing 6% polyacrylamide gel. Following denaturation and renaturation of PCR 
products, the presence of homoduplexes in samples 96-130, 96-134A, 96-1348, and 96-136 proves the 
monoclonal character of these samples. The smear of heterodup!exes that is seen in 96-137 is indicative 
of a polyclonal cell population. The additional bands that are seen in samples 96-130, 96-134A, and 96-
1348 represent clonal heteroduplexes, resulting from renaturation of single-stranded fragments derived 
from bia!!elic rearrangements. The two homoduplexes from these biallelic rearrangements are easily seen 
in 96-134A and 96-1348 (bone marrow and peripheral blood samples. respectively. from the same 
patient), but not in 96-130 owing to comigration. 
(B) Heteroduplex PCR analysis of IGH in precursor-B-ALL patient. Malignant lymphoblasts at diagnosis 
contained a monoclonal VH1-JH gene rearrangement. Dilution of the diagnosis bone marrow DNA into 
polyclonal MNC DNA derived from healthy blood donors showed a sensitivity threshold of approximately 
1%. he = heteroduplexes; ho = homoduplexes: Mw marker= 1 00-bp molecular weight marker. 
mediated via the Kde sequence, which implies that !GK gene deletions can be iden-
tified as Kde rearrangements, which occur on one allele or both alleles in 20% and 
30% of precursor-B-ALL cases, respectively. 103 Cross-lineage TCR gene rearrange-
ments occur in high frequency in precursor-B-ALL cases: TCRB, TCRG, and TCRD 
gene rearrangements and/or deletions are found in 35%, 60%, and 90% of cases, 
respectively.129 -130 
Several studies have shown that newly diagnosed precursor-B-ALL are fre-
quently oligoclonal because they contain multiple IGH gene rearrangements (30% to 
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40% of cases) and even multiple IGK gene rearrangements (5% to 10% of 
cases).128.131 These multiple lg gene rearrangements can result from both continu-
ing rearrangement processes (e.g .• continuing VH to DH-JH joining) and from sec-
ondary rearrangements (e.g .. DH-JH replacements. VH-JH replacements. and VK-JK 
replacements). which result in one or more subclones.131-135 
Comparative studies between cell samples taken at diagnosis and at relapse 
revealed that the ongoing rearrangements and secondary rearrangements can 
cause changes in the lg and TCR gene configuration at the time of relapse.134.136-
139 Such changes are particularly prevalent in cases of precursor-B-ALL that already 
contain subclones at diagnosis.137 
TCR and lg gene rearrangements in T-All 
The immunophenotype of T-ALL is fully comparable to those of cortical thymo-
cy1es. Subclassification of T-ALL into CD3-, TCRyo+, and TCRo:~+ subgroups also 
reveals major differences in TCR gene rearrangement patterns.19.64 Although the 
frequency of TCR gene rearrangements in the total group of T-ALL is very high, 
approximately 10% of CD3- T-ALL still have all TCR genes in germline configura-
tion;19.64 this mainly concerns immature CD1-/CD3- T-ALL of the prothymocy1ic/pre-
T-ALL subgroup (see Table 2). The TCRD genes in CD3- T-ALL are rearranged in 
most cases (approximately 80%) and contain biallelic deletions in approximately 
10% of cases.19.94 As expected, all TCRyo+ T-ALL have TCRG and TCRD gene 
rearrangements and the majority (approximately 95%) also contain TCRB gene 
rearrangements21.94.112 All TCRo:~+ T-ALL contain TCRB and TCRG gene 
rearrangements and have at least one deleted TCRD allele ( = TCRA rearrange-
ment); the second TCRD allele is also deleted in two-third of cases.64.94 Cross-line-
Table 6. Frequencies of detectable ig and TCR gene rearrangements and deletions in ALL. 
IGH IGK IGL TCRB TCRG 
R D R D R R R 
Precursor-B-ALL 96% 3% 30%0 50%0 20% 35% 60% 
T-ALL 
CD3- 20% 0% 0% 0% 85% 90% 
TCRyo• 50% 0% 0% 0% 95% 100% 
TCRaV <5% 0% 0% 0% 100% 100% 
a. A total of -60% of precursor-B-ALL have IGK gene rearrangements and/or deletions_103 
R. at least one allele rearranged; D, both alleles deleted. 
TCRD 
R D 
55% 35% 
80% 10% 
100% 0% 
35% 65% 
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{A) Analysis at diagnosis with the restriction enzyme Bg!l! and the JGHJ6 probe (see Figure 12). Multiple 
rearranged bands are present in each precursor-B-ALL Jane. In patient SL, this is due to trisomy 14, but 
in all other cases subclone formation (biclonality or oligoclonality) is the cause. 
(B) Comparative analysis of DNA samples of patient peripheral blood at diagnosis and relapse with Bg/11 
and BamHI/Hindll! digests and the IGHJ6 probe. Multiple rearranged bands of different density are pres-
ent in both digests at diagnosis. However, at relapse only two rearranged bands are present, which prob-
ably have the same size as two faint rearranged bands at diagnosis. 
age lg gene rearrangements occur at low frequency in T-ALL (approximately 20%) 
and involve virtually only IGH genes (Table 6)_64,140 
Comparative studies at diagnosis and at relapse revealed that continuing and 
secondary TCR rearrangements could also occur in 40% to 50% of T-ALL 
patients_13?-139 Nevertheless, TCR oligoclonality is rarely seen at diagnosis in T-ALL 
cases, 64,137 except for a few CD3- cases that showed a faint band of oREC-\IfJa 
rearrangements normally involved in TCRD gene deletionsB2 Detailed studies of 
these T-ALL cases revealed that the detected oREC-\IfJa rearrangements were fully 
polyclonal but were derived from otherwise monoclonal T-ALL141 
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Analysis of ALL at diagnosis and subsequent relapse 
Analysis of lg and/or TCR gene rearrangement patterns at diagnosis and subse-
quent relapse can prove whether the recurrence of an ALL represents a relapse or 
a secondary malignancy. Southern blot analysis has been considered the gold stan-
dard for the comparison of the lg/TCR gene rearrangement patterns between diag-
nosis and recurrence of a lymphoid malignancy (Figure 16).137 Currently, compara-
tive junctional region analysis can be easily performed by mixing the PCR products 
of both disease stages and evaluating them by heteroduplex method. In case of 
relapsed leukemia, mixing will result in a single homoduplex band upon heteroduplex 
analysis, whereas in case of a secondary malignancy two distinct homoduplexes as 
well as two heteroduplexes will be found (Figure 17). These heteroduplexes result 
from cross-renaturation of single-strand molecules of the two different malignant cell 
populations. Finally, when only nonidentical clonal PCR products at diagnosis and at 
relapse are detected with mixed heteroduplex PCR analyses, direct sequencing of 
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Figure 17. 
Comparative heteroduplex analysis of VH3-JH PCR products in three precursor-B-ALL patients at diagno-
sis and at leukemia relapse. In two patients (0128 and 3510), identical clonal VH3-JH PCR products were 
found at both leukemia phases (identical size of homoduplexes and no heteroduplex formation after mix-
ing and subsequent denaturation/renaturation). In patient 2308 monoclonal homoduplexes found at diag-
nosis and at relapse slightly differed in size. Mixing of the VH3-JH PCR products followed by heteroduplex 
PCR analysis demonstrated clear heteroduplex formation, proving that these VH3-JH gene rearrange-
ments had different junctional regions. 
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clonal PCR products can be performed to exclude clonal evolution due to ongoing 
rearrangements; e.g. different VH to OH-JH rearrangements but with an identical pre-
existing DH-JH rearrangement. 
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ABSTRACT 
Because of developments in diagnosis of hemopoietic malignant diseases dur-
ing the past two decades, routine and reliable identification of very low numbers of 
malignant cells, known as minimal residual disease (MRD), is now possible. Several 
large-scale studies have shown that monitoring of MRD in hemopoietic malignant 
disease predicts clinical outcome. In acute lymphoblastic leukemia, MRD detection 
is useful for evaluating early response to treatment and consequently for improving 
stratification, including treatment reduction. In acute promyelocytic leukemia and 
chronic myeloid leukemia, MRD information at specific time points enables effective 
early treatment intervention. MRD monitoring is also possible in other leukemia sub-
types, but in these disorders the clinical value of MRD detection is not yet known. 
INTRODUCTION 
Modern treatment protocols lead to complete remission in a high proportion of 
patients with acute leukemia, but many of these patients relapse. Clearly, not all 
clonogenic malignant cells are killed. although the patients are classified as being in 
complete remission according to clinical and morphological criteria (Figure 1 ). For 
hemopoietic malignant disease to be detected with morphological techniques, malig-
nant cells must make up at least 1-5% of the total cells. Consequently, morphology 
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provides limited information about the effectiveness of treatment because only 
patients with a very poor prognosis (not achieving remission) can be identified. In 
patients who achieve remission, morphology cannot discriminate between patients 
with a high or low risk of relapse. Therefore, more sensitive techniques are needed 
to detect small numbers of malignant cells during and after treatment- detection of 
minimal residual disease (MRD). 
Reliable techniques to detect MRD should have the following features: 
sensitivity of at least 10·3 (one malignant cell within 103 normal cells), but 
sensitivities of 1 Q-4 to 1 Q-6 are preferred; 
ability to discriminate between malignant and normal cells, without false-
positive results; 
- stable leukemia-specific markers- it should not give false-negative results 
because the MRD targets are lost during the course of disease; 
- reproducibility between laboratories -this is essential for multicenter treat 
ment protocols; 
easy standardization and rapid collection of results; 
a method of quantifying MRD. 
MRD detection techniques can be used for more accurate stratification of thera-
PY in hemopoietic malignant disease. This stratification includes treatment intensifi-
cation in patients at high risk of relapse and reduction in low-risk patients, who are 
being overtreated. 
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TECHNIQUES AND TARGETS FOR MRD MONITORING 
During the past 15 years, several methods of MRD detection have been devel-
oped and evaluated. These include conventional cytogenetics, cell-culture systems, 
fluorescent in situ hybridization, Southern blotting, immunophenotyping, and poly-
merase chain reaction (PCR) techniques. Most of these techniques are not suitable 
for clinical MRO detection because of limited sensitivity, specificity, or applicability. 
However, current multiparameter flow-cytometric immunophenotyping and PCR-
based approaches for M RD monitoring can reach sensitivities of 1 o-3 to 1 o-6 and 
are quantitative, sufficiently specific, and broadly applicable. Flow-cytometric MRD 
detection is based on the occurrence of leukemia-associated immunophenotypes, 
such as aberrant, unusual, or ectopic antigen expression. PCR techniques can be 
used to detect tumor-specific sequences, such as junctional regions of rearranged 
immunoglobulin and T-cell receptor (TCR) genes, or breakpoint fusion regions of 
chromosome aberrations. 
Principles of MRD monitoring by flow-cytometric immunophenotyping 
Acute and chronic leukemias can be regarded as malignant counterparts of cells 
in immature and more mature stages of hemopoiesis, respectively (Figure 2). 
Consequently, the presence of normal hemopoietic cells limits the detection of 
leukemic cells.1 ,2 Nevertheless, immunophenotypic MRD detection is possible in 
many hemopoietic malignant disorders, because the cells express aberrant or 
unusual antigens, or have clonal patterns of immunoglobulin or TCR protein expres-
Figure 2. 
Immunofluorescence staining of terminal deoxynucleotidyl transferase (TdT) in the nucleus of ALL cells, 
representing a typical marker of immature lymphoid blast cells. 
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sion. 
Aberrant or unusual immunophenotypes are the result of cross-lineage antigen 
expression, maturational asynchronous expression of antigens, antigen overexpres-
sion, absence of antigen expression, and/or ectopic antigen expression (Figure 3). 1 ·2 
Such leukemia-associated immunophenotypes can be identified in the majority of 
acute leukemias, but they are rare in mature hemopoietic malignant diseases. 
Asynchronous antigen expression occurs when two or more antigens not present at 
the same time during normal differentiation are coexpressed. In cross-lineage anti-
gen expression, typical myeloid antigens are expressed on lymphoid cells or vice 
versa and B-lineage antigens on T-lineage cells or vice versa. 1·2 Ectopic antigen 
expression refers to the presence of particular antigens on cells outside their normal 
sites of production or homing areas, or to the expression of antigens that are nor-
mally expressed only on non-hemopoietic cells. Examples are the combined expres-
sion of terminal deoxynucleotidyl transferase (TdT) and aT-cell marker outside the 
thymus on T-lineage acute lymphoblastic leukemia (ALL) blasts, and the expression 
Figure 3. 
(Top panel) Flow cytometric MRD monitoring showing examples of aberrant or unusual antigen expres-
sion patterns in four AML patients at diagnosis. (A) Cross-lineage expression of the B-lineage marker 
C019 on CD34-positive myeloid blast cells. (B) Asynchronous expression of the more mature marker 
CD56 on CD34-positive myeloid blast cells. (C) Lack of CD34 expression on CD117 weakly-positive non-
monocytic blast cells. (D) Overexpression of C034 in a subset of AML blasts. 
(Lower panel) Flow cytometric MRO monitoring in one AML patient. (E1 ) 70% of CD33-positive AML 
blasts at diagnosis showed aberrant lack of HLA-DR expression as well as lack of CD34, CD15, C014, 
and CD11 b expression (detected with a cocktail of antibodies used with a third fluorochrome). Two follow-
up samples show the persistence of moderate MRD levels (O_g% and 0.4%) at the time of first complete 
remission (E2) and nine months after diagnosis (E3 ), respectively. At relapse (16 months after diagnosis) 
75% of AML blasts showed the aberrant immunophenotype again (E4). 
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of the NG2 antigen in a subset of ALL and acute myeloid leukemias (AML) with MLL 
gene rearrangements, respectively. Since ALL blasts frequently display complex 
aberrant immunophenotypic features, they fall into so-called 'empty spaces' outside 
the multi parameter ftow-cytometric dot plot templates of normal lymphoid cells in nor-
mal bone marrow and peripheral blood.3,4 
Clonal immunoglobulin molecules are expressed by most chronic 8-cell 
leukemias and 8-cell lymphomas, and can be identified by single immunoglobulin 
light chain expression, i.e. immunoglobulin K or immunoglobulin 'A (Table 1 ). Clonal 
TCRcx~ molecule expression is detectable with antibodies against the variable (V) 
domains of TCRJ3 chains, which together cover 65-75% of TCRcx~-positive cells, and 
consequently allow detection of monotypic Vj3 domain expression in most TCRcxj3-
positive T-cell malignant disorders.S-7 Antibodies against the variable domains of 
TCRy and TCRo chains might contribute to clonality assessment of suspect TCRyo-
positive T-cell proliferations, but their sensitivity is limited because ofthe limited num-
ber of y and o variable domainsB 
One pitfall of immunophenotypic MRD detection is that patterns of antigen 
expression can change during the course of disease. This is a particular character-
istic of acute leukemias and may affect up to two-thirds of patients9,1D Frequently, 
leukocyte antigens are involved, which are not essential for MRD detection. In fact, 
at least one leukemia-associated antigen combination is retained by leukemic cells 
at relapse in more than 80% of patients.1D·11 Nevertheless, preferably two leukemia-
associated antigen combinations per patient should be used for immunophenotypic 
MRD monitoring, in order to prevent false-negative results. 
Immunoglobulin and TCR gene rearrangements as patient-specific 
'fingerprints' 
During early differentiation of 8 and T-cells, the germ line variable (V), diversity 
(D) and joining (J) gene segments of the immunoglobulin and TCR gene complexes 
rearrange. Each lymphocyte gets a specific combination of V-(D-)J segments that 
codes for the variable domains of immunoglobulin or TCR molecules. The random 
insertion and deletion of nucleotides at the junction sites of V, (0,) and J gene seg-
ments make the junctional regions of immunoglobulin and TCR genes into finger-
print-like sequences, which probably differ in each lymphocyte and thus also in each 
malignant lymphoid disease. Therefore, junctional regions can be used as leukemia-
specific targets for PCR analysis of MRD. Such targets can be identified at initial 
diagnosis in > 95% of patients with lymphoid malignant disease and in about 10% of 
patients with AML (Table 1) by us·,ng various PCR pr1mer sets (Figure 4 ). The PCR 
products need to be analyzed for their clonal origin, e.g. by heteroduplex analysis or 
by gene scanning, to confirm that they are derived from the malignant cells and not 
from contaminating normal cells with similar immunoglobulin or TCR gene 
rearrangements.12 Subsequently, the precise nucleotide sequence of the junctional 
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Table 1. Application of MRD techniques in hemopoietic malignancies.a 
Disease Flow cytometric immunophenotyping PCR or RT-PCR analysis 
category (sensitivity) (sensitivity) 
Aberrant lgldlg/.. distribution Junctional regions Chromosome 
immunophenotypes or TCR-V analysis of lg/TCR genes aberrations 
(1Q-3-1Q-4) (1 o-2-1 o-3)b (1Q-3-1Q-6) (1Q-4-1Q-6)C 
Precursor-B-ALL 
-children 80-90% NA -95% 40-50% 
-adults 70-80% NA -90% 35-45% 
T-ALL 
-children >95% 30-35%d >95% 10-25% 
-adults >95% ? -90% 5-10% 
Chronic B-cell rare (<5%) >95% >95% rare (<5%) 
leukem·las 
Chronic T -cell rare (5-10%) 60-65%e -95% rare (<5%) 
leukemias 
B-cell lymphomas rare (<5%) >95% 70-80%f 25-30% 
T-celllymphomas 20-25%9 5Q-6Qo/oC -95% 10-15% 
AML 70-90% NA -10% 10-30%h 
CML NA NA NA >95% 
a. The percentages Indicate the applicability of the MRD techniques per category of hemopoietic malignancies; J.J.M. 
van Dongen, unpublished results. NA =not applicable. 
b. Sensitivity can be improved to :0::10~3 in triple labelings with specific markers like BCL2, cytoplasmic C03, or ALK pro-
teins. 
c. Only concern chromosome aberrations with fusion genes because of their detectability at the DNA level or RNA level, 
such as t(14;18) with the BCL2-/GHfusion in some B-celllymphomas, and t(2;5) with the NPM-ALKfusion gene in 
some T-cell lymphomas. 
d. Based on the expression of TCRo:.l3 molecules (20% of cases) or TCRtO molecules (-10% of cases): this information 
is not available for adult ALL. 
e. Antibodies to TCR-V recognize 65% to 70% of TCRa.l3 molecules and most TCRyO molecules. 
f. Somatic mutations hamper primer annealing in some patients with B~CLL or B-celllymphomas. 
g. Mainly based on T-ALL-like immunophenotype in T-lymphoblastic lymphoma and NPM-ALK expression in -50% of 
large cell anaplastic lymphomas ofT-cell lineage. 
h. Frequency of PCR-detectable chromosome aberrations (with fusion genes) is age dependent: -30% in childhood AML; 
-20% in adult AML (::;:;60 years); -10% in elderly AML (>60 years): see also Table 2. 
Abbreviations: B-ALL. B-cell lineage acute lymphoblastic leukaemia.T-ALL, T-cell lineage acute lymphoblastic 
leukaemia; AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia: lg, immunoglobulin; PCR, polymerase 
chain reaction; RT-PCR. reverse transcriptase PCR: TCR, T -cell receptor. 
100 bp 
5' 
Minimal residual disease in leukemia patients 
V02 
junctional 
region 
003 
-I I -<11111 
3' 
V02 primer -------------- \ 083 primer 
/ -4 TCCAGGG -2 l 
/3'GACGTCCCCGTTTTCACGGTAAAGATCTAGATG 5' 
S'CGCGTCGACCAAACAGTGCCTGTGTCAATAGG 3' 
~ 2 ~ X 0 m ~ 00 -0 6 6 b b b 'o z 0, " N 0 ·;;; E 
"' 
I u 
V02-D03 PCR products 
hybridization with junctional region probe {CTGTGAlC_CAG_G_G_TGGGGGA) 
Figure 4. 
55 
PCR target for MRD detection in a patient with precursor-B-ALL with a V02-D03 rearrangement. The 
specificity of the junctional region is based on the deletion of six nuc!eotides and the random insertion of 
seven nucleotides {top panel). This sequence information was used to design a patient-specific junction-
al region probe. DNA from the ALL cells was diluted into DNA from normal blood mononuclear cells (MNC) 
and analyzed by PCR with V02 and 003 primers. PCR products were size-separated on an agarose gel 
(middle panel), blotted onto a nylon membrane, and hybridized with the junctional region probe (inserted 
nucleotides are underlined) (lower panel). In all dilution steps and in the mononuclear cells, V02-D03 PCR 
products were found, but only the first five dilution steps showed leukemia-derived PCR products, i.e. a 
sensitivity of 1 o-s was reached. 
regions should be determined. This sequence information allows the design of junc-
tional region-specific oligonucleotides. These oligonucleotides can be used to detect 
malignant cells among normal lymphoid cells during follow-up of patients in two dif-
ferent ways. One uses the oligonucleotides as patient-specific junctional region 
probes in hybridization experiments to detect PCR products derived from the malig-
nant cells (Figure 4). Alternatively, the junctional-region-specific oligonucleotide can 
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be used as a primer to specifically amplify the rearrangements of the malignant 
clone.12 
During B-cell differentiation, immunoglobulin gene rearrangements can undergo 
further rearrangement, or might be subjected to somatic hypermutation processes. 
These events may modify PCR targets for MRD during the disease course and 
potentially generate false-negative results- this should be taken into account in the 
design of PCR strategies to detect MRD in ALL as well as for follicular B-cell malig-
nant diseases. 
Breakpoint fusion regions of chromosome aberrations as leukemia-specific 
markers 
An advantage of using chromosome aberrations as tumor-specific PCR targets 
for MRD detection is their stability during the disease course. However, many hemo-
poietic malignant diseases do not have specific chromosome aberrations that can be 
detected by PCR (Table 1 ). 
Chromosome aberrations can be used as targets only if the PCR primers are 
chosen at opposite sides of the breakpoint fusion region, preferably within a distance 
of < 2 kb. However, only in a few hemopoietic malignant diseases the breakpoints 
cluster in a small area, enabling PCR-mediated amplification of breakpoint fusion 
sequences at the DNA level. This is the case in t(14;18) in follicular-cell lymphoma, 
where most breakpoints are clustered in a few small regions of the BCL2 gene, 
which are next to one of the JH gene segments of the immunoglobulin heavy-chain 
locus. Other examples include T-ALL-associated aberrations involving the TAL 1 
gene (Table 2). The nucleotide sequences of breakpoint fusion regions differ 
between patients; therefore, these regions are unique patient-specific MRD-PCR tar-
gets, which can be reliably identified by use of patient-specific oligonucleotide 
probes. 
In most translocations, the breakpoints of different patients are spread over one 
or more introns, which makes identification of breakpoint fusion regions at the DNA 
level laborious and time-consuming. However, several malignant diseases with chro-
mosome aberrations have tumor-specific fusion genes, which are transcribed into 
fusion-gene mRNA molecules that are similar in individual patients despite distinct 
breakpoints at the DNA level (Figure 5).13 The most frequently occurring fusion 
genes in acute leukemias are summarized in Table 2.13,14 Other examples include 
BCR-ABL transcripts in the case of chronic myeloid leukemia (CML) and NPM-ALK 
transcripts in anaplastic large-cell lymphoma with t(2;5). Depending on the type of 
chromosome aberration, sensitivities of 1Q-3 to 10-6 can be reached with PCR.13 
However, because of this high sensitivity, cross-contamination of reverse transcrip-
tase PCR (RT-PCR) products between patients' samples is a major pitfall in PeR-
mediated MRD detection studies. Such cross-contamination is difficult to recognize, 
since leukemia-specific fusion-gene RT-PCR products are not patient-specific. 
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Table 2. Chromosome aberrations with fusion genes as PCR targets for MRD detection in acute 
leukemias. a 
Disease category 
Aberration 
Target Frequency of applicabilityb 
Precursor-B-ALL 
!(1 ;19)(q23:p13) 
!(4;11 )(q21 :q23) 
t(9;22)(q34;q11) 
11q23 aberrations 
!(12;21 )(p13:q22) 
TOTAL: 
T-ALL 
TAL 1 deletion 
AML 
!(8;21 )(q22;q22) 
t(15;17)(q23;q21 )0 
inv(16)(p13q22) 
11q23 aberrations 
TOTAL: 
(mRNA or DNA level) 
E2A-PBX1 (mRNA) 
MLL-AF4 (mRNA) 
BCR-ABL (mRNA) 
MLL fusion genes (mRNA) 
TEL-AML 1 (mRNA) 
S/L-TAL1 (DNA or mRNA) 
AML1-ETO (mRNA) 
PML-RARA (mRNA) 
CBFB-MYH11 (mRNA) 
MLL fusion genes (mRNA) 
children 
5-8% 
3-5%C 
5-8% 
5-6% 
25-30% 
40-50% 
10-25% 
10-15% 
8-10% 
5-8% 
15-20% 
35-40% 
a. Detection limit of PCR analysis of chromosome aberrations is 10-s to 10-s. 
b. Represent frequencies within the precursor-B-ALL, T-ALL, and AML groups. 
c. In infant ALL, the frequency of t(4:11) can be as high as 70%. 
adults 
3-4% 
3-4% 
25-40% 
<5% 
1-3% 
35-45% 
5-10% 
2-5% 
1-3% 
2-5% 
3-7% 
10-20%d 
d. Mainly concern adult AML patients <60 years old. In AML patients >60 years the total frequency of 
PCR-detectable fusion genes is <1 0%. 
e. In southern European regions the frequency of t(15:17) with PML-RARA is essentially higher than in 
northern European regions. 
B-ALL, B-cell lineage acute lymphoblastic leukaemia: T-ALL, T-cell lineage acute lymphoblastic 
leukaemia: AML, acute myeloid leukaemia; PCR, polymerase chain reaction; MRD, minimal residual dis-
ease. 
Quantification of MRD by use of PCR analysis 
Whereas immunophenotyping gives direct quantitative information, MRD quan-
tification by PCR analysis is a complex process. First, the isolated DNA or RNA must 
be of good quality and have potential to be amplified. Furthermore, minor variations 
in RT efficiency, primer annealing, and primer extension may lead to major variations 
at the end of PCR, i.e. after 30-35 PCR cycles. The difficulty of quantifying MRD in 
follow-up samples can be partly overcome by comparison with serial dilutions of 
leukemic-cell DNA or RNA from diagnosis into DNA or RNA of normal mononuclear 
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RT-PCR analysis of BCR-ABL fusion gene transcripts for MRO detection. (A) Schematic diagram of the 
exon/intron structure of the BCR and ABL genes involved in t(9;22)(q34;q11). The centromeric (cen) and 
telomeric (tel) orientation, exon numbering, and relevant breakpoint regions are indicated. The old nomen-
clature for BCR exon 1 and ABL exons 2 and 3 is also shown. (B) Schematic diagrams of the BCR-ABL 
p190 type fusion gene transcripts. The numbers under the fusion gene transcript refer to the first (5') 
nucleotide of the involved exon, except when the last (3') nucleotide of the upstream gene is indicated. 
The arrows indicate the relative position of the primers, the numbers refer to the 5' nucleotide position of 
each primer. The outer primers A and B (BCR-e1-A and ABL-a3-B) are used for first round amplification 
and the internal primers C and D (BCR-e1-C and ABL-a3-D) are used for the nested RT-PCR reaction. 
Primer E is the so-called 'shifted' primer used exclusively to confirm the positive results obtained with 
A<0->B primers. See reference 1 3 for detail of development of primers (C) Agarose gel electrophoresis of 
first round amplification of serially diluted leukemic cells derived from a patient with precursor-B-ALL. In 
the first round, RT -PCR products can be detected down to 1 o-1 to 1 Q-2 dilution mixtures. (D) Agarose gel 
electrophoresis of a nested RT-PCR reaction of the same serially diluted samples. (E) Agarose gel 
electrophoresis of a control RT -PCR amplification using primers for the constitutively expressed ABL 
gene. 
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cells. This dilution series is run in parallel with the follow-up samples to estimate the 
tumor load in each follow-up sample semiquantitatively by comparison of the 
hybridization signals. 12 A more precise, but laborious, quantification method is based 
on limiting dilution of MRD-positive follow-up samples. 15 To make this assay reliable, 
replicate experiments need to be done to find out the amount of MRD. Another less 
tedious strategy for quantification is 'competitive PCR', which uses an internal stan-
dard that is coamplified with the target This technique compares the PCR signal of 
the leukemia-specific target with that of known concentrations of an internal standard 
(the competitor).16 
Recently, a new technology has become available, 'real-time quantitative PCR' 
(RQ-PCR). In contrast to PCR endpoint quantification techniques, RQ-PCR permits 
accurate quantification during the exponential phase of PCR amplification. This 
method has a very large dynamic detection range over five orders of magnitude, 
thereby eliminating the need for serial dilutions of follow-up samples. Also, the quan-
titative data are quickly available since post-PCR processing is not necessary. 
Therefore, RQ-PCR is suitable for the quantitative detection of MRD, by use of junc-
tional regions of immunoglobulin and TCR gene rearrangements, or breakpoint 
fusion regions of chromosome aberrations as PCR targets (Figure 6).17·18 
CLINICAL VALUE OF MRD MONITORING IN HEMOPOIETIC MALIGNANT 
DISEASES 
MRD monitoring in ALL for assessment of early treatment response 
Several studies, mainly in children and based on immunoglobulin/TCR gene 
rearrangements as PCR targets for monitoring MRD, have shown that the most 
important application of MRD monitoring in ALL is to assess initial responses to cyto-
toxic therapy.19-22 Low amounts or absence of MRD in bone marrow after induction 
therapy seem to predict good outcome, and the risk of relapse is proportional to the 
level of MRD.19-22 Multivariate analyses showed that the level of MRD after induc-
tion therapy is the most powerful prognostic factor, independent of other clinically rel-
evant risk factors, such as age, blast count, immunophenotype, presence of chro-
mosome aberrations at diagnosis, and response to prednisone20-22 The results from 
the large prospective MRD study of the International BFM Study Group showed that 
information on the kinetics of the decrease in tumor load after induction treatment 
and before consolidation treatment, is more useful than analyzing MRD at one time 
point (Figure 7)22 It makes distinctions between patients at low risk, with no MRD at 
both time points (5-year relapse rate of 2%); patients at high risk, with intermediate 
(10-3) or high (<:10-2) MRD at both time points (5-year relapse rate of 80%); and 
patients at intermediate risk (5-year relapse rate of 22%). The low-risk group is of 
substantial size (about 45%), similar to the frequency of survivors of childhood ALL 
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(A) Schematic representation ofVKIII-Kde rearrangement as MRD-PCR target in a patient with precursor-
B-ALL treated with the International BFM Study Group treatment protocol. The junctional region sequence 
of this rearrangement had a delef1on of 18 germline nucleotides and a random insertion of nine 
nucleotides. Sequences and positions of the germline VKIII and Kde primers are indicated as well as the 
patient-specific TaqMan probe (with junctional region nucleotides underlined), which was used for RO~ 
PCR analysis (see ref.17 for details). (B) MRD kinetics during the follow-up of the patient measured by 
RO-PCR using the Vxiii~Kde gene rearrangement. Based on high MRD levels during the first two time 
points this patient was classified into MRD-based high-risk group (see Figure 7). Although the patient 
achieved an MRD~negative status during treatment, he relapsed after cessation of maintenance treat-
ment. 0, diagnosis; I, induction treatment; C, consolidation treatment; II, re-induction treatment; CR, com-
plete remission; R, relapse. 
in the 1970s, before treatment intensification was introduced. This group might par-
ticularly profit from treatment reduction. On the other hand, the high-risk group is 
larger than any previously identified high-risk group in childhood ALL (about 15%) 
and has an unusually high 5-year relapse rate of 80%. This group might benefit from 
further intensification of treatment, including bone-marrow transplantation during first 
remission or new treatment approaches. 
Results from MRD studies based on fiow-cytometric immunophenolyping were 
similar. In a large series of studies in pediatric patients with ALL, Coustan-Smith and 
colleaguesz3 showed that patients with high amounts of MRD (<:1 o-2) at the end of 
induction phase (6 weeks) or moderate to high levels of MRD (<:10-3) at week 14 of 
continuation therapy, had particularly poor outcome. Moreover, detectable MRD lev-
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Relapse-free survival of the three MRD-based risk groups of children treated for ALL according to proto-
cols of the International BFM Study Group. The three risk groups were defined by combined MRD infor-
mation at the end of induction treatment (time point 1) and before consolidation treatment (time point 2).22 
Patients in the !ow-risk group have no MRO at both time points (43% of patients), patients in the high-risk 
group have MRD degrees of?=1Q-3 at both time points (15% of patients). and the remaining patients form 
the MRD-based intermediate-risk group (43% of patients). 
els (;:,1 0-4) at each consecutive time point were associated with a higher relapse 
rate. Thus, flow cytometric MRD monitoring also provides independent prognostic 
information in children with ALL. Ciudad and colleagues24 showed that flow cyto-
metric detection of MRD was associated with relapse not just in childhood ALL, but 
also in adult ALL . 
Continuous MRD monitoring in ALL throughout chemotherapy has shown that 
steady decrease of MRD levels is associated with a favorable prognosis, whereas 
persistently high or steadily increasing MRD levels generally lead to clinical 
relapse2°-24 This information is of limited clinical value when compared with assess-
ment of early treatment response, but might be advantageous for high-risk patients 
to evaluate the effectiveness of bone marrow transplantation or alternative treatment 
approaches. For example, no detectable MRD before bone marrow transplantation 
seems to be a prerequisite for a successful outcome in childhood ALL patients.zs 
MRD detection in CML for post-bone marrow transplantation monitoring 
In virtually all (>95%) CML patients, MRD monitoring can be performed by RT-
PCR detection of BCR-ABL fusion transcripts (Table 1 and Figure 5). The most rel-
evant clinical application of MRD in CML is the assessment of treatment response 
after bone marrow transplantation, because virtually all patients on chemotherapy, 
interferon-a therapy, and the novel STI-571 therapy, remain RT-PCR positive.16,26,27 
After bone marrow transplantation, the vast majority of patients are PCR positive dur-
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ing the first 6-9 months, and in vitro experiments have shown that some BCR-ABL-
positive cells keep their clonogenic potential. Negative PCR results within 1 year of 
bone marrow transplantation indicate that disease has been cured, while patients 
with positive PCR results more than 1 year after bone marrow transplantation have 
a significantly greater risk of relapse.16 The group of high-risk patients could be iden-
tified with serial quantitative PCR analyses, which generally show increasing MRD 
levels several months before hematological or cytogenetic relapse. Patients who 
stay in remission generally have decreasing or persistently low MRD levels, but 
some patients test positive for BCR-ABL mRNA up to 10 years after allogeneic bone 
marrow transplantation28 Quantitative MRD studies in CML have enabled the defi-
nition of molecular relapse after allogeneic bone marrow transplantation. It is equiv-
alent to rising or persistently high MRD levels (BCR-ABUABL ratio of> 0.02%) in two 
consecutive specimens more than 4 months after bone marrow transplantation 29 
Quantitative MRD analysis has also been used for monitoring the response to 
immunotherapy, i.e. donor lymphocyte infusions for patients relapsing after allo-
geneic bone marrow transplantation.30 Preliminary data indicate that such 
immunotherapy is more effective when given at the cytogenetic or molecular relapse 
phase, when the burden of disease is low. In responders, this early treatment can 
lead to sustained negative PCR results.30 
MRD detection in APL as example of continuous monitoring for treatment 
titration 
Current acute promyelocytic leukemia (APL) treatment protocols combine all-
trans-retinoic acid (ATRA) with consolidation chemotherapy. Most patients achieve 
clinical remission, but 20-30% relapse. MRD studies in APL are based on RT-PCR 
monitoring of PML-RARA fusion mRNA associated with t(15;17), which is present in 
about 90% of APL patients. The results from several retrospective and prospective 
RT-PCR studies in APL patients, showed variable MRD levels during chemotherapy. 
To get clinically relevant information, continuous prospective MRD monitoring is 
required during the first 6-12 months after consolidation treatment. Reappearance 
of detectable MRD in this time characterizes patients at increased risk of relapse and 
generally precedes hematological relapse at a median time of 2-3 months. This 
information helped to define molecular relapse in APL, which is manifested by con-
version from negative to positive RT-PCR results in two successive bone marrow 
samplings during follow-up.31 Patients treated at the time of molecular relapse have 
much better 2-year event-free survival rates compared with patients treated at the 
time of hematological relapse (92% versus 44%).32 
Relevance of MRD detection in non-APL subtypes of AML 
PCR targets for MRD investigation in AML subtypes other than APL are only 
available in less than 20% of patients (Table 2). Therefore, the only MRD technique 
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available for the vast majority of AML patients is flow cytometric immunophenotyp-
ing (Table 1 ). Multiparameter flow cytometry studies indicate that persistence and/or 
increase of cells with leukemia-associated immunophenotypes precede hematologi-
cal relapse (Figure 3). This suggests that continuous MRD monitoring in AML could 
be beneficial. However, three studies showed a strong prognostic association 
between MRD levels at the end of induction treatment and the risk of AML relapse. 
This is consistent with the estimation of early treatment response.33-35 San Miguel 
and colleagues34 showed that the level of MRD detected both after induction and 
intensification therapy, is associated with the risk of relapse, as well as with multidrug 
resistance at diagnosis. In a more recent study involving 126 patients with AML, 
early flow cytometric MRD analysis after induction therapy was used to identify dif-
ferent risk groups. Such information can contribute to post-induction treatment strat-
ification36 The three-year cumulative frequency of relapse was 84% for high-risk 
patients (MRD > 1 o-2 ), 45% for the intermediate-risk group, and 14% for the low-risk 
group (MRD < 1 o-3 ). High MRD levels were also indicative of a poor prognosis when 
APL and other AMLs were analyzed separately. Adverse cytogenetic subtypes, 
necessity for two or more chemotherapy cycles to induce complete remission, and 
high leukocyte counts at diagnosis, were all associated with high MRD levels. 
Moreover, multivariate analysis showed that the MRD level was the most powerful 
independent prognostic factor, followed by cytogenetics, and the number of cycles 
required to achieve complete remission.36 
The clinical value of the RT-PCR-based MRD studies in AML patients with either 
t(8;21) or inv(16) is not certain. These chromosome aberrations are present in a 
small subset of AML patients (1 0-20%) with a fairly good prognosis. Also, several 
RT-PCR studies suggest that AML 1-ETO or CBFB-MYH11 fusion transcripts are 
detectable in the bone marrow and peripheral blood of patients in long-term remis-
sion, while other research shows that the transcripts disappear in individuals in com-
plete remission.37-40 Preliminary results from several semi-quantitative RT-PCR 
and/or RQ-PCR studies indicate that a gradual reduction of fusion mRNA levels or a 
change from positive to negative PCR results during the course of disease, is asso-
ciated with durable clinical remission. In contrast, persistently high MRD levels dur-
ing treatment are associated with hematological relapse41 
MRD detection in chronic B-lineage malignant diseases 
MRD monitoring is possible in virtually all mature lymphoid malignant diseases 
through PCR analysis of immunoglobulin/TCR gene rearrangements and, to lesser 
extent, by immunophenotyping {Table 1 ). The detection of MRD might be particular-
ly valuable in more aggressive disorders, which can be cured with intensive treat-
ment approaches including bone marrow transplantation 4 2.43 
MRD data in 8-CLL are preliminary, mostly retrospective, and lack obvious clin-
ical value. It is clear that MRD kinetics in 8-CLL differs depending on the treatment 
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protocol4 2 Nevertheless, patients with high-risk B-CLL might profit from more pre-
cise treatment monitoring. 
MRD detection might be particularly important in high and intermediate-grade 
lymphomas, where circulating lymphoma cells are frequently found in bone marrow 
and peripheral blood. The vast majority of clinical studies have concentrated on fol-
licular lymphomas with t(14;18) using the 8CL2-/GHfusion gene as a DNA target for 
MRD-PCR analysis. Some studies showed that no detectable MRD during cytotoxic 
treatment is associated with longer relapse-free survival.44 In contrast, others 
showed that there are circulating 1(14;18)-positive cells in patients in long-term clini-
cal remission after therapy for localized follicular lymphoma or even in healthy indi-
viduals45,46 These data imply that positive results in sensitive BCL2-IGH PCR stud-
ies should be interpreted with caution. Further investigations and standardization 
between laboratories are needed to establish quantitative criteria for molecular 
remission in follicular lymphoma, so that MRD information may be used in clinical 
decision making. 
Patients with mantle-cell lymphoma continuously tested positive for MRD in bone 
marrow and/or peripheral blood during chemotherapy when IGH gene rearrange-
ments and BCL 1-/GH fusion genes are used as DNA targets. In the majority of 
patients, MRD levels varied between 1 o-2 and 10-3, indicating significant resistance 
to conventional chemotherapy regimens47 
CONCLUSIONS 
Reliable quantitative PCR and immunophenotyping techniques are available for 
MRD detection in patients with hemopoietic malignant diseases. Each MRD tech-
nique has its advantages and disadvantages, which have to be weighed up careful-
ly before making an appropriate choice for each disease category. False-positive and 
false-negative results should be prevented and the MRD detection techniques 
should be sufficiently sensitive. These requirements can generally be met with PCR 
analysis of chromosome aberrations, if adequate precautionary measures are taken 
to prevent cross-contamination of PCR products. PCR analysis of junctional regions 
of immunoglobulin/TCR gene rearrangements can be used in all categories of lym-
phoid malignant disease, and are highly sensitive. However, the ongoing and sec-
ondary rearrangements in ALL as well as continuing somatic hypermutation in a sub-
set of mature B-lineage malignant diseases, poses a risk for false-negative results. 
Flow cytometric immunophenotyping is less sensitive than PCR-based MRD tech-
niques. However, this sensitivity can still be satisfactory for obtaining clinically rele-
vant information in some disease categories. Particularly in AML, immunophenotyp-
ing is the only MRD detection technique available for the majority of patients. 
Even when highly sensitive MRD detection techniques give negative results, 
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there may still be malignant cells present Each MRD test only screens 1 a5 to 1 as 
cells, which is a tiny fraction of the total number of hemopoietic cells in a human 
body. In addition, the distribution of low numbers of malignant lymphoid cells 
throughout the body may not be homogeneous, so the cell sample may not be rep-
resentative. 
Finally, the clinical impact of MRD detection in different hemopoietic diseases is 
not the same. In ALL, the main application of MRD information is the evaluation of 
early treatment response, with precise measurement of tumor-load reduction during 
remission induction therapy. In contrast, in CML and APL, MRD levels have to be 
monitored over a period of time before the information is clinically useful- it can then 
be used for attuning treatment By analyzing MRD in CML and APL, patients at high 
risk of relapse can be identified at an early stage, when the tumor load is low 
(molecular relapse) and when restarting treatment is more effective. This might also 
apply in other subtypes of AML and mature lymphOid malignant diseases. However, 
further studies are required to fully define the disease-specific 'MRD windows' (time-
span and minimal sensitivity) for obtaining clinically relevant MRD information in 
AML, chronic lymphocytic leukemias, and malignant lymphomas. Furthermore, MRD 
detection techniques can be applied for several other specific aims, like detection of 
minimal central nervous system involvement in ALL, early diagnosis of leukemia and 
lymphoma in patients with unexplained cytopenias, improved staging of lymphomas, 
and the detection of malignant cells in autologous stem-cell grafts. 
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CHAPTER 2.1 
JUNCTIONAl REGIONS OF REARRANGED IMMUNOGLOBULIN 
AND T-CEll RECEPTOR GENES AS lEUKEMIA-SPECIFIC 
'FINGERPRINTS' 
The variable domains of the immunoglobulin (lg) and T-cell receptor (TCR) mol-
ecules are involved in antigen recognition and constitute the enormous antigen-spe-
cific receptor diversity of the immune system. Each variable domain is encoded by 
two or more gene segments, which are joined to each other via gene rearrangement 
processes during early lymphoid differentiation. 1 ·2 The combinations of variable (V), 
diversity (D), and joining (J) gene segments and the combination of two protein 
chains with different variable domains per antigen-receptor molecule determines the 
so-called combinatorial diversity. The repertoire of lg and TCR molecules is further 
extended by the so-called junctional diversity, which is based on deletion of germline 
nucleotides by trimming the ends of the rearranging gene segments and by random 
insertion of nucleotides between the joined gene segments.1·2 
Consequently, the junctional regions of rearranged lg and TCR genes are unique 
"fingerprint-like" sequences, which are assumed to be different in each lymphoid cell 
and thus also in each lymphoid malignancy3 .4 Therefore, junctional regions can be 
used as tumor-specific targets for PCR-based detection of minimal residual disease 
(MRD).S-7 For this application, the various clonal lg and/or TCR gene rearrange-
ments have to be identified in each lymphoid malignancy at diagnosis by use of 
selected PCR primer sets and distinguished from polyclonal rearrangements derived 
from normal lymphocytes. For that purpose, we applied a modified heteroduplex 
PCR technique, which generated results largely comparable to Southern blotting, 
which is considered as gold standard for lg/TCR clonality assessment (see Chapters 
2.2, 2.4 and 2.8). 
This chapter presents PCR-based strategies for detection and identification of 
lineage-specific and cross-lineage lg/TCR gene rearrangements as molecular tar-
gets for MRD monitoring in acute lymphoblastic leukemia (ALL). Firstly, we devel-
oped a PCR approach for the detection of clonal incomplete DH-JH gene rearrange-
ments (see Chapters 2.3 and 2.7), since previous PCR studies in precursor-B-ALL 
employing VH-JH primer sets showed generally lower frequencies of IGH gene 
rearrangements as compared to Southern blot analyses8-10 Because IGH gene 
rearrangements in precursor-B-ALL are frequently oligoclonal and thus potentially 
unstable during the disease course, 11 we evaluated the occurence of cross-lineage 
TCR gene rearrangement patterns (see Chapter 2.4 ). We also developed a multiplex 
PCR approach for identification and characterization of cross-lineage V82-Ja gene 
rearrangements in precursor-B-ALL patients (see Chapter 2.5). 
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In T-ALL, we focused on the comprehensive characterization of TCR gamma 
gene rearrangements as principal MRD targets (see Chapter 2.6) in addition to pre-
viously characterized TCR delta gene rearrangements.12 lmmunobiology and MRD 
applicability of cross-lineage !GH gene rearrangements in T-ALL were the subjects 
of another study (see Chapter 2.7). 
We also thoroughly characterized lg and TCR gene rearrangements in adult ALL 
patients and compared them to rearrangement patterns in childhood ALL patients 
(see Chapter 2.8). Particularly in precursor-B-ALL, we and others showed that the 
gene rearrangement patterns seem to be age-related.13 Finally, information on lg 
and TCR gene rearrangement patterns in ALL provides insight in immunobiological 
aspects of normal lymphopoiesis as well as in oncogenetic processes in early lym-
phoid precursors (reviewed in Chapter 2.9). 
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ABSTRACT 
Molecular analysis ofT-cell receptor (TCR) genes is frequently used to prove or 
exclude clonality and thereby support the diagnosis of suspect T-cell proliferations. 
PCR techniques are more and more being used for molecular clonality studies. The 
main disadvantage of the PCR-based detection of clonal TCR gene rearrangements, 
is the risk of false-positive results due to 'background' amplification of similar 
rearrangements in polyclonal reactive T lymphocytes. Therefore, PCR-based clonal-
ity assessment should include analyses that discern between PCR products derived 
from monoclonal and polyclonal cell populations. One such method is heteroduplex 
analysis, in which homo- and heteroduplexes resulting from denaturation (at 94°C) 
and renaturation (at lower temperatures) of PCR products, are separated in non-
denaturing polyacrylamide gels based on their conformation. After 
denaturation/renaturation, PCR products of clonally rearranged TCR genes give rise 
to homoduplexes, whereas in case of polyclonal cells heteroduplexes with hetero-
geneous junctions are formed. 
We studied heteroduplex PCR analysis of TCR gene rearrangements with 
respect to the time and temperature of renaturation and the size of the PCR prod-
ucts. Variation in time did not have much influence, but higher renaturation temper-
atures (>30°C) clearly showed better duplex formation. Nevertheless, distinction 
between monoclonal and polyclonal samples was found to be more reliable at a 
renaturation temperature of 4°C, using relatively short PCR products. To determine 
the sensitivity of heteroduplex analysis with renaturation at 4°C, (c)DNA ofT-cell 
malignancies with proven clonal rearrangements was serially diluted in (c)DNA of 
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polyclonal mononuclear peripheral blood cells and amplified using V and C primers 
(TCRB genes) or V and J primers (TCRG and TCRD genes). Clonal TCRB and 
TCRD gene rearrangements could be detected with a sensitivity of at least 5%, 
whereas the sensitivity for TCRG genes was somewhat lower (10-15%). The latter 
could be improved by use of Vy member primers instead of Vy family primers. 
We conclude from our results that heteroduplex PCR analysis of TCR gene 
rearrangements is a simple, rapid and cheap alternative to Southern blot analysis for 
detection of clonally rearranged TCR genes. 
INTRODUCTION 
Acute lymphoblastic leukemias can easily be diagnosed by routine cytomorpho-
logic examination and/or by immunophenotyping. The latter is based on homoge-
nous expression of particular atypical leukemia-specific marker combinations, includ-
ing the expression of terminal deoxynucleotidyl transferase (TdT).1-3 
lmmunophenotypic diagnosis of the more mature leukemias and lymphomas is gen-
erally more complex. In case of mature B-cell proliferations, single immunoglobulin 
(lg) light chain (i.e. lgK or lgJ,) expression as determined by immunophenotyping, is 
indicative of the presence of a clonal B-cell population.4,5 However, clonality of sus-
pect mature (TdT-negative) T-cell proliferations is difficult to establish by 
immunophenotyping, because of the absence of tumor-specific markers. As lym-
phoid leukemias and lymphomas can be considered as malignant counterparts of 
normal T-cells in their various differentiation stages, 6,? most T-cell malignancies con-
tain rearranged T-eall receptor (TCR) genes. Similar to other neoplasms, T-cell 
malignancies are derived from a single malignantly transformed cell, implying that 
the TCR gene rearrangements within all the malignant cells are identical. Molecular 
analysis of TCR genes is therefore generally performed to prove or exclude clonali-
ty.8·12 So far, this mainly concerned Southern blot analysis, which is a reliable 
method, if proper probe/restriction enzyme combinations are used.1D· 11 Because 
Southern blot analysis of TCR genes is time-consuming and labor-intensive, PCR 
techniques are frequently being used as alternatives. 
Although PCR techniques can be sensitive and fast, there are two major draw-
backs in diagnostic clonality studies of TCR genes. Firstly, the possibility of identify-
ing clonal rearrangements by PCR is limited by the choice of primers. Incomplete V-
D or D-J rearrangements (in case of TCRB and TCRD genes) will remain undetect-
ed if only V and J primers are used. Furthermore, rearrangements involving particu-
lar V gene segments (for the TCRB genes) might remain undetected when only con-
sensus primers are used. The second more important drawback is the risk offalse-
positive results due to 'background' amplification of similar rearrangements in poly-
clonal, reactive T lymphocytes. The latter implies that PCR analysis is not sufficient 
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for clonality assessment, unless it is followed by analyses that discern between PCR 
products derived from polyclonal and monoclonal T-cell populations. Methods that 
have been applied to solve this PCR 'background problem' include: direct sequenc-
ing of the PCR products, 13.14 single-strand conformation polymorphism (SSCP)-
based analysis,15.16 denaturing gradient gel electrophoresis (DGGE),17-20 heterodu-
plex analysis,21-23 temperature gradient gel electrophoresis (TGGE),24 and gene 
scanning analysis.25-28 From these techniques, heteroduplex analysis is probably 
the simplest, fastest, and cheapest method for analysis of PCR products of 
rearranged TCR genes. 
In heteroduplex analysis, PCR products are denatured at high temperature and 
subsequently renatured to induce homo- or heteroduplex formation. Originally the 
heteroduplex technique was designed for mutation detection in genetic diseases. 
However, it has been shown in several reports that it can also be applied for analy-
sis of PCR products from TCR gene rearrangements21-23 Usage of heteroduplex 
analysis enables discrimination between PCR products derived from monoclonal 
and polyclonal lymphoid cell populations, based on the presence of homoduplexes 
(PCR products with identical junctional regions) or a smear of heteroduplexes 
(derived from PCR products with heterogeneous junctional regions), respectively 
(Figure 1 ). In this report heteroduplex analysis of rearranged TCR genes is studied 
with respect to time and temperature of renaturation and the size of the PCR prod-
ucts in order to further optimize the applicability of this technique and to determine 
its sensitivity for clonality assessment in suspect T-cell proliferations. 
MATERIALS AND METHODS 
Ceil samples 
Cell samples were obtained from several TCRy8+ T-ce!l acute lymphoblastic leukemias (T-ALL) and 
TCRaj)+ T-ee!! large granular lymphocyte (T-LGL) proliferations, containing >90% of malignant cells at ini-
tial diagnosis. Clonality of the T-cells was proven with Southern blot analysis of TCR genes.10 
Mononuclear cells (MNC) were isolated from peripheral blood (PB) or bone marrow (BM) by Ficoli-Paque 
(density: 1.077 g/ml; Pharmacia. Uppsala, Sweden) density centrifugation. The eel! samples were frozen 
and stored in liquid nitrogen. 
DNA isolation, RNA isolation, and reverse transcriptase (RT) reaction 
DNA was isolated from frozen MNC as described previously.10 Total RNA was isolated essentially 
according to the method of Chomczynski.29 eDNA was prepared from mRNA as described before,30using 
oligo(dT) and AMV reverse transcriptase. 
(RT -)PCR amplification 
PCR was essentia!!y performed as described previously.31 In each 100 J.ll PCR reaction 0.1-1 J..lg DNA 
sample, 12.5 pmol of 5· and 3· oligonucleotide primers. and 1 U Taq polymerase (Perkin-Elmer Cetus, 
Norwalk, CT. USA) were used. The oligonucleotides used for amplification of TCRG and TCRD gene 
rearrangements were published before.12 For TCRB RT -PCR amplification eDNA (5 J.ll out of 20 )..ll RT 
reaction volume) was amplified in 100 )..ll reaction mixtures, containing 12.5 pmol of 5' and 3' primers and 
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Figure 1. 
Schematic diagram of the heterodup!ex analysis technique. In order to discern between PCR products 
derived from monoclonal and polyclonallymphoid cell populations, the junctional region heterogeneity of 
PCR products of rearranged !g or TCR genes can be studied by heteroduplex analysis. In heteroduplex 
analysis PCR products are heat·denatured and subsequently rapidly cooled to induce duplex (homo- or 
heteroduplex) formation. In cell samples which consist of clonal lymphoid ce!!s, the PCR products of 
rearranged lg or TCR genes give rise to homoduplexes after denaturation and renaturation, whereas in 
samples which contain polyclonal lymphoid cell populations the single-strand PCR fragments will mainly 
form heteroduplexes upon renaturation (left part). In case of admixture of monoclonal cells in a polyclon-
al background, both hetero- and homoduplexes are formed. Because of differences in conformation, 
homo- and heteroduplexes can be separated from each other by electrophoresis in non-denaturing poly-
acrylamide gels. Homoduplexes with perfectly matching junctional regions migrate more rapidly through 
the gel than heteroduplex molecules with less perfectly matching junctional regions. The latter form a 
background smear of slower migrating fragments (right part). 
1 U Taq polymerase. An RT -PCR procedure with a single Cj3 primer in combination with 30 Vj3 family-spe-
cific framework 3 (FR3) primers was set up, in order to avoid differences in primer annealing to the mem-
bers of the 25 well-defined Vj3 families when using a consensus Vj3 primer.32 The Vj3 family-specific 
primers as we!l as the Cl3 primer used for this TCRB RT-PCR were adapted from Gorski et aJ.33 All 
oligonucleotides were synthesized on an ABI 392 DNA synthesizer (Applied Biosystems. Foster City, CA, 
USA) using the solid-phase phosphotriester method. PCR conditions were 1 min at 94°C, 1 min at sso to 
65°C, and 2 min at 72°C for 30 to 40 cycles using a Perkin-Elmer thermal cycler (Perkin-Elmer Cetus). 
After the last cycle an additional step of 7 min at 72°C was performed for final extension. RT-PCR condi-
tions were 1 min at 94°C, 1 min at 65°C, and 2 min at 72°C for 35 cycles, also followed by a final exten-
sion step (7 min, 72°C). 
Heteroduplex analysis 
For heteroduplex analysis, the PCR or RT-PCR products were denatured at 94°C for 5 min, after the 
final cycle of amplification. and subsequently cooled (to a !ower temperature) to induce duplex formation. 
This renaturation step was performed at different temperatures (range 4-40°C) for different time periods 
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(range 15-60 min). After duplex formation the hetero- and/or homoduplexes were immediately loaded on 
6% non-denaturing polyacrylamide gels in 0.5 x Tris-Boric acid-EDTA (TBE) buffer, run at room tempera-
ture. and visualized by ethidium bromide staining. Pstl-digested lambda DNA was used as a size marker. 
RESULTS 
Influence of renaturation time and temperature on duplex formation 
To find the optimal conditions for renaturation in heteroduplex analysis, the infiu-
ence of both time and temperature of renaturation was studied for PCR products of 
rearranged TCR genes. For this purpose we used DNA from a TCRy8+ T-ALL patient 
with biallelic Vy8-Jy2.3 rearrangements. As both TCRG gene rearrangements in this 
patient involve the same gene segments, PCR amplification with Vyl and Jy1.3/2.3 
primers 12 resulted in almost identical PCR products of around 450 bp. The two prod-
ucts only differed in their junctional regions. The heterogeneity was characterized by 
a 13 bp-size difference and a difference in nucleotide composition. Upon denatura-
tion and renaturation of these PCR products, four double-strand fragments were 
formed. These included two homoduplexes, representing the two PCR amplified 
rearranged alleles, and two distinct heteroduplex molecules resulting from renatura-
tion of single-strand fragments of the PCR products from the two different alleles 
(Figure 2). 
Following PCR amplification with Vyl and Jy1.3/2.3 specific primers, heterodu-
plex analysis was performed at variable renaturation temperatures to compare the 
degree of duplex formation on polyacrylamide gels. When renaturation was per-
formed for one hour at relatively high temperatures (30°C or 40°C) the two homodu-
plexes and the two slower migrating heteroduplexes were clearly detectable (Figure 
2). After renaturation at room temperature (22°C), duplex formation was not com-
plete, as slow-migrating single-strand products were also visible. At renaturation 
temperatures of 1 ooc or 4°C, single-strand fragments were even more clearly pres-
ent in parallel with a lower intensity of the duplex band (Figure 2). This is probably 
due to the slower renaturation process at these lower temperatures. Analysis of bial-
lelic Vy8-Jy2.3 rearrangements (11 nucleotides size difference) from a second 
TCRy8+ T-ALL patient revealed a similar pattern of duplex bands and single-strand 
products. Analysis of biallelic V81-J81 PCR products (around 450 bp, with a size dif-
ference of 33 nucleotides) in the latter patient sample also showed a comparable 
effect of temperature on duplex formation. Interestingly, in all cases the single-strand 
fragments showed different migration patterns at the different renaturation tempera-
tures, suggesting that the conformation of single-strand DNA products is also tem-
perature-dependent. 
To test the effect of renaturation time on duplex formation, several different 
TCRG and TCRD gene rearrangements were amplified and subsequently denatured 
and renatured for different time periods (15-60 min.). However, in contrast to the dif-
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Figure 2. 
Analysis of the influence of the renaturation temper-
ature on duplex formation of (biallelic) TCRG PCR 
products from T-ALL DNA. After amplification of the 
clonal TCRG rearrangements with Vyl and Jy1 .3/2.3 
primers, PCR products were denatured for 5 min at 
94°C and renatured for 1 h at the indicated renatu-
ration temperatures. Electrophoresis was performed 
in 6% non~denaturing polyacrylamide gels, using 
Pstl-digested lambda DNA as size marker. As a 
result two homo- and two heteroduplexes can be 
identified. At higher temperatures (>30°C) the renat-
uration process is (almost) complete, whereas upon 
renaturation at lower temperatures single-strand 
fragments can still be identified as more retarded 
fragments. ss, single-strand fragments: he, het-
eroduplexes (of clonal origin); ho, homoduplexes. 
ferences observed upon variation in renaturation temperature, differences in time of 
renaturation (at a given temperature) did not have much effect on duplex formation 
(data not shown). Irrespective of the type of PCR product and the renaturation tem-
peratures, maximum levels of homo- and heteroduplexes were generally observed 
after 30 to 45 min of renaturation. Duplex formation was only slightly lower after 15 
min of reannealing. This illustrates that the degree of duplex formation is largely 
dependent on renaturation temperature rather than duration of the renaturation 
process. To guarantee optimal renaturation, we used renaturation times of one hour 
in all further experiments. 
Influence of renaturation temperature and size of the PCR product on 
clonality assessment 
Although the above-mentioned results clearly indicate that duplex formation is 
more optimal at higher renaturation temperatures, we wanted to know whether the 
discussed denaturation/renaturation strategy can effectively be applied to discern 
between monoclonal and polyclonal cell populations. For this we took 100%, 20%, 
and 0% dilutions ofT-ALL DNA in polyclonal MNC DNA, PCR amplified the D82-J81 
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rearrangement, and subsequently performed heteroduplex analysis with renaturation 
at either 40°C or 4°C for one hour. After renaturation the samples were kept on ice 
until loading of the gel, using ice-cold loading buffer. The polyacrylamide gels were 
run at room temperature. 
The 082-J81 rearrangement was amplified using a J81 primer in combination 
with either one of two distinct 082 primers. The proximal primer, 082, is located rel-
atively close to the 082 gene segment, resulting in a PCR product of around 240 
nucleotides, whereas the distal primer (082up) lies far more upstream of the 082 
gene segment (and even upstream of the 081 gene segment), giving rise to a much 
larger PCR product of around 800 bp. These two different 082 primers were 
employed to see whether the size of the PCR product might be an important deter-
minant for reliable clonality assessment as well. Amplification with the 082up and 
J81 primers, followed by denaturation and renaturation at 40°C, resulted in clear 
homoduplex bands of the expected size in the 100% and 20% leukemic samples, but 
a band of comparable size was also observed in the healthy control MNC sample 
(Figure 3A). When renaturation was performed at 4°C, the intensity of the homodu-
plex bands in the 100% and 20% samples was slightly lower (Figure 3A), as was 
expected from the above described temperature experiments. Most importantly how-
ever, no homoduplexes were found in the control sample at this low renaturation 
temperature. The problem of detecting a 'false-positive' homoduplex band in the 
non-leukemic control sample could also largely be resolved when the more proximal 
082 primer was used for 082-J81 amplification (Figure 3B). Nevertheless, using this 
smaller PCR product, a faint homoduplex band could still be detected within a back-
ground smear in the polyclonal control sample. The 'false-positive' homoduplex band 
again entirely disappeared when renaturation was performed at 4°C (Figure 3B). 
Similar results were obtained with V~-C~ RT-PCR products of even smaller size 
(around 200 bp), where renaturation at 40°C resulted in faint homoduplex bands that 
disappeared when reannealing was performed at 4°C (data not shown). These 
experiments showed that larger PCR products gave rise to stronger false-positive 
homoduplex-like bands at 40°C renaturation, whereas renaturation at 4°C never 
gave false-positive results. 
Sensitivity of heteroduplex analysis for clonality detection 
The above data suggested that a reliable distinction between monoclonal and 
polyclonal samples by heteroduplex PCR analysis requires renaturation at a low 
temperature (4°C). However, the initial experiments clearly indicated that duplex for-
mation is less optimal at lower temperatures, suggesting that the sensitivity of the 
heteroduplex technique would be lowered by performing renaturation at 4'C. We 
therefore performed dilution experiments for several targets to study the sensitivity 
of detection of clonal homoduplexes upon renaturation at 4°C. 
Firstly, sensitivity of clonality detection was determined for several frequently 
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Clonality assessment via heteroduplex analysis of TCRjunctional regions. T-ALL DNA was ser·lally dilut-
ed (100%, 20%, and 0%) in polyclonal MNC DNA. The clonal TCRD rearranged gene was subsequently 
PCR amplified using either Di52up and Ji51 primers (A) or 082 and J01 primers (B). The resulting PCR 
products were subjected to heteroduplex analysis; denaturation (5 min. 94°C) was followed by renatura-
tion for 1 h at 40°C or 4°C. Samples were run in 6% non-denaturing polyacrylamide gels. Pstl-digested 
lambda DNA was used as size marker. In case of the large PCR products (A) a homoduplex-!ike band 
was visible in the polyclonal control sample after renaturation at 40°C, but not at 4°C. Although Jess clear-
ly, this band was also visible upon renaturation of smaller PCR products (B) at 40°, but again disappeared 
upon renaturation at 4°C. The single-strand fragments as visible in panel (B) (4°C) are not visible in panel 
(A) due to the slow mobility of the larger single-strand fragments. ss, single-strand fragments; he, (smear 
of) heterodup!exes: ho, homoduplexes. 
occurring TCRG and TCRD gene rearrangements. Heteroduplex analysis ofV61-J61 
and 062-J61 amplified products, using serial dilutions of several TCRy6+ T-ALL, 
yielded clear homoduplex bands in samples containing only 5% tumor cells (Figure 
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4A and 48). Occasionally faint homoduplex bands were even observed in 1% dilu-
tions. Homoduplexes were never found when using polyclonal DNA. Vyii(Vy9)-
Jy1.3/2.3 homoduplexes could also be detected with a sensitivity of around 5% 
(Figure 58). However, clonality detection of Vyi-Jy1.3/2.3 rearrangements by het-
eroduplex analysis turned out to be more difficult, resulting in a sensitivity of around 
10% (Figure 5A). This limited sensitivity can probably be explained by the fact that 
all rearrangements involving members of the Vyl family are amplified when using a 
Vyl family-specific oligonucleotide primer. We therefore determined the detection 
limit using Vyl member-specific primers to amplify TCRG rearrangements. This 
resulted in improved detection of homoduplexes with a sensitivity of at least 5%, 
which is at least two-fold better than in the case of the consensus Vyl family primer 
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Figure 4. 
Sensitivity of heteroduplex analysis for clonality detection of TCRD rearranged gene products. T-ALL DNA 
was serially diluted in polyclonal MNC DNA. The clonal V81-J81 and D82-J81 rearrangements in this DNA 
sample were amplified with specific primer sets. i.e. either V81 (A) or D82 (B) primers in combination with 
a J81 primer. The resulting PCR products were subjected to heterodup!ex analysis (5 min, 94°C; 1 h 4°C) 
prior to electrophoresis in 6% non-denaturing polyacrylamide gels. In both panels clonal homoduplexes 
could be detected with a sensitivity of 1-5%. ss, single-strand fragments; he. (smear of) heteroduplexes; 
ho, homoduplexes. 
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(Figure 5A). 
PCR analysis of TCRG and TCRD genes can easily be performed at the DNA 
level because of the relatively limited number ofV, (D), and J gene segments. As the 
high number of VJ3 and Jj3 gene segments would require many different primer com-
binations, analysis of TCRB genes is often performed via RT-PCR with VJ3 family-
specific primers and a single CJ3 primer. Using this RT-PCR procedure, TCRB analy-
sis was performed on several T-LGL proliferations as well as TCRaj3+ T-ALL. 
Subsequently, eDNA from clonal VJ32, VJ37, and VJ323 positive lymphoproliferations 
was serially diluted in polyclonal MNC eDNA and the PCR products were subjected 
to heteroduplex analysis with renaturation at 4°C. Homoduplexes were clearly visi-
ble in the 5% dilutions, whereas in the 1% dilutions a faint homoduplex could still be 
detected (Figure 6). In the polyclonal eDNA lane only a smear of heteroduplexes was 
seen. 
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Sensitivity of heteroduplex analysis for clonality detection of TCRG rearranged gene products. T-ALL DNA 
was serially diluted in polyclonal MNC DNA. The clonal VyS-Jy/2.3 and Vy9-Jy2.3 rearrangements in this 
DNA sample were amplified with a family-specific V primer (Vyl) or a member-specific V primer (Vy8) in 
combination with a Jy1.3/2.3 primer (A) and a Vyll primer in combination with a Jy1.3/2.3 primer (B). The 
resulting PCR products were subjected to heteroduplex analysis (5 min, 94°C; 1 h 4°C) before elec-
trophoresis in 6% non-denaturing polyacrylamide gels. Clonal Vyii-Jy2.3 homoduplexes could be detect-
ed with a sensitivity of 1-5%. Sensitivity of detection of clonal Vyl-Jy1.3/2.3 duplexes was similar. provid-
ed that member-specific Vy primers were used. ss, single-strand fragments; he, (smear of) heteroduplex-
es; ho. homodup!exes. 
Figure 6. 
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Sensitivity of heteroduplex analysis for clonality detection of TCRB rearranged gene products. T-LGL 
eDNA was serially diluted in polyclonal MNC eDNA. After reverse transcription, the clonal Vf3-Jf3 
rearrangement in this sample was amplified with specific primers. i.e. a family-specific V primer (Vf323) in 
combination with a Cf3 primer. The resulting PCR products were subjected to heteroduplex analysis (5 
min, 94°C; 1 h 4°C) before electrophoresis in 6% non-denaturing polyacrylamide gels. Clonal homodu-
plexes could be detected with a sensitivity of 1-5%. ss, single-strand fragments; he, (smear of) heterodu-
p!exes; ho, homoduplexes. 
DISCUSSION 
Southern blot analysis has long been the only reliable method for clonality 
assessment in suspect lymphoproliferations, but over the last years several PCR-
based methods have been devised as an alternative. One of the main difficulties of 
PCR-based clonality detection is discrimination between monoclonal and polyclonal 
PCR products. This problem can be solved by further analyzing the PCR products in 
various ways, ranging from high resolution polyacrylamide gel electrophoresis (fin-
gerprinting) and gene scanning25-28 to DGGE17-20 and heteroduplex analysis.21-23 
In heteroduplex analysis hetero- and homoduplexes, resulting from denaturation 
and renaturation of PCR products, are separated in non-denaturing polyacrylamide 
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Calculated frequencies of clonal homoduplexes within the total pool of hetero· and homoduplexes, assum-
ing that duplex formation is a fu!!y random process as it seems to be at 4"C. The seven curves illustrate 
that the frequency of normal polyclonal T-ce!ls within the non-tumor cell fraction (0%, 1 %, 5%, 10%, 25%, 
50%, and 100%) drastically influences donal homoduplex formation, since the frequency of clonal homod-
uplexes progressively decreases with the increase in the polyc!onal T-cell frequency. The percentage of 
clonal homoduplexes being formed by renaturation of single strand fragments. was calculated according 
to the formula H = M/{M+(100·M).P/100) x M/(M+{100·M).P/100) x 100%. in which His the percentage of 
homoduplexes, M is the percentage of monoclonal T-cells. and Pis the percentage of polyclonal T-cells 
in the non-tumor fraction. 
gels based on their conformation. The presence of clear homoduplex bands or a 
smear of heteroduplexes enables discrimination between monoclonality and poly-
clonality, respectively (Figure 1 ). Therefore, heteroduplex analysis seems to be a 
simple, rapid and cheap technique of PCR product analysis, which can be introduced 
easily in most diagnostic laboratories, as no radioactive substrates are involved and 
no expensive equipment other than ordinary laboratory tools is required. 
The number of clonal homoduplexes that is formed upon renaturation of dena-
tured PCR products is related to the percentage of clonal T -cells in the analyzed 
sample (Figure 7). However, based on the assumption that random pairing occurs 
between single-strand fragments of clonal and polyclonal T lymphocytes, the pres-
ence of polyclonal T-cells in the same cell sample will lead to the formation of het-
eroduplexes. The more polyclonal T-cells are present in the sample, the less homod-
uplexes (derived from monoclonal T-cells) are formed (Figure 7). Therefore, the sen-
sitivity of heteroduplex PCR analysis for identification of clonal T-cell populations 
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between polyclonal T-cells is dependent on the delectability of (renatured) homodu-
plexes amongst heteroduplexes. To optimize the heteroduplex technique for clonali-
ty assessment in suspect T-cell proliferations further, we studied several assay 
parameters, like the time and temperature of renaturation and the size of the ana-
lyzed PCR products. 
The temperature at which the denatured fragments renature rather than the time 
used for renaturation appeared to be an important determinant in duplex formation. 
Duplex formation is more optimal at higher renaturation temperatures (40°C) but 
clonality analysis appears to be more reliable at lower temperatures (4°C), especial-
ly in case of small suspect cell populations. This is caused by the presence of a faint, 
somewhat fuzzy homoduplex band in polyclonal control samples at 40°C, which is 
absent when renaturation is performed at 4°C. We assume that the higher movement 
of molecules at higher temperatures (e.g. 40°C) supports the non-random formation 
of 'non-clonal' homoduplexes due to preferential pairing of 'matching' polyclonal sin-
gle-strand molecules. As a result many non-clonal homoduplexes with Gaussian size 
distribution are present at this high temperature, causing the fuzzy homoduplex band 
in polyclonal control samples (Figs. 3A and 38). This problem of 'false-positive' 
homoduplex bands is more prominent in case of larger PCR products (>600 bp) than 
in case of smaller (<250 bp) PCR products, in which the contribution of the junction-
al region is relatively high. It is our assumption that for large PCR products, in which 
the contribution of the junctional region nucleotides to the entire size of the PCR 
product is relatively small, the resolution of the PAGE system was not sufficient to 
discern between homoduplexes of identical size derived from clonal cells and differ-
ently-sized non-clonal homoduplexes derived from polyclonal cells. Furthermore, 
large heteroduplex molecules with a few non-matching nucleotides will differ only 
slightly from homoduplexes in their mobility rate, since differences in electrophoretic 
mobility between heteroduplexes and homoduplexes progressively decrease when 
the PCR products become larger. 
Heteroduplex analysis of TCR genes is thus a reliable technique for clonality 
assessment in suspect T-cell proliferations, provided that the appropriate conditions 
are used, i.e. PCR products of preferably 150-250 bp and renaturation at 4°C. 
Analysis of serial dilutions of tumor DNA in polyclonal control DNA, revealed sensi-
tivities of 1-5% for PCR products of TCRD gene rearrangements and also for RT-
PCR products of TCRB transcripts. In case of Vyli(Vy9)-Jy1.3/2.3 rearrangements a 
sensitivity of 5% was achieved as well, but Vyl-Jy1.3/2.3 rearrangements showed 
sensitivities of only around 10%. This reduced sensitivity is probably caused by the 
high background of these rearrangements, as they frequently occur in normal 
TCRaj3+ T-cells (Figure 7). Use of Vy member-specific primers instead of a Vyl fam-
ily-specific primer can help to improve the sensitivity to at least 5% (Figure 5A). The 
less optimal duplex formation at 4°C could partly be compensated by prolonged 
renaturation (24 or even 48 hours), without formation of false homoduplex bands in 
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polyclonal control samples (data not shown). Increasing the renaturation time exten-
sively may thus help to improve the sensitivity of heteroduplex analysis, which seems 
especially important for TCRG gene rearrangements. A detection limit of 1-5% for 
most TCR gene rearrangements is similar to or even better than Southern blot analy-
sis. Moreover, the sensitivities that we reach under conditions that guarantee reliable 
clonality assessment, are largely comparable to those mentioned by other authors 
who used serial dilutions in polyclonal MNC DNA and performed high resolution non-
denaturing PAGE24 or DGGE.17-20 
Sensitivities of around 5% are clinically relevant for initial diagnosis, but they are 
certainly not sufficient for detection of minimal residual disease (MRD) in ALL 
patients which requires sensitivities of 10-4 to 1 o-5.35 It has been suggested that sen-
sitivities of 1 o-2 to 1 o-3 as determined by PCR might be predictive for slow remission 
upon chemotherapy, 36 but such sensitivities cannot easily be reached via heterodu-
plex analysis of PCR products, unless most of the polyclonal T-cells are depleted 
before DNA or RNA extraction. Nevertheless, heteroduplex PCR analysis of TCR 
gene rearrangements is sufficiently sensitive for monitoring patients with chronic 
T-cell leukemias as well as patients with oligoclonal T-cell proliferations in order to 
predict the possible outgrow1h of a dominant cell population. 
Heteroduplex analysis of rearranged TCR gene products can be a valuable 
technique in several other applications as well. Proof or exclusion of the common 
clonal origin of two distinct lymphoproliferations in one patient can be obtained upon 
analysis of homo- and heteroduplexes after mixing PCR products of the two sam-
ples. Another application involves direct sequencing of homoduplex bands of PCR 
amplified rearranged TCR genes which obviates the need for cloning in order to 
sequence their junctional regions for MRD studies. Furthermore, heteroduplex analy-
sis can also be employed for studying the diversity of the TCR repertoire in immune 
responses during infections or in autoimmune disorders, as has already been report-
ed for the TCRB and TCRG genes21,22 However, this application suffers from a few 
technical limitations. Firstly, the heteroduplex method is more qualitative than quan-
titative; secondly, scarcity of material or low frequencies ofT lymphocytes in the stud-
ied cell sample may give rise to a kind of pseudo-oligoclonality or even pseudo-mon-
oclonality, which does not reflect the actual heterogeneity. 
We conclude from our data that the described PCR procedure of TCR gene 
amplification followed by denaturation of the resulting PCR products and renatura-
tion at 4°C seNes to assess clonality in suspect T-cell proliferations. This is espe-
cially the case when relatively short PCR products (150-250 bp) are analyzed. 
Heteroduplex analysis of PCR products is a simple, rapid, and cheap alternative to 
Southern blot analysis for TCR gene clonality assessment Moreover, heteroduplex 
analysis may even be superior to other methods like fingerprinting, DGGE, and gene 
scanning, since no expensive equipment is needed, no radioactivity is involved, and 
different conditions do not seem to be required for all different TCR gene primer 
Heteroduplex PCR analysis of TCR gene rearrangements 89 
combinations. Our current results suggest that this procedure is not only useful for 
TCR gene analysis, but might also be applied for clonality assessment in suspect 
B-cell proliferations via analysis of IGH, IGK, and /GL genes. However, one should 
be aware that PCR studies of rearranged lg genes in mature (post)follicular B-cells 
might be hampered by the occurrence of somatic mutations. 
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ABSTRACT 
The /GH gene configuration was investigated in 97 childhood precursor-B-ALL 
patients at initial diagnosis. Rearrangements were found by Southern blotting in all 
but three patients (97%) and in 30 cases (31 %) we observed oligoclonal /GH gene 
rearrangements. Heteroduplex PCR analysis revealed at least one clonal PCR prod-
uct in all Southern blot-positive cases. In 89 patients (92%) complete V(D)J 
rearrangements were found, while incomplete DH-JH rearrangements occurred in 
only 21 patients (22%). In 5% of cases the DH-JH rearrangements were the sole IGH 
gene rearrangements Sequence analysis of the 31 identified incomplete rearrange-
ments revealed preferential usage of segments from the DH2, DH3 and 0H7 families 
(78%). While DH2 and DH3 gene rearrangements occur frequently in normal B-cells 
and B-cell-precursors, the relatively frequent usage of DH7-27 (19%) in precursor-B-
ALL patients is suggestive of leukemic transformation during prenatal lymphopoiesis. 
Among JH gene segments in the incomplete DH-JH rearrangements, the JH6 seg-
ment was significantly overrepresented (61%). This observation together with the 
predominant usage of the most upstream DH genes indicates that many of the iden-
tified clonal DH-JH gene rearrangements in precursor-B-ALL probably represent sec-
ondary recombinations, having deleted pre-existing DH-JH joinings. 
The patients with incomplete DH-JH gene rearrangements were frequently char-
'Leukemia 2001; 15: 1415-1423 93 
94 CHAPTER 2.3 
acterized by hyperdiploid karyotype with additional copies of chromosome 14 and/or 
by IGH oligoclonality. The presence of incomplete DH-JH joinings was also signifi-
cantly associated with a less mature immunogenotype: overrepresentation of VH6-1 
gene segment usage, absence of biallelic TCRD deletions, and low frequency of 
TCRG gene rearrangements. This immature immunogenotype of precursor-B-ALL 
with incomplete IGH gene rearrangements was not associated with more aggressive 
disease. 
INTRODUCTION 
DH-JH joinings are assumed to be the first steps in the recombination process of 
the immunoglobulin heavy chain (/GH) locus and represent one of the earliest events 
in 8-cell development (reviewed in Ref. 1 ). DH-JH joinings hallmark the differentiation 
of common lymphoid precursors into the 8-cell lineage and are already found in 
CD34+/CD19-JCD1 o+ precursor cells2,3 Most of the more mature 
CD34+/CD19+/CD10+ 8-lineage precursors contain at least one DH-JH rearranged 
allele and frequently also complete VH-(DH-)JH rearrangements.3.4 
Based on their immunophenotype, precursor-S acute lymphoblastic leukemias 
(ALL) are generally regarded as clonal malignant counterparts of normal 
-CD34+/CD19+/CD1 o+ 8-lineage precursors in the bone marrow. In line with this 
assumption, Southern blot studies have shown that >95% of precursor-B-ALL have 
!GH gene rearrangements, that most of them contain immunoglobulin (I g) kappa light 
chain gene rearrangements (60%), and that even 20% of precursor-B-ALL have lg 
lambda light chain gene rearrangements.S-8 Newly diagnosed childhood precursor-
B-ALL are frequently oligoclonal and contain multiple IGH gene rearrangements 
(30% to 40% of cases).6,9 These multiple !GH gene rearrangements are caused by 
continuing rearrangement processes (e.g. continuing VH to DH-JH joining) as well as 
secondary rearrangements (e.g. OH-JH replacements, VH replacements), which 
result in one or more subclones.9-13 
PCR studies in precursor-B-ALL employing VH-JH primer sets showed generally 
lower frequencies of !GH gene rearrangements as compared to Southern blot analy-
ses.14-18 This was assumed to be caused in large by the presence of incomplete DH-
JH rearrangements. Two limited studies indeed revealed clonal DH-JH rearrange-
ments in a total of 14 out of 19 precursor-B-ALL patients (74%) with biallelic 
rearrangements in Southern blotting but no clonal VH-(DH-)JH rearrangements by 
PCR.16-19 However, no systematic investigations have been published on the fre-
quency and types of clonal DH-JH rearrangements in a random group of precursor-
B-ALL patients. Most published data on OH-JH rearrangements in precursor-B-ALL 
have in fact been obtained indirectly from the sequences of clonal VH-(DH-)JH join-
ings.15-20 This limited information about OH-JH rearrangements is partly caused by 
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the fact that the complete sequence of the OH region was published only recent-
ly21,22 
In this study we aimed at a thorough analysis of OH-JH rearrangements in child-
hood precursor-B-ALL patients using combined Southern blot and heteroduplex 
PCR analyses. We first determined the precise frequency of clonal OH-JH rearrange-
ments in a non-selected series of 97 children with precursor-B-ALL. Secondly, we 
correlated the presence of clonal incomplete OH-JH joinings with several immunobi-
ological and clinical features of these patients. Finally, we critically assessed the 
potential application of clonal DH-JH rearrangements as PCR targets for monitoring 
of minimal residual disease (MRD). 
MATERIALS AND METHODS 
Patients 
Peripheral blood (PB) or bone marrow (BM) samples from 97 precursor-B-ALL patients were 
obtained at initial diagnosis. The age distribution ranged from 3 months to 190 months. Four children (4%) 
were infants (age <1 year). The diagnosis of precursor-B-ALL was made according to FAB and standard 
immunophenotypic criteria.23-25 Immunological marker analysis of the precursor-B-ALL revealed that four 
(4%) were pro-B-ALL, 64 (66%) were common ALL, and 29 (30%) were pre-B-ALL The status of chro-
mosome 14 was based on routine cytogenetics as available in the Dutch Childhood Leukemia Study 
Group (DCLSG) database. Most patients (91 out of 97) were treated according to the DCLSG ALL-8 treat-
ment protocols_26 
Southern blot analysis 
Mononuclear cells (MNC) were separated from PB or BM samples by Ficoii-Paque centrifugation 
(density 1.077 g/cm3; Pharmacia, Uppsala, Sweden). DNA was isolated from MNC, digested, and blotted 
to nylon membranes as described previously.27 IGH gene rearrangements were studied by use of the 32p 
labeled IGHJ6 probe (DAKO. Carpinteria, CA, USA) in Bgll! and BamH!/Hindlll digests.28 In 88 patients 
the configuration of the T-cell receptor (TCR) genes was established as previously reported_29 
PCR amplification and heteroduplex analysis of PCR products 
PCR was essentially performed as described previously_30.31 In each 50)11 PCR reaction 50 ng DNA 
sample, 6.3 pmol of the s· and 3· oligonucleotide primers. and 0.5 U AmpliTaq Gold polymerase (Applied 
Biosystems, Foster City. CA, USA) were used. The sequences of the 12 oligonucleotides used for ampli-
fication of complete VH-JH and incomplete DH-JH gene rearrangements (Figure 1) were published 
before.32-33 In addition 91 patients were tested with a special VH6-JH primer combination to identify 
patients with VH6-1 gene rearrangements.32 PCR conditions were pre-activation of the enzyme for 10 min 
at 94°C, followed by 35 cycles of 45 sat 92°C, 90s at 60°C. and 2 min at 72°C using a Perkin-Elmer 480 
thermal cycler (Applied Biosystems). After the last cycle an additional extension step of 10 min at 72°C 
was performed. Appropriate positive and negative controls were included in all experiments.31 
In order to distinguish between polyclonal and monoclonal rearrangements, heteroduplex analysis of 
the obtained PCR products was performed as described previously.34 In short, the PCR products were 
denatured at 94°C for 5 min to obtain single-stranded PCR products. Subsequently the single-stranded 
products were cooled to 4°C for 60 min to induce random renaturation {duplex formation).34 In case of 
monoclonal gene rearrangements homoduplexes are formed {identical junctional regions), whereas het-
eroduplexes are found in case of polyclonal gene rearrangements (heterogeneous junctional regions). 
The duplexes obtained were immediately loaded on 6% non-denaturing polyacrylamide gels in 0.5 x Tris-
Borate-EDTA {TBE) buffer, run at room temperature, and visualized by ethidium bromide staining in order 
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to discriminate between the presence of rapidly migrating homoduplex bands or slowly migrating het-
eroduplexes smears; the remaining single-strand molecules migrate very slowly {Figure 2). 
Sequence analysis of IGH gene rearrangements 
Sequence analysis concerned both VH-JH and DH-JH gene rearrangements in all patients in whom at 
least one clonal incomplete DH-JH rearrangement was found by heteroduplex analysis. When heterodu-
plex PCR analysis revealed more than two clonal bands i.e. either two homoduplexes, or an additional 
upper band resulting from extension to downstream JH segments, or a DH7-27-JH1 germ line band accom-
panying a DH?-27-JH rearrangement, homoduplexes were excised from the polyacrylamide gel and elut-
ed as described before.33 The eluted PCR products were either directly sequenced or subjected to sec-
ond step PCR with the same primer pair to increase the amount of template for sequence analysis. 
Sequencing was performed using the dye-terminator cycle sequencing kit with AmpliTaq DNA polymerase 
FS on an ABI377 sequencer (Applied Biosystems) as described before.33 VH, DH, and JH segments were 
identified using DNAPLOT software (W. MOiler. H-H. Althaus, University of Cologne, Germany) by search-
ing for homology with all known human germline VH, DH, and JH sequences obtained from the VBASE 
directory of human lg genes (http://www.mrc-cpe.cam.ac.uk!imt-doc/).35 
Statistical analysis 
Statistical analyses using the x2 test or Fisher's exact test on a 2 x 2 table were performed for com-
parison of patient and disease characteristics (age, sex, white blood count at diagnosis, immunopheno-
type, DNA ploidy, the presence of cross-lineage TCR gene rearrangements, steroid response) between 
precursor-B-ALL patients with DH-JH gene rearrangements (DH-JH-positive group) vs. patients without OH-
JH gene rearrangements (DH-JH-negative group). A value of p < 0.05 was regarded to be statistically sig-
nificant. 
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Schematic diagrams of VH-DH-JH and DH-JH junctional regions with primers for PCR analysis. The 
sequence, approximate position and orientation (5' -> 3') of the VH family specific framework 1 (VH-FR1) 
and DH family specific primers as well as of the JH-consensus primer are indicated.32.33 
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Event-free survival (EFS) was defined as the time from diagnosis to induction failure, relapse, death 
in remission, or the occurrence of a second tumor. For patients event-free alive at the latest follow~up time 
point (censored observations) EFS was calculated till this latest follow~up. Patients who did not achieve 
remission, were included in the analysis and considered as treatment failures with EFS of 0 days. Survival 
curves and standard errors were calculated according to the Kaplan-Meier method. 
RESULTS 
Southern blot configuration of IGH genes 
Clonal /GH gene rearrangements were demonstrated by Southern blot analysis 
in 94 out of 97 precursor-B-ALL patients (97%). In the other three patients monoal-
lelic (two cases) or biallelic (one patient) IGH deletions were assumed based on the 
percentages of leukemic blasts and the relative density of rearranged and germline 
bands. Biallelic rearrangements were found in 85 out of 97 patients (88%), in eight 
patients the second IGH allele was deleted (8%), and only in a single patient the sec-
ond allele was in germ line configuration. In 13 patients three and in two patients four 
IGH gene rearrangements with Southern blot bands of identical density were found 
suggesting trisomy and tetrasomy 14, respectively. In 30 out of 97 precursor-B-ALL 
patients (31%) the presence of rearranged bands of different densities or additional 
weak bands suggested oligoclonality. 
Complete VH-(DH-)JH and incomplete DH..JH rearrangements 
Detailed heteroduplex PCR analysis of the IGH locus in the 97 precursor-B-ALL 
patients was based on 12 primer combinations (Figure 1) theoretically covering the 
majority of complete VH-(DH-)JH joinings and all incomplete DH-JH rearrangements. 
With this approach at least one clonal PCR product was demonstrated in all 94 
patients with Southern blot detectable IGH gene rearrangements. However, in only 
43 patients (46%) the number of clonal PCR products exactly matched the number 
of Southern blot bands. In 45 patients (48%) the number of clonal homoduplexes 
was lower as compared to the number of rearrangements in Southern blot analysis. 
This concerned 29 patients with monoclonal IGH rearrangements and 16 patients 
with oligoclonai/GH gene rearrangements. In contrast, in six patients (6%) the num-
ber of clonal homoduplexes exceeded the number of rearrangements in Southern 
blot analysis. Five of these six patients were considered to have monoclonal IGH 
gene rearrangements based on Southern blotting, which indicates that the addition-
al clonal PCR products most probably represented minor subclones, not detectable 
by Southern blotting. 
Clonal complete VH-(DH-)JH rearrangements were found in 89 patients (92%) as 
exemplified in Figure 2, while incomplete DH-JH rearrangements were demonstrated 
in only 21 patients (22%) (exemplified in Figure 3 for the most frequently observed 
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OH-JH couplings). In only five patients (5%) the incomplete DH-JH joinings were the 
sole /GH rearrangements. Hence, 16 patients had both complete and incomplete 
IGH gene rearrangements. 
Usage of DH gene segments in incomplete DH-JH gene rearrangements 
In 21 patients with clonal DH-JH rearrangements we identified a total of 31 DH-JH 
joinings, including five of the DH-DH-JH type. The frequencies of the different DH fam-
ily members found among the 36 identified DH sequences are summarized in Table 
1. Usage of gene segments from the DH2 and 0H3 families was most prominent 
(36% and 33%, respectively), with the DH2-2 and DH3-9 gene segments being used 
most frequently (each comprising 19% of all identified OH sequences) (Table 1 and 
Figure 3). The single member of the DH7 family (0H7-27) is located most proximal to 
the JH cluster and was also found in seven DH-JH joinings (19%). Three rearrange-
ments (8%) contained DH segments of the DH1 family, whereas a single rearrange-
ment utilized the DH6-13 gene segment (Table 1). Taken together, 26 of the 36 
rearranged DH segments (72%) belonged to the more upstream part of the DH region 
(Table 1 ). 
The sizes of the DH-JH junctional regions ranged from 0 to maximally 43 
VH3-JH 
Figure 2. 
Heteroduplex PCR analysis in 17 precursor-B-ALL patients to distinguish between polyclona! and mono-
clonai/GH gene rearrangements. Using the VH3-JH primer combination clonal homoduplexes were found 
in the majority (16/17) of the presented precursor-B-ALL patients. ho, position of homoduplexes; he, het-
eroduplexes; ss, single strand PCR products. 
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Table 1. Usage of different DH families and gene segments in incomplete DH-JH gene 
rearrangements in childhood precursor-B-ALL 
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New family namea Old family namea Number and frequency Segments used 
of rearrangements 
DH1 DM 3 (8%) DH1-1: 2 
DH1-7: 1 
DH2 DLR 13 (36%) DH2-2: 7 
DH2-8: 3 
DH2-15: 2 
DH2-21: 1 
DH3 DXP 12 (33%) DH3-3: 3 
DH3-9: 7 
DH3-10: 2 
DH4 DA 0 
DH5 DK 0 
DH6 DN 1 (3%) DH6-13: 1 
DH7 DQ52 7 (19%) DH7-27: 7 
a. The new nomenclature is derived from Corbett et al.21 , whereas the old nomenclature is according to 
lchihara et al.49 
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Figure 3. 
Heteroduplex PCR-based detection of incomplete DH-JH gene rearrangements in several precursor-B-
ALL patients. As illustrated, the usage of gene segments from the DH2, DH3, and DH7 families was most 
prominent. 
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nucleotides with an average of 8.1 nucleotides. Seven out of 31 DH-JH junctions 
(23%) in six patients did not show any randomly inserted N-region nucleotides. 
Usage of JH gene segments in incomplete DH-JH gene rearrangements 
The frequencies of different JH gene segments in the 31 DH-JH gene rearrange-
ments are summarized in Table 2. Remarkably, the JH6 gene segment was found in 
more than 60% of the joinings, followed by JH4 and JH5, each occurring in 16% of 
cases. The JH3 gene segment was found in two DH-JH gene rearrangements (7%), 
while the two most upstream JH1 and JH2 genes were not utilized in the 31 analyzed 
ncomplete DH-JH joinings. 
Sequences of complete VH-(DH)-JH gene rearrangements in precursor-B-All 
patients with incomplete OH-JH gene rearrangements 
A total of 27 VH-(OH)-JH sequences were identified in the 16 precursor-B-ALL 
patients showing both complete VH-JH and incomplete DH-JH gene rearrangements. 
This series of 16 patients included 10 oligoclonal patients. Remarkably, the most 
downstream VH6-1 gene segment was found most frequently, i.e. in 10 sequences 
(37%), while 12 different VH gene segments were used in the remaining 17 
sequences. Because of the unexpectedly high frequency of the VH6-1 gene segment 
in the DH-JH-positive group, we also performed a VH6-JH specific PCR analysis (see 
ref. 32) on 70 patients of the DH-JH-negative group and found that the VH6-1 gene 
segment was utilized in only 11% of !GH rearrangements in the OH-JH-negative 
group, which is significantly less than in the DH-JH-positive group (p < 0.01 ). 
Table 2. Usage of JH gene segments in complete and incomplete IGH gene rearrangements in 
human BM precursor~B-cells, PB B~lymphocytes, precursor-B-ALL, and in cross-lineage 
IGH gene rearrangements in T-ALL. 
JH segment Human BM Human PB Precursor-B-ALL Precursor-B-ALL T-ALL 
precursor-S-cells B lymphocytes VH-DH-JHC DH-JH VH-OH-JH and 
VH-0H-JH8 VH-DH-JHb DH-JHd 
(n=63) (n=111) (n=68) (n=31) (n=39) 
JH1 0% 1% Zio 0% 13% 
JH2 4% 0% 2% 0% 15% 
JH3 14% 9% 11% 7% (2) 10% 
JH4 32% 53% 32% 16% (5) 33% 
JH5 17% 15% 22% 16% (5) 8% 
JH6 33% 22% 32% 61%(19) 21% 
a. Raaphorst et al.43 
b. Yamada et ar_37 
c. Steenbergen et a1.1s 
d. Szczepariski et al.33 
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Sequence analysis helped to establish the relationship between VH-(DH)-JH and 
DH-JH gene rearrangements in the DH-JH-positive group. In four of the ten oligoclon-
al patients and also in three monoclonal patients a common D-J stem was identified 
in VH-(DH)-JH and DH-JH joinings indicating ongoing VH to DH-JH joining (see exam-
ples in Table 3). In another four of the ten oligoclonal patients the VH-(DH)-JH and DH-
JH sequences were not related, which might be caused by secondary rearrange-
ments, which replaced pre-existing rearrangements. In the last two patients, the 
oligoclonality was based on the presence of two rearranged bands of different den-
sity on Southern blot analysis; in one of the two patients the identified sequences 
were not related and in the other patient the type of relation could not be established 
because one of the IGH rearrangements remained unidentified. 
IGH gene configuration and chromosome 14 status in precursor-B-ALL 
patients with incomplete DH-JH gene rearrangements as compared to 
DH-JH-negative patients 
Based on Southern blot analysis, 10 of the 21 precursor-B-ALL patients with 
incomplete DH-JH rearrangements were classified as oligoclonal (48%), which is 
markedly higher than in the DH-JH-negative group (19 of 76 patients, 25%). In addi-
tion, five DH-JH-positive patients (24%) were assumed to have trisomy 14 and one 
patient probably had tetrasomy 14, based on the presence of three or four 
rearranged bands of equal density on Southern blot analysis. Although these fre-
quencies are higher than in the DH-JH-negative group, the differences did not reach 
statistical significance. However, patients with monoclonal biallelic IGH gene 
rearrangements were significantly underrepresented in the DH-JH-positive group 
(24% vs. 59% in the DH-JH-negative group, p < 0.01 ). 
Cy1ogenetic analysis revealed the presence of additional copies of chromosome 
14 in 23 out of 83 patients (28%) with conclusive cy1ogenetic data (Table 4). Trisomy 
14 and tetrasomy 14 were demonstrated in nine and one of 18 DH-JH-positive 
patients with conclusive cy1ogenetic data (56%) as compared to 12 and one out of 
65 DH-JH-negative cases (20%, p < 0.01 ). The presence of additional copies of chro-
mosome 14 was correctly anticipated by Southern blot data in seven of the 23 
patients. Nine patients showed monoclonal biallelic /GH rearrangements, which 
might indicate that the additional copies of chromosome 14 in these cases charac-
terized minor subclones. In the remaining seven patients the Southern blot based 
IGH configuration was oligoclonal. Interestingly, two of these oligoclonal cases were 
classified as biclonal based on the presence of two rearranged bands of different 
densities in Southern blotting. In both patients two clonal VH-(DH)-JH rearrangements 
were demonstrated by heteroduplex PCR analysis. This suggests that trisomy 14 in 
these patients resulted from duplication of a chromosome 14 with an existing 
rearranged IGH gene. In another two oligoclonal patients and in at least three mono-
clonal cases with trisomy 14, the sequence analysis revealed identical DH-JH stems 
~ 
1'3 
Table 3. Examples of junctional region sequences of IGH gene rearrangements in patients with incomplete DH-JH recombinations and 
oligoclonai/GH gene configuration due to ongoing VH to DH-JH joinings. 
VH gene N-region VH/DH gene N-region DH gene N-region JH gene 
Patient 5498 
DH2-2 (-1) AAG (-7) DH6-13 (0) CGGGGATG (-6) JH6b 
VH6-1 (-6) GAGGGAGGG (-14) DH2-2 (-1) AAG (-7) DH6-13 (0) CGGGGATG (-6) JH6b 
DH3-3 (-5) CCTAATCCCTCTTATAC (-7) DH1-7 (0) CCACGAGA (-6) JH6b 
VH5-51 (-2) GG (-5) DH3-3 (-5) CCTAATCCCTCTTATAC (-7) DH1-7 (0) CCACGAGA (-6) JH6b 
0 
Patient 5565 ~ 
DH3-10 (-6) GG (-10) JH6b ., iii VH6-1 (-1) CGGG (-6) DH3-10 (-6) GG (-10) JH6b 
"' VH1-3 (0) AGGGAC (-6) DH3-10 (-6) GG (-10) JH6b f" 
VH6-1 (-1) GG (0) DH3-16 (-4) CTCCCTCAGACGCTCCAAA (-6) JH4b "' 
Patient 5696 
DH2-2 (-3) TTGAAGTGACGGTATTAC-
GACCTCGCCTAGGCTTCCCCGT (-4) JH6b 
DH2-2 (-7) TGCCCCTCCGAGGTTCTCTTT-
GACCTCGCCTAGGCTTCCCCGT (-4) JH6b 
VH1-3 (0) TGTAC (-4) DH2-2 (-7) TGCCCCTCCGAGGTTCTCTTT-
GACCTCGCCTAGGCTTCCCCGT (-4) JH6b 
DH2-2 (-4) CGACGCTTG (-10) JH6C 
VH3-11 (-1) CTCCCATCAGAGTA (-13) DH2-2 (-4) CGACGCTTG (-10) JH6C 
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in at least two of the rearrangements. Apparently. in these patients the chromosome 
duplication developed after the incomplete DH-JH recombination, but before ongoing 
VH to DH-JH joining. Finally, in two oligoclonal cases the sequences of IGH 
rearrangements were completely unrelated, which is indicative of duplication of chro-
mosome 14 as a very early event preceding recombination in the JGH locus. 
TCR gene configuration in precursor-B-All patients with incomplete DH-JH 
gene rearrangements as compared to DH-JH-negative patients 
Cross-lineage TCR gene rearrangements were found in 66 of 69 (96%) DH-JH-
negative patients and in 17 of 19 (90%) of DH-JH-positive patients. However, detailed 
TCR gene rearrangements patterns significantly differed between the two groups. 
TCR gamma (TCRG) gene rearrangements were observed in only two DH-JH-posi-
tive patients (11%) as compared to 49 DH-JH-negative patients (71%, p < 0.01). 
Although the recombination in TCR alpha/delta locus occurred with similar frequen-
cies in both groups (approximately 90% of patients), it rarely concerned TCR delta 
(TCRD) deletions in the DH-JH-positive group: monoallelic deletions in two patients 
(11%) and no biallelic deletions. This was in striking contrast (p < 0.01) to the DH-JH-
negative group, where monoallelic and biallelic deletions were found in 19 (28%) and 
21 patients (30%), respectively. Finally, TCR beta (TCRB) gene rearrangements 
were slightly less prevalent in the DH-JH-positive group (4/19 patients, 21% vs. 26/69 
DH-JH-negative patients, 38%; not significant) and exclusively concerned monoallel-
ic incomplete D~-J~2 rearrangements. In striking contrast, TCRB gene rearrange-
ments were biallelic in 50% (13/26) of DH-JH-negative patients, while complete V~­
J~2 joinings were found in 69% (18/26) of patients. 
Clinical and laboratory characteristics of DH-JH-positive patients 
Clinical and laboratory characteristics of DH-JH-positive vs. DH-JH-negative 
patients are summarized in Table 4. The two patient groups showed similar age and 
sex distribution. The only significant clinical difference concerned the frequency of 
infant ALL, which comprised 14% (three cases) of DH-JH-positive precursor-B-ALL 
as compared to 1% (one case) of DH-JH-negative patients (p <0.05). However, owing 
to the low frequency of infant ALL this difference should be interpreted with caution. 
Both DH-JH-positive and DH-JH-negative groups showed similar distribution of pre-
cursor-S immunophenotypes. Strikingly, cytogenetic and DNA index analyses 
demonstrated a statistically significant overrepresentation of patients with hyper-
diploidy >50 chromosomes and increased DNA index (<o1.16) in the DH-JH-positive 
group (40-50% as compared to 20% in DH-JH-negative patients; p < 0.01 ). The strat-
ification into the three treatment risk groups was comparable between the DH-JH-
positive and the DH-JH-negative patients. Both groups showed similar early treat-
ment response to prednisone. Finally, the presence of incomplete DH-JH rearrange-
ments influenced neither the event-free survival nor the overall survival (Figure 4). 
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Table 4. Clinical and laboratory characteristics of DH..JH positive and DH-JH negative subgroups of 
precursor-B-ALL 
Parameters DH-JH positive group (n = 21) DH-JH negative group (n = 76) 
Age 
(14%)b (1%)b < 1 year 3 1 
1-5 years 13 (62%) 42 (55%) 
5-10 years 1 (5%) 23 (30%) 
> 10 years 4 (19%) 10 (14%) 
Gender 
Boys 12 (57%) 42 (55%) 
Girls 9 (43%) 34 (45%) 
Treatment group3 
SRG 6 (29%) 21 (30%) 
MRG 12 (57%) 43 (61%) 
HRG 3 (14%) 6 (9%) 
Steroid response 
good 20 (95%) 72 (95%) 
poor 1 (5%) 2 (3%) 
not determined 0 2 (3%) 
lmmunophenotype 
pro-S ALL 2 (10%) 2 (3%) 
common ALL 14 (67%) 50 (65%) 
pre-S ALL 5 (24%) 24 (32%) 
Cytogenetics 
diploid 1 (5%) 14 {18%) 
hypodiploid(< 46 chr.) 0 4 (5%) 
hyperdiploid (47-50 chr.) 2 (10%)b 6 (8%) 
hyperdiploid (> 50 chr.) 11 (52%) 15 (20%)b 
pseudodiploid 4 (19%) 19 (25%) 
not determined 3 (14%) 18 (23%) 
DNA index 
< 1.00 0 0 
1.00 7 (33%) 51 (67%) 
>1.00 and< 1.16 4 (19%) 5 (7%) 
<:1.16 and ;S; 1.60 9 (43%)b 12 (16%)b 
>1.60 0 1 (1%) 
not determined 1 (5%) 7 (9%) 
Chromosome 14 status 
monosomy 0 1 (1%) 
normal 8 (38%)b 51 (67%)g 
trisomy 9 {43%)b 12 (16%) 
tetrasomy 1 (5%) 1 (1%) 
not determined 3 (14%) 11 (14%) 
6-year relapse-free survival 61% ± 11% {8) 64%±6% (25) 
(No. of relapses )a 
a. These data exclusively concern 91 patients treated with OCLSG ALL-8 treatment protocol 
b. Parameters statistically significantly different between the DH-JH positive and the DH-JH negative subgroups 
of precursor-B-ALL (p < 0.05). 
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Figure 4. 
Event-free survival of the DH-JH positive vs. DH-JH negative patients treated with DCLSG ALL-8 
chemotherapy protocols. 
DISCUSSION 
The frequency and molecular characteristics of incomplete DH-JH gene 
rearrangements were investigated in precursor-B-ALL patients. Using seven DH fam-
ily specific primer combinations, covering theoretically all incomplete recombina-
tions, we identified clonal DH-JH gene rearrangements in 21 of 97 patients (22%). 
DH-JH joinings were the sole clonal IGH rearrangements in only 5% of patients. At 
first sight, this might suggest that the final oncogenic event in precursor-B-ALL rarely 
concerns early-B progenitors, characterized by the exclusive presence of incomplete 
IGH gene rearrangements. However, the continuing rearrangement processes in 
ALL can easily change the original lg gene configuration present at the time of the 
oncogenic transformation.36 This probably also explains the relatively low frequency 
of incomplete DH-JH gene rearrangements on the second IGH allele (18% of cases 
with biallelic IGH rearrangements). 
We observed non-random DH gene segment usage in incomplete DH-JH gene 
rearrangements with predominance of three families, i. e. DH2, DH3, and DH7, com-
prising 36%, 33% and 19%, respectively (Table 1 ). Gene segments of the DH2 and 
DH3 families are known to be preferentially utilized in complete VH-DH-JH joinings in 
normal and malignant B-cells and B-cell precursors.15.20,37,38 In contrast, the seg-
ments of the DH5 and 0H6 families, accounting for 10-15% of identified DH genes in 
the third IGH complementarity-determining regions (HCDR3) in B-lineage cells, were 
virtually absent in incomplete DH-JH gene rearrangements in precursor-B-ALL. 
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Another striking finding was the frequent usage of the DH7-27gene (19%), which is 
located immediately upstream to JH gene complex. This single member of the DH7 
family is rarely (approximately 1 %) identified in HCDR3 of normal and malignant 8-
cells and B-cell precursors,15.20.3?.38 while DH7-27gene rearrangements are pre-
dominantly (approximately 40%) found in fetal B-lineage cells.39.40 This finding 
together with the frequent lack of N-nucleotide insertions in DH-JH junctions supports 
the hypothesis that a significant proportion of childhood precursor-B-ALL originates 
in utero41 .42 
Concerning the JH gene usage, we observed a striking predominance of the 
most downstream JH6 segment, which was found in 61% of clonal DH-JH gene 
rearrangements. This is twice as much as reported for HCDR3 in normal and malig-
nant B-lineage-cells (Table 2).15.3?,43 This observation together with the finding of 
predominant usage of DH genes from the more upstream part of the OH region (78%) 
suggests that most DH-JH gene rearrangements in precursor-B-ALL actually repre-
sent secondary recombinations deleting pre-existing DH-JH joinings. 
The patients with incomplete DH-JH gene rearrangements were frequently char-
acterized by hyperdiploid karyotype (52%) with additional copies of chromosome 14 
(56%) and/or by IGH oligoclonality (52%). Combined cy1ogenetic, Southern blot and 
PCR data revealed a complex relationship between the hyperdiploidy 14, IGH gene 
configuration, and subclone formation. In our series, additional copies of chromo-
some 14 were found in 28% of precursor-B-ALL patients, which is in line with previ-
ously published cy1ogenetic data44 Sequence analysis showed that this type of 
chromosomal aberration might occur before !GH gene rearrangements, but more fre-
quently parallels ongoing VH to DH-JH joining or might even affect cells with an end-
stage (stable) !GH configuration. Although it is difficult to explain how the presence 
of DH-JH rearrangements is related to trisomy 14, it suggests that having extra copies 
of chromosome 14 freezes the ALL cells in a more immature immunogenotypic 
stage. In this context it was striking to observe that hyperdiploidy of chromosome 14 
was inversely associated with TCRD gene deletions, which are regarded as a more 
mature immunogenotypic feature. The association between DH-JH gene rearrange-
ments and IGH oligoclonality is obviously explained by the presence of ongoing and 
secondary recombination events. The presence of incomplete DH-JH joinings was 
also significantly associated with a less mature immunogenotype as reflected by 
overrepresentation of the most downstream VH6-1 gene segment, the virtual 
absence of monoallelic TCRD deletions, the full absence of biallelic TCRD deletions, 
low frequency of TCRG gene rearrangements, the absence of complete V~-J~ 
rearrangements, and the absence of biallelic TCRB rearrangements. However, these 
distinct immature immunogenotypic features of precursor-B-ALL with clonal incom-
plete IGH gene rearrangements were not associated with more aggressive disease 
(Figure 4). The frequency of high-risk features at diagnosis, early treatment 
response, as well as long-term event-free survival, did not significantly differ between 
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DH-JH-negative and DH-JH-positive patients (Table 4 ). Thus, the presence of clonal 
incomplete IGH gene rearrangements has no direct clinical implications, although 
associated with immunobiological features of immature B-cell differentiation stages. 
In this study, we demonstrated that clonal VH-(DH-)JH gene rearrangements can 
be easily identified in the vast majority of precursor-B-ALL patients and can serve as 
PCR targets for MRD monitoring (Figure 2). However, in almost half of the cases the 
number of clonal PCR products was lower than the number of rearrangements in 
Southern blot analysis, including 29 monoclonal cases with an undetectable second 
allele. Our PCR analyses correctly assigned 105 alleles in 67 patients with mono-
clonal biallelic IGH rearrangements, which gives an overall sensitivity of 78%. 
Although chromosome translocations involving the /GH gene might occur, the 
recombinations undetectable by PCR most probably represent unidentified 
VH-(DH-)JH gene rearrangements. Particularly the newly discovered VH pseudo-
genes might be involved in these rearrangements since many of them contain prop-
er recombination signal sequences, while they frequently lack framework one 
sequences, which are recognized by the currently used VH family-specific primers22 
Since the types of preferential DH-JH gene rearrangements have now been iden-
tified, it would be relatively easy to screen precursor-B-ALL patients for the presence 
of incomplete IGH gene rearrangements and apply them as PCR targets for MRD 
monitoring, particularly in patients without detectable clonal complete VH-(DH-)JH 
joinings. Three primer combinations (DH2, DH3, and 0H7 in combination with a JH 
consensus primer) can identify 89% of incomplete DH-JH rearrangements in precur-
sor-B-ALL (Figure 3) and result in clonal PCR products in all patients without VH-JH 
rearrangements. However, it should be noted that incomplete DH-JH gene rearrange-
ments are associated with IGH oligoclonality in at least 52% of patients. Moreover, 
in one third of patients with clonal DH-JH gene rearrangements we found evidence 
for continuing VH to DH-JH recombination already at diagnosis (Table 3). /GH-based 
MRD detection in such patients is still possible and could rely on so-called common 
OH-JH stems, which are preserved in different VH-(DH-)JH joinings. Such an approach 
is feasible with the currently used real-time quantitative PCR approaches for MRD 
detection based on TaqMan technology4 5-48 In some cases this strategy might be 
hampered by the lack of N-nucleotide insertions, which concerns 20-30% of IGH 
gene rearrangements in precursor-B-ALL.15 DH-JH stems in rearrangements involv-
ing the most downstream JH6 gene segment (i.e. 60% of all incomplete joinings) 
could be perceived as "end-stage" rearrangements, which probably are stable 
throughout the disease course. This is not the case with the DH-JH rearrangements 
involving upstream JH gene segments, which might be subjected to DH-JH replace-
ments. We found evidence for such secondary (replacement) rearrangement pat-
terns in 20% of patients at diagnosis. If they occur during the disease course, they 
might lead to false-negative MRD-results. In conclusion, incomplete DH-JH gene 
rearrangements can be perceived as a supplementary MRD-PCR target, particular-
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ly useful for patients, who do not have other leukemia-specific targets, such as com-
plete VH-(DH-)JH joinings, lg kappa deleting element (Kde) rearrangements, and 
cross-lineage TCRG and TCRD gene rearrangements or in whom the other MRD-
PCR targets are not suitable because of insufficient sensitivity. 
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ABSTRACT 
A large series of 202 childhood precursor-S-cell acute lymphoblastic leukemia 
(ALL) patients was analyzed by Southern blotting (SB) for cross-lineage rearrange-
ments and/or deletions in the T-cell receptor TCRB, TCRG, and TCRD loci. In 93% 
(187/201) of the precursor-B-ALL patients one or more genes were rearranged 
and/or deleted. TCRB gene rearrangements were found in 35% (69/196), TCRG 
gene rearrangements in 59% (113/192), TCRD gene rearrangements in 55% 
(112/202), and isolated monoallelic or biallelic deletions of TCRD loci in 34% 
(68/202) of the cases. 
TCRB gene rearrangements involved exclusively the Jj32 locus with complete 
V(O)Jj32 joinings in 53% of gene rearrangements and incomplete Oj3-Jj32 gene 
rearrangements in 33%. TCRG gene rearrangements frequently occurred on both 
alleles (65% of cases) and in approximately 70% concerned rearrangements to Jy1 
gene segments. Most rearranged TCRD alleles (80%) represented incomplete V82-
083 or 082-083 gene rearrangements, while the remaining TCRD gene rearrange-
ments remained unidentified. 
"Leukemia 1999; 13: 196-205 113 
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Subsequently, we evaluated, whether heteroduplex PCR analysis of rearranged 
TCRG and TCRD genes can be used for reliable identification of PCR targets for 
detection of minimal residual disease (MRD). The concordance between SB and het-
eroduplex PCR analysis for detection of the various types of clonal TCRG and TCRD 
gene rearrangements ranged between 78% and 87%. The discrepancies could be 
assigned to the presence of 'atypical' TCRD gene rearrangements or translocations 
only detecable by SB, but also to efficient PCR-based detection of rearrangements 
derived from small subclones, which are difficult to detect with SB. Indications for 
oligoclonality were observed in 38% and 30% of patients with TCRG and TCRD 
gene rearrangements, respectively, which is comparable to the frequency of oligo-
clonality in IGH locus. 
Based on the combined data it was possible to reduce the broad panel of six 
TCRD and 12 TCRG primer combinations for MRD studies to two TCRD combina-
tions (V82-D83 and 082-083) and six TCRG combinations (Vyl, Vyll, VyiV family-
specific primers with Jy1.1/2.1 and Jy1.3/2.3 primers) resulting in the detection of 
80% and 97% of all TCRD and TCRG gene rearrangements, respectively. Finally, 
the heteroduplex PCR data indicate that MRD monitoring with TCRG and/or TCRD 
targets is possible in approximately 80% of childhood precursor-B-ALL patients; 
-55% of patients even have two TCRG and/or TCRD targets. 
INTRODUCTION 
The enormous diversity of immunoglobulin (I g) and T-cell receptor (TCR) mole-
cules is generated during B and T-cell differentiation by a series of ordered 
rearrangements of variable (V), diversity (D), and joining (J) gene segments.1·2 
Initially, lg and TCR gene rearrangements were regarded as B-lineage and T-lineage 
specific markers, respectively. However, the finding of cross-lineage expression of 
'lineage-specific' immunological markers and cross-lineage lg and TCR gene 
rearrangements has disputed this view2,3 
Cross-lineage rearrangements of lg heavy-chain (IGH) genes have been 
observed in 10-15% ofT acute lymphoblastic leukemia (T-ALL) and in -5% of mature 
T-cell leukemias and lymphomas, but cross-lineage rearrangements of lg light chain 
genes in malignant T-cell proliferations are rare (<1 %).4-5 On the other hand, TCR 
beta (TCRB), TCR gamma (TCRG), and TCR delta (TCRD) gene rearrangements 
and/or deletions have been found in -30%, -50%, and -80% of precursor-B-ALL, 
respectively.S-13 However, only a few limited studies have described the configura-
tion of all three TCR genes in precursor-B-ALL.5.?,10. 11 The detection of rearrange-
ments in the TCR alpha (TCRA) locus by Southern blotting (SB) and PCR is difficult 
due to the long stretch of Ja: gene segments (about85 kb) (Figure 1 ), but the occur-
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Figure 1. 
Schematic diagram of the four human TCR genes. The TCRA gene complex consists of >50 V gene seg-
ments, a remarkably long stretch of 61 functional J gene segments, and one C gene segment. The major 
part of the TCRD gene complex is located between the Va and Ja gene segments and consists of eight 
V, three D, and four J gene segments and one C gene segment. The 8REC and \j/Ja gene segments play 
a role in TCRD gene deletions, which precede TCRA gene rearrangements in developing T-cells. The 
TCRB gene complex consists of 65 V gene segments and two C gene segments, both of which are pre-
ceded by one D and six or seven J gene segments. The TCRG gene complex consists of a restricted num-
ber of V gene segments (six functional V gene segments and nine pseudogene segments) and two C 
gene segments, each preceded by two Jy1 or three Jy2 gene segments. Pseudo genes (\jf) are indicated 
with open symbols. 
renee of TCRA gene rearrangements in precursor-B-ALL can be deduced from 
TCRD gene deletions. Therefore, whenever TCRD gene deletions are detected, 
rearrangements in the TCRA locus can be anticipated. 
Junctional regions of rearranged lg and TCR genes in lymphoid malignancies 
can be regarded as clonal 'tumor-specific' markers, because they arise during the 
recombination of different V, (D), and J gene segments by deletion and random 
insertion of nucleotides at the junctions of the gene segments. 1 Hence, each junc-
tional region of rearranged lg and TCR genes is different in each leukemia and lym-
phoma. Therefore, the polymerase chain reaction (PCR) has been used for amplifi-
cation of the 'tumor-specific' junctional regions of cross-lineage rearranged TCRG 
and TCRD genes to detect minimal residual disease (MRD) in precursor-B-ALL_14-17 
The aims of our study were firstly to determine the precise frequency of cross-
lineage TCR gene rearrangements in a large series of childhood precursor-B-ALL 
and to evaluate the occurrence of preferential TCR gene rearrangements and the 
occurrence of oligoclonality at the TCR gene leveL Secondly, based on SB data we 
estimated the number of precursor-B-ALL patients with identifiable cross-lineage 
TCR gene rearrangements, which can be used for PCR-mediated MRD detection. 
Thirdly, we wished to evaluate whether heteroduplex analysis of PCR products can 
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be used for reliable identification of rearranged TCRG and TCRD genes as 
molecular targets for MRD monitoring, because heteroduplex PCR analysis was 
shown to be a rapid, cheap, non-radioactive, and easy alternative approach for 
detection of clonal lg and TCR gene rearrangements with a sensitivity of 1-5%.18-
21The configuration of the TCRB, TCRG, and/or TCRD genes was analyzed by SB 
in 202 well-characterized cases of precursor-B-ALL and the results were compared 
with previously published childhood precursor-B-ALL cases. In addition, 62 precur-
sor-B-ALL patients were subjected to detailed heteroduplex PCR analysis of the 
TCRG and TCRD gene loci. 
MATERIALS AND METHODS 
Cell samples 
Bone marrow (BM) or peripheral blood (PB) samples from 202 children with precursor-B-ALL were 
obtained at initial diagnosis. The age d'1str'lbution was from 2 months until16 years and 6 months (mean 
5 years and 8 months). Twenty-five children were younger than 2 years and eight of them were infants 
(age <1 year). The diagnosis of ALL was made according to the FAB classification22 and was always con-
firmed by the laboratory of the Dutch Childhood Leukem'1a Study Group. 
Mononuclear cells (MNC) were isolated from PB or BM samples by Ficoii-Paque centrifugation (den-
sity 1.077 g/cm3; Pharmacia, Uppsala, Sweden). The freshly obtained MNC samples were subjected to a 
detailed immunophenotyping according to standard protocols.23-25 Rema·ming MNC were stored in liquid 
nitrogen. A leukemia was considered to be a precursor-B~ALL if the malignant cells were positive for ter-
minal deoxynucleotidyl transferase (TdT), CD19 and HLA-DR (pro-B~ALL), for TdT, CD10, CD19 and 
HLA-DR (common ALL). orforTdT, CD10, CD19, HLA-DR and cytoplasmic lg heavy-chain fl (Cylg11) (pre-
B-ALL). Immunological marker analysis of the precursor-B-ALL revealed that eight were pro-B-ALL, 135 
were common ALL, and 59 were pre-B-ALL. 
Southern blot analysis 
DNA was isolated from fresh or frozen MNC fractions as described previously.2 Fifteen micrograms 
of DNA were digested with the appropriate restriction enzymes (Pharmacia), size-separated in 0.7% 
agarose gels and transferred to Nytran-13N nylon membranes (Schleicher and Schuell. Dassel, Germany) 
as described.2 Incomplete and complete TCRB gene rearrangements were detected with TCRBD1U. 
TCRBD1. TCRBJ1. TCRBD2U, TCRBD2, TCRBJ2, and TCRBC probes (DAKO Corporation, Carpinteria. 
CA. USA) in EcoRI and Hind!!! digests.47 TCRG gene rearrangements were analyzed with the Jy1.2 probe 
in Bg/!1 digests and the Jy1 .3 and Jy2.1 probes in EcoRI digests.2,26,27 The configuration of the TCRD 
genes was analyzed with the TCRDJ1 probe in Bg/11, EcoRI, and Hind!!! digests and in 102 cases addi-
tionally with TCRDV1, TCRDV2, TCRDV3, TCRDRE. TCRDD1. TCRDD3, TCRDJ2, TCRDJ3. TCRDC. 
and TCRAPJ probes (DAKO Corporation).13 
PCR amplification 
Sixty-two precursor-B-ALL patients were subjected to detailed PCR study of TCRG and TCRD gene 
loci. PCR was essentially performed as described previously.13,28.29 In each 100 111 PCR reaction 0.1 ,u.g 
DNA sample, 12.5 pmol of the s· and 3· oligonucleotide primers, and 1 U Taq polymerase (PE 
Biosystems, Foster City, CA, USA) were used. The sequences of the majority of oligonucleotides used for 
amplification of TCRG and TCRD gene rearrangements were published before.13.29 Some primers were 
newly designed during the BIOMED-1 Concerted Action 'Investigation of minimal residual disease in acute 
leukemia: international standardization and clinical evaluation'. so All primers were synthesized on an AS! 
392 DNA synthesizer (PE Biosystems) using the solid-phase phosphotriester method. PCR conditions 
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Table 1. Frequencies of cross-lineage TCR gene rearrangements in childhood precursor-B-ALL. a 
Precursor-B-ALL TCR gene rearrangements and/or deletions 
TCR TCRB TCRG TCRD 
GIG RIG or RIR RIG or RIR 
RIG, RIR or D/R DiG or DiD 
Pro-B-ALL 25% 0% 13% 38% 25% 
(2/8) (0/8) (1/8) (318) (2/8) 
Common ALL 2% 40% 63% 61% 32% 
(3/134) (51/129) (79/125) (83/135) (43/135) 
Pre-B-ALL 15% 31% 56% 44% 39% 
(9159) (18/59) (33/59) (26/59) (23/59) 
Total 7% 35% 59% 55% 34% 
(14/201) (69/196) (113/192) (112/202) (68/202) 
a. Number of patients with germ line or rearranged cross-lineage TCR genes per total group of precursor-
B-ALL patients in parentheses. 
G, allele in germline configuration; R, rearranged allele; D, deletion of the CO gene segment. 
were: initial denaturation step of 3 min at gzoc followed by 45 s at 92°C, 90 s at 60°C, and 2 min at 72°C 
for 35 cycles using a PE Biosystems thermal cycler. After the last cycle an additional extension step of 10 
min at 72°C was performed. Appropriate positive and negative controls were included. 3D 
Heterodupiex analysis of PCR products 
For heteroduplex analysis, the PCR products were denatured at 94°C for 5 min after the final cycle 
of amplification and subsequently cooled to 4°C for 60 min to induce duplex formation.19 Afterwards the 
duplexes were immediately loaded on 6% non-denaturing polyacrylamide gels in 0.5 x Tris-Boric acid-
EDTA (TBE) buffer. run at room temperature, and visualized by ethidium bromide staining.19 Pstl-digest-
ed lambda DNA or a 100-bp DNA ladder (Promega Corporation, Madison, WI, USA) were used as size 
markers. 
Both SB and heteroduplex analysis of PCR products were performed in parallel in a double-blind 
manner. Concordance between the two methods was calculated assuming that the following gene con-
figurations concerned the same alleles: rearranged band in SB ::: presence of clonal homoduplex after 
PCR; germ line band and/or deletion in SB ::: no clonal PCR product. 
RESULTS 
SB analysis of TCRB gene rearrangements 
DNA samples from 196 precursor-B-ALL at diagnosis were examined for the 
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Table 2. Allelic frequencies of TCRB gene rearrangements in 196 childhood precursor-B-ALL 
patients as detected by SB analysis. 
TCRB gene configuration Pro-B-ALL Common ALL Pre-B-ALL Total group of 
(No. of alleles) (n•16) (n•260f' (n=118) precursor-B-ALL 
(n•394)a 
Germline alleles 16 (100%) 184 (71%) 94 (80%) 294 (75%) 
Rearranged alleles 0 76 (29%) 24 (20%) 100 (25%) 
Number of rearrangementsb 0 79b 27b 106b 
TCRB1 region: V~- 0~1, 0 0 0 0 
0~1- J~1, and/or V~- J~1 
TCRB2 region: V~- 0~2 0 3 (4%) 2 (7%) 5 (5%) 
0~1- 0~2 0 2 (3%) 0 2 (2%) 
V~- J~2 0 43 (54%) 14 (52%) 57 (53%) 
0~1- J~2 0 12 (15%) 5 (19%) 17 (16%) 
0~2- J~2 0 16 (20%) 2 (7%) 18 (17%) 
Unidentified to f32 0 3 (4%) 4 (15%) 7 (7%) 
a. The number of indicated alleles includes two precursor-B-ALL patients showing three monoclonal 
rearrangements, most probably as a result of trisomy 7. 
b. The number of rearrangements is higher than the number of rearranged alleles, because of the inci-
dental occurrence of subclones in these patients. 
presence of rearranged TCRB genes by SB (Figure 2A). In all eight pro-B-ALL no 
TCRB gene rearrangements were detected. In common ALL and pre-B-ALL, TCRB 
gene rearrangements were detected in 40% (51/129) and 31% (18/59), respectively 
(Table 1 ). The allelic frequencies of TCRB gene rearrangements are summarized in 
Table 2. Germline configuration was found in 75% (294/394) of the TCRB alleles. No 
rearrangements were detected with the TCRBD1 and Jj31 probes; only rearrange-
ments in the TCRB2 locus were observed. The majority concerned complete 
V(D)Jj32 rearrangements (53%) or incomplete Dj3-Jj32 rearrangements (33%) (Table 
2). In six patients (3%), SB analysis revealed weak bands, most probably derived 
from subclones. 
SB analysis of TCRG gene rearrangements 
Diagnosis DNA samples from 192 precursor-B-ALL patients were analyzed by 
SB for the presence of rearranged TCRG genes (Figure 2B). We detected TCRG 
gene rearrangements in 59% (113/192) of precursor-B-ALL; this finding concerned 
monoallelic rearrangements in 35% (39/113) and biallelic rearrangements in 65% 
(74/113). The distribution of the TCRG gene rearrangements in the three precursor-
B-ALL subgroups was 13% (1/8) in pro-B-ALL, 63% (79/125) in common ALL, and 
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Table 3. Allelic frequencies of TCRG gene rearrangements in childhood precursor-B-ALL.3 
TCRG gene configuration Total group (n::;192) Subgroup of 62 patients 
analyzed by SB 
Analyzed by PCR Analyzed by combined 
SB/PCRb 
Germline alleles 196 
Deleted alleles 1 
Rearranged alleles 187 
Number of rearrangements 187 
Involving Jy1.1/2.1 56 
Vyi-Jy1.1/2.1 37 
Vyii-Jy1.1/2.1 12 
Vyiii-Jy1.1/2.1 0 
Vy1V-Jy1.1/2.1 5 
not identified to Jy1.1/2.1 2 
Involving Jy1.2 1 
Involving Jy1.3/2.3 130 
Vyi-Jy1.3/2.3 93 
Vyii-Jy1.3/2.3 29 
Vyiii-Jy1.3/2.3 1 
Vy1V-Jy1.3/2.3 6 
not identified to Jy1.3/2.3 
(51%) 
( < 1%) 
(49%) 
84 56 
(30%) 17 
(20%) 15 
(6%) 1 
0 
(3%) 1 
(1%) 0 
(< 1%) 1 
(70%) 66 
(50%) 47 
(16%) 15 
(< 1%) 0 
(3%) 4 
(< 1%) 0 
84 
(20%) 
(18%) 
(1%) 
0 
(1%) 
0 
(1%) 
(79%) 
(56%) 
(18%) 
0 
(5%) 
0 
68 (55%) 
0 
56 (45%) 
12 (21%) 
10 (18%) 
1 (2%) 
1 (2%) 
(2%) 
43 (77%) 
31 (55%) 
9 (16%) 
3 (5%) 
a. Since frequencies of particular TCRG gene rearrangements are slightly different in the group studied 
by heteroduplex PCR analysis from the total group analyzed by SB, both groups are described sepa-
rately. 
b. Excluding weak gene rearrangements, probably derived from subclones. 
56% (33/59) in pre-B-ALL (Table 1 ). The allelic frequencies of TCRG gene 
rearrangements are summarized in Table 3. TCRG genes in germline configuration 
were found in 51% of alleles. Rearrangements to Jy1.3 or Jy2.3 gene segments pre-
dominated, comprising 70% of recombinations, while Jy1.1 or Jy2.1 gene rearrange-
ments were found in the vast majority of the remaining cases. Whenever SB allowed 
a reliable discrimination between Jy1 and Jy2 gene rearrangements (Figure 1) (172 
of the 187 rearranged alleles), we found that approximately 70% of the TCRG gene 
rearrangements occurred to Jy1 gene segments. 
V gene segments of the Vyl family were used most frequently (70% ), followed by 
Vyll (Vy9) (22%) and VyiV (Vy11) (6%). In up to 10% of all patients (19/192), i.e. 17% 
(19/113) of patients with TCRG gene rearrangements, either multiple bands of het-
erogeneous densities or weak bands in addition to germ line bands were found sug-
gesting oligoclonality in the TCRG locus (Figure 3). 
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Table 4. Allelic frequencies of TCRD gene rearrangements or deletions in childhood 
precursor~B-ALL as detected by SB analysis. 
TCRD gene configuration Pro-B-ALL Common ALL Pre-B-ALL Total group of 
(no. of alleles) (n=16) (n=273)a (n=119)a precursor-B-ALL 
(n=408)a 
Germline configuration 8 (50%) 47 (17%) 31 (26%) 86 (21%) 
TCRD gene rearran~ements 3 (19%) 121 (44%) 38 (32%) 162 (40%) 
TCRD gene deletion 5 (31%) 105 (38%) 50 (42%) 160 (39%) 
Number of rearrangementsc 3 131 47 181 
V02-D03 3 (100%) 92 (70%) 27 (57%) 122 (67%) 
002-003 0 15 (11%) 8 (17%) 23 (13%) 
otherd 0 24 (18%) 12 (26%) 36 (20%) 
a. The number of indicated alleles includes four precursor-B-ALL patients showing three monoclonal 
rearrangements, most probably as a result of trisomy 14. 
b. Based on rearrangements of V02 or 082 gene segments in the absence of the CO gene region, we 
assume that in 35% (36/1 02) of these TCRD gene deletions a V82 or 082 gene segment rearranged to 
a Ja gene segment. A Va-Ja rearrangement was assumed in 60% (61/102) based on the fact that no 
hybridization signal was obtained when all TCRD and yJa probes were used for hybridization. 
c. The number of rearrangements ·Is higher than the number of rearranged alleles. because of the occur-
rence of subclones. 
d. Rearranged TCRD bands in the presence of the CO gene segment are probably caused either by 
rearrangements of Va gene segments to the D03-J01 locus or by translocations or other chromosomal 
aberrations in the TCRD locus. 
SB analysis of TCRD gene rearrangements 
DNA samples from 202 precursor-B-ALL were analyzed for the presence of 
TCRD gene rearrangements and/or deletions (Figure 2C). In the total group of pre-
cursor-B-ALL patients monoallelic or biallelic TCRD gene rearrangements were 
found in 55% (112/202) and monoallelic or biallelic TCRD gene deletions in the 
absence of TCRD rearrangements were found in 34% (68/202), equally distributed 
over the three different precursor-B-ALL subgroups (Table 1 ). The allelic frequencies 
of germline TCRD genes (21%), TCRD gene rearrangements (40%), and deletions 
(39%) are summarized in Table 4. In 67% of rearranged alleles a Vo2-Do3 rearrange-
ment and in 13% a Do2-Do3 rearrangement was found. The remaining TCRD gene 
rearrangements detected by use of the Jo1 probe could not be identified precisely. 
They are probably caused either by rearrangements of a Va. gene segment to the 
Do3-Jo1 region or by translocations or other chromosomal aberrations in the TCRD 
locus. 
In addition, 102 patients were subjected to detailed SB TCRD analysis with mul-
tiple Vo, Do, Jo, probes as well as Co, oREc, and \[!Ja. probes. Rearrangements of Vo 
or Do gene segments in the absence of the Co gene region allowed us to conclude 
that in 36% (36/1 02) of the TCRD gene deletions a Vo2 or Do2 gene segment most 
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Figure 2. 
SB analysis of TCR genes in several precursor-B-ALL patients. Control DNA and DNA from precursor-B-
ALL patients were digested with the appropriate restriction enzymes, size-separated and blotted onto 
nylon membrane filters, which were hybridized with 32P-labeled probes. (A) TCRB gene analyses using 
EcoRl with the TCRBD2U probe. (B) TCRG gene analyses using EcoRI with the Jy1.3 probe. (C) TCRD 
gene analyses using Bg/11 with the TCRDV2 probe. The germline bands (G) and several TCR gene 
rearrangements are indicated. 
likely rearranged to a Ja gene segment (Figure 2C). Furthermore, we assume that 
in the majority of TCRD gene deletions (60%) a Va-Ja gene rearrangement 
occurred, because upon hybridization with all TCRD and \j!Ja probes no hybridiza-
tion signal was observed. In four precursor-B-ALL patients (five alleles) a unique 
hybridization pattern was found in which Vo (except for the Vo3 probe), oREC, and 
Do1 probes resulted in germline hybridization signals, whereas all Jo, Co, and the 
\j!Ja probes showed no hybridization signal, indicating deletion of these DNA gene 
segments. Therefore, it cannot be excluded that potential targets for rearrangements 
are present within the Do2-Do3 region or that chromosome aberrations in the 
TCRD!A locus are present. In four patients three TCRD gene rearrangements of 
identical intensity were found suggesting trisomy 14 (Table 4 and Figure 4). In up to 
7% (15/202) of precursor-B-ALL patients, i.e. 13% (15/112) of cases with TCRD 
gene rearrangements, the presence of additional weak SB bands suggested oligo-
clonality. 
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Figure 3. 
Clonality assessment via SB analysis and heteroduplex PCR analysis of TCRG genes. 
(A) DNA from precursor-B-ALL patients was digested with EcoRI. The filter was hybridized with the 32P-
Iabeled Jy1.3 probe. In two patients (5566 and 5575) multiple rearranged bands of different densities were 
found reflecting TCRG oligoclonality. (B) Heteroduplex PCR analysis with four family specific V primers in 
combination with Jy1.1/2.1, Jy1.2, and Jy1.3/2.3 primers. Five clonal PCR products were found in patient 
5566 sample, and three in patient 5575. There was no obvious difference in the intensity of homoduplex-
es between true 'allelic' rearrangements (patient 5531) and recombinations derived from subclones 
(patient 5575) 
Comparison of SB and heteroduplex PCR analysis of TCRG and TCRD 
DNA-based PCR amplification was simultaneously performed with SB analysis 
in a double-blind manner for TCRG and TCRD genes in 62 cases. Heteroduplex 
PCR analysis of TCRG with 12 primer pair combinations (four Vy family-specific 
primers with Jy1.1/2.1, Jy1.2, and Jy1.3/2.3 primers) revealed all except one allelic 
gene rearrangements detected by the SB technique. In seven cases with TCRG 
gene rearrangements estimated as monoallelic based on SB, two homoduplexes 
were found, indicating the presence of two rearrangements of the same gene seg-
ments. Furthermore, with the same primer combinations we were able to amplify 10 
minor TCR gene rearrangements, demonstrated by SB analysis as weak bands 
(Figure 3). They were visualized as 12 homoduplexes of intensities equal to products 
derived from monoallelic gene rearrangements. Finally, nine rearrangements were 
detected exclusively by heteroduplex PCR analysis (six rearrangements to Jy1.1/2.1, 
two Vyii-Jy1.3/2.3, and one Vy1V-Jy1.3/2.3 recombination). Overall, combined SB 
and PCR data indicate the presence of minor subclones of TCRG gene rearrange-
ments in up to 26% (16/62) of childhood precursor-B-ALL patients, i.e. 38% (16/42) 
of the patients with TCRG gene rearrangements. 
Using six primer pair combinations for heteroduplex PCR analysis of TCRD 
(V81-J81, V82-J81, V83-J81, V82-D83, D82-D83, D82-J81) we have not found any 
clonal PCR products of rearrangements to the J81 segment. Moreover, samples 
shown by SB to contain clonal V82-D83 gene rearrangements revealed monoclonal 
homoduplexes in all but four cases (Figure 4). In those four patients heteroduplex 
PCR analysis showed an oligoclonal pattern of the V82-D83 joining. All samples 
found by SB to contain clonal D82-D83 recombinations were also monoclonal in het-
eroduplex PCR analysis (Figure 4 ). This also concerned weak SB bands, probably 
derived from subclones. In cases, when 'atypical' rearrangements to D83/J81 locus 
were detected with SB (the sizes of clonal bands could not be assigned to a partic-
ular V8-J8 joining) we did not find any clonal PCR products with the applied primer 
sets. Based on combined SB and PCR data there was an evidence for oligoclonali-
ty in TCRD gene locus in up to 21% of precursor-B-ALL patients (13/62), i.e. 30% 
(13/43) of the patients with TCRD gene rearrangements. The overall concordance 
between SB and heteroduplex PCR analysis for detection of clonal TCRG and TCRD 
gene rearrangements ranged from 78 to 87%. 
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Clonality assessment via SB analysis and heteroduplex PCR analysis of TCRD genes. 
(A) DNA from precursor-B-ALL patients was digested with Bgf!l and EcoR!. The filter was hybridized with 
the 32P-Iabeled TCRDJ1 probe. Based on SB band intensity and sizes 'triallelic' TCRD rearrangement 
was assumed in patients 5324 (two times V02-D03, and single 002-083) and 5380 (two times 082-083, 
and single V82-Do3). and biallelic in patients 5135 (V82-Do3 and ?-Do3/Jo1) and 5399 (V82-Do3 and 082-
003), respectively. (B) Heteroduplex PCR analysis with V02 and 082 primers in combination with a 083 
primer showed fully concordant results with SB analysis. ss, single-strand fragments; he, heteroduplexes; 
ho, homodup!exes; Mw marker, 1 00-bp molecular weight marker. 
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Combinations of cross-lineage TCR gene rearrangements based on SB 
analysis 
The different combinations of cross-lineage TCR gene rearrangements in our 
total group of precursor-B-ALL are summarized in Table 5. Twenty-seven percent of 
all precursor-B-ALL patients had simultaneously rearranged and/or deleted TCRB, 
TCRG, and TCRD genes. These combined rearrangements were not found in eight 
pro-B-ALL patients, whereas in common ALL and pre-B-ALL 30% and 25% of cases 
had all three TCR genes rearranged or deleted. 
Twenty-six percent of all precursor-B-ALL cases showed TCRD gene rearrange-
ments and/or deletions, with germline TCRB and TCRG genes. In contrast, TCRB 
and/or TCRG gene rearrangements without TCRD gene rearrangements and/or 
deletions were observed in only 4% of cases. Similarly, 32% of all precursor-B-ALL 
cases had a rearranged TCRG gene with a germline TCRB gene, while only 8% 
showed TCRB gene rearrangements without TCRG gene rearrangements. These 
data indicate that TCRD gene rearrangements and/or deletions occur most fre-
quently and that virtually all TCRB and TCRG rearrangements coincide with TCRD 
gene rearrangements and/or deletions. 
Table 5. Combination of TCR gene rearrangements as detected by SB analysis in childhood precursor-B-ALL 
from our data and data reviewed from the literature. 
Cross-lineage TCR gene rearrangements and/or deletions 
References G only 13 onlyy only a only 13+ y only 13+ a on!yy+ 0 )3+ y+ 0 
Hara7 (n=29) 10% (3) 0% (0) 0% (0) 34% (10) 0% (0) 3% (1) 24% (7) 28% (8) 
DyerS (n=12) 0% (0) 0% (0) 0% (0) 25% (3) 0% (0) 8% (1) 17% (2) 50% (6) 
Fe!ix10 (n=52) 15% (8) 4% (2) 0% (0) 25%(13) 0% (0) 6% (3) 29% (15) 21% (11) 
Fey11 (n=7) 0% (0) 0% (0) 0% (0) 43% (3) 0% (0) 14% (1) 29% (2) 14% (1) 
This study (n=192) 7%(14) 2% (3) 2%(4) 26%(50) 0%((0) 6% (12) 30% (57) 27% (52) 
Total group of 9%(25) 2% (5) 1% (4) 27% (79) 0% (0) 6% (18) 28% (83) 27% (78) 
precursor-B-ALL 
(n=292) 
G. germline configuration; 13. TCRB gene rearrangement; y. TCRG gene rearrangement; a. TCRD gene rearrangement 
and/or deletion 
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DISCUSSION 
We investigated a large group of 202 precursor-B-ALL patients for the configu-
ration of their cross-lineage TCR gene rearrangements. Rearrangements and/or 
deletions of the TCRB. TCRG and TCRD genes were found in 35%, 59% and 89%, 
respectively. Most TCRB gene rearrangements (53%) were monoallelic complete 
V(D)J~2 rearrangements, TCRG genes most frequently (-70%) contained 
rearrangements to the Jy1 gene segments, and 80% of TCRD gene rearrangements 
represented incomplete V82-D83 or D82-D83 rearrangements, which is in agreement 
with previously published data.S-12 Our earlier literature review on cross-lineage TCR 
gene configuration in childhood precursor-B-ALL,6 suggested that TCRB gene 
rearrangements occur in 33% of precursor-B-ALL, TCRG gene rearrangements in 
44%, and TCRD gene rearrangements and deletions in 57% and 26%, respectively. 
These percentages of TCR gene rearrangements and/or deletions are all lower than 
in the current study of childhood precursor-B-ALL (Table 1 ). This difference is prob-
ably due to the extended panels of TCR DNA probes and restriction enzymes used 
for this study2-13.27 lg and TCR gene rearrangements can be missed when only one 
DNA probe is used in combination with a single restriction enzyme, especially when 
this results in large germline restriction fragments. Furthermore, especially the use 
of upstream and downstream D~ probes has given more detailed insight in the con-
figuration of the TCRB locus. We found a significantly higher frequency of incomplete 
TCRB gene rearrangements (42% of all TCRB gene rearrangements) than reported 
previously (Table 2).5.7.10.11 This is most probably owing to the usage of the four dif-
ferent D~ probes, which allow identification of incomplete V-D~. D-D~, and D-J~ 
gene rearrangements. 
Four other research groups analyzed and compared all three cross-lineage TCR 
genes in a total number of 100 cases.5·7·10.11 Combining these published data and 
the data presented here show that TCRD gene rearrangements and/or deletions 
occurred in the majority of cases (-90%) and that 27% of childhood precursor-B-ALL 
had TCRD gene rearrangements and/or deletions with germline TCRG and TCRB 
genes (Table 5). In contrast, TCRG and/or TCRB gene rearrangements without 
TCRD gene rearrangements and/or deletions were found in only 3% (9/292) of cases 
(Table 5). Similarly, 29% (87/292) of precursor-B-ALL cases had rearranged TCRG 
genes with germline TCRB genes, while only 8% (23/292) showed TCRB gene 
rearrangements without TCRG gene rearrangements (Table 5). Apparently in pre-
cursor-B-ALL, similarly to the hierarchy during early T-cell development, rearrange-
ments in the TCRD locus occur first, followed by TCRG gene rearrangements, and 
subsequently by TCRB gene rearrangements. 
The frequencies of cross-lineage TCR gene rearrangements seem to be related 
to the maturation stages of B-cells. The frequency of TCR gene rearrangements is 
lower in immature precursor-B-ALL (pro-B-ALL) as compared to CD10+ precursor-
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B-ALL (common ALL and pre-8 ALL) (Table 1) and if present, rearrangements exclu-
sively concern a single locus in pro-B-ALL. When comparing our common ALL and 
pre-B-ALL subgroups, it is striking that in the 'mature' (Cylgll+) pre-B-ALL group a 
higher frequency of patients have all TCR genes in germline configuration (15% in 
pre-B-ALL vs 2% in common ALL; Table 1 ). Moreover, cross-lineage TCR gene 
rearrangements are rare (<5%) in mature B-cell malignancies, such as chronic lym-
phocy1ic leukemias (CLL) or non-Hodgkin's lymphomas (NHL)6,31,32 
The occurrence of cross-lineage TCR gene rearrangements in precursor-B-ALL 
can be explained in several ways. Based on the fact that cross-lineage TCR gene 
rearrangements seem to be rare in normal precursor-S-cells, TCR gene rearrange-
ments may only occur in early precursor cells and the occurrence of TCR gene 
rearrangements in precursor-S-cells may stop their further differentiation and matu-
ration.• As a consequence, similarly to cortical thymocy1es in the thymus, a large 
fraction of proliferating, immature BM precursor-S-cells without functional !GH 
rearrangement and/or with cross-lineage gene rearrangements undergo apoptosis 
unless they become neoplastic_3,33,34 However, this would imply that oncogenic 
transformation preferentially affects precursor-S-cells with cross-lineage TCR gene 
rearrangements. An alternative explanation could be that cross-lineage TCR gene 
rearrangements in precursor-B-ALL result from the continuing activity of the V(D)J 
recombinase system after the malignant transformation and maturation arrest.3 We 
favor the latter hypothesis, since this would explain the low frequency of cross-line-
age TCR gene rearrangements in normal precursor-S-cells and in mature B-cell 
malignancies. From our data it is also apparent that common ALL is a seemingly dis-
tinct subentity with a highly active recombination machinery and accessible lg and 
TCR genes. In very immature B-cells (pro-B-ALL) and more mature 8-cells (pre-B-
ALL, 8-CLL, and 8-NHL) the V(D)J recombinase is less active and the mature B-cell 
malignancies have already passed the lineage commitment point so that TCR genes 
are not accessible any more and rearrangements are no longer possible. 
Owing to their enormous diversity, junctional regions of rearranged lg and TCR 
genes represent ideal PCR targets for the detection of MRD.14-17-35 In precursor-B-
ALL, this especially concerns junctional regions of /GH, IGK, TCRG and TCRD 
genes.15 For this purpose the precise configuration of the gene rearrangements (i.e. 
the V(D), and J gene segments) has to be identified at diagnosis. We determined the 
frequency of precursor-B-ALL, which have an identifiable type of TCRG (59%) and/or 
TCRD (49%) gene rearrangement and found that in at least 79% (159/202) of pre-
cursor-B-ALL one or more rearranged TCRG and/or TCRD genes can be used as 
targets for PCR-mediated MRD detection. In 55% of patients even two TCRG and/or 
TCRD targets were present. 
Comparative SB and heteroduplex PCR analysis of TCRG and TCRD in 62 
patients showed concordance of approximately 80% between the two techniques. 
One explanation for the discrepancies is the efficient PCR detection of rearrange-
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ments derived from small subclones, which are difficult do detect by SB. Secondly, 
15 rearrangements to the D83/J81 region as detected by SB could not be assigned 
to a particular V8-J8 joining based on the sizes of clonal bands. In those cases no 
clonal PCR products were found with the TCRD applied primer sets. These 
rearrangements probably reflect Va-J81 rearrangements or translocations into the 
TCRD locus. Furthermore, four precursor-B-ALL patients with seemingly 'clonal V82-
D83 bands' on SB analysis revealed an oligoclonal pattern by heteroduplex PCR 
analysis. 
Based on combined SB/PCR data and on reports from the literature the fre-
quency of cross-lineage TCR oligoclonality in precursor-B-ALL can be estimated to 
be -20%. This seems to be significantly lower as compared to IGH, where multiple 
rearranged IGH gene bands, generally differing in density, were found in 30-40% of 
patients.3641 However, when focusing on the group of patients with TCRG and 
TCRD rearrangements, the frequency of oligoclonality is comparable to IGH gene. 
Taking into account JGH oligoclonality and the relative instability of IGH rearrange-
ments,36-38.42.43 TCR gene rearrangements seem to be at least equally suitable 
MRD-PCR targets. The stability of the leukemia-specific TCR gene junctional 
regions is reasonably high as found in studies of ALL patients at diagnosis and 
relapse, which showed that in 80-90% of leukemias at least one rearranged TCR 
allele remained stable.37.44.45 
Heteroduplex PCR analysis appeared to be a valuable method for the identifica-
tion of TCRG and TCRD MRD-PCR targets. This method is more rapid and less 
expensive than SB analysis and requires only small amounts of DNA. Heteroduplex 
PCR data indicate that MRD monitoring is possible using TCRG and TCRD targets 
in approximately 80% of childhood precursor-B-ALL patients. Nevertheless, reliable 
quantitative molecular techniques such as TaqMan technology are needed to distin-
guish between rearrangements from major and minor subclones46 
Our study indicates that cross-lineage TCR gene rearrangements and/or dele-
tions in childhood precursor-B-ALL occur at high frequency, in a hierarchical order, 
and are incomplete in a large number of cases (TCRB and TCRD genes). In at least 
79% of precursor-B-ALL one or more of the TCRG and TCRD gene rearrangements 
can be identified and can be used as targets for PCR-mediated MRD detection. 
Based on the combined data it is also possible to reduce the broad panel of six 
TCRD and 12 TCRG primer combinations to two TCRD combinations (V82-D83 and 
082-083) and six TCRG combinations (Vyl, Vyll, VyiV family specific primers with 
Jy1.1/2.1 and Jy1.3/2.3 primers) resulting in the detection of 80% and 97% of all 
TCRD and TCRG gene rearrangements, respectively. 
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ABSTRACT 
This study aimed at identification and detailed immunobiological characterization 
of Vo2-Ja; gene rearrangements in precursor-B-ALL. We developed a multiplex het-
eroduplex PCR assay wit 61 Ja primers and analyzed 339 childhood precursor-B-
ALL, of which 153 cases were also studied by Southern blotting. 
A total of 158 clonal V82-Ja gene rearrangements were identified in 141 of the 
339 patients (41 %). The combined PCR!Southern blot studies in the subgroup of 153 
patients showed that among 70 cases containing V82-Ja rearrangements, 39 (56%) 
showed monoclonal and 31 (44%) showed oligoclonal rearrangement patterns. 
Based on sequence analysis, preferential usage of the Ja29 gene segment was 
found in 85 of the 158 Vo2-Ja sequences (54%). The remaining 73 sequences used 
26 other Ja segments, which included two additional clusters, one involving the most 
upstream Ja segments, i.e. Ja48 to Ja61 (23%), and the second cluster located 
around the Ja9 gene segment (8%). The stability of Vo2-Ja joinings analyzed at 
relapse in 42 patients was excellent for monoclonal rearrangements (88% stable) as 
compared to oligoclonal V82-Ja rearrangements (only 40% stable). Finally, real-time 
quantitative (RQ)-PCR experiments revealed that V82-Ja rearrangements can be 
used as patient-specific targets for detection of minimal residual disease (MRO) with 
reproducible sensitivities of at least 1 Q-4 in most cases. Using RQ-PCR, we demon-
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strated that Vo2-Ja rearrangements were detectable in normal bone marrow and 
peripheral blood samples, albeit at very low levels (generally below 1 o-3 ). In conclu-
sion, monoclonal Vo2-Ja gene rearrangements might serve as principal MRD-PCR 
targets in -25% of precursor-B-ALL. 
INTRODUCTION 
Current diagnostics in hematopoietic malignancies frequently employs poly-
merase chain reaction (PCR)-based techniques for detection of low levels of malig-
nant cells, known as minimal residual disease (MRD).1 In childhood acute lym-
phoblastic leukemia (ALL), MRD information has high prognostic value, as was 
shown by several large multi-center prospective studies2-6 MRD studies can pre-
cisely assess the early response to induction treatment and thereby contribute to an 
improved definition of remission in ALL. Consequently, MRD detection is currently 
being incorporated into stratification of treatment protocols.7 ·8 
In childhood ALL, detection of MRD most frequently relies on patient-specific 
junctional regions of immunoglobulin (lg) and T-cell receptor (TCR) gene rearrange-
ments, mainly concerning lg heavy chain (/GH) gene, lg kappa deleting element 
(/GK-Kde), TCR gamma (TCRG) gene and TCR delta (TCRD) gene.8-11 These 
lg/TCR gene rearrangements can be identified at initial diagnosis in approximately 
95% of ALL patients, comprising at least two sufficiently sensitive targets (:s;1 Q-4) for 
real-time quantitative (RQ)-PCR based MRD detection in approximately 80% of 
patientsB Thus, in 20-25% of ALL cases, the lg/TCR MRD-PCR targets need still to 
be optimized. For instance, TCRG gene rearrangements are potentially less sensi-
tive markers owing to the limited number of different Vy and Jy gene segments and 
the frequent occurrence of TCRG gene rearrangements in polyclonal T-cells in bone 
marrow (BM) follow-up samples.12 In fact, in not more than half of the TCRG gene 
rearrangements in precursor-B-ALL patients, a maximal sensitivity of 1 Q-4 could be 
reached in RO-PCR experiments.13 Moreover, in approximately 15% of precursor-B-
ALL patients, oligoclonal IGH gene rearrangements are the only available MRD tar-
getsB In such patients all oligoclonal targets should be monitored to prevent false 
negative results, which is costly and time consuming. 14 In addition, substantial 
expansions of normal precursor-B-cells with polyclonal IGH gene rearrangements in 
regenerating BM after cessation of maintenance therapy might affect the sensitivity 
of MRD detection using lg gene rearrangements as PCR targets.15 Therefore, par-
ticularly precursor-B-ALL patients might profit from the introduction of new MRD-
PCR targets. 
Vo2-Ja gene rearrangements might be attractive new MRD-PCR targets, but 
have not yet been evaluated for this purpose. Several earlier studies indicated that 
TCRD gene deletions with rearrangements in the Ja locus occur frequently in pre-
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cursor-B-ALL (Figure 1).16-21 Our detailed Southern blot study indicated that at least 
40% of TCRD alleles in precursor-B-ALL are deleted. which might be largely due to 
V82-Ja gene rearrangements.21 Therefore, we developed a multiplex PCR strategy 
for easy identification and characterization of clonal Vo2-Ja gene rearrangements in 
a large series (n = 339) of precursor-B-ALL patients. In a subset of patients, we 
assessed the stability of these rearrangements at relapse of ALL. We also investi-
gated the presence of the most frequent Vo2-Ja rearrangements in normal lymphoid 
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Figure 1. 
(A) Consecutive rearrangements in the TCRD/A locus involving the V02 gene segment, which are char-
acteristic for precursor-B-ALL. The main pathway concerns consecutive V02-003 ->- V02-Ja recombina-
tions. 002-003 and 002-Jo. gene rearrangements can also occur albeit at much lower frequencies. Solid 
boxes below the gene segments represent the probes used for Southern blot hybridization. 
(B) Southern blot analysis with TCROV2 probe in 10 precursor-B-ALL patients. V02-D03 and/or V02-Jo:29 
gene rearrangements in patients 5602, 5675, 5683, and 5696 are monoclonal. The presence of several 
rearranged bands of different densities in patients 5515, 5647, 5662, and 5698 is consistent with oligo-
c!onality. Both V02 alleles in patient 5670 are deleted. while patient 5565 has both V02 alleles in germ line 
configuration. 
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tissues. Finally, we evaluated the sensitivity of V82-Ja rearrangement as RQ-PCR 
targets for MRD monitoring_ 
PATIENTS, MATERIALS AND METHODS 
Patients 
BM or peripheral blood (PB) samples from 339 children with precursor-B-ALL were obtained at initial 
diagnosis. The age distribution ranged from 1.5 months until 15.9 years. The diagnosis of precursor-B-
ALL was made according to FAB and standard immunophenotypic criteria.22.23 Immunological marker 
analysis of the precursor-B-ALL revealed that 12 were pro-B-ALL, 226 were common ALL. and 101 were 
pre-B-ALL. 
Southern blot analysis 
Mononuclear cells (MNC) were isolated from BM or PB samples by Ficoii-Paque centrifugation (den-
sity 1.077 g/cm3; Pharmada, Uppsala, Sweden). DNA was isolated from fresh or frozen MNC fractions 
as described previously.24 ,25 Fifteen micrograms of DNA were digested with the appropriate restriction 
enzymes (Pharmacia). size-separated in 0.7% agarose gels and transferred to Nytran-13N nylon mem-
branes (Schleicher and Schuell. Dassel, Germany) as described.24 The configuration of the TCRD genes 
was analyzed w·1th the TCRDJ1 and TCRDV2 probes (DAKO Corporation. Carpinteria. CA. USA) in Bg/11, 
EcoRI, or Hind Ill digests_26 
Primer design and heteroduplex PCR analysis 
V02 and 002 primers have been developed by the BIOME0-2 Concerted Action BMH4-CT98-3936 
~peR-based c!onality studies for early diagnosis of lymphoproliferative disorders" {Van Oongen et al. sub-
mitted for publication). Based on the available nucleotide sequence of the human 3' terminal end of the 
TCRAID locus (EMBL accession no. M9408127). 61 Ja. primers were designed compatible to the V02 
primer, using OLIGO 6.0 software (Or. W. Rychlik; Molecular Biology Insights. Inc., Cascade. CO, USA) 
and applying previously described guidelines (Table 1).11 Oligonucleotide Ja. primers of 17 to 23 bp were 
positioned 111 to 169 bp downstream of the involved recombination signal sequence (RSS). Secondary 
structures such as pr"1mer dimers and ha'1rpins were avoided, and the melting temperature (Tm) was 68°C 
± 3°C. The 61 Ja. primers were subsequently checked for absence of ~cross"-dimer formation, using the 
OLIGO 6.0 software. This a!! owed as to design seven V02-Ja multiplex PCR tubes (Table 2). 
The multiplex V02-Ja. PCR analyses were performed in all 339 patients. essentially as described pre-
viously.28.29 In each 50 !J.I PCR reaction 100 ng DNA sample, 10 pmol of the s· and 3' oligonucleotide 
primers, and 1 U AmpliTaq Gold polymerase (PE Biosystems, Foster City, CA) were used. PCR conditions 
were: initial denaturation for 10 min at 94°C, followed by 35 cycles of 45 sec at 92°C, 90 sec at 60°C, and 
2 min at 72°C using a Perkin-Elmer 480 thermal cycler (PE Biosystems). After the last cycle an addition-
al extension step of 10 min at 72°C was performed. Appropriate positive and negative controls were 
included in all experiments.11 
Additionally, the presence of clonal V02-003 and 002-003 gene rearrangements was tested using 
our classical monoplex approach.11 Multiplex 082-Ja. PCR was performed in 11 patients, pre-selected 
based on Southern blot and PCR information (i.e., germline V02 allele with deleted 003/J01 area and the 
absence of clonal V02-Ja. rearrangements). 
For heteroduplex analysis, the PCR products were denatured at 94°C for 5 min after the final cycle 
of amplification and subsequently cooled to 4°C for 60 min to induce duplex formation_30 Afterwards the 
duplexes were immediately loaded on 6% non-denaturing polyacrylamide gels in 0.5 x Tris-borate-EDTA 
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(TBE) buffer, run at room temperature, and visualized by ethidium bromide staining (Figure 1).30 A 100-
bp DNA ladder (Promega Corporation, Madison, WI, USA) was used as size marker. 
Comparative heterodup!ex analysis of PCR products 
Comparative heteroduplex analysis of V02-Ja PCR products at diagnosis and relapse concerned 42 
relapsed precursor-B-ALL, which contained Vi52-Ja rearrangements at diagnosis. The relapse samples of 
these patients were at first analyzed in monoplex PCR with those primer combinations, which showed 
clonal PCR products at diagnosis. When the clonal PCR product was also found at relapse, its identity 
was subsequently compared with the PCR product found at diagnosis by means of mixed heteroduplex 
analysis, ·,.e. m·,x·mg of the diagnosis and relapse PCR products followed by heteroduplex analys-IS (F'1gure 
2).14-31 When clonal PCR products found at diagnosis were undetectable at relapse, the relapse sample 
was analyzed with all 7 V02..Ja multiplex tubes. 
Sequence analysis of V02-Ja. gene rearrangements 
Direct sequencing of V02-Ja rearrangements was performed with the V02 primer using the dye-ter· 
minator cycle sequencing kit with AmpliTaq DNA polymerase FS on an ABI 377 sequencer (PE 
Biosystems) as previously described.1o When heteroduplex PCR analysis revealed more than two clonal 
bands i.e. two homoduplexes. or an additional upper band resulting from extension to downstream Ja 
segments, homoduplexes and/or heterodup!exes were excised from the polyacrylamide gel, eluted and 
directly sequenced as described before.32 Also clonal PCR products discordant between diagnosis and 
relapse of precursor-B-ALL as found by mixed heteroduplex analysis. were subsequently sequenced and 
the sequences were evaluated for the presence of common V02-D03 stems. Ja gene segments were 
identified by comparison to germline sequences as previously described.33 For alignments of D02 and 
D03 segments in V02-Ja junctional regions, it was required to have at least 4 and 5 consecutive match· 
ing nucleotides. respectively.33 
RQ·PCR-based detection of clonal V02-Ja. gene rearrangements 
RQ-PCR-based detection of clonal V82·Ja gene rearrangements relied on allele specific oligonu-
cleotide (ASO) primer approach as described previously.13,34 The germline TaqMan probe (5'·AGACC-
CTICATCTCTCTCTGATGGTGCAAGTA-3') and forward primer (5'-TGCAAAGAACCTGGCTGTACT-
TAA-3') were designed in the V32 gene segment. The ASO primers were positioned at the junctional 
regions, preferably covering the D03-Ja, and sometimes also the Vd2-Dd3 junction (Table 3). A standard 
annealing temperature of 60°C was used. To determine the efficiency of amplification and sensitivity of the 
PCR target, diagnostic DNA was diluted in 1 0-fold steps into control MNC DNA, from 1 o-1 down to 1 o·6. 
The serial dilutions of diagnostic DNA were subjected to RQ-PCR analysis together w'rth negat'1ve controls 
(H20 and control MNC DNA). Serial dilutions of diagnostic samples were analyzed in triplicate. To correct 
for the quantity and quality (amplifiability) of DNA, RO·PCR analysis of the albumin gene was used.35 
Non-specific amplification was defined as any amplification observed in control MNC DNA. The 
reproducible sensitivity of a primers/probe combination was defined as the maximal 1 0-fold dilution step 
with a maximal difference in cycle threshold (CT) value of 1.5 between the duplicate of the involved dilu-
tion samples and with a maximal CT value of 40 cycles.13.36 The standard curve within this reproducible 
range should have a correlation coefficient of at least 0.95 for precise quantification. Furthermore, the CT 
values of the reproducible sensitivity had to be at least three cycles lower than the CT values of control 
MNC DNA (tested in two· to six-fold). In case non-specific amplification was observed, the maximal sen-
sitivity was defined as the maximal1 0-fold dilution of the diagnostic sample giving a reproducible ~value 
and with the highest CT at least 1 cycle lower than the lowest CT of non-specific amplification. !f non-spe-
cific amplification was not observed, the maximal sensitivity was defined as the maximal 1 0-fold dilution 
of the diagnostic sample giving specific but non-reproducible amp!ification.13,3s 
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Table 1. Primers developed for PCR and sequence analysis of V02-Ja. and DS2-Ja gene 
rearrangements. 
Primer code Size of primer (bp) Position in bp~ Sequence { 5' -)o 3' ) 
Ja1 18 153 GGGACCCAGAAATCAGAA 
Ja2 18 166 CTACAGCAAGCCTCACCA 
Ja3 20 160 GAGCCCACAGAGGAAAATAC 
Ja4 21 151 CCCCAAGTTTGCTATAGATCA 
Ja5 23 129 TTCATCATCTAAGAAAGCAGAGT 
Ja6 23 160 GATGGAATAGATCACAACACAAA 
Ja7 18 131 AGAGGCTCTCCAGCACAG 
Ja8 23 113 ATATATGCCCAATATTGAGGATA 
Ja9 23 169 TTTAACTGGCAGACAAAACTATG 
Ja10 22 123 TTCTTCCACTTATTGTCACCAG 
Ja.11 21 139 ATGAGGATAACACGCAATACA 
Ja12 22 151 TCCAGCTCATTTTGCATTATAC 
Ja.13 22 120 TTACGGTCTGAGAGAAGACAAC 
Ja14 22 120 GCAGTAAGTTTAGTGGGTCTCA 
Ja15 20 133 ATTTGGTCACCTGTGCAATA 
Ja16 20 150 AACATTTGGCAGTCCACTTA 
Ja.17 21 144 GACATTAATTTGGGCCAATAC 
Ja.18 21 124 CTCCCCTTTTAATTTCTCCAC 
Ja19 21 162 CTCCCATCAGAAAGCAATTAC 
Ja20 23 169 TGGGAAAGCTCTTAGAATTTAGT 
Ja.21 20 153 GACCCAAAATGCAAAATAAA 
Ja.22 21 146 CTCAGGCCCATTAAGTTACAT 
Ja23 21 163 TCCCCCTCTCTAAACATTCTT 
Ja.24 20 167 GGCTTCCTTTCAGATGTGTT 
Ja25 23 115 AGTTTTCCTCTTGGAGATAATCA 
Ja26 18 141 GACTCCTGGCCTCAAGAC 
Ja27 21 162 ATTAATAAAGAGCCCAACCAG 
Ja28 19 157 GCAAAGAAAACACCACCTG 
Ja29 21 146 GGCAAAAGCATTCTAGGTACA 
Ja.30 18 153 GCCACCCACATGTCTTAG 
Ja31 23 125 ATTAAATCTCCACTAACTTCACG 
Ja32 19 129 TGCTGTCGCTTCCTACTTG 
Ja33 21 157 GCAGGCTGACTTGTTCTTAAA 
Ja34 20 146 CAACAAGGAGCAAAACTTCA 
Ja.35 19 159 ACTGGAAAATGGGTGTGTG 
Ja36 20 125 GTGTCTGGGATGTGAGAACT 
Ja37 23 148 TTTGGTTAGAAGTTGAGACAGAG 
Ja.38 22 107 AGGAGGCAGTTTCTGAGATATT 
Ja39 18 127 GCTCAGTGCTACGGCTTC 
Ja40 20 120 CCTCAAACATGAACACCAAC 
Ja41 18 120 AACAGGTCCCATTGGATT 
Ja.42 20 124 TTGCCCAGAGTGACAAAGTA 
Ja.43 18 124 GAAACTGCCCAGAACAGC 
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Continued Table 1 
Primer code Size of primer (bp) Position in bpa Sequence ( 5' -> 3' ) 
Ja44 21 127 TCTGCAGTATCCCCTGTTTTA 
Ja45 21 148 ATGAGCCAAGGTTTAGAAATG 
Ja46 19 144 CCAAAGGAGGACAACTCAA 
Ja47 18 128 TCCCAGCCAGAAAAAGTT 
Ja48 19 114 TCCCCAGAATCTTATGCAG 
Ja49 19 111 GCAGTTTAAAGGGTTTGCT 
Ja50 17 154 CAACCACGATGCCATCT 
Ja51 19 143 GGATTTATGCTGCCACTGA 
Ja52 17 118 GGGGAAGGGAGCAAAAG 
Ja53 18 130 ACCTGACACTGGGGTGAC 
Ja54 21 130 GAGGGGCAAGTAATTAAATCA 
Ja55 21 152 AGTATACGTCCCTCAAGGAGA 
Ja56 21 142 AGGAGATTCGGTTATCTTTCA 
Ja57 21 143 GGACCTGGGTTATAAAACAGA 
Ja58 19 163 GACTTGAATGTGGCAGAGA 
Ja59 20 149 ATCAAATCCTCAGGGAGAAG 
Ja60 19 120 CTGATTGCCAGGTGTTAGG 
Ja61 23 135 GTTTGTTAAGGCACATTAGAATC 
a. The position of the 5' end of the primer is indicated downstream relative to the RSS of the involved Ja 
gene segments. 
RQ-PCR-based detection of polyclonal V02-Ja. gene rearrangements in normal cell samples 
Normal tissue samples tested for the presence of V32-Ja gene rearrangements included normal PB, 
E-rosette+ PB-cells (T-cells). E-rosette- PB-cells (B-cells. NK-cells and monocytes). normal BM, sorted 
BM B-cells and B-cell precursors. tonsils, lymph nodes. thymuses, and post-chemotherapy regenerating 
BM samples, which are known to contain high frequencies of normal precursor-B-cells.15.37 Whenever 
possible, at least two different samples were tested per category. each sample in triplicate. To analyze the 
presence of V32-Ja gene rearrangements in normal tissue samples. the above-described germline 
Table 2. Composition of the multiplex tubes for detection of V02-Ja gene rearrangements. 
Tube code 
V32-Ja Tube 1 
V32-Ja Tube 2 
V32-Ja Tube 3 
V82-Ja Tube 4 
V82-Ja Tube 5 
V82-Ja Tube 6 
V82-Ja Tube 7 
Tube composition 
V82 + Ja1, Ja6, Ja7, Jo22, Ja26, Ja40, Ja54, Ja57 
V02 + Ja2, Ja3, Ja5, JaB, Ja11, Ja12, Ja13, Ja19 
V02 + Ja4, Ja10, Ja14, Ja20, Ja23, Ja29, Ja42, Ja48 
V32 + Ja9, Ja16, Ja35. Ja37, Ja38, Ja41, Ja49, Ja51, Ja56, Ja60 
V02 + Ja15, Ja18, Ja28, Ja34, Ja36, Ja43, Ja44, Ja45, Ja46 
V82 + Ja17, Ja21, Ja24, Ja25, Ja27, Ja31, Ja32, Ja33, Ja39 
V02 + Ja30, Ja47, Ja50, Ja52, Ja53, Ja55, Ja58, Ja59, Ja61 
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5199A 
51999 
5354 
5378 
5393 
5450 
5462 
5504A 
55048 
'"' 
Germline V02 sequence 
BI.G.C.C.I.GJ_GACAQQ 
GTGCCTGTGAC 
GTGCC 
GTGCCTGT 
GTGCCTGTGAC 
GTGCC 
GTGCCTGTGA 
GTGCCTGTGAC 
GTGCCTGTGA 
GTGCCTGTGACA 
GTGCCTGTG 
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VS2 
juncf1onal 
region 
033 Ja.29 ,. 
Germline 003 sequence 
8-CI.G~_GJ;i.GATAQ.G_ 
Germline Ja29 sequence 
9.GAATIC.S.l3.G_~6A-..C..8Q8.C_C.I._CTTGI 
CCACTTTITACTGGGGGAccccCAAAA AGGAAACACACCTCTTGT 
CTAAAACGGCC GAATICAGGAAACACACCTCTTGT 
TCACTGGGGGACITA GAATTCAGGAAACACACCTCTTGT 
TCTGGGGGCCGGCG GGAAACACACCTCTTGT 
CCCCTCTTATCC TICAGGAAACACACCTCTTGT 
GGTCAGGGGATACGCATACGGTCIT TTCAGGAAACACACCTCTTGT 
TCCCAGGGATAGGGG AACACACCTCTTGT 
GGGGTGGGGGAccccccGAG TTCAGGAAACACACCTCTTGT 
nCTGGGGATCAAc TGT 
CCTTGGGGGTCCTT ATICAGGAAACACACCTCTIGT 
5530 GTGCCTGTGACACC GAAAACTTACTGGGGGATACGCCCTGCCAACC GGAAACACACCTCTIGT 
5575 
"" 5602 
5609A 
56098 
B 
800 
700 
600 
500 
400 
GTGCCTGT 
GTGCCTGTG 
GTGCCTG 
GTGCCTGTGACA 
GTGCCTGTGACACC 
300 
200 
CTAGGGGGATACAGGCAC TICAGGAAACACACCTCTIGT 
cGGGGG CACCTCTIGT 
GGCTTCCcccccCTGGGGGcnc GAATICAGGAAACACACCTCTIGT 
TIGCT ACTGGGGGATCCGGGG TICAGGAAACACACCTCTTGT 
GCCCOTACTGGGGGATACGOTCG AGGAAACACACCTCTTGT 
ho 
V02-Ja mix3 
(A) Schematic diagram of the V02 gene segment joined to the Ja29 gene segment via a junctional region. 
The presented V02-Ja29 junctional region sequences are derived from precursor-B-ALL patients and 
i!!ustrate the deletion of nucleotides from the germline sequences as we!! as the size and composition of 
the junctional regions. DO gene segments and inserted nucleotides are indicated by capital letters and 
sma!! capita! !etters. respectively. 
(B) Multiplex heteroduplex PCR analysis with V02 in combination with a Ja primers (mix 3) showed c!on-
a! V82-Ja homoduplexes (ho) in a!! patients tested. Sequence analysis (see part A) showed that a!! these 
rearrangements ·Involved the Ja29 gene segment. The presence of heteroduplexes (he) in patients 5199, 
5504, and 5609 indicated the presence of double V02-Ja29 rearrangements. 
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TaqMan probe and forward primer, positioned in the V32 gene, were used together with a reverse Ja 
primer. Based on the frequencies of particular V32-Ja gene rearrangements in precursor-B-ALL (see 
below), Ja9, Ja29, Ja58. and Ja61 primers were tested (Table 1 ). To determine the efficiency of amplifi-
cation and sensitivity of the PCR target, diagnostic DNA from the precursor-B-ALL containing particular 
V02-Ja gene rearrangement was diluted in 10-fold steps (10-1 down to 1Q-6) into DNA from the cell line 
CEM, known to have deleted both TCRD alleles. To correct for the quantity and quality {amplifiability) of 
DNA, RQ-PCR analysis of the albumin gene was used.35 
RESULTS 
Clonal TCRD gene rearrangements in precursor-B-All 
Southern blot analysis with two TCRD probes (TCRDJ 1 and TCRDV2 probes) 
was performed in 153 patients. Based on the combined Southern blot and PCR 
results, clonal V82 gene rearrangements were found in 77% (117/153) of precursor-
B-ALL patients. Clonal V82-D83 rearrangements were detected in 39% (60/153) of 
patients. In an additional 7% (11/153) of cases Southern blot indicated the presence 
of a clonal V82-D83 recombination, which turned out to be oligo/polyclonal by PCR 
analysis2 9.38 V82-Ja. rearrangements were found in 46% (70/153) of patients and 
combined Southern blot/PCR data showed that 56% (39/70) of these V82-Ja. joinings 
were monoclonal. The vast majority (79%) of monoclonal V82-Ja. rearrangements 
were monoallelic. A significant proportion (44%; 31/70) of V82-Ja joinings were 
oligonoclonal. Oligoclonality was assumed either when the Southern blot revealed 
presence of rearranged bands of different densities (13 patients; Figure 1 B) or when 
the number of clonal V82-Ja and V82-D83 homoduplexes exceeded the number of 
V82 rearrangements in Southern blot analysis (18 patients). 
Clonal 082-083 rearrangements were detected in 10% (15/153) of patients. 
Monoclonal 082-Ja gene rearrangements were found in only 3 of the 11 patients with 
a germline V82 allele but a deleted D83/J81 region. This indicates that 082-Ja 
rearrangements are rare (-2%) in childhood precursor-B-ALL. 
Spectrum of V82-Ja gene rearrangements in precursor-B-ALL 
In the total group of 339 patients studied with our multiplex PCR strategy, a total 
of 158 clonal V82-Ja. gene rearrangements were detected in 141 cases (42%). The 
sequence analysis of clonal V82-Ja. PCR products revealed that 26 different Ja. seg-
ments were used (Figure 3). Surprisingly, the Ja29 gene segment was present in 
54% (85/158) of all clonal Vo2-Ja. joinings (Figures 2 and 3). Together with Ja.30 and 
Ja.31 genes they formed a first cluster comprising 59% of V82-Ja gene rearrange-
ments. A second cluster frequently involved in V82-Ja. recombination concerned the 
Ja. segments most proximal to the TCRD locus. Altogether, 10 of the most upstream 
Ja. genes were found in 23% (36/158) of V82-Ja. joinings, with Ja.48, Ja.54, Ja.58, and 
;(;) 
Table 3. RQ-PCR analysis of V02-Ja gene rearrangements for sensitive detection of MRD in precursor-B-ALL patients. 
Patient V02-Ja Junctional region 8 ASO sequence 5'---)3'b T('C)0 Reproducible Maximal Non-specific CT 1Q-1 
rearrangement sensilivityd sensitivity amplificatione dilution 
5161 V02-Ja29 2/24(0o3)/7 TTCCTTGTCCCCAGTACCCC 60 1Q-3 1Q•4 5/6 28.3 
5172 V02-Ju29 3/15/3 CCTGAATAAGGGTCGGGGT 60 1Q-5 1Q-5 25.0 
5236 V02-Jn29 1/30(083)/5 AGCCATCTTTAGGAATTCTCGATC 60 1Q•4 1Q-4 27.5 
5462 V02-Ju29 3/15(0&3)/11 GTTCCCCTATCCCTCGGAGTC 60 1o·4 10"5 1/6 25.9 
6338 V02-Ja29 3/16(0o3)/8 AAGAGGTGTGTTTCCCCCGTAT 60 1Q-2 1Q·2 6/6 30.5 
6395 V02-Jo:54 3/21(082, 0&3)/0 GTTTATAGTTGCTACCTCCACTATTCTCCTAT 60 1Q-4 1Q-5 23.9 
6403 V02-Jn29 9/22(083)/3 GGTGTGTTTCCTGAATCCTCGT 60 1Q-4 1Q-5 1/6 23.5 0 
6436 V02-Ju29 4/14/12 TGTGTCCCTAACGGTCGAAT 60 1Q-4 10"5 1/6 23.5 i'i ., 
6439 V02-Ja48 3/25(083)/15 AAAGGTTAATTTCTCATCGGGAGTAT 60 1Q-4 10·5 25.2 m 
6464 V02-Jo.56 3/13/21 GTCAGCCCCTGGACAGTAAGTC 60 10"5 1Q-5 25.5 :u 
6527 V62-Ju29 0/20/18 GTCCCGTAAGAAACCCTCTCG 60 1Q•4 1Q-5 26.7 !'.> 
"' 6571 V02-Ju29 1/11(0&3)/6 TGTTTCCTGGGAGTATCCTCGT 60 1Q-3 1Q-3 30.7 
6615 V02-Ja29 5/13(083)/12 AAAGACAAGAGGTGTGTCGGI 60 1Q-4 1Q-5 23.4 
6673 V02-J(I29 0/28(0&3)/0 TGTTTCCTGAATTCCGAGGAT 60 1Q-4 1Q-5 23.5 
6687 V02-Jn58 3/18(0&3)/3 TGGTTTCTTCCCACTATCCCTGA 60 1Q-3 1Q-4 1/6 29.2 
a. Sequences of the junctional region were aligned with the 3' end of the V02 germline sequence and the 5' end of the Ja germline sequences. The number of 
5'-deleted, inserted, and 3'-deleted nucleotides as well as the presence of 002 and 003 segments are indicated. 
b. The nucleotides of the ASO primer that overlap with the D03 segment are underlined. 
c. Temperature of annealing and extension during the RQ-PCR reaction. 
d. The reproducible sensitivity of a primers/probe combination was defined as the dilution step with a maximal difference in CT value of 1.5 between the dup!i-
cate dilution samples and with a maximal CT value of 40 cycles. 
e. Non specificity refers to amplification of normal MNC DNA. The number of positive wells per total number of welts is shown. 
V02-Ja gene rearrangements in precursor-B-ALL 143 
Ja61 genes used most frequently (Figure 3). The third and most downstream clus-
ter was located around the Ja9 segment and comprised 8% (12/158) ofV82-Ja gene 
rearrangements. In line with these results, the three identified 082-Ja gene 
rearrangements contained the Ja9, Ja29, and Ja58 gene segments, respectively. 
Characteristics of clonal Vo2-Ja gene rearrangements in precursor-B-ALL 
The vast majority of V82-Ja gene rearrangements (78%, 122 of 156 fully 
sequenced clonal PCR products) contained a part of the 083 gene segment (9 
nucleotides on average, range 5-13 nucleotides). In striking contrast, remnants of the 
082 gene segment were found in only 7% (11 /156) of the V82-Ja sequences. Overall 
sizes of the V82-Ja junctional regions were extensive with 18.8 nucleotides on aver-
age (range 0-47). The sizes of the V82-083 and 083-Ja junctions were comparable: 
5.9 nucleotides on average (range 0-26). The 3' deletions of the V82 gene segment 
(mean 4.4, range 0-43 nucleotides) were comparable to the 5' deletions in the Ja 
gene segments (mean 5.9, range 0-33 nucleotides). 
Stability of Vo2-Ja gene rearrangements in monoclonal and oligoclonal pre-
cursor-B-ALL patients at relapse 
A total of 55 clonal V82-Ja gene rearrangements in 42 precursor-B-ALL patients 
were subjected to comparative heteroduplex PCR analysis at diagnosis and relapse: 
60 
50 ~ 
n In~ n n n n n n nn nnn n n nn 0 61 59 57 55 53 51 49 47 45 43 41 39 37 35 33 31 29 27 25 23 21 19 17 15 13 11 9 7 5 3 1 
Ja gene segments (n=158) 
Figure 3. 
Bar diagram summarizing the usage of particular Ja segments in V02-Ja gene rearrangements in pre-
cursor-B-ALL. 
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33 ofthe 55 rearrangements were found to be stable (60%). In 27 patients (64%) at 
least one V82-Jcx rearrangement was preserved at relapse. The stability of the V82-
Jcx gene rearrangements was markedly different between monoclonal and oligoclon-
al patients; i.e. at least one rearrangement was preserved in 86% (18/21) and 43% 
(9/21) of patients, respectively. The significant difference between monoclonal and 
oligoclonal rearrangements was even more pronounced at the allelic level, with 21 
of 24 monoclonal V82-Jcx gene rearrangements being stable (88%) as compared to 
only 12 of 31 oligoclonal rearrangements (39%). 
Owing to clonal evolution phenomena, 22 V82-Jcx rearrangements were lost in 18 
patients. In 13 patients, this concerned either "regression" of (sub )clonal rearrange-
ments to germline configuration or disappearance {deletion) of the V82-Jcx joinings, 
probably owing to secondary Vcx-Jcx recombinations. In five patients, new V82-Jcx 
gene rearrangements were detected at relapse. In one of these five patients, the 
V82-Ja23 sequence at diagnosis and the V82-Jcx29 sequence at relapse shared a 
common V82-D83 stem confirming their origin from a common (pre)leukemic pro-
genitor cell with a V82-D83 rearrangement In the remaining four cases, the junc-
tional regions of the V82-Jcx gene rearrangements at diagnosis and at relapse were 
completely different suggesting that the presumed leukemic progenitor probably had 
germline TCRD genes. 
Vi52-Jcx gene rearrangements as MRD-PCR targets in precursor-B-ALL patients 
V82-Jcx gene rearrangements were tested as MRO-PCR targets in TaqMan-
based RQ-PCR assays employing a germline V82 forward primer and a germline 
V82 TaqMan probe together with patient-specific reverse primers located in the V82-
Jcx junctional regions (Table 3). In 11 of 15 patients (73%), a reproducible sensitivity 
of 10-4 was achieved at the routine annealing temperature of 60°C, i.e. no optimiza-
tion was necessary. In all except two patients the maximal sensitivity was at least 
10-4. Repeated background amplification in normal MNC was found in only two 
cases (Table 3). 
Vo2-Jcx gene rearrangements in normal lymphoid tissues 
Using RQ-PCR assays with a germline V82 forward primer and TaqMan probe 
and one of four reverse germ line Jcx primers (Jcx61, Jcx58, Jcx29, and Jcx9), accord-
ing to the most frequent V82-Jcx gene rearrangements in precursor-B-ALL, we 
demonstrated that such preferential Jcx usage is not characteristic for normal lym-
phoid tissues. Relatively high levels of V82-Jcx58 and V82-Jcx61 gene rearrange-
ments (10-3 to 10-2 ) were only found in thymus samples (Table 4). Ten-fold lower 
levels (1 0-4 to 10-3 ) were repeatedly detected in PB, particularly in a fraction of E-
rosette selected T-cells. Lower frequencies of Vo2-Jcx58 and V82-Jcx61 gene 
rearrangements were detected in normal BM, lymph nodes, and tonsils (generally 
:>1 0-4). V82-Jcx29 gene rearrangements were consistently found in the thymus sam-
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Table 4. V02.Ja. rearrangements in normal lymphoid tissues as compared with precursor~B~ALL. 
Vo2-Ja61 Vo2-Ja58 Vo2-Ja29 V32-Ja.9 
Precursor-B-ALL 4.4% 3.8% 53.8% 6.3% 
(%of V32-Ja. positive patients) 
CD19 ..... /CD10 .......... /CD2Q- sorted normal 
BM B-cell precursors (n = 1 }a 
CD19 ..... /CD10 ..... /C02Q:t sorted normal ± 
BM B-cell precursors (n = 1 )a 
C019 ..... /CD10-/C020+ sorted normal 
BM B-cells (n = 1 )0 
Regenerating BM (n = 3)b ± 
Normal BM (n = 3) ±!+ ± 
Normal PB (n = 2) + ± 
E-rosette+ PB MNC (n = 1) + ±/+ 
E-rosette- PB MNC (n = 1) 
Tonsil {n = 2) ± ± ± 
Lymph node (n = 3) ± ±!+ ± 
Thymus (n = 3) ++ +!++ ± 
a. Normal BM was stained with C010, C020, and CD19 monoclonal antibodies and the indicated cell 
populations were sorted using a Becton Dickinson Diva flow cytometer. 
b. Regenerating BM after cessation of chemotherapy is known to contain high frequencies of precursor-
S-cells (5-30%)15.37 
Symbols: ++, V02-Ja levels > 1Q·3; +, V02-Ja levels between 104 and 1 Q-3; ±, V82-Ja levels between 
1 0·5 and 1 04 ; -, V02-Ja. levels :5: 1 a-s or undetectable. 
pies at very low levels of -10-s. Incidental positivity at similarly low levels was also 
found in PB, BM, and tonsils. In contrast, V82-Ja9 gene rearrangements were virtu-
ally undetectable in all tested normal lymphoid tissues, including the thymus (Table 
4). Overall, these RQ-PCR data indicate that V82-Ja gene rearrangements in normal 
lymphoid tissues are restricted to T-cell compartment and the prevalence of particu-
lar Ja segments in V82-Ja gene rearrangements is mainly determined by the prox-
imity to the TCRD locus. 
DISCUSSION 
The results of our study indicate that the V82 gene segment is a 'hot spot' for 
V(D)J recombination in precursor-B-ALL. This single gene segment is involved in 
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various gene rearrangements in 75 to 80% of patients. In 39% of cases, V82-083 
joinings were found, which are known to be the most prevalent TCRD gene 
rearrangements in precursor-B-ALL.21,26,39 In 42% of patients our combined 
Southern blot and PCR analyses confirmed the presence of V82 rearrangements to 
various Ja segments. The junctional regions of most (78%) V82-Ja gene rearrange-
ments contained the 083 segment, which indicates that recombination to Ja was 
preceded by a V82-083 rearrangement (Figure 1 ). The 082 segment is another 
gene, which is reported to be involved in TCRDIA gene rearrangements in precur-
sor-B-ALL.19.26 However, 082-083 gene rearrangements were found in only approx-
imately 10% of precursor-B-ALL patients, which is in line with literature data.19.21 ,26 
Parts of the 082 gene segments were found in 7% of V82-Ja junctional regions, 
which is in striking contrast to the frequent detection of 083 segments. Clonal 082-
Ja gene rearrangements occur even more seldom, since we were able to show clon-
al 082-Ja PCR products in only 3 patients (2%), who were pre-selected based on 
Southern blot data. Thus V82, 082, 083, and several Ja genes are preferentially 
involved in recombinations in the TCRO/A locus in precursor-B-ALL, with the main 
pathway being V82-083 -> V82-Ja29 (Figure 1 ). The next step might concern sec-
ondary Va-Ja rearrangements, deleting the whole TCRO locus as well as pre-exist-
ing V82-Ja joinings.19,21 An explanation for the limited number of gene segments 
involved in the V82 gene rearrangements is differential accessibility of gene seg-
ments within the TCRD locus in precursor-B-ALL. Some TCRO regions, particularly 
V81 and all J8 genes, seem to be fully closed for the persistent activity of the V(O)J 
recombinase in precursor-B-ALL, because rearrangements involving these gene 
segments were reported only anecdotally4 0 On the other hand, there might be addi-
tional factors related to the oncogenic process such as over-expressed transcription 
regulators, which might infiuence selection of particular gene segments, i.e. V82, 
083, or Ja29. 
The spectrum of V82-Ja gene rearrangements in precursor-B-ALL is clearly not 
random. The single gene segment Ja29 was found in 54% of all Vo2-Ja joinings. 
Such non-random usage of Ja gene segments was previously suggested by 
Southern blot data but was never confirmed at the PCR and sequence level.17,18 
The remaining V82-Ja sequences contained 25 different Ja segments, most of them 
belonging to two additional clusters. The first cluster involved gene segments locat-
ed most proximally to the TCRO locus, with Ja61, Ja58, Ja54, and Ja48 gene seg-
ments used most frequently. Altogether, 23% of V82-Ja gene rearrangements 
involved Ja gene segments in this proximal cluster. The second cluster was located 
around the Ja9 gene segment and accounted for 8% of V82-Ja joinings. The prefer-
ential usage of Ja29 might be related to the fact that the RSS of Ja29 is fully identi-
cal to the consensus RSS. However, no preferential usage was found for the other 
Ja gene segments with a full consensus RSS, i.e. Ja15 and Ja34. Apparently, a 
combination of several factors determines the preferential usage of several Ja gene 
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segments, such as: (1), proximity to the TCRD locus (e.g. for Ja61, Ja58, Ja54, and 
Ja48)41 -43; (2), leukemia-associated differential accessibility, potentially related to 
specific transcription factors; and (3), presence of consensus RSS. 
V82-Ja gene rearrangements can also occur at low levels in normal lymphoid tis-
sues (Table 4 ). They are relatively frequent in the thymus, where they represent one 
of the TCRD deletion pathways for commitment to the TCRa~ lineage4143 Similarly 
to our previously published data,43 the majority of V82-Ja gene rearrangements in 
the thymus involved the most proximal Ja genes (in our study represented by Ja58 
and Ja61) and the frequency of such recombinations ranged from 1 o-3 to 1 o-2. The 
same type of rearrangements were also detectable in other lymphoid tissues includ-
ing PB-MNC, BM, lymph nodes, and tonsils but at generally more than 1 0-fold lower 
levels as compared to the thymus (i.e.< 1 o-3). Such difference in frequency of V82-
Ja gene rearrangements between the thymus and PB was suggested before based 
on qualitative PCR data43 In striking contrast, V82-Ja29 and V82-Ja9 joinings were 
virtually undetectable in normal lymphoid tissues (Table 4 ). This suggests that the 
preferential usage of the Ja9 and Ja29 clusters in the V82-Ja rearrangements of 
precursor-B-ALL (Figure 3) is a leukemia-specific characteristic. 
Our multiplex PCR strategy can easily identify clonal V82-Ja gene rearrange-
ments, which can be applied as PCR targets for MRD monitoring. In fact, based on 
the limited number of Ja segments involved in the V82-Ja gene rearrangements in 
precursor-B-ALL, the multiplex strategy can be further simplified. The junctional 
regions of V82-Ja joinings are extensive, containing approximately 19 nucleotides on 
average. Therefore, it should be relatively easy to design optimal patient-specific 
oligonucleotides reaching sensitivities of at least 104 , which is required for recogni-
tion of the MRD-based low-risk patients_3,6 Our preliminary results in 15 patients 
showed that in 11 of these cases V82-Ja gene rearrangements were sufficiently sen-
sitive and specific MRD-PCR targets, without need for any assay optimization. This 
is in striking contrast to TCRG gene rearrangements, which fail as MRD-PCR targets 
in approximately 60% of precursor-B-ALL due to their limited specificity and/or sen-
sitivity.13 Another advantage of V82-Ja gene rearrangements as MRD-PCR targets 
is the extremely low background of polyclonal V82-Ja joinings in normal BM and PB, 
irrespective of the treatment phase. 
The major disadvantage of V82-Ja gene rearrangements is their potential insta-
bility owing to different clonal evolution phenomena with secondary rearrangements 
causing oligoclonality. Approximately 45% of V82-Ja joinings in precursor-B-ALL are 
oligoclonal. Comparative studies on IGH, /GK-Kde, and TCRD gene rearrangements 
at diagnosis and relapse reported a much lower stability for the oligoclonal 
rearrangements as compared to monoclonal gene rearrangements.1 4.36.44 This is 
also the case for V82-Ja gene rearrangements, where 87% of monoclonal 
rearrangements were preserved as compared to only 40% of the oligoclonal 
rearrangements. Oligoclonal V82-Ja gene rearrangements usually refiect ongoing 
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V82-D83 to Ja joinings. In fact, small V82-Ja subclones with a common V82-083 
stem were reported in the vast majority of precursor-B-ALL with clonal V82-D83 gene 
rearrangements2° Monoclonal V82-Ja gene rearrangements as confirmed by com-
bined Southern blot and PCR strategy, are excellent MRD-PCR targets that are 
equally valuable to monoclonal IGH and TCRD gene rearrangements. The usage of 
oligoclonal V82-Ja gene rearrangements as MRD-PCR targets is not recommended 
owing to their low stability. When the applied MRD-PCR strategy does not include 
Southern blotting, V82-Ja gene rearrangements can only be used as supplementary 
MRD-PCR targets in exceptional cases. 
In conclusion, V82-Ja gene rearrangements are frequent cross-lineage recom-
binations in TCRDIA locus of precursor-B-ALL, which is in striking contrast to their 
infrequent occurrence in normal B-cells and B-cell precursors. The spectrum of V82-
Ja gene rearrangements in precursor-B-ALL is not random with preferential usage of 
Ja29 gene segment. The extensive junctional regions, the low background in normal 
BM and PB, and the good stability (87%) of monoclonal rearrangements are the fea-
tures that favor the usage of monoclonal V82-Ja gene rearrangements as principal 
MRD-PCR targets in approximately 25% of precursor-B-ALL. 
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ABSTRACT 
The T-cell receptor gamma (TCRG) gene configuration was established in a 
large series of 126 T-cell acute lymphoblastic leukemia (T-ALL) patients using com-
bined Southern blotting (SB) and heteroduplex PCR analyses. The vast majority of 
T-ALL (96%) displayed clonal TCRG gene rearrangements, with biallelic recombina-
tion in 91% of patients. A small immature subgroup of CD3- T-ALL (n = 5) had both 
TCRG genes in germ line configuration, three of them having also germ line TCRD 
genes. In five patients (4%) combined SB and PCR results indicated oligoclonality. 
In five rearrangements detected by SB, the Vy gene segment could not be identified 
suggesting illegitimate recombination. Altogether, 83% of TCRG gene rearrange-
ments involved either the most upstream Vy2 gene (including four cases with inter-
stitial deletion of 170 bp in Vy2) and/or the most downstream Jy2.3 segment, which 
can be perceived as 'end-stage' recombinations. 
Comparative analysis of the TCRG gene configuration in the major immunophe-
notypic subgroups indicated that TCRyo+ T-ALL display a less mature immunogeno-
type as compared to TCRa~+ and most CD3- cases. This was reflected by a signif-
icantly increased usage of the more downstream Vy genes and the upstream Jy1 
segments. Comparison between adult and pediatric T-ALL patients did not show any 
'Leukemia 2000; 14: 1208-1214 153 
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obvious differences in TCRG gene configuration. 
The high frequency, easy delectability, rare oligoclonality, and frequent 'end-
stage' recombinations make TCRG gene rearrangements principal targets for PCR-
based detection of minimal residual disease (MRD) in T-ALL. We propose a simple 
heteroduplex PCR strategy, applying five primer combinations, which results in the 
detection of approximately 95% of all clonal TCRG gene rearrangements in T-ALL. 
This approach enables identification of at least one TCRG target for MRD monitor-
ing in 95% of patients, and even two targets in 84% of T-ALL. 
INTRODUCTION 
Nowadays, T-cell receptor gamma (TCRG) gene rearrangements are frequently 
utilized as clonality markers and as PCR targets for the detection of minimal resid-
ual disease (MRD) in lymphoproliferative disorders. The latter application is particu-
larly relevant in acute lymphoblastic leukemia (ALL), since TCRG gene rearrange-
ments occur in the vast majority of T-ALL and in approximately 60% of precursor-B-
ALL patients.1·2 Several retrospective studies and recently also two large prospec-
tive MRD studies successfully employed TCRG gene rearrangements as leukemia-
specific PCR targets.3-7 
The frequencies and patterns of TCRG gene rearrangements in T-ALL were 
addressed by several Southern blot (SB)-based studies8-12 Biallelic rearrangements 
were found in the vast majority of patients and preferential usage of the Jy2 gene 
complex was strongly suggested.1·12 There was some indication on differential Vy 
gene utilization in CD3+ versus CD3- negative T-ALL subsets, but such observations 
were generally based on limited numbers of patients. 11 Currently, PCR-based 
methodologies are more frequently applied for the detection of clonal TCRG gene 
rearrangements. However, the vast majority of PCR-based studies on TCRG genes 
in T-ALL, were based either on small or restricted patient groups or on limited primer 
combinations. 13-17 Therefore, we performed extensive heteroduplex PCR analysis of 
TCRG gene rearrangements in a large group of 126 T-ALL patients. The majority of 
patient samples were also studied in parallel by SB as a reference technique. Based 
on the combined SB and heteroduplex PCR results, we were able to determine the 
presence of oligoclonality and illegitimate recombinations as well as to compare 
TCRG gene rearrangement patterns between childhood and adult T-ALL patients, 
and to compare between different immunophenotypic subgroups of T-All. 
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MATERIALS AND METHODS 
Patient description 
Peripheral blood (PB) or bone marrow {BM) samples from 126 T-ALL patients {90 children and 36 
adults) were obtained at initial diagnosis.16-18 Mononuclear cells (MNC) were isolated from PB or BM sam-
ples by Ficoli-Paque centrifugation (density 1.077 g/cm3; Pharmacia, Uppsala, Sweden) and subjected to 
detailed immunophenotyping according to standard protocols.19,20 To analyze sufficient numbers of CD3+ 
T-ALL (especially TCRyO'" T-ALL) T-ALL cell samples were selected based on their CD3/TCR 
immunophenotype resulting in 64 CD3- T-ALL (51% of the total series), 33 TCRa~+ T-ALL (26%), and 29 
TCRyo+ T-ALL (23%). In an entirely random series of T-ALL this immunophenotype distribution would 
approximate 70%, 20%, and 10%, respectively_21 
Southern blot analysis 
SB analysis was performed in 117 of the 126 patients. DNA was isolated from frozen MNC, digest-
ed. and blotted to nylon membranes as described previously.22 The TCRG gene configuration was stud-
ied using the TCRGJ13 probe (DAKO Corporation, Carpinteria, CA, USA) in EcoRI digests together with 
either the TCRGJ21 probe (DAKO) in Pstl digests or a combination of the Jy2.1 probe in EcoRI digests 
and the Jy1.2 probe in Bg/11 digests.12.23 The information on the SB configuration of TCRG genes was 
reported before for 70 T-ALL patients.12,16,17 
PCR amplification and heteroduplex analysis of PCR products 
All patient samples were subjected to detailed PCR analysis, which was essentially performed as 
described previously.16-24 In each SOfll PCR reaction 50 ng DNA sample. 6.3 pmol of the 5' and 3· oligonu-
cleotide primers, and 0.5 U AmpliTaq Gold polymerase (PE Biosystems, Foster City, CA, USA) were used. 
The sequences of the oligonucleotides used for amplification of TCRG gene rearrangements (four Vy fam-
ily-specific primers. six Vyl member-specific primers, and three Jy primers) were published before.24 PCR 
conditions were: initial denaturation for 10 min at 94°C, followed by 35 cycles of 45 sat 94°C, 90s at 60°C, 
and 2 min at 72°C using a Perkin-Elmer 480 thermal cycler (PE Biosystems). After the last cycle an addi-
tional extens'1on step of 10 min at 72°C was performed. Appropriate positive and negative controls were 
included in all experiments_24 The results of PCR analysis of TCRG gene rearrangements in 22 adult T-
ALL patients were reported before.16 All other 104 T-ALL patients were newly analyzed for this study. 
For heteroduplex analysis, the PCR products were denatured at 94°C for 5 min after the final cycle 
of amplification and subsequently cooled to 4°C for 60 min to induce duplex formation.25 Afterwards the 
duplexes were immediately loaded on 6% non-denaturing polyacrylamide gels in 0.5 x Tris-borate-EDTA 
{TBE) buffer, run at room temperature. and visualized by ethidium bromide staining.25 A 100-bp DNA lad-
der {Promega Corporation. Madison, WI. USA) was used as size marker. 
Sequence analysis of TCRG gene rearrangements 
When assignment for Vy and/or Jy gene segments was not possible in particular rearrangements 
based on combined SB and PCR information, clonal PCR products as found by heteroduplex analysis 
were sequenced directly. Sequencing was performed using the dye-terminator cycle sequencing kit with 
Amp!iTaq09 DNA polymerase FS on an AB! 377 sequencer (PE Biosystems) as previously described.26 Vy 
and Jy gene segments were identified by comparison to germline TCRG sequences as described 
before.27 
Statistical analysis 
Statistical analysis using the x2 test on a 2 x 2 table was performed to compare the frequencies of 
particular TCRG gene rearrangements between childhood and adult T-ALL patients, and between differ-
ent immunophenotypic subgroups of T-ALL. A value of p < 0.05 was regarded to be statistically signifi-
cant. 
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RESULTS 
Spectrum of TCRG gene rearrangements in T-All 
Based on the combined SB and heteroduplex PCR analyses, we were able to 
determine the TCRG gene configuration in a large group of 126 T-ALL patients in 
detail (Table 1). In the vast majority of cases (115 patients; 91%) both TCRG alleles 
were rearranged (Figure 1 ). In one of these patients three rearranged bands of com-
parable density were found by SB, strongly suggesting trisomy 7. In five patients 
(4%) both TCRG alleles were in germline configuration, suggesting an immunogeno-
typically very immature T-ALL. Monoallelic rearrangements were found in six 
patients (5%), with the second allele in germline configuration in three cases and 
deleted in the other three cases. In only five patients (4%) did combined SB and PCR 
data indicate the presence of minor subclones as identified by additional TCRG gene 
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Figure 1. 
Southern blot analysis of the TCRG gene configuration in ten of the studied T-ALL patients. Hybridization 
of Pstl digests with the TCRGJ21 probe and EcoRI digests with the TCRGJ13 probe revealed biallelic 
rearrangements in a!! ten cases. ln two patients (T178 and T192) SB indicated the presence of a trun-
cated Vy2 segment, which was subsequently confirmed by heteroduplex PCR analysis. In patient T015 
the rearrangement of the 1fVy7 gene to Jy2.3 segment is virtually indistinguishable from the germline Jy2.3 
band derived from the other allele. 
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Table 1. TCRG gene rearrangement patterns in childhood versus adult T-ALL patients. 
Childhood T-ALL AdultT-ALL Total T-ALL 
{90 patients; 180 alleles) (36 patients; 73 alleles)a (126 patients; 253 al!eles)a 
Germline alleles 6 (3%) 7 (10%) 13 (5%) 
Deleted alleles 2 (1%) 1 (1%) 3 (1%) 
Rearranged alleles 172 (96%) 65 (89%) 237 (94%) 
Vyl Vy2 44 (26%) 18 (28%) 62 (26%) 
Vy3 16 (9%) 4 (6%) 20 (8%) 
Vy4 24 (14%) 10 (16%) 34 (14%) 
Vy5 9 (5%) 3 (5%) 12 (5%) 
"fVy7 4 (2%) 1 (2%) 5 (2%) 
Vy8 30 (17%) 12 (19%) 42 (18%) 
Vyll Vy9 22 (13%) 4 (6%) 26 (11%) 
Vylll "fVy10 12 (7%) 6 (9%) 18 (8%) 
VyiV lj!Vy11 7 (4%) 6 (9%) 13 (5%) 
Not identified 4 (2%) (2%) 5 (2%) 
Jy1 Jy1.1 7 (4%) 7 (11 %) 14 (6%) 
Jy1.2 1 (1%) 1 (2%) 2 (1%) 
Jy1.3 14 (8%) 6 (9%) 20 (8%) 
Jy2 Jy2.1 19 (11%) 3 (5%) 22 (9%) 
Jy2.3 131 (76%) 48 (75%) 179 (76%) 
a. In a single adult T-ALL patient three rearranged bands of comparable density were found on SB 
analysis, suggesting trisomy 7. 
rearrangements, demonstrating that oligoclonality in TCRG genes is rare in T-ALL. 
Analysis of Vy gene segment usage revealed the utilization of the most upstream 
Vy2 segment (Figure 2) in 62 (26%) rearrangements. Interestingly, in four patients 
the Vy2-Jy2.3 rearrangement contained an interstitial deletion of approximately 170 
bp (Figure 1 ). Two other members of the Vyl family were also frequently used, i.e. 
the Vy4 and the Vy8 gene segments on 34 (14%) and 42 (18%) alleles, respective-
ly. Altogether, the Vyl family segments were involved in 175 (73%) rearrangements. 
The single members of the other three families were identified in 57 joinings, with the 
Vy9 (Vyll) gene used most frequently (26 rearrangements; 11 %). In five rearrange-
ments detected by SB the Vy segment could not be identified, which suggests that 
in these cases an illegitimate recombination might have occurred, e.g. a chromoso-
mal translocation involving the TCRG locus. 
Analysis of Jy gene utilization showed a preferential usage of the most down-
stream Jy2.3 segment (Figure 2), which was identified in 179 (76%) rearrangements. 
The other gene segment of the second Jy cluster, i.e. the Jy2.1 gene, was identified 
in 22 rearrangements (9%). Recombination to the first Jy cluster was found on 36 
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Figure 2. 
Organization of the human TCRG locus on chromosome 7p14-p15. The TCRG locus consists of two con-
stant region gene segments (Cy) preceded by two or three joining gene segments (Jy) and at least 14 vari-
able gene segments (1./y) located upstream of the two Jy-Cy regions. Six Vy gene segments are function-
a! {solid blocks), three pseudogenes can rearrange to Jy gene segments (shaded blocks), whereas the 
other pseudogenes (open blocks) have no functional recombination signal sequences. Nine upstream Vy 
gene segments belong to family I, whereas families II, Ill and IV each consist of a single gene segment 
assigned as Vy9, Vy1 0 and Vy11, respectively. Five joining segments have been identified: 3 Jy1 segments 
i.e. Jy1.1, Jy1.2 and Jy1.3 upstream of Cy1 and 2 Jy2 segments i.e. Jy2.1 and Jy2.3 upstream of Cy2. 
alleles (15%) with Jy1.1 and Jy1.3 segments used most frequently on 14 (6%) and 
20 (8%) alleles, respectively. Rearrangements involving the Jy1.2 gene segment 
were identified in only two patients; both joinings concerned the Vy9 gene coupling. 
One of these Vy9-Jy1.2 rearrangements contained a canonical junctional region 
based on the absence of N-nucleotide insertion and with a deletion of three overlap-
ping homologous nucleotides, which is preferentially expressed by normal peripher-
al blood TCRy&+ cells28 In contrast, the junctional region of the other Vy9-Jy1.2 
rearrangement contained 11 inserted N-nucleotides. 
TCRG gene rearrangements in adult versus pediatric patients 
TCRG gene rearrangement patterns were compared between adult and pediatric 
patients (Table 1 ). This analysis revealed that the TCRG configuration was largely 
comparable between these two patient groups. Although in adult patients the TCRG 
alleles were more frequently in germline configuration (11% vs. 4% in pediatric ALL), 
frequently involved the Jy1 segments (22% vs. 13%), and used the Vy9 gene seg-
ment less frequently (6% vs. 13%), these findings did not reach statistical signifi-
cance. 
TCRG gene rearrangements in different immunophenotypic subsets 
Analysis of TCRG gene rearrangements in the three major immunophenotypic T-
ALL groups revealed largely comparable configuration patterns (Table 2). 
Nevertheless, several discrete differences were observed. Firstly, within the C03-
group there was a small subset with TCRG genes in germline configuration (5 
patients), whereas all CD3+ leukemias displayed at least a monoallelic rearrange-
ment Secondly, TCRyo+ T-ALL displayed several distinct characteristics. This 
immunophenotypic subset was characterized by preferential usage of the Vy9 (Vyll) 
gene, which was found in 22% of rearrangements, as compared to 8% in the non-
TCRy&+ T-ALL group (p < 0.01). This was still significant when TCRy8+ T-ALL was 
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independently compared to TCRcx~+ and C03- T-ALL (p < 0.05). Altogether, the 
three most downstream Vy members were slightly overrepresented in TCRyo+ T-ALL 
(36% versus 20% in non-TCRyo+ T-ALL; p < 0.05). Moreover, the Jy segments of the 
upstream Jy1 cluster, particularly the Jy1.3 gene, were more frequently used in 
TCRyo+ T-ALL (28%), when compared to non-TCRyo T-ALL (11%; p < 0.01). 
DISCUSSION 
We studied the TCRG gene configuration in a large series of 126 T-ALL patients. 
Based on the combined SB and PCR results, we were able to establish several char-
Table 2. TCRG gene rearrangement patterns in major immunophenotypic subsets ofT ~ALL 
CD3- T-ALL TCRyO+ TMALL TCRaV T-ALL 
(64 patients; 129 alleles) (29 patients; 58 a!!eles) (33 patients; 66 alleles) 
Germline alleles 10 (8%) 3 (5%) 0 
Deleted alleles 2 (2%) (2%) 0 
Rearranged alleles 117 (91%) 54 (93%) 66 (100%) 
Vyl Vy2 37 (32%)- 10 
''"'' ~ 15 ~'] Vy3 9 (8%) 6 (11%) 5 (8%) Vy4 15 (13%) 77% 8 (15%) 62% 11 (17%) 77% 
Vy5 5 (4%) 3 (6%) 4 (6%) 
'VVy7 2 (2%) 0 3 (4%) 
Vy8 23 (20%)- 6 (11%) 13 (20% 
Vyll Vy9 10 (9%) 
]20% 
12 (22%)~ 4 (6%) -; 
Vylll 'VVy10 7 (6%) 4 (7%) 36%b 7 (11%) 21% 
VyiV 'VVy11 6 (5%) 4 (7%) 3 (4%)-
Not identified 3 (3%) (2%) (2%) 
Jy1 Jy1.1 3 (3%) J 10% 6 (11%)- 5 (8%) J Jy1.2 2 (2%) 0 28%b 0 16% 
Jy1.3 6 (5%) 9 (17%)- 5 (8%) 
Jy2 Jy2.1 9 (8%) J 90% 3 (6%) -72% 10 (15%)] 84% 
Jy2.3 97 (83%) 36 (67%)- 46 (70%) 
a. In a single adult CD3- T~ALL patient three rearranged bands of comparable density were found on SB 
analysis. suggesting trisomy 7. 
b. Gene segments significantly overrepresented in TCRG gene rearrangements of TCRyo+ T-ALL as 
compared to non-TCRyO T-ALL. 
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acteristics of TCRG genes in T-ALL, which were also suggested in previous 
molecular studies8 ·10 Firstly, we found TCRG gene rearrangements in 96% of 
patients, involving both alleles in most cases. Nevertheless, we could identify a small 
subset of five C03- T-ALL with both TCRG genes in germline configuration. They 
most probably are immunogenotypically very immature leukemias, because three of 
these patients also had germline T-cell receptor delta (TCRD) genes. Secondly, we 
confirmed the earlier observation of preferential usage of Jy segments from the 
downstream Jy2 cluster (85% of rearrangements), particularly of the Jy2.3 gene 
segment (76%).12,29 In addition, we showed preferential usage of the Vy2 segment, 
which was present in more than a quarter of all joinings. Together, rearrangements 
concerning this most upstream Vy2 gene segment and/or the most downstream 
Jy2.3 gene were found on 83% of rearranged alleles and can be perceived as 'end-
stage' recombination events. Moreover, four of the Vy2-Jy2.3 joinings contained an 
interstitial deletion of approximately 170 bp in the Vy2 gene segment, most probably 
resulting from rearrangement to a recombination signal sequence within the Vy2 
gene.3° 
We could also demonstrate that TCRG oligoclonality is a rare phenomenon in T-
ALL, occurring in less than 5% of patients. The TCRG gene rearrangement patterns 
in T-ALL are strikingly different from the cross-lineage TCRG gene rearrangements 
in precursor-B-ALL. The latter involve Jy1 segments in approximately 70% of alleles 
and show oligoclonality in 38% of precursor-B-ALL patients with TCRG gene 
rearrangements2 This on one hand might reflect differences in accessibility of the 
TCRG locus to V(D)J recombinase activity between T-ALL and precursor-B-ALL. On 
the other hand, lineage promiscuity of TCRG rearrangements in precursor-B-ALL 
and lack of lineage-specific enhancement might favor the usage of more proximal 
gene segments. The rare occurrence of TCRG oligoclonality in T-ALL might indicate 
that the malignant transformation occurred in thymocytes with completed TCRG 
gene rearrangement processes. In contrast, the more frequent TCRG gene oligo-
clonality in precursor-B-ALL is one of the indicators that such cross-lineage recom-
binations are post-oncogenic events_2.31 
Comparative immunogenotypic analysis of pediatric and adult T-ALL subgroups 
showed largely similar TCRG gene rearrangement patterns. This confirms our previ-
ous observation and is in striking contrast to precursor-B-ALL, where immunoglobu-
lin and TCR gene rearrangement patterns are clearly less mature in adults than in 
children.16 
Comparison of TCRG gene configurations between the three major immunophe-
notypic T-ALL subgroups revealed limited but significant differences. The TCRy8+ 
subgroup was distinct from non-TCRy8 cases with respect to a more frequent usage 
of the more downstream Vy segments (with a striking preference for Vy9) and the 
more upstream Jy1 segments (particularly Jy1.3). This might reflect the rapid cessa-
tion of TCRG gene accessibility to V(D)J recombinase activity as soon as a func-
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tional TCRG gene rearrangement has been achieved. This is in line with a previous 
hypothesis that TCRy8+ T-ALL should be regarded as cells that branched off T-cell 
development at an early stage of completion of TCRD and TCRG gene rearrange-
ment processes, while the recombinase activity is still retained.17.21.31 Retained 
V(D)J activity is for instance reflected by the frequent occurrence of complete Vj3-Jj3 
and cross-lineage IGH gene rearrangements, detectable in 60% and 50% of TCRy8+ 
T-ALL patients, respectively. 17.32 We could not confirm the previous observation of 
Hara et al. 11 suggesting that in CD3- T-ALL Vy genes more proximal to Jy are more 
frequently rearranged, whereas CD3+ T-ALL show a high frequency of rearrange-
ments involving Vy genes more distal from Jy. We believe that this might be a bias 
owing to the relatively small group of T-ALL (24 cases) studied. 
Our study also aimed at establishment of an optimal PCR strategy for identifica-
tion of clonal TCRG gene rearrangements as molecular targets for MRD monitoring 
in T-ALL patients. Using five principal Vy-Jy primer combinations (Table 3), we found 
94% of clonal TCRG gene rearrangements. These five primer combinations detect-
ed at least one rearrangement in all but one T-ALL patient with rearranged TCRG 
genes. Therefore, we routinely apply this set of primers on new diagnostic T-ALL 
samples. With three supplementary Vy-Jy primer combinations (Table 3), an addi-
tional 3% of clonal rearrangements were detected. This set may be reserved forT-
ALL cases negative with the first set of primers, while SB analysis can be limited to 
rare cases with questionable PCR results. 
Occurrence of TCRG gene rearrangements in virtually all patients, easy 
delectability of these rearrangements, and rare oligoclonality make TCRG genes 
principal molecular targets for MRD monitoring in T-ALL, particularly when TCRD 
Table 3. PCR primer combinations for optimal detection of TCRG gene rearrangements as 
molecular targets for MRD monitoring in T-ALL. 
PCR primer combination 
I. Principal combinations 
Vyi-Jy1.3/2.3 
Vyi-Jy1.1/2.1 
Vyii-Jy1.3/2.3 
Vyiii-Jy1.3/2.3 
VyiV-Jy1.3/2.3 
II. Supplementary combinations 
Vyii-Jy1.2 
Vyiii-Jy1.1/2.1 
VyiV-Jy1.1/2.1 
Relative frequency of 
TCRG gene rearrangements 
60% 
13% 
10% 
7% 
4% 
1% 
1% 
1% 
162 CHAPTER2.6 
genes are deleted. The only potential disadvantage is a decreased sensitivity of 
patient-specific PCR owing to competition with TCRG gene rearrangements in nor-
malT-cells. Nevertheless, in the extensive study of the BIOMED-1 Concerted Action, 
86% of TCRG targets reached a sensitivity of at least 10-4 , wh"1ch is a prerequisite 
for reliable identification of MRD-based risk groups.7.24 Moreover, the 'end-stage' 
character of most TCRG gene rearrangements in T-ALL probably results in stability 
during the disease course. This was also suggested by several studies comparing 
TCRG gene configuration at diagnosis and at relapse of T-ALL.7.33-37 Interestingly, 
a single study by Taylor et al.37 described a so-called clonal regression in two T-ALL 
patients with biallelic TCRG gene rearrangements at diagnosis and both alleles in 
germ line configuration at relapse. This observation was not confirmed by other stud-
ies, which showed that clonal evolution of TCRG genes is a rare event in T-ALL, and 
if clonal evolution occurred, this mainly concerned 'non-end-stage' rearrangements 
resulting in ongoing recombination of more upstream Vy and more downstream Jy 
segments. 7.33.34,36 
In conclusion, we could determine the TCRG gene configuration in a large group 
of T-ALL patients, showing biallelic gene rearrangements in the vast majority of 
cases. Analysis of different immunophenotypic subsets showed that TCRyo+ T-ALL 
are characterized by a less mature TCRG gene configuration when compared to 
CD3- and TCRaj3+ cases. Since the majority of TCRG gene rearrangements in T-
ALL represent 'end-stage' recombinations, they presumably are relatively stable 
molecular MRD targets. Based on our study, we propose a rapid and easy het-
eroduplex PCR strategy enabling identification of approximately 95% of clonal TCRG 
gene rearrangements with only five primer combinations, resulting in at least one 
MRD-PCR target in 95% of T-ALL patients and two PCR targets in 84% of cases. 
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CHAPTER 2.7 
IG HEAVY CHAIN GENE REARRANGEMENTS IN T-CEll ACUTE 
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REARRANGEMENTS, AND ARE RARE IN 
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ABSTRACT 
Rearranged IGH genes were detected by Southern blotting in 22% of 118 cases 
ofT-cell acute lymphoblastic leukemia (ALL) and involved monoallelic and biallelic 
rearrangements in 69% (18/26) and 31% (8/26) of these cases, respectively. IGH 
gene rearrangements were found in 19% (13/69) of CD3· T-ALL and in 50% of 
TCRy8+ T-ALL (12/24), whereas only a single TCRaj3+ T-ALL (1/25) displayed a 
monoallelic /GH gene rearrangement. The association with the T-cell receptor (TCR) 
phenotype was further supported by the striking relationship between IGH and TCR 
delta (TCRD) gene rearrangements, i.e., 32% of T-ALL (23/72) with monoallelic or 
biallelic TCRD gene rearrangements had IGH gene rearrangements, whereas only 1 
of 26 T-ALL with biallelic TCRD gene deletions contained a monoallelic IGH gene 
rearrangement. 
Heteroduplex polymerase chain reaction (PCR) analysis with VH and DH family-
specific primers in combination with a JH consensus primer revealed a total of 39 
clonal products, representing 7 (18%) VH-(DH-)JH joinings and 32 (82%) DH-JH 
rearrangements. Whereas the usage of VH gene segments was seemingly random, 
preferential usage of DH6-19 (45%) and DH7-27 (21%) gene segments was 
"Blood 1999; 93: 4079-4085 167 
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observed. Although the JH4 and JH6 gene segments were used most frequently 
(33% and 21%, respectively), a significant proportion of joinings (28%) used the most 
upstream JH1 and JH2 gene segments, which are rarely used in precursor-B-ALL 
and normal B-cells (1% to 4%). In conclusion, the high frequency of incomplete OH-
JH rearrangements, the frequent usage of the more downstream DH6-19 and DH7-27 
gene segments, and the most upstream JH1 and JH2 gene segments suggests a pre-
dominance of immature IGH rearrangements in immature (non-TCRaf3+) T-ALL as a 
result of continuing V(O)J recombinase activity. More mature af3-lineage T-ALL with 
biallelic TCRD gene deletions apparently have switched off their recombination 
machinery and are less prone to cross-lineage IGH gene rearrangements. The com-
bined results indicate that IGH gene rearrangements in T-ALL are post-oncogenic 
processes, which are absent in T-ALL with deleted TCRD genes and completed TCR 
alpha (TCRA) gene rearrangements. 
INTRODUCTION 
When rearranged immunoglobulin (lg) and T-cell receptor (TCR) genes were 
found to be useful clonal leukemia-specific markers, they were initially considered to 
be lineage-specific.1 ,2 However, the recognition of "abnormal" TCR gene rearrange-
ments in precursor-S-acute lymphoblastic leukemia (ALL) and in some mature B-cell 
malignancies together with the finding of rearranged lg heavy chain (/GH) genes in 
some T-ALL raised the question of lineage infidelity or promiscuity_2,3 TCR gene 
rearrangements in precursor-B-ALL were observed in 60% to 80% of patients, indi-
cating that these recombinations should rather be regarded as an ubiquitously occur-
ring (cross-lineage) phenomenon in this type of B-cell malignancy4-7 In a recent 
study on 202 precursor-B-ALL patients, we even found cross-lineage TCR gene 
rearrangements in 93% of the patients. a The occurrence of cross-lineage rearranged 
TCR genes is related to the maturation stage, being significantly lower in immature 
C01 o- precursor-B-ALL as compared with C01 o+ precursor-B-ALL8,9 Analogous to 
the hierarchical order during early T-cell development, rearrangements and/or dele-
tions in the TCR delta (TCRD) locus occur most frequently (89% of patients), fol-
lowed by TCR gamma (TCRG) (59%) and TCR beta (TCRB) (35%) gene rearrange-
ments4-6.8 Furthermore, most TCRB gene rearrangements are restricted to the J[32 
locus, the majority of TCRG gene rearrangements involve the Jy1 gene segments, 
and a striking predominance of incomplete V82-083 and 082-083 rearrangements in 
the TCRD locus is observed.4-11 
In contrast to the high frequency of cross-lineage TCR gene recombinations in 
precursor-B-ALL, IGH gene rearrangements in T-ALL are relatively rare. In a meta-
analysis of previously reported small patient groups, the prevalence of rearranged 
JGH genes was estimated at 10% to 15% of lymphoblastic T-cell malignancies.11 All 
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early studies were exclusively based on Southern blotting (SB) and at that time, the 
configuration of IGH diversity (D) regions was not completely known. Therefore, it 
was not possible to reliably discern between incomplete DH-JH and complete VH-(DH-)JH 
gene rearrangements and to identify cross-lineage IGH gene rearrangement pat-
terns, which are characteristic for T-ALL. 11 -12 The only consistent finding was, that a 
significant proportion of IGH rearrangements in human leukemic T-cells involved the 
DH7-27 (DQ52) gene segment, which is located immediately upstream of the JH 
region (Figure 1).13.14 
To study cross-lineage !GH gene rearrangements in T-ALL in detail, we analyzed 
a large group of 118 T-ALL patients by Southern blotting to determine the precise 
incidence of rearranged IGH genes. Heteroduplex polymerase chain reaction (PCR) 
analysis and subsequent sequencing were applied to identify the rearranged IGH 
gene segments as well as the junctional regions of the rearrangements. In addition 
to VH family-specific primers and a JH consensus primer, we designed a new set of 
DH family-specific primers to detect and identify all complete VH-JH and incomplete 
DH-JH gene rearrangements. 
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Figure 1. 
Schematic representation of the human IGH locus on chromosome 14q32.3. The IGH gene complex con-
sists of numerous (>120) V gene segments, 27 D gene segments. 6 functional J gene segments, and C 
gene segments for the constant domains of the various JgH classes and subclasses, most of which are 
preceded by switch sequences (s).23.28.s2.53 Pseudogenes are represented as open bars. The 27 DH 
gene segments are grouped in seven families based on sequence homology. Members of the same DH 
family are depicted with the same shading pattern. 
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MATERIALS AND METHODS 
Cell samples 
Peripheral blood {PB) or bone marrow (BM) samples from 118 T-ALL patients (84 children and 34 
adults) were obtained at initial diagnosis_7,15 Mononuclear cells (MNC) were isolated from PB or BM sam-
ples by Ficoii-Paque centrifugation (density 1.077 g/cm3; Pharmacia, Uppsala, Sweden) and subjected to 
detailed immunophenotyping according to standard protocols.16-17 To analyze sufficient numbers of CD3 ... 
T-ALL (especially TCRyO+T-ALL) we selected T-ALL cell samples based on their CD3/TCR immunophe-
notype, resulting in 69 CD3-T-ALL (58% of the total series). 25 TCRa.~+T-ALL (21%). and 24 TCRyO+T-
ALL (20%). In an entirely random series of T-ALL this immunophenotype distribution would approximate-
ly be 70%, 20%, and 10%, respectively.18 Although in two CD3+T-ALL cases no information about TCR 
protein expression was available, they were included into the TCRyO+T-ALL group based on the Southern 
blot finding of biallelic TCRD rearrangements in both cases. 
Southern blot analysis 
DNA was isolated from fresh or frozen MNC fractions as described previous!y.2 Fifteen micrograms 
of DNA was digested with the appropriate restriction enzymes (Pharmacia), size-separated in 0.7% 
agarose gels, and transferred to Nytran-13N nylon membranes (Schleicher and Schuell, Dassel, 
Germany) as described.2-19 IGH gene configuration was analyzed in the 118 T-ALL patients with the 
IGHJ6 probe (DAKO Corporation, Carpinteria, CA) in Bg/11, BamHI/Hindl!l, EcoRI and/or Hindlll digests.20 
The configuration of the TCRD genes was analyzed in 101 out of 118 patients with the TCRDV2, 
TCRDD2. TCRDJ1, TCRDJ2, TCRDJ3, TCRDRE, and TCRAPJ probes (DAKO Corporation) in Bgnl, 
EcoRI, and Hindlll digests.15 
Primer design and heteroduplex PCR analysis 
PCR was essentially performed as described previously.?-19 In each 50J..l.l PCR reaction 50 ng DNA 
sample, 6.3 pmol of the 5" and 3" oligonucleotide primers. and 0.5 U AmpliTaq Gold polymerase {PE 
Biosystems, Foster City. CA) were used. The sequences of the oligonucleotides used for amplification of 
complete VH-JH gene rearrangements (6 IGH framework-1 VH-family specific primers, and 1 JH consen-
sus primer) were published before_21.22 Based on recently published data of germline DNA D-region 
sequences of the human IGH locus23 (EMBL accession no. X97051; for the detailed organization of the 
!GH D-reg ion see Figure 1 ), 7 family-specific DH primers were designed using OLIGO 6.0 software (Or. 
W. Rychlik; Molecular Biology Insights, Inc., Plymouth, MN) applying previously described guidelines 
(Table 1 ).24 Oligonucleotide primers of 22 to 24 bp were positioned at least 50 bp upstream of the 
involved recombination signal sequence (RSS). Secondary structures such as primer dimers and hairpins 
were avoided, and the melting temperature (Tm) was 68"C ± 3"C. All primers were synthesized on an ABI 
392 DNA synthesizer (PE Biosystems) using the solid-phase phosphotriester method. 
PCR conditions were: initial denaturation for 3 minutes at 92°C, followed by 35 cycles of 45 seconds 
at 92°C, 90 seconds at 60°C, and 2 minutes at 72°C using a Perkin-Elmer 480 thermal cycler (PE 
Biosystems). After the last cycle, an additional extension step of 10 minutes at 72°C was performed. 
Appropriate positive and negative controls were included in all experiments.24 
Heteroduplex analysis of PCR products included denaturation at 94°C for 5 minutes after the final 
cycle of amplification and subsequent renaturation at 4°C for 60 minutes to induce duplex formation.25 
Afterwards the duplexes were immediately loaded on 6% nondenaturing polyacrylamide gels in 0.5 x Tris-
Boric acid-EDTA (TBE) buffer, run at room temperature, and visualized by ethidium bromide staining.25 A 
1 00-bp DNA ladder (Prom ega Corporation, Madison, WI) was used as size marker. 
Sequence analysis of IGH gene rearrangements 
PCR products found to be clonal by heteroduplex analysis were directly sequenced except for cases 
in which heteroduplex PCR analysis showed more than two clonal bands, i.e., either two homoduplexes, 
or an additional upper band resulting from extension to downstream JH segments, or a DH7-27-JH1 
germline band accompanying a 0H7-27-JH rearrangement. In such cases homoduplexes were excised 
from the polyacrylamide gel and eluted as described before_26.27 The eluted PCR products were either 
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Table 1. Forward primers developed for PCR and sequence analysis of incomplete OH..JH gene 
rearrangements. 
Primer code Size of primer {bp) Position in bpa Sequence ( 5' ~> 3' ) 
DH1 22 -79 A(CIT)CCAGGAGGCCCCAGAGC(AIT)CA 
DH2 24 -187 CAGCACTGGGCTCAGAGTCCTCTC 
DH3 24 
-109 CCTCCTC(NC)GGTCAGCCC(CIT)GGACAT 
DH4 24 -129 CCCAGGACGCAGCACC(NG)CTGTCAA 
DH5 23 -245 ACCCAGCCTCCTGCTGACCAGAG 
DH6 22 -144 CAGGCCCCCCA(NG)AACCAG(T/G)G(AIT)T 
DH7 24 -181 GGGCTGGGGTCTCCCACGTGTTTT 
a.The position of the 5' end of the primer is indicated upstream (-)relative to the 3' RSS of the involved 
DH gene segment. 
directly sequenced or subjected to second step PCR with the same primer pair to increase the amount of 
template for sequence analysis. Sequencing was performed using the dye-terminator cycle sequencing 
kit with AmpliTaq DNA polymerase FS on an ABI 377 sequencer (PE Biosystems). Briefly, 50-200 ng of 
PCR product and 3.2 pmol primer were used in a 15 ).LI reaction volume. The cycling protocol was 96°C 
for 30 seconds followed by 60°C for 4 minutes for a total of 25 cycles. Each PCR product was sequenced 
in two directions. 
Interpretation of sequence data 
VH, DH, and JH segments were identified using DNAPLOT software (W. MUller, H-H. Althaus. 
University of Cologne, Germany) by searching for homology with all known human germline VH. DH, and 
JH sequences obtained from the VBASE directory of human lg genes (http://www.mrc-cpe.cam.ac.uk!imt-
doc/)28. For alignments of 0 segments in VH-DH-JH or DH-DH-JH rearrangements, it was required to have 
at least 10 consecutive matching nucleotides.23 Palindromic (P-region) nucleotides (maximally 2) gener-
ated during the joining process were recognized as being palindromic to the juxtaposed nuc!eotides of an 
untrimmed rearranged gene segment.29 Extensive N-regions (nucleotides that cannot be assigned to V, 
0, J gene segments or P-regions) were analyzed in more detail by comparing them to the most recent 
update of GenBank using the BLAST sequence similarity-searching tool (National Center for 
Biotechnology Information; http://www.ncbi.nlm.nih.gov/ BLAST/)_30 
RESUlTS 
Southern blot analysis of IGH gene rearrangements in T-All 
IGH gene rearrangements were found in 22% (26/118) of T-All patients, and 
were equally distributed between different age groups, i.e., 23% (19/84) of children 
and 21% (7/34) of adults. In the majority of cases this concerned monoallelic 
rearrangements (69% [18/26]), and in 31% (8/26) biallelic rearrangements were 
observed. In 2 of these patients, SB analysis revealed weak bands, most probably 
derived from subclones. Cross-lineage JGH gene rearrangements were found in 19% 
(13/69) of CD3- T-ALL and in 50% of TCRyo+ T-ALL (12/24 ), whereas only a single 
TCRaf)+ T-ALL (4% [1/25]) displayed a rearranged IGH gene on one allele. 
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Figure 2. 
Heterodup!ex PCR analysis of DH7-27-JH cross-lineage rearrangements in T-ALL. Subsequent to agarose 
gel electrophoresis samples containing PCR products were subjected to heteroduplex PCR analysis. sep-
arated in a 6% polyacrylamide gel, and visualized by ethidium bromide staining. Based on the size of clon-
al PCR products DH7-27-JH rearrangements (-250 bp) were identified in T-ALL patients T009, T038, 
T042, T062. T150, and T184 as well as in aT-cell pro lymphocytic leukemia (T-PLL). In addition to homod-
uplexes resulting from DH?-27-JH rearrangement, the germline 0H7-27-JH1 and DH7-27-JH2 homodu-
plexes were consistently present, except for cases with biallelic IGH rearrangements and a very high 
tumour load (i.e., patient T150). To obtain a clonal sequence of DH7-27-JH rearrangements. homoduplex-
es of the correct size were excised from the polyacrylamide gel, eluted, and sequenced. ss =single strand 
DNA. 
IGH gene rearrangements coincide with TCRD gene rearrangements 
Because Co3- T-ALL theoretically represent precursor stages of both TCRa~+ 
and TCRy8+ T-ALL, we analyzed the configuration of the TCRD genes in 57 CD3-
T-ALL cases and used it as an additional marker for further subdivision of this 
group_15,16 The TCRD gene configuration of each allele can potentially pass three 
consecutive stages: germ line, rearrangement, and deletion, 15-18 Except for 1 case, 
all IGH gene rearrangements were found in patients with at least one TCRD gene 
rearrangement; in this single CD3- T-ALL a monoallelic /GH gene rearrangement 
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Table 2. Usage of different DH families in (in)complete cross-lineage IGH gene rearrangements in 
T-ALL 
New family namea 
DH1 
DH2 
DH3 
DH4 
DH5 
DH6 
DH7 
Old family namea 
of rearrangements 
DM 
DLR 
DXP 
DA 
DK 
DN 
0052 
No. (frequency) 
7 (18%) 
1 (3%) 
1 (3%) 
2 (5%) 
1 (3%) 
18 (47%) 
8 (21 %) 
Segments used 
DH1-7: 2 
DH1-20: 2 
DH1-26: 3 
DH2-2: 1 
DH3-22: 
DH4-4: 
DH4-23: 
DH5-18: 
DH6-6: 
DH6-19: 17 
DH7-27: 8 
a. The new nomenclature is derived from Corbett et al.23 whereas the old nomenclature is according to 
lchihara et aJ.51 
was observed in combination with deletion of both TCRD alleles. 
Based on the above-described results, we analyzed the association of cross-lin-
eage IGH gene rearrangements and TCRD gene configuration for 101 of the 118 T-
ALLs. Rearrangements in the IGH locus appeared to be almost exclusively associ-
ated with TCRD gene rearrangements. They were evenly distributed between cases 
with 1 rearranged and 1 germline TCRD allele (1 of 3 cases [33%]), cases with bial-
lelic TCRD rearrangements (15 of 47 cases [32%]) and cases with 1 rearranged and 
1 deleted TCRD allele (7 of 22 cases [32%]). Remarkably, only 1 of 26 cases with 
biallelically deleted TCRD genes (4%) displayed a cross-lineage /GH gene 
rearrangement 
Taking these data together, cross-lineage IGH gene rearrangements occurred in 
only 5% (2/38) of a~-lineage T-ALL, i.e., either TCRa~+ T-ALL (n = 25) or Co3-
T-ALL with biallelic TCRD deletion (n = 13). 
Complete VH-(DH-)JH and incomplete DH-JH rearrangements 
Detailed PCR analysis of the IGH locus in the 26 patients with Southern blot doc-
umented /GH gene rearrangements was based on 13 primer combinations covering 
the vast majority of complete VH-(DH-)JH joinings and potentially all incomplete OH-
JH rearrangements. Heteroduplex PCR analysis revealed a total of 39 clonal homod-
uplexes, reflecting seven (18%) complete VH-(DH)-JH joinings and 32 (82%) incom-
plete DH-JH rearrangements. Complete VH-(DH)-JH rearrangements were found in 4 
CD3- T-ALL and 2 TCRyo+ T-ALL patients, with 1 TCRyo+ T-ALL showing biallelic 
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VH-(DH-)JH joinings. Heteroduplex PCR analysis for incomplete 0H7-27-JH 
rearrangements is shown in Figure 2. 
Sequence analysis confirmed monoclonality in 7 complete VH-(OH-)JH rearrange-
ments, which involved 7 different gene segments from 4 families: VH1-3, VH1-69, 
VH3-13, VH3-23, VH3-33, VH4-4, and VH6-1. None of the rearrangements was poten-
tially functional. Six sequences were out-of-frame joinings, whereas the single 
rearrangement with an in-frame VH-JH contained a stop codon in the junctional 
region. 
DH6-19 and DH7-27 are preferentially used in IGH gene rearrangements in 
T-ALL 
Sequence analysis of the junctional regions of complete VH-(DH-)JH recombina-
tions allowed identification of a D segment in 5 of 7 joinings. Moreover, 1 incomplete 
rearrangement was of the OH-DH-JH type. The frequencies of different DH family 
members found among the 38 identified DH sequences in the complete and incom-
plete cross-lineage IGH gene rearrangements are summarized in Table 2. Usage of 
the DH6 family was most prominent (47%), with the 0H6-19 gene segment being 
preferentially used (45% of all identified DH sequences; Table 3). The second most 
frequently used DH segment was 0H7-27 (21 %). Seven rearrangements (18%) con-
tained DH segments of the 0H1 family, whereas 5 other rearrangements used vari-
ous segments of the remaining 4 DH families (Table 2). Taken together, only 5 of the 
38 rearranged DH segments belonged to the most upstream part of the DH region, 
whereas all other 33 DH gene segments (87%) belonged to the most downstream 
part of the DH region (Table 2). No relationship between age and DH gene segment 
usage was observed. 
The sizes of the DH-JH junctional regions ranged from 0 to maximally 32 
nucleotides, with an average of 7.6 nucleotides. Three of 37 DH-JH junctions (8%) did 
not have any randomly inserted N-region nucleotides. P-nucleotides, indicating the 
absence of deletion, were present in 7 DH-JH joinings (19%). 
Table 3. Junctional region sequences of oligoclonal IGH gene rearrangements in a T~ALL patient (T061) illus-
trating the ongoing recombination process. 
No Upstream N- and P-nucleotidesb DH6-19 N-and P-nucleotides<:~ JH gene 
VH segment segments 
1. GGGTATAGCAGTGGCTGGT (-2) TTTTCTICTA (-6) JH6C 
2. VH1-03 (0) IAGT {-2) GTATAGCAGTGGCTGGT (-2) TTTTCTTCTA (-6) JH6C 
3. VH3-33 (-1) TAAGGGTGTGATG- (-11} TGGCTGGTAC (0) ~AGGCTGGCAGGGGGA (-14) JH6b 
TGTTTTGTGGA 
a. Underllned nucleotides represent P-nucleotides. 
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Table 4. Usage of different JH gene segments in incomplete and complete cross-lineage IGH gene 
rearrangements in T-All as compared with precursor-B-All, human SM precursor-S-
cells, and PB B lymphocytes. a 
JH segment T-ALL (n=39) Precursor-B-ALL Human BM Human PB 
precursor-B-cells B lymphocytes 
JH1 13% (5) 2% 0% 1% 
JH2 15% (6) 2% 4% 0% 
JH3 10% (4) 11% 14% 9% 
JH4 33% (13) 32% 32% 53% 
JH5 8% (3) 22% 17% 15% 
JH6 21% (8) 32% 33% 22% 
a. The B-lineage data were obtained in comparable PCR-based studies by Steenbergen et al.37 for pre-
cursor-B-ALL, by Raaphorst et al.36 for human BM precursor-S-cells and by Yamada et al.35 for human 
blood B lymphocytes. 
Usage of JH gene segments in cross-lineage fGH gene rearrangements 
The frequencies of different JH gene segments in IGH gene rearrangements in 
T-ALL are summarized in Table 4. The JH4 gene segment was found most frequent-
ly in approximately one third of joinings, followed by JH6 in 20% of cases. The 
remaining 4 JH segments were almost equally used, each comprising 10% to 15% 
of the rearrangements. 
Oligoclonality in cross-lineage fGH gene rearrangements in T-ALL 
SB analysis and heteroduplex PCR analysis showed fully concordant results in 
20 of 26 cases with cross-lineage IGH gene rearrangements in T-ALL. In 1 case with 
a single rearranged band on SB, we were not able to amplify the clonal rearrange-
ment with the applied primer sets. In the remaining 5 cases the number of clonal 
PCR-detected homoduplexes was higher than the number of rearranged bands in 
SB, which may suggest the presence of minor subclones undetectable by SB. In 1 
of these seemingly oligoclonal cases the identified incomplete and complete 
rearrangements (1 and 2 in Table 3) shared the same DH-JH fragment suggesting 
ongoing VH to DH-JH joining. In 4 other patients, the detected rearrangements were 
not related in their used gene segments. This may reflect secondary DH-JH joining, 
with concomitant deletion of a pre-existing DH-JH rearrangement. 
Based on the combined SB/PCR results, we found evidence for JGH oligoclonal-
ity at diagnosis in 27% (7/26) ofT-ALL patients with this type of cross-lineage recom-
bination. This includes the above-mentioned 5 cases with the higher number of PCR-
detected homoduplexes than the number of rearranged bands in SB and 2 addition-
al PCR-positive cases with weak bands on SB analysis, apparently derived from sub-
clones20 
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DISCUSSION 
We investigated a large group of 118 T-ALL patients for the presence of cross-
lineage !GH gene rearrangements. Based on SB analysis we identified such 
rearrangements in 22% of T-ALL, which is slightly higher than previously report-
ed.11.12 The vast majority (82%) of IGH gene rearrangements in T-ALL concerned 
incomplete DH-JH joinings. However, complete VH-(DH-)JH recombinations were also 
documented in our group of T-ALL patients. The usage of VH gene segments was 
seemingly random and not limited to the ones most proximal to the JH cluster. 
Nevertheless, 6 of 7 involved VH gene segments were derived from the proximal 3' 
portion of the IGH locus, a pattern that is seen in first trimester fetal VH-(DH)-JH 
rearrangements.31 None of the seven VH-(DH-)JH rearrangements was potentially 
functional. To our knowledge this is the first extensive evidence for the occurrence of 
clonal complete !GH gene rearrangements in T-ALL. They were previously reported 
in a single case of T-lymphoblastic non-Hodgkin's lymphoma, which is the lym-
phomatous counterpart of T-ALL.32 
In both the VH-(DH-)JH and DH-JH rearrangements we found a strikingly prefer-
ential usage of the more downstream DH gene segments (87% of identified OH 
sequences), especially DH6-19 (45%) and DH7-27 (21 %). The DH6-19 gene segment 
is one of the gene segments that were recently discovered thanks to complete 
sequencing of the OH region.23 Retrospective analysis of nearly 900 IGH junctional 
regions of B-lineage cells showed DH6-19 involvement in approximately 5% of the 
rearrangements, which is significantly higher than would be expected on a random 
basis23 The same holds true for 8 other DH segments, but 6 of them were not found 
in our T-ALL patients. The preferential usage of 0H6-19 could not be explained by a 
more optimal RSS at the 3' end in comparison to other OH segments, either. Further 
studies are needed to define whether this gene segment is also preferentially 
rearranged in precursor-S-cells or whether this finding only relates to the cross-line-
age phenomenon in T-ALL. In contrast to DH6-19, earlier reports indicated that the 
DH7-27 gene segment is involved in a significant proportion of IGH gene rearrange-
ments in T-ALL.13.14 Interestingly, we also found this gene segment in a cross-line-
age !GH gene rearrangement of a TCRa~+ T-prolymphocytic leukemia (Figure 2). 
The DH7-27 gene segment is also preferentially used by fetal B-cells but is rarely 
observed in adult BM and PB.33-36 In the analysis of nearly 900 IGH junctional 
regions of B-lineage cells, DH7-27 was found in only 0.5% of the rearrangements23 
Since DH7-27 consists of only 11 nucleotides, it is more difficult to identify this gene 
segment in a junctional region after moderate trimming during V(D)J recombination, 
if stringent assignment criteria are used. 
The analysis of JH segment usage revealed a more frequent use of JH4 and JH6 
gene segments, which is also the case in normal and leukemic B-lineage cells {Table 
4).35-37 However, in our T-ALL group a significant proportion of joinings involved the 
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most upstream JH1 and JH2 gene segments (28%), which are rarely used by B-lym-
phocytes (-1 %) and B-cell precursors (3% to 4%)35-37 In conclusion, the high fre-
quency of incomplete OH-JH rearrangements together with the frequent usage of the 
more downstream OH gene segments and the most upstream JH1 and JH2 gene seg-
ments suggest a predominance of the most immature !GH rearrangements in T-ALL. 
This particular DH-JH rearrangement pattern appears to be nonrandom and is not 
comparable with any known stage of B-cell ontogeny or B-cell differentiation31 
Since the types of preferential IGH gene rearrangements have now been identi-
fied, it would be relatively easy to screen T-ALL patients for the presence of cross-
lineage !GH gene rearrangements and apply them as PCR targets for monitoring of 
minimal residual disease (MRD) in T-ALL. Three primer combinations (DH1, 0H6, 
and DH7 in combination with a JH consensus primer) can identify 85% of incomplete 
DH-JH rearrangements in T-ALL. However, we observed oligoclonality in the /GH 
locus in 27% of T-ALL patients with rearranged !GH genes. In 1 case, we found evi-
dence for continuing VH to DH-JH recombination, whereas VH replacements have 
been described previously during disease progression of a T-lymphoblastic lym-
phoma32 Secondary rearrangements via continuing VH to OH-JH joining, VH gene 
replacements, and de novo IGH gene rearrangements have been reported for pre-
cursor-B-ALL38-40 These processes may lead to the emergence of clones with sec-
ondary IGH rearrangements. In a previous study, we compared the IGH gene 
rearrangement patterns between diagnosis and relapse in 40 ALL patients and found 
that at least one major !GH rearrangement was stable in most cases41 Therefore, 
cross-lineage IGH gene rearrangements might be useful as supplementary MRD 
target in addition to leukemia-specific TCRG and TCRD gene rearrangements, and 
TAL1 gene deletions.24,42 
Cross-lineage IGH gene rearrangements occurred most frequently in TCRy8+ T-
ALL (50% of patients) and in 20% of C03- T-ALL, but we found them in a single case 
of TCRcx~+ T-ALL (4%). Moreover, there was a striking association between the 
presence of rearranged TCRD genes and the occurrence of IGH recombination. A 
similar association was previously found for cross-lineage gene rearrangements in 
acute myeloid leukemia, suggesting that TCRD and IGH genes are concomitantly 
accessible for V(D)J recombinase in early hematopoietic precursors43 Furthermore, 
in the genotypically most mature T-ALL subgroup with biallelic TCRD gene deletions, 
an /GH gene rearrangement was observed in only 1 of 26 cases. Because IGH gene 
rearrangements are also rare in mature T-cell malignancies (-5%), 11 this suggests 
that the IGH locus may be accessible to V(D)J recombinase activity only in cells at 
earlier stages of T-cell differentiation. In this context, TCRy8+ T-ALL should be 
regarded as cells that branched off T-cell development at an early stage of comple-
tion of TCRD and TCRG gene rearrangement processes, when the recombinase 
activity is still retained_16 
178 CHAPTER2J 
Incomplete DH-JH rearrangements are one of the earliest events during normal 
B-cell development and are already found in CD34+/CD19-JCD10+ precursor 
cells.44-45 Most of the more mature CD34+/CD19+/CD10+ B-lineage precursors con-
tain at least 1 DH-JH rearranged allele and frequently also complete VH-(DH-)JH 
rearrangements.4 5-46 One could therefore speculate that cross-lineage /GH gene 
rearrangements in T-All might reflect malignant transformation of a thymocyte 
derived from a CD34+/CD19-/CD10+ precursor cell with rearranged IGH genes. 
This idea may be supported by a murine model, in which JGH rearrangements were 
only found at an intermediate stage of thymocyte development47 Nevertheless, this 
phenomenon was not observed in normal human thymocytes.44 Furthermore, the 
absence of D-J-C~ transcripts in fetal human thymocytes depleted of CD34+- and/or 
CD19+-bearing cells suggest that DH-JH rearrangements in humans may be restrict-
ed to normal B-lineage differentiation.44-48 It has also been suggested, that IGH gene 
rearrangements in T-cell-precursors may be an aberrant event directing cells into 
apoptotic pathway, unless they become immortalized by malignant transformation.3 
An alternative explanation could be that cross-lineage IGH gene rearrangements in 
T-All are postoncogenic events resulting from the ongoing activity of the common 
B-and T-cell V(D)J recombinase system on accessible gene loci_3.49.50 We favor the 
last hypothesis, because this would explain the virtual absence of IGH gene 
rearrangements in normal thymocytes and mature T-cell malignancies on the one 
hand and the presence of !GH oligoclonality and secondary VH-(DH-)JH rearrange-
ments in T-All on the other hand41 The virtual absence of /GH gene rearrange-
ments in a~-1ineage T-All with biallelic TCRD gene deletions suggests that the 
recombination system is not active in this more mature type ofT-All. Apparently, the 
recombinational activity is switched off as soon as the rearrangement and deletion 
processes in the TCRA/TCRD locus are completed. 
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ABSTRACT 
In order to gain insight into immunoglobulin (lg) and T-cell receptor (TCR) gene 
rearrangements in adult acute lymphoblastic leukemia (ALL), we studied 48 adult 
patients: 26 with precursor-B-ALL and 22 with T-ALL. Southern blotting (SB) with 
multiple DNA probes for the /GH, IGK, TCRB, TCRG, TCRD and TAL 1 loci revealed 
rearrangement patterns largely comparable to pediatric ALL, but several differences 
were found for precursor-B-ALL patients. Firstly, adult patients showed a lower level 
of oligoclonality in the IGH gene locus (five out of 26 patients; 19%) despite a com-
parable incidence of IGH gene rearrangements (24 out of 26 patients; 92%). 
Secondly, all detected !GK gene deletions (n = 12) concerned rearrangements of the 
kappa deleting element (Kde) to VK gene segments, which represent two thirds of 
the Kde rearrangements in pediatric precursor-B-ALL and only half of the Kde 
rearrangements in mature B-cell leukemias. Thirdly, a striking predominance of 
"Leukemia 1998; 12; 1081-1088 183 
184 CHAPTER 2.8 
immature 082-083 cross-lineage recombinations was observed (seven out of 16 
TCRD rearrangements; 44%), whereas more mature V82-D83 gene rearrangements 
occurred less frequently (six out of 16 TCRD rearrangements; 38% versus > 70% in 
pediatric precursor-B-ALL). Together these data suggest that the lg/TCR genotype 
of precursor-B-ALL is more immature and more stable in adults than in children. 
We also evaluated whether heteroduplex analysis of polymerase chain reaction 
(PCR) products of rearranged lg and TCR genes can be used for identification of 
molecular targets for minimal residual disease (MRD) detection. Using five of the 
major gene targets (IGH, IGK, TCRG, TCRD and TAL 1 deletion), we compared the 
SB data and heteroduplex PCR results. High concordance between the two methods 
ranging from 96 to 100% was found for !GK, TCRG, and TAL 1 genes. The concor-
dance was lower for /GH (70%) and TCRD genes (90% ), which may be explained by 
incomplete or 'atypical' rearrangements or by translocations detectable only by SB. 
Finally, the heteroduplex PCR data indicate, that MRD monitoring is possible in 
almost 90% of adult precursor-B-ALL and >95% of adult T-ALL patients. 
INTRODUCTION 
Recent advances in molecular biological and cytogenetic analysis of acute lym-
phoblastic leukemia (ALL) have revealed great heterogeneity within the disease1·2 
Based on the biological features of the leukemic clone, it is possible to predict the 
clinical aggressiveness of the malignant process and to select a treatment strategy 
in several subtypes. 
In contrast to pediatric ALL with long-term event-free survival in more than 70% 
of patients, adult ALL is not associated with such a favorable prognosis.3.4 Some fac-
tors responsible for this difference have been characterized, namely advanced age 
and hyperleukocytosis at presentation, higher frequency of more immature B or T lin-
eage phenotypes, lack of TEL gene rearrangements, and the relatively high fre-
quency of the Ph 1 translocation t(9;22), that is found in 30% of adult precursor-B-
ALL patients.3,5 So far, information about the immunogenotype of adult ALL is sparse 
and usually is derived from studies involving both adult and childhood patients.2,6,? 
This information is determined by analyzing the configuration of immunoglobulin (lg) 
and T-cell receptor (TCR) genes, generally by means of Southern blotting (SB).S 
SB of lg and TCR gene rearrangements is a very reliable technique for clonality 
assessment in suspect lymphoproliferations, with a sensitivity of 1-5%8 It is consid-
ered to be the gold standard for this type of diagnostics.S-10 However, SB is time-
consuming, laborious and relatively expensive, limiting its applicability to specialized 
molecular laboratories. During the last decade polymerase chain reaction (PCR) 
techniques have proven to be extremely useful in molecular diagnostics. PCR analy-
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sis is also successfully applied for clonality assessment based on the analysis of lg 
and TCR gene recombinations. 11 -14 However, due to the sensitivity of PCR methods, 
gene rearrangements in normal lymphocytes are also amplified, generally resulting 
in PCR products detectable in agarose or polyacrylamide gels. In order to distinguish 
between monoclonality and polyclonality, additional analysis of PCR products is nec-
essary by means of denaturing gradient gel electrophoresis, fingerprinting technique, 
gene scanning analysis, or direct sequencing; these techniques require special 
equipment and/or radioactivity facilities.15-19 Heteroduplex analysis of PCR-ampli-
fied junctional regions of lg and TCR genes was found to be a cheap, non-radioac-
tive, and easy alternative approach leading to reliable detection of clonal lymphoid 
cell populations in a polyclonal background.20-22 
In order to determine the configuration of the lg and TCR genes in adult ALL, we 
performed SB analysis on a series of 48 cases with an extensive set of DNA probes. 
Using the SB results as a reference, heteroduplex PCR analysis was evaluated for 
clonality assessment in this series of adult ALL This PCR approach is especially 
important for rapid and easy identification of lg and TCR gene rearrangements as 
PCR targets for sensitive monitoring of minimal residual disease (MRD).23-25 
MATERIALS AND METHODS 
Cell samples 
Cell samples were obtained from 48 newly identified adult ALL paf1ents enrolled in the HOVON-18 
study in four centers (University Hospital Rotterdam, Free University Hospital Amsterdam, University 
Hospital Leuven and University Hospital Utrecht). This concerned 15 female patients and 33 male patients 
with a mean age of 33 years (range: 15-61 years). The precursor-SorT lineage of the ALL samples was 
determined by flow cytometric immunophenotyping, based on standard criteria, using a wide panel of 
monoclonal antibodies.26.27 Mononuclear cells (MNC) were isolated from peripheral blood (PB) or bone 
marrow (BM) by Ficoii-Paque (density: 1.077 g/ml; Pharmacia, Uppsala, Sweden) density centrifugation. 
Some of the cell samples were frozen and stored in liquid nitrogen. 
Southern blot analysis 
DNA was isolated from fresh or frozen MNC fractions as described previously. a Fifteen micrograms 
of DNA were digested with the appropriate restriction enzymes (Pharmacia), size-separated in 0.7% 
agarose gels and transferred to Nytran-13N nylon membranes (Schleicher and Schuell, Dassel. Germany) 
as described. a lg heavy chain (/GH) and lg kappa light chain (/GK) gene configurations were analyzed 
with the IGHJ6. IGKJS, IGKC and IGKDE probes (DAKO Corporation, Carpinteria, CA, USA) in Bgfll and 
BamHI/Hindlll digests.28.29 Incomplete and complete TCR beta (TCRB) gene rearrangements were 
detected with TCRBD1U, TCRBD1. TCRBJ1. TCRBD2U, TCRBD2. TCRBJ2 and TCRBC probes 
(Langerak et al, manuscript in preparation, DAKO Corporation) in EcoRI and Hindi II digests. TCR gamma 
(TCRG) gene rearrangements were analyzed with the Jy1.2 probe in Bgfll digests and the Jy1.3 and Jy2.1 
probes in EcoRI digests.8,30.31 The configuration of the TCR delta (TCRO) genes was analyzed with the 
TCRDV2, TCRDD2, TCRDJ1, TCRDJ2, TCRDJ3. TCRDRE, and TCRAPJ probes (DAKO Corporation) in 
Bg/11, EcoRI. and Hindlll digests.32 The TAL 1 gene was screened by means of the SILOS probe in Bgfll, 
Hind!ll, and EcoRI digests.33 
186 CHAPTER 2.8 
?CR amplification 
PCR was essentially performed as described previously.34!n each 100J-LI PCR reaction 0.1 J.t9 DNA 
sample, 12.5 pmol of the s· and 3· oligonucleotide primers, and 1 U Taq polymerase (Perkin-Elmer Cetus, 
Norwalk, CT, USA) were used. The sequences of the majority of oligonucleotides used for amplification of 
IGH, JGK (kappa deleting element; Kde), TCRG, TCRD, and TAU gene rearrangements were published 
before.33.35-37 Some of the primers were newly designed during the B!OMED-1 Concerted Action 
'Investigation of minimal residual disease in acute leukemia: international standardization and clinical 
evaluation' (Pongers-Willemse et al., manuscript in preparation). All primers were synthesized on an ABI 
392 DNA synthesizer (Applied Biosystems, Foster City, CA. USA) using the solid-phase phosphotriester 
method. PCR conditions were 1 min at 94°C, 1 min at 55° to 60°C, and 2 min at 72°C for 30 to 35 cycles 
using a Perkin-Elmer thermal cycler (Perkin-Elmer Cetus). After the last cycle an additional extension step 
of 7 min at 72°C was performed. Appropriate positive and negative controls were included. 
A 
"' 
<{ ro 
m B ~ ;£ "' ~ ~ ~ " 
~ 
"' 
• 
m ~ 
"' 
m ~ ~ ~ ~ N 
" " 
N N ~ 
" 
N N N 
" kb 0 
"' "' 
:;; 
"' "' "' "' "' "' 
bp :: <a 
"' "' 
:;; 
"' "' "' "' "' 
u m m m m m m m m m ::<E m m m m m m m m 
21.2-
- $$ 9.4-
- -6.6-
5.0-
-4.3-
.... 
G-
--- - -3.5-
- -
--
-
2.3-
-2.0- "0 
1.9-
1.6-
1.4-
-
Bg/11 I IGHJ6 probe 
Figure 1. 
(A) SB analysis of the IGH genes in several adult precursor-B-ALL and one T-ALL. Control DNA and DNA 
from ALL samples were digested with Bg/11, size separated, and blotted onto nylon membrane filters, 
which were hybridized with the 32P-Iabeled IGHJ6 probe. The sizes (in kb) of the molecular weight mark-
er are indicated. In all presented precursor-B-ALL cases at least one !GH gene rearrangement was detect-
ed, while the single T-ALL case (96-116) revealed germline configuration. In one precursor-B-ALL patient 
(96-117) three rearranged bands of comparable density were demonstrated, suggesting trisomy 14. (B) 
Heteroduplex PCR analysis for three patients showing the results with VH family primers for the three most 
commonly used VH families and a JH consensus primer. Samples showing positivity on an agarose gel 
were subsequently subjected to heteroduplex PCR analysis. In patients 96-118 and 96-126 one clonal 
VH3-JH homoduplex was found whereas SB showed biallelic rearrangements. In patient 96-128 the 
monoclonal VH3-JH homodup!ex corresponded to the monoalle!ic rearrangement as detected by SB. 
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Heteroduplex analysis of PCR products 
For heteroduplex analysis, the PCR products were denatured at 94°C for 5 min after the final cycle 
of amplification and subsequently cooled to 4°C for 60 min. to induce duplex formation.22 After duplex for-
mation the hetero- and/or homoduplexes were immediately loaded on 6% non-denaturing polyacrylamide 
gels in 0.5 x Tris~Boric acid-EDT A (TBE) buffer, run at room temperature, and visualized by ethidium bro-
mide staining. Pstl-digested lambda DNA was used as a size marker. Both SB and heteroduplex analysis 
of PCR products were performed ln parallel in a double-blind manner. Concordance between the two 
methods was calculated assuming that the following gene configurations concerned the same alleles: 
rearranged band in SB :;;:; presence of clonal homodup!ex in PCR; germ line band and/or deletion in SB :;;:; 
no clonal PCR product. 
RESULTS 
Patients 
A total of 48 adult ALL patients enrolled in the HOVON-18 study were analyzed 
for lg and TCR gene rearrangements as well as for the presence of TAL 1 gene dele-
tion. This concerned 26 precursor-B-ALL and 22 T-ALL. 
SB analysis of IGH gene rearrangements 
DNA samples from 47 adult ALL patients were examined for the presence of IGH 
gene rearrangements (Figure 1 ). In the total group of 26 precursor-B-ALL patients, 
/GH gene recombination was detected in 24 cases (92%)(Table 1 ), while the remain-
ing two cases revealed a germline configuration. In four precursor-B-ALL patients 
(15%) more than two rearrangements were found. Obvious differences in density of 
two or more rearranged bands, suggesting the presence of subclones, were 
observed in five precursor-B-ALL patients (19%). In one patient three rearranged 
Table 1. Frequencies of lg, TCR, and TAL 1 gene rearrangements in adult All as detected by SB 
analysis. 
Type of gene rearrangement Precursor-B-ALL (n :;;:; 26)a T-ALL (n = 22) 
IGH 24 (92%) 5 (24%)b 
/GK(Jx) 4 (15%) ob 
!GK (Kde) 9 (35%) ob 
TCRB 7 (27%) 18 (82%) 
TCRG 15 (58%) 19 (86%) 
TCRD 12 (46%) 15 (68%) 
TAL 1 deletion 0 2 (9%) 
a. Excluding patients with weak gene rearrangements only, probably derived from subclones. 
b. One T-ALL patient was not analyzed by SB with IGH and !GK probes. because of an insufficient 
amount of DNA. 
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bands of comparable density were demonstrated (Figure 1), suggesting trisomy 14 
but cytogenetic analysis was inconclusive. Additionally, !GH gene rearrangements 
on one or even both alleles were found in five of the 21 tested T-ALL patients (24% 
of cases) (Table 1). 
SB analysis of IGK gene rearrangements 
46% (12 out of 26) of precursor-B-ALL patients contained rearranged IGK genes. 
Four patients (15%) demonstrated VK to JK rearrangements (Table 1). The deletion-
a! Kde rearrangements (n = 12) exclusively involved VK genes and were found in 
nine patients (35%) (Table 1 ). No deletional rearrangements of Kde to the recombi-
nation signal sequence in the JK.-CK intron (intron RSS) were found.29 !GK gene 
rearrangements were not detected in any of the 21 T-ALL patients studied (Table 1 ). 
SB analysis of TCRB gene rearrangements 
Using our well-defined TCRBD1U, TCRBD1, TCRBJ1, TCRBD2U, TCRBD2, 
TCRBJ2, and TCRBC probes, it was possible to distinguish between complete Vj)-
Jj) and incomplete Dj)-Jj) rearrangements in the j31 and j32 regions. 
Table 2. Allelic frequencies of particular TCRB gene rearrangements in adult ALL as detected by 
SB analysis. 
TCRB gene configuration 
Germ line 
Rearranged 
Number of rearrangements3 
TCRB1 region: 
V~-0~1 
0~1-J~1 
V~-J~1 
Unidentified to [31 
TCRB2 region: 
V~-0~2 
0~1-D~2 
V~-J~2 
0~1-J~2 
0~2-J~2 
Unidentified to [32 
Precursor-B-ALL 
(n = 26 patients, 52 alleles) 
42 (81%) 
10 (19%) 
0 
0 
0 
0 
0 
0 
5 (36%) 
1 (7%) 
1 (7%) 
7 (50%) 
T-ALL 
( n ::;: 22 patients, 44 a!!eles) 
11 (25%) 
33 (75%) 
0 
4 (10%) 
6 (15%) 
1 (2%) 
0 
0 
19 (46%) 
2 (5%) 
6 (15%) 
3 (7%) 
a. The number of rearrangements is higher than the number of rearranged alleles. because of the inci-
dental occurrence of rearrangements in the [31 region as well as the [32 region of the same allele and/or 
because of subclones. 
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Eighteen T-ALL patients (82%) had rearranged TCRB genes (Table 1). Allelic 
frequencies of the different types of TCRB recombinations are summarized in 
Table 2. Predominance of TCRB2 rearrangements was characteristic for T-ALL 
('TCRB2!TCRB1 ratio' of 2.7:1). More than half (61%) of the detected TCRB 
rearrangements in T-ALL concerned complete Vf3-Jf3 recombinations (Table 2). 
Cross-lineage TCRB gene rearrangements were found in seven (27%) precur-
sor-B-ALL (Table 1 ). These were all restricted to the TCRB2 locus; no rearrange-
ments were detected with the TCRB1 region probes (Table 2). 
SB analysis of TCRG gene rearrangements 
Eighty six percent (19 out of 22 cases) of T-ALL patients were found to have 
rearranged TCRG genes (Table 1 ), predominantly on both alleles (77%). In the vast 
majority V gene segments of the Vyl family were found to be rearranged to Jy1.3 or 
Jy2.3 gene segments (Figure 2 and Table 3). Only two T-ALL patients were found to 
have rearrangements to Jy1.1 or Jy2.1 gene segments, while in a single case a cion-
Table 3. Allelic frequencies of particular TCRG gene rearrangements in adult All as detected by 
SB analysis. 
TCRG gene configuration 
Germ line 
Deletion 
Rearrangements 
Number of rearrangements 
Involving Jy1.1/2.1 
Involving Jy1.2 
Involving Jy1.3/2.3 
Vyl: Vy2/4-Jy1.3/2.3 
Vy3-Jy1.3/2.3 
Vy5-Jy1.3/2.3 
Vy 7 -Jy1.3/2.3 
Vy8-Jy1.3/2.3 
Vyll-Jy1.3/2.3 
Vylll-Jy1.3/2.3 
Vy1V-Jy1.3!2.3 
Unidentified to Jy1.3/2.3 
Precursor-B-All 
(n::; 26 patients, 52 alleles) 
28 (54%) 
2 (4%) 
22 (42%) 
23b 
3 (13%) 
0 
20 (87%) 
5 (22%) 
3 (13%) 
2 (9%) 
1 (4%) 
0 
7 (30%) 
0 
2 (9%) 
0 
T-ALL 
(n::; 22 patients, 45 alleles)a 
7 (16%) 
1 (2%) 
37 (82%) 
37 
2 (5%) 
1 (3%)0 
34 (92%) 
14 (38%) 
3 (8%) 
1 (3%) 
0 
8 (22%) 
2 (5%) 
5 (14%) 
0 
1 (3%) 
a. The number of indicated alleles is 45 instead of 44, because one T-All patient showed three mono 
clonal rearrangements, most probably as a result of trisomy 7. 
b. Including one weak rearrangement, probably derived from a subclone. 
c. One T-All patient showed a monoclonal Vy9-Jy1.2 rearrangement, typical for peripheral blood T -cells, 
but rarely found in T-ALL cells. 
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al Vy9-Jy1.2 rearrangement was discovered. In one patient three rearranged bands 
of comparable density were demonstrated, suggesting trisomy 7. Allelic frequencies 
of TCRG gene rearrangements are shown in detail in Table 3. 
Cross-lineage TCRG recombinations were discovered in 58% of precursor-B-
ALL (Table 1 ), and in two patients this was associated with TCRG gene deletion on 
one allele. Similarly to T-ALL, rearrangements to Jy1.3 or Jy2.3 gene segments pre-
dominated, being demonstrated in 15 patients on 19 alleles, while Jy1.1 or Jy2.1 
rearrangements were found on only three alleles (Table 3). 
SB analysis of TCRD gene rearrangements 
TCRD gene rearrangements and/or deletions were observed in 21 out of 22 T-
ALL patients studied. In 15 patients (68%) a rearranged TCRD gene was found on 
at least one allele (Figure 3 and Table 1 ). TCRD deletion of at least one allele 
occurred in 12 patients. Only one T-ALL patient had both TCRD alleles in germline 
configuration. This patient also had germline TCRB and TCRG genes. Precise fre-
quencies of different TCRD gene rearrangements are summarized in Table 4. 
In 12 out of 26 patients (46%) with precursor-B-ALL TCRD rearrangements were 
found (Table 1 ). In 13 patients (50%) TCRD genes were deleted on one or both alle-
les. All SB identifiable TCRD rearrangements were incomplete V82-083 or 082-083 
recombinations (Table 4). In three precursor-B-ALL patients (12%) weak rearranged 
Table 4. Allelic frequencies of particular TCRD gene rearrangements in adult All as detected by 
SB analysis. 
TCRD gene configuration 
Germline 
Deletion 
Rearrangement 
Number of rearrangements 
Vo2-Do3 
Do2-Do3 
Vo1-Jo1 
Do2-Jo1 
Vo2-Jo1 
Vo3-Jo1 
Vo6-Jo2 
Unidentified to J01 
Precursor-B-ALL 
(n = 26 patients, 52 alleles) 
21 (40%) 
18 (35%) 
13 (25%) 
16a 
6 (38%) 
7 (44%) 
0 
0 
0 
0 
0 
3 (19%) 
T-ALL 
(n = 22 patients, 44 alleles) 
3 (7%) 
17 (39%) 
24 (54%) 
24 
0 
1 (4%) 
9 (38%) 
4 (17%) 
(4%) 
(4%) 
1 (4%) 
7 (29%) 
a. Including weak rearrangements (one V02-D03 and two unidentified rearrangements) most probably 
derived from subclones. 
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bands were observed suggesting the presence of subclones in these cases (Figure 
4). Thirty-one percent of precursor-B-ALL patients were found to have the TCRD 
genes in germline configuration on both alleles. 
SB analysis of TAL 1 gene rearrangements 
All ALL patients were tested for the presence of TAL 1 rearrangements using the 
SILDB probe. A typical type 1 TAL 1 deletion, resulting from fusion of sildb and tal1 db 
breakpoints was discovered in two T-ALL patients (Table 1 ). Both TCRD alleles were 
deleted in these two cases. No other TAL 1 gene rearrangements were found. 
Comparison of SB and heteroduplex PCR analysis of lg, TCR, and TAL 1 
genes 
DNA-based PCR amplification was simultaneously performed in a double blind 
manner for several of the lg and TCR genes studied by SB analysis. Clonal VH-JH 
rearrangements were found by heteroduplex PCR analysis in 17 out of 25 analyzed 
precursor-B-ALL patients and in a single T-ALL patient (Figure 1 ). In contrast to 49 
rearranged alleles found by classical SB, heteroduplex PCR analysis revealed 27 
monoclonal products assumed to be derived from those alleles (Table 5). Using VK. 
~ - Vy8-Jy1-3/2.3 
G-'1\11111-
EcoRI: Jy1.3 probo Vyi·Jy1.3J2.3 Vy4-Jy1.312.3 Vy8..Jy1.312.3 
Figure 2. 
Clonality assessment via SB analysis and heteroduplex PCR analysis of TCRG genes. 
(A) DNA from a T-ALL patient was digested with EcoRI. The filter was hybridized with the 32 P-Iabeled 
Jy1.3 probe and two rearrangements were found: Vy2/4 to Jy1.3 or Jy2.3 and Vy8 to Jy1.3 or Jy2.3. (B) 
Heteroduplex PCR analysis with a family-specific V primer (Vyl) in combination with a Jy1.3/2.3 primer 
showed two clonal Vyl-Jy1.3/2.3 homoduplexes as well as two heteroduplexes of clonal origin. (C and D) 
Further analysis with member-specific primers revealed two rearrangements: Vy4-Jy1.3/2.3 and Vy8-
Jy1.3/2.3. identical to those detected by SB. ss. single-strand fragments: he, heteroduplexes; ho, homod-
uplexes. 
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Clonality assessment via SB analysis and heteroduplex PCR analysis of TCRD genes. 
(A) DNA from a T-ALL patient was digested with Bg/11 and Hind Ill. The filter was hybridized with the 32P-
Iabeled TCRDJ1 probe and bia!!elic V01-J01 rearrangements were found. (B) Heteroduplex PCR analy-
sis with a V01 primer in combination with a J01 primer showed two clonal V01-J01 homoduplexes as well 
as (comigrating) heteroduplexes of clonal origin. ss, single-strand fragments; he, heteroduplexes; ho. 
homoduplexes. 
family-specific primers and a Kde primer it was possible to amplify VK-Kde 
rearrangements in the eight precursor-B-All patients, which were also detected by 
means of SB. In contrast to 12 rearranged alleles found by SB, heteroduplex PCR 
analysis resulted in clonal products in 10 out of these 12 alleles (Table 5). PCR 
analysis of the TCRG genes revealed all except one rearrangement detected by the 
SB technique as well as three additional recombinations, all of them involving Jy1.1 
or Jy2.1 gene segments (Table 5). Except for the presumed V83-J81, V86-J82 and 
ten unidentified rearrangements to J81, all DNA samples that were found to contain 
clonal TCRD rearrangements with SB also revealed clonal PCR products (Figure 3 
and Table 5). However, in contrast to the SB results, two precursor-B-All patients 
were found to have an oligoclonal pattern of V82-D83 rearrangements by heterodu-
plex PCR analysis (as exemplified in Figure 4). In concordance with the SB results, 
TAL 1 deletion PCR products were observed in both T-All patients (Table 5). 
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Table 5. Comparison of results obtained by SB analysis and heteroduplex PCR analysis. a 
Gene (segment) Rearrangements Rearrangements Concordance 
detected by SB analysis detected by heteroduplex between the two 
PCR analysis techniques 
/GH 49 (57) 27b 71% (65%) 
/GK (Kde) 12 10 98% 
TCRG 58 (60) 62 94% (96%) 
TCRD 37 (40) 28° 91% (90%) 
TAL1 2 2 100% 
a. Concordance between SB analysis and heterodup!ex PCR analysis was calculated assuming that the 
following gene configurations concerned the same alleles: rearranged band in SB = presence of 
clonal (homoduplex) PCR product; germ line band and/or deletion in SB = no clonal PCR product. 
The numbers and percentages in brackets express concordance between the two methods when weak 
rearranged SB bands (most probably derived from subclones) were included. 
b. Including one precursor-B-ALL patient with a single PCR product of low intensity. 
c. Including two precursor-B-ALL patients with oligoclonal V02-DS3 rearrangements in heteroduplex PCR 
analysis. 
DISCUSSION 
The samples of leukemic cells from 48 adult ALL patients were analyzed for the 
configuration of lg and TCR genes. Based on SB results IGH gene recombinations 
were detected in 92% of precursor-B-ALL patients. most of them (-80%) having two 
rearranged alleles. This is comparable to childhood ALL. 3S.39 Germline IGH genes 
were found in two patients, probably reflecting malignant transformation of a very 
early B-cell precursor. Multiple rearranged bands were found in only 19% of cases, 
which is essentially lower than the 30-45% observed in childhood ALL.39.40 Similarly 
to childhood precursor-B-ALL, IGK gene rearrangements were found in 46% of adult 
patients.29 However, Kde rearrangements to intron RSS were not found in any of our 
adult ALL cases, although they comprise 31% of Kde rearrangements in childhood 
precursor-B-ALL and 54% of Kde rearrangements in chronic B-cell leukemias.29,37 
These differences in lg gene rearrangement patterns might reflect biological differ-
ences between adult and childhood ALL, with adult precursor-B-ALL showing ten-
dency towards a more immature and stable genotype. 
Analysis of TCR gene rearrangements in adult ALL revealed configurations com-
parable to those previously discovered for childhood ALL patients.25.41.42 
Nevertheless, several discrepancies were found considering cross-lineage TCRD 
gene rearrangements in precursor-B-ALL. First of all, complete germline TCR gene 
patterns were found in 19% of adult precursor-B-ALL patients, which was mainly 
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caused by a lower incidence of TCRD deletions (35%) as compared to childhood 
ALL (45%).32 In addition, incomplete Do2-Do3 rearrangements occurred most fre-
quently, comprising approximately 45% of the TCRD recombinations, followed by the 
more mature Vo2-Do3 rearrangements (38%). The latter rearrangement was found 
to be dominant in childhood precursor-B-ALL, comprising >70% of the rearrange-
ments, while Do2-Do3 occurred in only 10% of the TCRD gene rearrange-
ments.32.43.44 Furthermore, heteroduplex PCR analysis demonstrated that three out 
of six Vo2-Do3 rearrangements were derived from minor subclones. This phenome-
non was previously reported in some cases of pediatric ALL44.45 Taken together, 
these data suggest that adult ALL has a more immature genotype as compared to 
pediatric ALL. 
Southern blotting is considered to be the gold standard for clonality diagnostics. 
However, this technique is laborious, time consuming, relatively expensive, and 
requires large amounts of high quality DNA. This generally limits the applicability of 
the method to more specialized laboratories. PCR techniques offer good alterna-
tives, as they are more rapid, less expensive, and require only small amounts of 
DNA. However, due to the enormous sensitivity, false-positive results might be 
obtained, if monoclonal PCR products cannot be distinguished from the background 
signals resulting from similar gene rearrangements in normal polyclonal lympho-
cytes. Heteroduplex analysis of PCR products was shown to be an effective proce-
dure for such discrimination between monoclonal and polyclonal rearrangements22 
Comparison of SB analysis and heteroduplex PCR analysis of /GK (Kde), TCRG, 
TCRD, and TAL1 gene rearrangements showed a high concordance (>90%) 
between the two techniques. In four cases (two Vx-Kde, one presumed Vo3-Jo1, and 
one presumed Vo6-Jo2 recombination) no clonal PCR products were obtained 
repeatedly. Unusual gene recombinations resulting in restriction fragments of com-
parable size on SB and/or extensive deletions of nucleotides in junctional regions 
might explain these negative PCR results. Ten rearrangements to Jo1 as detected by 
SB could not be assigned to a particular V8-Jo joining based on the sizes of clonal 
bands.32 In those cases no clonal products were found with the applied TCRD primer 
sets. These rearrangements might therefore reflect Va-J81 rearrangements or 
translocations into the TCRD locus. In contrast, three additional rearrangements to 
Jy1.1/2.1 were detected with the heteroduplex PCR technique as compared to SB 
analysis. These additional positive PCR results may be the consequence of the low 
sensitivity of the currently used Jy2.1 SB probe. Furthermore, in two precursor-B-ALL 
patients with 'clonal V82-D83 bands' on SB analysis, heteroduplex PCR analysis 
revealed an oligoclonal pattern. Homoduplexes representing VH-JH rearrangements 
were found on only 27 alleles in contrast to 49 clonal bands detected by SB with the 
IGHJ6 probe. The overall concordance between SB and heteroduplex PCR analysis 
for IGH reached only 71%. Rearrangements not identified by PCR may include 
incomplete DH-JH recombinations or translocations to the JH region46 The overall 
lg and TCR gene rearrangements in adult ALL 195 
results indicate that heteroduplex PCR analysis is an effective, rapid, and reliable 
approach for lg and TCR gene rearrangement studies in ALL. However, particular 
rearrangements like biallelic TCRD deletions or atypical rearrangements (e.g. Va-
Jo1, incomplete DH-JH rearrangements or translocations) can only be detected by 
conventional SB analysis, unless many additional sets of PCR primers are used. An 
additional advantage of heteroduplex PCR analysis is that excised homoduplex 
bands can be successfully used for direct cycle sequencing, as was demonstrated 
by Beishuizen et al.37 for VK-Kde rearrangements. 
Based on clonal lg and TCR gene rearrangements identified at diagnosis, it is 
possible to monitor MRD by use of PCR analysis in most adult ALL patients 
(Table 6). Heteroduplex PCR analysis revealed at least one patient-specific MRD-
PCR target in 95% ofT-ALL and almost 90% of precursor-B-ALL. Monitoring with two 
MRD-PCR targets would be possible for> 75% of precursor-B-ALL cases and 86% 
of T-ALL cases. 
In conclusion, our data indicate a largely comparable pattern of lg and TCR gene 
rearrangements between adult ALL and pediatric patients. However, the lower fre-
Table 6. Frequencies of lg and TCR gene rearrangements in adult AlL, which can be used for 
PCR~based MRD detection.a 
lg and TCR gene rearrangements Precursor-B-ALL T-ALL 
IGH: 
VH-JH 68%b 6%b 
IGK: 
Vx-Kde 31% 0% 
intron-Kde 0% 0% 
TCRG: 
Vy-Jy 62% 91% 
TCRD: 
V\32-003 or 002-003 35% 5% 
002-J01 or VO-DO-J01 0% 41% 
total TCRD 35% 46% 
TAL 1 deletion 0% 9% 
at least one PCR target 88% 95% 
at least two PCR targets 77% 86% 
at least three PCR targets 58% 50% 
a. Weak rearranged bands as detected by SB and oligoclonal rearrangements as detected by heroduplex 
PCR analysis were excluded. This exclusion mainly concerned TCRD gene rearrangements (V02-D03 
rearrangements) in precursor-B-ALL. 
b. One precursor-B-ALL patient and six T-ALL patients were not analyzed by VH-JH PCR because of an 
insufficient amount of DNA 
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quency of oligoclonal IGH gene rearrangements, the absence of intron RSS-Kde 
rearrangements, the higher frequency of germline TCRD genes and incomplete Do2-
D83 rearrangements, and the lower frequency of TCRD deletions were characteris-
tic for adult precursor-B-ALL patients as compared to childhood precursor-B-ALL, 
suggesting a more immature genotype in adults. Furthermore, our results show that 
the genotype of malignant cells can be studied reliably by means of both SB and het-
eroduplex PCR analysis, because these techniques give highly comparable results 
in ALL. Finally, identification of clonally rearranged lg and/or TCR genes as 
molecular targets for PCR-based MRD monitoring is possible in almost 90% of pre-
cursor-B-ALL and 95% of T-ALL in adults. 
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ABSTRACT 
Immunoglobulin (lg) and T-cell receptor (TCR) genes are rearranged in virtually 
all acute lymphoblastic leukemia (All) cases. However, the recombination patterns 
display several unusual features as compared to normal lymphoid counterparts. 
Cross-lineage gene rearrangements occur in more than 90% of precursor-B-ALL and 
in -20% of T-ALL, whereas they are rare in normal lymphocytes. Approximately 25-
30% of the lg and TCR gene rearrangements at diagnosis are oligoclonal, and can 
undergo continuing or secondary recombination events during the disease course. 
Based on our extensive molecular studies we hypothesize that the unusual lg and 
TCR gene rearrangements in ALL occur as an early postoncogenic event resulting 
from the continuing V(D)J recombinase activity on accessible gene loci. This hypoth-
esis is on the one hand supported by the virtual absence of cross-lineage gene 
rearrangements in normal lymphocytes and mature lymphoid malignancies and on 
the other hand by the presence of oligoclonality and secondary lg and TCR gene 
rearrangements in ALL. 
INTRODUCTION 
Acute lymphoblastic leukemia (ALL) is a malignancy of immature lymphoid cells. 
Leukemic lymphoblasts are considered as the malignant counterparts of normal 
bone marrow B-cell precursors and thymic T-cell precursors that have undergone 
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malignant transformation resulting in precursor-B-ALL and T-ALL, respectively. The 
oncogenic events block further differentiation, freezing the cell in a particular stage 
of the development, and subsequently enable uncontrolled proliferation. In virtually 
all ALL cases leukemic cells contain rearranged immunoglobulin (I g) and/or T-cell 
receptor (TCR) genes.1 ,2 This is probably related to the fact that lg and TCR gene 
rearrangements take place very early during lymphoid differentiation i.e. before sur-
face expression of the pan-B-cell marker CD19 in B-cell progenitors and in 
CD34+/CD1a- thymocy1es, respectively.3.4 In exceptional ALL cases, most probably 
derived from very immature progenitor cells, the lg and TCR gene loci are preserved 
in germ line configuration. 
In contrast to normal lymphoid development, lg and TCR gene rearrangements 
in ALL have several unusual characteristics. Owing to the observation of cross-line-
age TCR gene rearrangements in precursor-B-ALL and in some mature B-cell malig-
nancies together with the finding of rearranged lg heavy chain (/GH) genes in some 
T-ALL, lg and TCR gene rearrangements cannot be regarded as specific markers for 
B-lineage and T-lineage, respectively.5 In contrast, cross-lineage gene rearrange-
ments are not observed in normal human thymocy1es, whereas their frequency in 
normal B-cells is very low (below 0.5%).3.6 Other unusual characteristics of lg and 
TCR gene rearrangements in ALL as compared to their normal counterparts are the 
overrepresentation of particular rearrangement types, e.g. the restriction to certain 
gene segments, the usage of pseudogenes, the presence of 'end-stage' rearrange-
ments, and the occurrence of asynchronous combinations of gene rearrange-
ments.1·2,? 
Since a leukemic clone originates from a single malignantly transformed lym-
phoid cell, alllymphoblasts in principle have identically rearranged lg and TCR genes 
i.e. monoclonal gene rearrangements. However, in a substantial proportion of ALL 
there is evidence of oligoclonality. Subclones frequently show junctional region 
sequences related to the major clone, reflecting a continuing rearrangement 
process. Ongoing recombinations may also result in changes of leukemia-specific 
rearrangements at relapse of the disease.S-11 
The occurrence of unusual gene rearrangements in ALL can be explained in sev-
eral ways. It could be that cross-lineage gene rearrangements occur in early lym-
phoid progenitors leading to a stop in further differentiation and maturation. As a con-
sequence, a large fraction of such proliferating, immature lymphoid precursor cells 
without functional lineage-specific rearrangements and/or with cross-lineage gene 
rearrangements would normally undergo apoptosis unless they become neoplastic. 
An alternative explanation could be that unusual and cross-lineage gene rearrange-
ments in ALL represent postoncogenic events resulting from the ongoing activity of 
the common Band T-cell V(D)J recombinase system on gene loci, which are acces-
sible at the stage of maturational arrest and initial proliferation. Secondary and ongo-
ing rearrangements would then take place during the proliferative phase as well. 
Unusual fg and TCR gene rearrangements patterns in ALL 203 
Here we present the results of our extensive studies on lg and TCR gene 
rearrangements patterns in ALL, which in our opinion favor the hypothesis of unusu-
al gene recombination in ALL as a predominantly postoncogenic event. 
RESULTS AND DISCUSSION 
Lineage-specific Gene Rearrangements in ALL 
During the last years we performed detailed analysis of lg and TCR gene 
rearrangements in 340 ALL patients at diagnosis (Table 1 ).1. 12-16 In virtually all pre-
cursor-B-ALL cases (>95%) Southern blot analysis revealed clonal IGH gene 
rearrangements. In a significant proportion of these patients (-40%) obvious differ-
ences in density of two or more rearranged bands were found, refiecting oligoclon-
ality at the !GH locus.12 Since PCR analysis is more sensitive than Southern blotting, 
one can expect that IGH oligoclonality might in fact even concern a larger fraction of 
precursor-B-ALL cases. Figure 1 illustrates a case with multiple clonal IGH gene 
rearrangements at diagnosis as detected by heteroduplex PCR analysis.17 
Furthermore, PCR studies have already shown that the vast majority of IGH gene 
rearrangements were not functional, and that OH-DH-JH fusions could be identified in 
-20% of patients.18,19 
lg light chain gene rearrangements were found in 60% of cases (Table 1 ). 
Rearrangements of the lg kappa light chain (/GK) gene occur more frequently than 
in the lg lambda light chain (IGL) gene locus and often concern deletional rearrange-
ments to the kappa deleting element (Kde).2o In contrast to normal B-cells we 
observed an unusually high frequency of /GK deletional rearrangements compared 
to IGK and IGL gene rearrangement frequencies. Oligoclonality of IGK gene 
rearrangements was observed in <10% of precursor-B-ALL patients.12 Interestingly, 
Table 1. Relative frequencies of lg and TCR gene rearrangements in ALL.3 
/GH 
R D R 
Precursor-B-ALL 95% 3% 30% 
(children) 
T-ALL 20% 0% 0% 
Total ALL 85% 2% 25% 
IGK 
D 
30% 
0% 
25% 
IGL 
20% 
0% 
15% 
TCRB 
30% 
90% 
45% 
TCRG 
60% 
95% 
65% 
TCRD 
R D 
55% 35% 
70% 25% 
60% 35% 
a. Gene configurations as determined by interpretation of Southern blot results: R, rearrangement of at 
least one allele; D, deletion on both alleles or one allele deleted and the other in germ line configuration. 
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900- ss 800-
700-
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500-
400-
ho 
300-
B VH N-region VH/DH DH N-region JH 
(Dx) VH6-1(-6) GAGGGAGGG (-14) DH2-2 (-1) AAG (-7) DH6-13 (0) CGGGGATG (-6) JH6b 
(Re) VH2-70 (-2) CCGCCG (-10) DH6-13 (0) CGGGGATG (-6) JH6b 
Figure 1. 
(A) Heteroduplex PCR analysis of bone marrow DNA from a precursor-B-ALL patient at diagnosis (Ox) 
and at relapse (Re) using six VH family-specific primers together with a JH consensus primer. The results 
illustrate oligoclonal1ty both at diagnos'1s (five IGH gene rearrangements) and at relapse (three IGH gene 
rearrangements). None of the rearrangements was identical between diagnosis and relapse. ss, single-
strand fragments; ho, homoduplexes; C, positive control: M, 100 bp molecular weight marker. 
(B) Fluorescent sequencing of clonal PCR products at diagnosis and relapse showed that two different 
rearrangements shared an identical 0H6-13·JH6b junctional region, thereby proving the clonal relationship 
between the diagnosis and relapse cell samples. 
a significant proportion (-20%) of IGL gene rearrangements in precursor-B-ALL 
involves the non-functional J-Cfi.6 gene region (TOmkaya et al., submitted for publi-
cation). 
Analysis of a small group of adult precursor-B-ALL patients revealed several 
intriguing differences as compared to childhood patients.21 Firstly, we observed a 
lower level of IGH oligoclonality (-20% versus -40% in children) despite a compa-
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rable incidence of /GH gene rearrangements. Secondly, all detected IGK gene dele-
tions concerned rearrangements of the Kde to VK gene segments, which represent 
two thirds of the Kde rearrangements in pediatric precursor-B-ALL and only half of 
the Kde rearrangements in mature B-cell leukemias20,21 
TCR gene rearrangements occur in more than 95% of T-ALL cases (Table 1 ). 
The TCR delta (TCRD) locus first undergoes rearrangement in normal thymocyte 
development and likewise is the most frequently rearranged gene in T-ALL (-95%). 
In contrast to frequent subclone formation in lg genes in precursor-B-ALL, this phe-
nomenon is rarely observed for TCR gene rearrangements in T-ALL (Langerak et al., 
unpublished data). 
Interestingly, in several T-ALL patients an atypical TCR gamma (TCRG) gene 
rearrangement was demonstrated showing an interstitial deletion of -170 bp of the 
downstream part of the Vy2 gene segment22 
Cross-lineage TCR Gene Rearrangements in Precursor-B-ALL 
Our analysis of a large group of 202 pediatric precursor-B-ALL patients revealed 
TCR beta (TCRB), TCRG, and TCRD gene rearrangements in 35%, 59%, and 89% 
of cases, respectively (Table 1 ).15 In total, in 93% of the precursor-B-ALL cases one 
or more TCR genes were rearranged and/or deleted, indicating that cross-lineage 
TCR gene rearrangements are ubiquitously present in malignant B-lineage lym-
phoblasts. However, the spectrum of cross-lineage TCR gene rearrangements in 
precursor-B-ALL is very limited (Table 2). TCRB gene rearrangements are restricted 
to the J~2 region. This is in contrast to normal T-cells and T-ALL, which employ both 
J~1 and J~2 gene regions. TCRG gene rearrangements in precursor-B-ALL most 
Table 2. Unusual TCR gene rearrangements in precursor~B~ALL as compared to normal T~cells 
and T-ALL. 
TCRBgenes 
TCRG genes 
TCRD genes 
Precursor-B-ALL 
exclusively to Jp2: 
VHP2: 53% 
Dp-Jp2: 35% 
Vy-Jy1.3: 40% 
Vy-Jy2.3: 28% 
Vy-Jy1. 1: 27% 
Vo2-Do3: 40-70% 
Do2-Do3: 10-40% 
Normal T-lymphocytesff-ALL 
both to JP1 and J~2 
TCRap+ T-cells: 
TCRyo+ T-cells : 
T-ALL blasts: 
mainly to Jy1.3/2.3 
mainly Vyii-Jy1.2 
mainly to Jy1.3/2.3 
TCRap+ T-ce!lsff-ALL: mainly biallelic deletion 
TCRy&+ T-ce!ls: mainly V&2-J&1 
TCRy&+ T-ALL: mainly V01-J&1 
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frequently (-70%) concern rearrangements to Jy1 region gene segments. Curiously, 
80% of TCRD gene rearrangements represent incomplete Vo2-Do3 or Do2-Do3 join-
ings, whereas complete rearrangements to the Jo1 gene segment, characteristic for 
normal T-cells and T-ALL blasts (particularly TCRyo+ 23) have never been reported 
in precursor-B-ALL Apparently, only certain parts of the TCRB and TCRD genes are 
accessible for continuing activity of the V(D)J recombinase in precursor-B-ALL 
Using a transgenic mouse model, Lauzurica et at.24 showed that V-D to J recombi-
nation in human TCRD genes is controlled by the TCRD enhancer, whereas 
rearrangements to the Do3 gene segment are controlled by a separate mechanism. 
It seems highly probable that in precursor-B-ALL TCRD gene rearrangements are 
restricted to those that are independent of the TCRD enhancer. Furthermore, Vo2 
and Do2 gene segments in precursor-B-ALL can further undergo rearrangements to 
Ja gene segments and the majority of TCRD gene deletions refiect secondary Va-
Ja rearrangements6, 15 
The analysis of combinations of cross-lineage TCR gene rearrangements in pre-
cursor-B-ALL patients showed that TCRD gene rearrangements and/or deletions 
occurred in the majority of cases (-90%) and that 27% of childhood precursor-B-ALL 
had TCRD gene rearrangements and/or deletions with germline TCRG and TCRB 
genes.15 This implies that the hierarchy of cross-lineage TCR gene events is similar 
to early T-cell development, where rearrangements in the TCRD locus occur first, fol-
lowed by TCRG, and subsequently by TCRB gene rearrangements. Nevertheless, in 
a few cases we found rearranged TCRB genes with TCRD and TCRG loci in 
germline configuration. Furthermore, the frequencies of cross-lineage TCR gene 
rearrangements seem to be related to the maturation stages of malignant B-cells. 
The frequency of TCR gene rearrangements is lower in immature precursor-B-ALL 
(pro-B-ALL) as compared to CD10+ precursor-B-ALL (common ALL and pre-B-ALL). 
When comparing common ALL and pre-B-ALL subgroups, it is striking that in the 
'mature' (Cylg~+) pre-B-ALL group a higher frequency of patients have their TCR 
genes in germline configuration (15% versus 2% in common ALL). TCR gene 
rearrangements are still present in the most mature precursor-B-ALL subgroup with 
simultaneous cytoplasmic and membrane lg~ expression (transitional-pre-B-ALL). 
However, in mature B-cell malignancies cross-lineage TCR gene rearrangements 
are rare (<5%)_1.25 
Based on combined Southern blotting and heteroduplex PCR analysis we 
showed oligoclonality in 38% and 30% of precursor-B-ALL patients with TCRG and 
TCRD gene rearrangements, respectively, which is comparable to the frequency of 
oligoclonality found in the IGH locus.15 
In adult precursor-B-ALL a striking predominance of immature Do2-Do3 cross-
lineage recombinations was observed (44%), whereas the more mature Vo2-Do3 
gene rearrangements occurred less frequently (38%). This is in contrast to the high 
frequency (>70%) of the more mature Vo2-Do3 gene rearrangements in childhood 
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precursor-B-ALL. Together with the characteristic IGH and IGK gene rearrangement 
patterns this suggests that the lg and TCR genotype of precursor-B-ALL in adults is 
less mature than in children21 
Cross-Lineage IGH Gene Rearrangements in T-ALL 
In contrast to the frequent cross-lineage TCR gene rearrangements in precursor-
B-ALL, /GH gene rearrangements in T-ALL occur in -20% of patients (19% of CD3-
T-ALL, 50% of TCRyo+ T-ALL, and only 4% of TCRaj3+). Using heteroduplex PCR 
analysis we found a high frequency (-80%) of incomplete DH-JH rearrangements as 
well as preferential usage of 0H6-19 and the most downstream DH7 -27 gene seg-
ment together with the most upstream JH1 and JH2 gene segments. We have not 
found VH gene restriction in the complete VH-JH recombinations, which comprised 
18% of cross-lineage IGH gene rearrangements in T-ALL patients. Furthermore, 
oligoclonality in the IGH locus was found in 27% of T-ALL patients with rearranged 
IGH genes (Szczepanski et al., submitted for publication). Cross-lineage IGH gene 
rearrangements are rare in mature T-cell malignancies and lg light chain gene 
rearrangements have only been reported anecdotally in malignant T lymphoblasts.1 
Secondary and Ongoing Gene Rearrangements in ALL 
Another striking feature of lg and TCR gene rearrangements in ALL is the occur-
rence of secondary recombination events. Secondary rearrangements via continuing 
VH to DH-JH joining, VH gene replacements, and 'de novo' /GH gene rearrangements 
have frequently been reported for precursor-B-ALL (Figure 1 ).26,27 Southern blot 
comparison between IGH configuration at diagnosis and at relapse provided evi-
dence for clonal changes in 40% of precursor-B-ALL cases8 A few limited PCR stud-
ies estimated the frequency of IGH clonal evolution at -30% of cases.9·28 
Recently, we found evidence for continuing VH to DH-JH recombination in T-ALL, 
while VH replacement has been described previously during disease progression of 
a T-lymphoblastic lymphoma.29 
Based on Southern blot analysis, differences in TCRB, TCRG, and TCRD gene 
rearrangements between diagnosis and relapse were found in 30%, 20%, and 10% 
of T-ALL, respectively8 Limited PCR studies estimated the frequency of TCRG and 
TCRD clonal evolution at 10-40% ofT-ALL cases.10· 11 Interestingly, we demonstrat-
ed in several T-ALL cases ongoing, polyclonal oREC-'IfJa gene rearrangements with-
in otherwise monoclonal leukemic populations. 3D 
Cross-lineage TCRG and TCRD gene rearrangement patterns in precursor-B-
ALL were found discordant between diagnosis and relapse in 30-50% of cases by 
Southern blotting. However, in a few cases seemingly clonal Vo2-Do3 rearrange-
ments appeared to be oligoclonal upon PCR analysis.15,21 Moreover, ongoing Vo2-
Do3 to Ja recombination was demonstrated in the vast majority of Vo2-Do3-positive 
precursor-B-ALL.6 Finally, in a few precursor-B-ALL cases with clonal TCRG 
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rearrangements at diagnosis the disease recurred with TCRG genes in germline 
configuration (clonal regression).8,10 
COIIICLUSIOIIIS 
ALL blasts display a variety of characteristic gene rearrangements. The majority 
of lineage-specific rearrangements probably reflect the gene configuration status of 
the lymphoid precursor cell that was transformed at a particular stage of differentia-
tion. Cross-lineage gene rearrangements that are found in ALL could potentially be 
acquired before malignant transformation as well. However, then one would expect 
them to occur in normal lymphocytes at much higher frequencies. Since the majori-
ty of cross-lineage gene rearrangements are monoclonal and not oligoclonal, they 
should have occurred early after malignant transformation. The rare occurrence of 
cross-lineage gene rearrangements in TCRa.~+ lineage T-ALL as well as in mature 
B-cell and T-cell malignancies can be explained by the absence of recombinase 
activity in these more mature types of lymphoid malignancies. Oligoclonality at diag-
nosis, clonal regression, ongoing and secondary recombination are unequivocally 
later postoncogenic events. Taken together, we hypothesize that the unusual gene 
rearrangements in ALL are caused by post-transformation continuing activity of the 
V(D)J recombinase enzyme system on accessible gene loci. 
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CHAPTER 3.1 
ClONAL EVOlUTION OF IMMUNOGlOBUliN AND T-CEll 
RECEPTOR GENE REARRANGEMENTS BETWEEN DIAGNOSIS 
AND RELAPSE OF ACUTE lYMPHOBlASTIC lEUKEMIA 
The initial enthusiasm after establishing PCR strategies for detection of minimal 
residual disease (MRO) in acute lymphoblastic leukemia (ALL) based on 
immunoglobulin (lg) and T-cell receptor (TCR) gene rearrangements was challenged 
by the description of clonal evolution phenomena. lg and TCR gene rearrangements 
in precursor-B-ALL and T-ALL might be prone to subclone formation due to continu-
ing rearrangements or secondary rearrangements mediated via the continuously 
active recombinase enzyme system in these immature lymphoid malignancies 
(reviewed in Chapter 2.9). Especially the /GH gene rearrangements are known to 
change during the disease course, resulting in different rearrangement patterns 
between diagnosis and relapse. In fact, at diagnosis multiple IGH gene rearrange-
ments are already found in 30 to 40% of precursor-B-ALL, indicating the presence of 
biclonality or oligoclonality.1 Such oligoclonality usually refiects continuing or sec-
ondary IGH gene rearrangements, representing VH to OH-JH rearrangements or VH 
replacements, respectively.2.3 The problem of oligoclonality at diagnosis is the uncer-
tainty which clone is going to emerge at relapse and should be monitored with MRO-
PCR analysis. Changes in /GH gene rearrangement patterns at relapse were shown 
to occur at high frequency in childhood precursor-B-ALL, particularly when subclone 
formation is already present at diagnosis4 ·5 
TCR gene oligoclonality is rarely seen at diagnosis in T-ALL (see Chapter 2.6) 4 •6 
In contrast, combined Southern blot and PCR data show that the frequency of oligo-
clonality in cross-lineage TCR gene rearrangements of precursor-B-ALL is approxi-
mately 20%, which is slightly less than in the /GH gene (see Chapter 2.4 ). Initially, 
subclone formation at diagnosis was thought to be less frequent for the TCRD gene 
complex, as suggested by Southern blottingl However, PCR heteroduplex analysis 
and sequencing have shown that V82-083 and 082-083 rearrangements in newly 
diagnosed precursor-B-ALL are oligoclonal in 30 to 40% of cases (see Chapters 2.4 
and 2.8).8 Again, frequent TCR oligoclonality in precursor-B-ALL might be associat-
ed with further clonal evolution and loss of particular rearrangements at relapse.4·5,9 
For instance, oligoclonal V82-083 rearrangements are prone to continuing 
rearrangements, particularly to Ja gene segments with concomitant deletion of the 
C8 exons.S·1 o 
False-negative results due to clonal evolution are a major drawback of using 
lg/TCR gene rearrangements as PCR targets for MRO detection. In order to mini-
mize false-negative results, detailed studies have been performed on the stability of 
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different lg and TCR gene rearrangements between diagnosis and relapse in large 
series of childhood precursor-B-ALL and T-ALL patients (see Chapters 3.2 and 3.3). 
Based on the comparative information, it is possible to define optimal strategies for 
MRD-PCR target selection. Furthermore, using a stepwise molecular approach, it is 
possible to identify rare cases of true secondary ALL, which can be distinguished 
from presumably late ALL relapses (Chapter 3.4). Finally, based on preserved iden-
tical lgffCR gene rearrangements, molecular analyses can identify cases among 
presumably secondary acute myeloid leukemias, which actually represent unusual 
phenotypic shifts of initial ALL (Chapters 3.2 and 3.5). 
REFERENCES 
1. Beishuizen A. Hahlen K. Hageme.1jer A, Verhoeven MA. Hooijkaas H. Adriaansen HJ, Wolvers-
Tettero JLM. van Wering ER, van Oongen JJM. Multiple rearranged immunoglobulin genes in child-
hood acute lymphoblastic leukemia of precursor B-ee! I origin. Leukemia 1991 ;5:657-667. 
2. Kitching man GR. Immunoglobulin heavy chain gene VH-D junctional diversity at diagnosis in patients 
with acute lymphoblastic leukemia. Blood 1993;81:775-782. 
3. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, von dem Borne AE, van der Schoot CE. Distinct 
ongoing lg heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic 
leukemia. Blood 1993;82:581-589. 
4. Beishuizen A, Verhoeven MA, van Wering ER, H8.hlen K. Hooijkaas H. van Dongen JJM. Analysis of 
lg and T-ee!! receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subse-
quent relapse: implications for the detection of minimal residual d'1sease by polymerase chain reac-
tion analysis. Blood 1994;83:2238-2247. 
5. Steward CG, Goulden NJ, Katz F, Baines D, Martin PG, Lang!ands K, Potter MN. Chessells JM, 
Oakhill A A polymerase chain reaction study of the stability of lg heavy-chain and T-cell receptor 
delta gene rearrangements between presentation and relapse of childhood B-lineage acute lym-
phoblastic leukemia. Blood 1994:83:1355-1362. 
6. Van Dongen JJM, Wolvers-Tettero ILM. Analysis of immunoglobulin and T-cell receptor genes. Part 
II: Possib·il-lties and !"imitations ·rn the d·1agnos'1s and management of !ymphoproliferative diseases and 
related disorders. Clin Chim Acta 1991;198:93-174. 
7. Breit TM, Wolvers-Tettero ILM. Beishuizen A. Verhoeven M-AJ. van Wering ER, van Dongen JJM. 
Southern blot patterns, frequencies and junctional diversity ofT-cell receptor 0 gene rearrangements 
in acute lymphoblastic leukemia. Blood 1993;82:3063-3074. 
8. Ghali OW, Panzer S, Fischer S, Argyriou-Tirita A, Haas OA, Kovar H, Gadner H. Panzer-Grumayer 
ER. Heterogeneity of the T-cell receptor delta gene indicating subclone formation in acute precursor 
8-cell leukemias. Blood 1995;85:2795-2801. 
9. Taylor JJ, Rowe 0, Kylefjord H, Chessells J, Katz F, Proctor SJ, Middleton PG. Characterisation of 
non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in 
acute lymphoblastic leukemia. Leukemia 1994;8:60-66. 
10. Steenbergen EJ. Verhagen OJ, van Leeuwen EF, van den Berg H, von dem Borne AE, van der 
Schoot CE. Frequent ongoing T-cell receptor rearrangements in childhood B-precursor acute lym-
phoblastic leukemia: implications for monitoring minimal residual disease. Blood 1995;86:692-702. 
CHAPTER 3.2 
COMPARATIVE ANALYSIS OF IG AND TCR GENE 
REARRANGEMENTS AT DIAGNOSIS AND AT RELAPSE OF 
CHILDHOOD PRECURSOR-B-ALL PROVIDES IMPROVED 
STRATEGIES FOR SELECTION OF STABLE PCR TARGETS 
FOR MONITORING OF MINIMAL RESIDUAL DISEASE* 
Tomasz Szczepariski1•2, Marja J. Willemse1, Bas Brinkhof1, 
Elisabeth R. van Wering2, Mirjam van der Burg\ 
and Jacques J.M. van Dongen1 
1 Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, 
The Netherlands 
2Department of Pediatric Hematology and Chemotherapy, Silesian Medical Academy, Zabrze, Poland 
3Dutch Childhood Leukemia Study Group, The Hague, The Netherlands 
ABSTRACT 
Immunoglobulin (lg) and T-cell receptor (TCR) gene rearrangements are excel-
lent patient-specific polymerase chain reaction (PCR) targets for detection of mini-
mal residual disease (MRD) in acute lymphoblastic leukemia (ALL), but they might 
be unstable during the disease course. Therefore, we performed detailed molecular 
studies in 96 childhood precursor-B-ALL at diagnosis and at relapse (n = 91) or at 
presumably secondary acute myeloid leukemia (n = 5). 
Clonal lg and TCR targets for MRD detection were identified in 94 patients, with 
71% of these targets being preserved at relapse. The best stability was found for 
/GK-Kde rearrangements (90%), followed by TCRG (75%), IGH (64%), and incom-
plete TCRD rearrangements (63%). Combined Southern blot and PCR data for IGH, 
/GK-Kde, and TCRD genes showed significant differences in stability at relapse 
between monoclonal and oligoclonal rearrangements: 89% versus 40%, respective-
ly. 
In 38% of patients all MRD-PCR targets were preserved at relapse, and in 40% 
most of the targets (<:50%) were preserved. In 22% of patients most targets (10 
cases) or all targets (1 0 cases) were lost at relapse. The latter 10 cases included four 
patients with secondary acute myeloid leukemia with germline lg/TCR genes. In five 
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other patients additional analyses proved the clonal relationship between both dis-
ease stages. Finally, in one patient all lgffCR gene rearrangements were complete-
ly different between diagnosis and relapse, which is suggestive of secondary ALL. 
Based on the presented data, we propose stepwise strategies for selection of 
stable PCR targets for MRD monitoring, which should enable successful detection of 
relapse in most (95%) of childhood precursor-B-ALL. 
INTRODUCTION 
Several large prospective studies have clearly demonstrated the high prognostic 
value of minimal residual disease (MRD) monitoring in childhood acute lymphoblas-
tic leukemia (ALL).1-4 Based on the sensitive measurement of early response to 
cy1otoxic treatment, tt is curren~y possible to identify not only patients at high risk for 
relapse but also a group of low-risk patients with an excellent relapse-free survival of 
more than 95% 4 Hence, MRD information provides a new definition of remission in 
childhood ALL, which justifies incorporation of MRD data in current treatment proto-
cols to reline risk assignmentS 
Most MRD studies in pediatric precursor-B-ALL applied immunoglobulin (lg) 
and/or T-cell receptor (TCR) gene rearrangements as polymerase chain reaction 
(PCR) targets for MRD detection. They can easily be identified in most patients at 
diagnosis with limited sets of PCR primers_6.7 Moreover, using these molecular tar-
gets, sensitivities of 10-" to 10-6 (one malignant cell within 104 to 106 normal cells) 
can be obtained routinely.l With the advent of novel real-time quantitative (RQ) PCR 
techniques, lgffCR based MRD techniques are now also quantitative.S-11 However, 
it is also known that lg and TCR gene rearrangements might change during the dis-
ease course, owing to secondary rearrangement processes mediated via ongoing 
activity of the V(D)J recombinase enzyme system (reviewed by Szczepariski et ai.12). 
This might lead to loss of the PCR target and consequently to false-negative MRD 
results. Such changes were most frequently described for lg heavy chain genes 
(IGH) and to lesser extent for TCR genes and were found particularly in cases of pre-
cursor-B-ALL that already contained subclones at diagnosis.13-18 
Although the presence of clonal evolution phenomena is widely acknowledged, 
its actual impact on the effectiveness of MRD monitoring has not been defined. So 
far, studies assessing the stability of lg and TCR gene rearrangements at diagnosis 
and relapse of ALL either did not compare junctional region sequences or were lim-
ited to particular gene loci.13-18 Therefore we studied the stability of the currently 
used lgffCR rearrangements (IGH, lg kappa light chain (/GK), TCR gamma (TCRG) 
and TCR delta (TCRD) gene rearrangements) in a large series of 96 childhood pre-
cursor-B-ALL patients. This information is essential for reliable selection of MRD-
PCR targets with minimal chance of false-negative results. 
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PATIENTS, MATERIALS, AND METHODS 
Patients 
Bone marrow or per"1pheral blood samples from 96 childhood precursor-B-ALL patients were obtained 
at initial diagnosis and at relapse (91 patients) or at presumably secondary acute myeloid leukemia (AML) 
(5 patients). The age distribution ranged from 1 month to 183 months. Eight children (8%) were infants 
(age < 1 year). The diagnosis of precursor-B-ALL was made according to French-American-British and 
standard immunophenotypic criteria.19•21 Immunological marker analysis of the precursor-B-ALL revealed 
that six (6%) were pro-B-ALL, 59 (61%) were common ALL. and 31 (32%) were pre-B-ALL. Seven patients 
were studied at two subsequent leukemia relapses. Cell samples of 52 patients were obtained from the 
cell bank of the Dutch Childhood Leukemia Study Group. 
Comparative immunophenotypic analysis revealed intralineage switches in 21% (18 of 86) of pre-
cursor-B-ALL patients with available detailed immunophenotypic data at relapse, which is slightly higher 
than reported previously.22 
The rationale. methodology, and pitfalls of the stepwise molecular comparison of the !g/TCR gene 
rearrangements between diagnosis and relapse of precursor-B-ALL were previously exemplified in the 
case report of patient 5498, also included in these series.23 A small subgroup of patients (n "" 21) was 
studied before by comparative Southern blotting and PCR analysis of K-deleting element (Kde) rearrange-
ments at diagnosis and relapse.24 
Comparative Southern blot analysis 
Mononuclear cells were separated from bone marrow or peripheral blood samples by Ficoii-Paque 
centrifugation (density 1.077 g/cm3; Pharmacia, Uppsala, Sweden). DNA was isolated from frozen 
mononuclear cells, digested with the Bgl!l enzyme, and blotted to nylon membranes as described previ-
ously.25 JGH and IGK gene configurations were analyzed with the IGHJ6. !GKJS, !GKC and IGKDE probes 
(DAKO, Carpinteria. CA).26·27 The configuration of the TCRD genes was analyzed with the TCRDJ1 probe 
{DAK0).28 The diagnosis and relapse samples of the 96 patients were always run in parallel lanes (Figure 
1 ). except for 6 patients who were exclusively analyzed at diagnosis because of insufficient amounts of 
DNA from relapse samples. The Southern blot configuration of the lg and/or TCR genes in 73 patients at 
diagnosis and in 30 patients at relapse has been reported previously.6·15 
PCR amplification and comparative heteroduplex analysis of PCR products 
Independent of Southern blotting, PCR analysis could be performed on both diagnosis and relapse 
samples in 89 patients. essentially as described previous!y.7·29 Four patients with a secondary AML and 
three precursor-B-ALL patients with insufficient remaining DNA at diagnosis were not analyzed. In each 
SOfll PCR reaction 50 ng DNA sample, 6.3 pM of the s· and 3' oligonucleotide primers, and 0.5 U 
Amp!iTaq Gold polymerase (PE Biosystems, Foster City, CA) were used. The sequences of the 25 
oligonucleotide primer pairs used for amplification of IGH (5 VH family-specific framework 1 primers, and 
7 DH family-specific primers with consensus JH primer), /GK-Kde (4 VK family-specific primers and intron 
recombination signal sequence [RSS] primer with Kde primer). TCRG (6 Vy-Jy primer combinations most 
frequently used in precursor-B-ALL), and TCRD gene rearrangements {V82-033 and D32-DS3 primer 
pairs) were previously published.7·30 ·31 PCR conditions were as follows: initial denaturation for 10 minutes 
at 94°C, followed by 40 cycles of 45 seconds at 9~C. 90 seconds at 60°C, and 2 m·mutes at 72°C using 
a Perkin-Elmer 480 thermal cycler (PE Biosystems). After the last cycle an additional extension step of 10 
minutes at 72°C was performed. Appropriate positive and negative controls were included in all experi-
ments.7 
For heteroduplex analysis, the PCR products were denatured at 94°C for 5 minutes after the final 
cycle of amplification and subsequently cooled to 4°C for 60 minutes to induce duplex formation.32 
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Comparative Southern blot analysis of IGH gene configuration in six precursor-B-ALL patients. 
Monodonal patients 5438 and 5260 (patient with trisomy 14) show ·Identical gene rearrangements at d·lag-
nosis and at relapse. In monoclonal patient 5117, one allele at relapse is deleted and another one is pre-
served. Patient 5257 demonstrates biallelic IGH deletion at both disease stages. Oligoclonal patient 4910 
and monoclonal patient 5282 (the upper weak band in the diagnosis lane is derived from previous 
hybridization) show completely changed JGH gene rearrangement patterns. While sequence analysis has 
proven a clonal relationship between diagnosis and relapse in patient 4910. patient 5282 most likely rep-
resents a secondary ALL. 
Figure 2. 
Examples of comparative heteroduplex PCR analysis. (A) Comparative heteroduplex analysis of !GH 
gene rearrangements. Monoclonal homoduplexes (ho) in patients 5766, 6335, and 6124 found at diag-
nos·ls and at relapse were of the same size. Mixing of the PCR products of these disease phases followed 
by heteroduplex PCR analysis demonstrated no heteroduplex (he) formation, proving that these gene 
rearrangements had identical junctional regions. In patient 5784, monoclonal homoduplexes found at 
diagnosis and at relapse slightly differed in size. Mixing of the VH4-JH PCR products followed by het-
eroduplex PCR analysis demonstrated clear heteroduplex formation, proving that these VH4-JH gene 
rearrangements had different junctional regions; (ss) indicates remaining single-strand fragments. (B) 
Comparative heteroduplex analysis of Kde rearrangements showed completely identical rearrangements 
at diagnosis and at relapse. (C) Comparative heteroduplex analysis of V&2-D&3 gene rearrangements. 
Patients 5373 and 5513 with monoallelic and bia!lelic rearrangements, respectively, had stable V&2-D&3 
rearrangements. In contrast, V02-D&3 joinings at diagnosis in patients 5171 and 5514 are oligoclonal. 
while in both cases two monoclonal V&2-D03 rearrangements were found at relapse. 
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Afterwards the duplexes were immediately loaded on 6% nondenaturing polyacrylamide gels in 0.5 x Tris-
borate-EDTA buffer, run at room temperature, and visualized by ethidium bromide staining.32 
Relapse samples were at first analyzed with those primer combinations, which showed clonal PCR 
products at diagnosis. When the clonal PCR product was also found at relapse, its identity was subse-
quently compared with the PCR product found at diagnosis by means of mixed heteroduplex analysis, i.e. 
mixing of the diagnosis and relapse PCR products followed by heteroduplex analysis (Figure 2).23 When 
clonal PCR products found at diagnosis were undetectable at relapse, the relapse sample was then ana-
lyzed with additional primer combinations for the involved gene loci. 
Sequence analysis of lg/TCR gene rearrangements 
Clonal PCR products discordant between diagnosis and relapse of precursor-B-ALL as found by 
mixed heteroduplex analysis were directly sequenced. Sequencing was performed using the dye-termi-
nator cycle sequencing kit with AmpliTaq DNA polymerase FS on an ABI377 sequencer (PE Biosystems) 
as previously described.31 VH, OH, and JH segments were identified using DNAPLOT software (W. MOiler, 
H-H. Althaus, University of Cologne, Germany) by searching for homology with all known human germ line 
VH, DH, and JH sequences obtained from the VBASE directory of human lg genes (http://www.mrc-
cpe.cam.ac.uklimt-doc/).33 Vy and Jy gene segments were identified by comparison to germline TCRG 
sequences as previously described.34 
Statistical analysis 
Statistical analysis using the x2 test on a 2 x 2 table was performed to compare the frequencies of 
particular lg/TCR gene rearrangements between different precursor-B-ALL patient subgroups. Pearson 
correlation coefficient was calculated to test an association between variables. P values less than or equal 
to 0.05 were considered to be statistically significant. 
RESULTS 
Southern blot configuration of lg and TCR genes in relapsed All patients 
The configuration of !GH, IGK, and TCRD genes was established with multiple 
Southern blot probes. This concerned all 96 patients at diagnosis of precursor-B-ALL 
and 91 patients at subsequent relapse or secondary AML (Figure 1 )- This gave us 
the unique opportunity to address the question of whether there are any differences 
in lg/TCR gene configuration between the patients who relapsed compared with the 
total childhood precursor-B-ALL group. This comparison is summarized in Table 1, 
which shows that the lg/TCR gene rearrangement patterns at diagnosis and at 
relapse in patients included in this study are largely comparable to each other and to 
previously published data derived from large series of random childhood precursor-
B-ALL cases at initial diagnosis.6,2? Only two immunogenotypic features were more 
prevalent in ALL at relapse. The TCRD gene configuration at relapse was charac-
terized by significantly less frequent V82-083 and 082-083 rearrangements and 
more frequent TCRD deletions (p<0.05), which reflects ongoing deletional 
rearrangements. Secondly, the frequency of IGH and TCRD oligoclonality at relapse 
was slightly less frequent, but this difference was only significant for TCRD (p<0.05). 
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Table 1. Comparison of lg and TCR gene rearrangement patterns based on Southern blotting. 
!GH 
Germ!ine 
RIG 
RIR 
RID 
DIG 
DID 
Oligoclonal 
!GK-Kde 
Germline 
RIG 
RIR 
Oligoclonal 
TCRG 
Germ line 
RIGorRIR 
TCRD 
Germ line 
RIG 
RIR 
RID 
DIG 
D/D 
O!igoclonal 
"' not significant 
•• p < 0.05 
Random precursor-B-ALL 
at diagnosisa 
0 
1% 11/97) 
88°/o \ ~"197) 
8% (8/S7) 
2% (2/9",) 
1% (1/97) 
36% (35/97) 
50% (55/111) 
28% (31/111) 
23% (25/111) 
Not Determined 
41% (79/192) 
59% (113/192) 
11% (221202) 
15% (30/202) 
23% (47/202) 
17% (35/202) 
5% (11/202) 
28% (57/202) 
21% (13/62) 
Relapsed precursor-B-ALL Precursor-B-ALL 
at diagnosisb at relapse 
0 0 
2% (2/92) 5% (4/85) 
88% (81/92) 85% (72/85) 
7% (6/92) 7% (6/85) 
1% (1/92) 1% (1/85) 
1% (1/92) 2% (2/85) 
42% (38/92)0 28% (24/85)' 
51% (47/92) 49% (42/86) 
21% (19/92) 23% (20/86) 
28% (26/92) 28% (24/86) 
3% (3/92) 1% (1/86) 
38% (35/91) 41% (37/91) 
62% (56/91) 59% (54/91) 
8% (7/91) 12% (1 0/85) 
11% (10/91) 8% (7/85) 
24% (22/91) 12% (10/85) .. 
20% (18/91) 22% (19/85) 
4% (4/91) 5% (4/85) 
33% (30/91) 41% (35/85) .. 
26% (24/91) 12% (10/85) .. 
a. The frequencies of particular lg!TCR gene rearran~ements in the random precursor-B-ALL group at 
diagnosis are derived from our previous studies_6,2 ,46 
b. Including one patient with phenotypic switch to AML at relapse 
c. The frequency of JGH oligoclona!ity was significantly higher in infant ALL compared with noninfantALL 
(75% versus 38%, p < 0.05) 
The configuration of lgffCR genes compared between two subsequent relapses 
in the seven patients analyzed showed evidence for clonal evolution in only two 
cases (concerning one or two gene rearrangements), while in five of the seven cases 
we observed some changes in gene rearrangement patterns between diagnosis and 
first relapse. 
Southern blot analysis in four out of five patients with a presumed secondary 
AML demonstrated the complete absence of clonal lgffCR gene rearrangements 
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Figure 3. 
lg!TCR gene rearrangement stability in five precursor-B-ALL patients sub-
jected to comparative heteroduplex PCR analysis at diagnosis and at pre-
sumably secondary AML. All lg/TCR gene rearrangements identified at 
diagnosis in patients 3797, 4522, 5407, and 5985 were lost which is in line 
with secondary AML. In contrast several IGH and IGK gene rearrangements 
in patient 3991 were preserved, suggesting a phenotypic shift from ALL to 
AML. Black squares represent monoclonal rearrangements; gray squares. 
biclonalloligoclonal rearrangements; white squares. oligoclonallpolyc!onal 
rearrangements. All squares above the line represent stable MRO-PCR tar-
gets. while all squares below the line represent lg!TCR gene rearrange-
ments lost owing to clonal evolution. VH indicates VH-JH gene rearrange-
ments; DH, DH-JH gene rearrangements; VK, VK-JK gene rearrangements; 
Vy, Vy-Jy gene rearrangements; JO. rearrangements to J81-D83 region 
detected by Southern blot analysis. 
(Figure 3), which is in line with the AML diagnosis. However, in one patient (3991) 
three clonal Southern blot bands were preserved in the AML clone, and the 
sequence identity was confirmed by comparative PCR analysis for two VH-JH gene 
rearrangements. Apparently the original ALL clone underwent a phenotypic switch to 
AML. This patient was included in our further comparative diagnosis-relapse analy-
ses despite the phenotypic shift, while the other four patients were excluded. 
PCR delectability of lg and TCR gene rearrangements in relapsed 
precursor-B-ALL patients 
A total of 362 clonal PCR products of different lg/TCR gene rearrangements 
were identified at diagnosis in 87 (98%) of 89 patients, with an average of four tar-
gets per patient. In one patient no clonal gene rearrangements were detected by 
PCR, while Southern blotting showed a single weak rearranged /GH band, identical 
between the diagnosis and relapse sample. The second patient had an infant ALL 
and was fully oligoclonal at diagnosis, which precluded identification of clonal lg/TCR 
markers for PCR-based MRD monitoring. Generally, IGH oligoclonality at diagnosis 
was more prevalent in infant ALL patients (6 of 8 cases), compared with the non-
infant precursor-B-ALL cases (32 of 84 cases), p<0.05. 
Stability of particular MRD-PCR targets in monoclonal and oligoclonal 
precursor-B-ALL patients at relapse 
A total of 256 (71 %) of 362 clonal lg/TCR gene rearrangements identified with 
heteroduplex PCR analysis at diagnosis in 87 patients were preserved at relapse. 
This concerned 99 (64%) of 155 !GH, 54 (90%) of 60 /GK-Kde, 65 (75%) of 87 
TCRG, and 38 (63%) of 60 TCRD gene rearrangements (Table 2). In three addition-
lg/TCR genes at diagnosis and at relapse of precursor-B-ALL 223 
Table2. Stability of MRD-PCR targets in patients with monoclonal and oligoc!onal lg and TCR 
gene configuration 
STABILITY OF MRD-PCR TARGETS STABILITY IN PATIENTS (all I ~1) 
monoclonal oligoclonal total monoclonal oligoclonal total 
IGH 
VH-JH 88% 47% 69% 81% I 98% 37% I 73% 63% I 88% 
(n = 67) (n = 60) (n = 127) 
DH-JH 57% 38% 43% 67%167% 27% I 53% 33%157% 
(n = 7) (n = 21) (n = 28) 
all 85% 44% 64% 76% I 98% 24% I 76% 52% I 88% 
(n = 74) (n = 81) (n = 155) (n=42) (n=33) (n=75) 
IGK-Kde 
Vx-Kde 95% 40% 91% 94% I 97% 33%166% 88% I 94% 
(n = 39) (n = 5) (n = 44) 
lntron-Kde 86% 0% 87% 92% I 92% 0% 85% I 85% 
(n = 15) (n = 15) 
all* 95% 40% 90% 95% I 95% 33%166% 88% I 93% 
(n =55) (n = 5) (n = 60) (n = 37) (n = 3) (n = 40) 
tCRG 
Vy-Jy NO NO 75% NO NO 64% I 83% 
(n = 87) (n =53) 
TCRD 
D82-D83 100% 14% 63% 100% 14% I 14% 60%/60% 
(n = 9) (n = 7) (n = 16) 
V82-D83 81% 31% 63% 75% I 80% 20% I 50% 59% I 71% 
(n = 27) (n = 16) (n = 43) 
all*" 86% 26% 63% 80% I 88% 14% I 36% 56%169% 
(n = 37) (n = 23) (n = 60) (n =25) (n =14) (n =39) 
including one Vx-intronRSS rearrangement 
including one VS3-J&1 rearrangement 
NO not done 
al patients, Southern blot analysis provided conclusive information about stability of 
gene rearrangement patterns. 6.15 
In 36 patients (including patient 4616 studied exclusively by Southern blotting) all 
MRD-PCR targets identified at diagnosis were preserved at relapse (Figure 4A). In 
38 cases (including patients 2665 and 4501 studied exclusively by Southern blotting) 
at least half of the targets remained stable during the disease course (Figure 48). In 
another ten patients (including patient 3991 with AML at relapse; Figure 3) most 
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Figure 4. 
lg/TCR gene rearrangement stability patterns in 87 precursor-B-ALL patients subjected to comparative 
heterodup!ex PCR analysis at diagnosis and at relapse. Black squares represent monoclonal rearrange-
ments; gray squares, biclona!/oligoclonal rearrangements; white squares, oligoclona!/polyclonal 
rearrangements detectable as weak Southern blot bands. All squares above the upper line represent sta-
ble MRD-PCR targets, while all squares below the lower line represent lg/TCR gene rearrangements lost 
owing to clonal evolution. VH squares between the two lines have common DH-JH stems shared by differ-
ent IGH rearrangements at diagnosis and at relapse. (A) 35 patients with all PCR-MRD targets identified 
at diagnosis preserved at relapse; {B) 36 cases with some targets (ranging from one target to half of the 
targets) lost during disease course; (C) 16 patients with most or all clonal markers absent at relapse. 
Patient 4790 was not included in our evaluation of MRD-PCR target stability because the detected IGH 
and TCRG gene rearrangements at diagnosis were oligoclonal. VH indicates VH-JH gene rearrangements; 
DH, DH-JH gene rearrangements; VK, VK-Kde gene rearrangements; iK, intronRSS-Kde gene rearrange-
ments; Vy, Vy-Jy gene rearrangements; VO, VS2-D03 gene rearrangements; 00, D02-DS3 gene rearrange-
ments. 
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MRD-PCR targets were absent at relapse but at least one rearrangement was com-
mon for both diagnosis and relapse samples (Figure 4C). Consequently, at least one 
MRD-PCR target was preserved at relapse in 84 (93%) of 90 patients with available 
clonal MRD-PCR targets at diagnosis. In the remaining six patients all clonal mark-
ers found at diagnosis seemed to be lost. However, in three of these six cases the 
clonal relationship between diagnosis and relapse was confirmed by the identifica-
tion of a common DH-JH stem shared by respective VH-JH gene rearrangements. In 
another two cases additional analyses35-36 showed at both disease stages identical 
DNA sequences of VK-JK (case 5771) and chimeric MLL-AF4 fusion genes (case 
5978), respectively (data not shown). Finally, in one patient (case 5282) there was 
no evidence for a common origin of diagnosis and relapse clones (Figures 1 and 4C). 
Because all original monoclonal rearrangements were lost in this case at relapse, we 
believe that this is in fact a secondary ALL. 
Stability of MRD targets is not related to age, blood cell counts, or remission 
duration 
Stability of MRD-PCR targets did not significantly correlate with age or white 
blood cell count at diagnosis or with remission duration, i.e. time span between diag-
nosis and relapse. 
IGH gene rearrangements 
Clonal IGH gene rearrangements were detected by PCR in 75 of the 90 studied 
childhood precursor-B-ALL patients. In 66 cases (88%) at least one !GH MRD-PCR 
target was preserved at relapse. In 12 additional patients PCR analysis did not result 
in identification of clonal IGH rearrangements, while Southern blot data suggested 
the preservation of at least one target in all 12 patients (fully identical IGH configu-
ration in 9 cases). In three patients deletions of JH region were identified by Southern 
blotting both at diagnosis and at relapse of ALL. The Southern blot results of these 
15 patients were not used for calculating the stability of the IGH PCR targets. 
The stability of the /GH PCR targets was markedly different between oligoclonal 
and monoclonal patients; i.e. at least one MRD-PCR target was preserved in 76% 
and 98% of patients, respectively (Table 2). This significant difference was even 
more pronounced at the MRD-PCR target level, with 63 (85%) of 74 monoclonai/GH 
gene rearrangements being stable compared with only 36 (44%) of 85 oligoclonal 
rearrangements. Taking into account the type of /GH gene rearrangement, complete 
VH-JH recombinations were characterized by a higher stability compared with incom-
plete DH-JH rearrangements, with 69% vs. 43% of targets preserved, respectively. 
IGK deletional rearrangements 
A total of 60 IGK deletional rearrangements were detected in 40 childhood pre-
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cursor-B-ALL patients at diagnosis: 44 VK-Kde, 15 intron-Kde and one rarely occur-
ring Vx-intron RSS recombination. At least one of the rearrangements was pre-
served in 37 cases (93%). In fact, /GK-Kde recombinations represented the most 
stable MRO-PCR targets, with 90% of all targets preserved. Most (55 of 60) Kde 
rearrangements were monoclonal and highly stable (52 targets preserved; 95%), 
while only two of five oligoclonal /GK-Kde targets were found at relapse. No signifi-
cant difference in stability was found between VK-Kde and intron-Kde rearrange-
ments. 
TCRG gene rearrangements 
A total of 87 TCRG gene rearrangements were detected in 53 precursor-B-ALL 
patients at diagnosis and in 44 cases (83%) at least one MRO-PCR target was pre-
served at relapse. Because accurate oligoclonality detection in TCRG locus is rather 
complex, even by Southern blotting,37 we didn't evaluate whether there were any dif-
ferences in MRO-PCR target stability between monoclonal and oligoclonal patients. 
TCRD gene rearrangements 
A total of 60 clonal TCRD gene rearrangements (43 V82-083, 16 082-083, and 
1 V83-J81) were identified by PCR in 39 precursor-B-ALL patients. At least one of 
the clonal rearrangements was preserved in 27 (69%) of 39 cases. Once again we 
observed striking differences in stability between monoclonal and oligoclonal 
patients; i.e. at least one target was preserved in 88% and 36% of patients, respec-
tively (Table 2). Only 26% of oligoclonal targets were preserved compared with 86% 
of monoclonal targets. Moreover, in 10 patients Southern blot data suggested the 
presence of a clonally rearranged band corresponding to V82-083 rearrangements, 
while heteroduplex PCR analysis of these rearrangements showed oligoclonality or 
even polyclonality. 
Patterns of clonal evolution in precursor-B-ALL patients with unstable 
targets 
Based on combined Southern blot, PCR, and sequence analysis it was possible 
to follow the patterns of clonal evolution leading to disappearance of rearrange-
ments, which were originally present at diagnosis. 
Clonal evolution in /GH locus 
Owing to clonal evolution phenomena, 62 IGH targets in 36 patients were lost. 
We could determine the exact patterns of clonal evolution in 8 patients with mono-
clonal IGH gene rearrangements and in 26 patients with an oligoclonal rearrange-
ment pattern. 
In seven patients (two monoclonal and five oligoclonal) Southern blot rearrange-
ment patterns between diagnosis and relapse were identical while PCR analyses 
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showed disappearance of a single rearrangement. This might be explained by the 
disappearance of minor subclones undetectable by Southern blotting. In three 
patients with monoclonal IGH configuration one of the rearrangements was changed 
both in Southern blotting and PCR. while sequence comparison showed VH replace-
ment with a preserved VH-N-DH-N-JH junction. In another two monoclonal patients 
we observed clonal "regression" of one of the rearrangements to germline. Finally in 
a single patient (5282) both monoclonal IGH rearrangements were replaced by two 
new unrelated rearrangements; this patient was suspected of having developed a 
secondary ALL (Figure 4C). 
In 11 oligoclonal patients, the IGH configuration at relapse was monoclonal, 
which is suggestive of clonal selection during the treatment. In another 10 oligoclon-
al patients, IGH was also oligoclonal at relapse with several rearrangements lost and 
with emergence of new (sub)clones. Sequence comparison was fully completed in 
12 oligoclonal patients with changes at relapse, indicating ongoing VH to DH-JH join-
ings with preservation of common DH-JH stems in five patients and possibly second-
ary rearrangements in five other cases. In the remaining two oligoclonal patients, the 
IGH sequences were unrelated and suggestive of the development of diagnosis and 
relapse clones from a common clonal progenitor via independent secondary 
rearrangements. 
Clonal evolution in TCRG locus 
Clonal evolution of TCRG gene rearrangements was observed in 19 patients 
leading to loss of 22 MRD-PCR targets. In 9 patients this concerned "regression" of 
clonal rearrangements most probably to germline configuration. In five patients the 
new rearrangements at relapse contained upstream Vy and downstream Jy seg-
ments compared with the Vy-Jy rearrangements at diagnosis, which is suggestive of 
ongoing recombination with Vy-Jy replacement. In the remaining five patients the 
sequence comparison of Vy-Jy rearrangements at diagnosis and at relapse exclud-
ed secondary rearrangements and indicated the emergence of a clone related to the 
initial (pre)leukemic clone but different from the predominant clone at diagnosis. 
Clonal evolution in TCRD locus 
Clonal evolution in the TCRD locus resulted in the loss of 22 MRD-PCR targets 
in 17 patients (5 monoclonal and 12 oligoclonal cases). In 6 patients (including four 
patients with monoclonal Vo2-Do3 rearrangements) ongoing deletions were 
observed. In contrast, in 8 patients (including one patient with monoclonal Vo2-Do3) 
the rearrangement pattern "regressed" to germline configuration. Finally, in the 
remaining 3 cases new rearrangements were found at relapse, including one Vo2-
Do3 joining and two unidentified rearrangements to the Do3-J81 region. Interestingly, 
5 out of 10 cases with oligo/polyclonal V82-D83 rearrangements at diagnosis had a 
monoclonal TCRD configuration at relapse with a single V82-Do3 joining. In the 
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remaining five patients, ongoing TCRD deletion was assumed in two cases, two 
patients demonstrated "regression" to germline configuration, and only a single 
patient preserved the oligo/polyclonal V82-D83 rearrangement pattern at relapse. 
DISCUSSION 
Our comparative Southern blot, PCR, and sequencing analyses of childhood pre-
cursor-B-ALL at diagnosis and relapse have provided detailed insight in the stability 
and changes of lg and TCR gene rearrangements during the disease course. This 
information is essential for reliable application of lg/TCR gene rearrangements as 
MRD-PCR targets in childhood ALL However, one should be cautious with extrapo-
lating these data to adolescent or adult precursor-B-ALL patients, because the 
immunogenotype of adult precursor-B-ALL has more immature features.29 
The lg/TCR gene rearrangement patterns at diagnosis in relapsed patients 
appeared to be comparable to those in a random series of newly diagnosed pediatric 
precursor-B-ALL, implying that the various lg/TCR gene characteristics at diagnosis 
have no prognostic value. This is in contrast to the previously reported strong pre-
dictive value of the V82-D83 gene rearrangement or the overall clonal diversity.38,39 
The overall lg/TCR gene configuration patterns at relapse were largely comparable 
to those at diagnosis but were characterized by less oligoclonality and more frequent 
TCRD gene deletions. These two differences fit with the concept of ongoing clonal 
selection and continuing rearrangements. 
The detailed molecular analyses proved the clonal relationship between diagno-
sis and relapse in 88 of 89 childhood precursor-B-ALL with identified MRD-PCR 
markers at diagnosis. In only one patient (5282) were the lg/TCR gene rearrange-
ment patterns at diagnosis and relapse completely different with unrelated junction-
al region sequences (Figures 1 and 4C). Consequently, the presumed ALL relapse 
in this child (3.5 years after diagnosis) might in fact represent a secondary leukemia. 
This single patient confirms previous observations that ALL rarely occurs as second 
malignancy after previous cy1otoxic treatment4 0 This is in contrast to secondary 
AML, which affects approximately 4% of children treated for ALL with cy1otoxic regi-
mens containing topoisomerase II inhibitors41 We indeed proved the presence of 
secondary AML with germline lg/TCR genes in four (4%) of the 96 patients (Figure 
3). However, in a fifth patient we demonstrated the clonal relationship between the 
precursor-B-ALL at diagnosis and the presumed secondary AML, which in fact rep-
resented a phenotypic switch. 
The comparison of lg/TCR gene rearrangement patterns between diagnosis and 
relapse showed marked heterogeneity in the occurrence of clonal evolution phe-
nomena. In 40% of patients all PCR-identified clonal lg/TCR rearrangements were 
present at relapse (Figure 4A), and in another 42% of cases, at least half of the iden-
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tified gene rearrangements remained stable at relapse (Figure 48). Extreme clonal 
evolution with differential outgrowth of subclones characterized the remaining 18% 
of cases (Figure 4C), in whom most or even all clonal lg/TCR gene rearrangements 
identified at diagnosis were lost during disease course. Interestingly, in contrast to 
the frequent occurrence of clonal evolution between diagnosis and relapse, we did 
not observe major clonal instability of lg/TCR genes between two consecutive 
relapses (7 cases), which is in line with previous observations.14 
Previous studies suggested that the risk of changes in lg/TCR rearrangement 
patterns increases with time.15,42 We did not find a significant correlation between 
remission duration and target stability in this extensive study. This is in line with the 
report that clonal selection processes can already occur in early treatment phases 
and the reports on clonal identity between diagnosis and very late relapse of pre-
cursor-B-ALL4345 
In this extensive molecular study, we wished to identify the factors associated 
with the occurrence of clonal evolution and therefore the increased risk offalse-neg-
ative MRD-PCR results. It is entirely clear from our study that discrimination between 
monoclonality versus oligoclonality at diagnosis is the most powerful predictor of 
clonal evolution during the ALL disease course. All other variables, such as age, 
white blood cell count, and immunophenotype at diagnosis, failed to identify patients 
prone to clonal evolution of their lg/TCR gene rearrangements. Monoclonal MRD-
PCR targets were characterized by high stability, with 89% of all targets detectable 
at relapse. In contrast, only 40% of the oligoclonal MRD-PCR targets were preserved 
at relapse. Therefore, it is probably important to discriminate between monoclonal 
and oligoclonal lg/TCR rearrangements, which requires a combined Southern blot 
and PCR approach. Southern blotting is particularly informative for detection of 
oligoclonality in IGH and JGK gene rearrangements, whereas heteroduplex PCR 
analysis in combination with Southern blotting is informative for detection of oligo-
clonal TCRD gene rearrangements. Southern blotting needs more DNA and is more 
labor intensive and time consuming than PCR techniques. However, with a single 
Bg/11 restriction enzyme digestion it is possible to detect oligoclonality in JGH, JGK, 
and TCRD loci.26-28 Judging clonality solely from the number of PCR products per 
gene would result in marked underestimation of oligoclonality; e.g. at least one third 
of the oligoclonai/GH targets (29 of 85, including 15 lost MRD-PCR markers) would 
have been classified as monoclonal. 
The herein presented detailed comparison of lg/TCR gene rearrangement pat-
terns provides important information for appropriate selection of PCR targets for 
MRD monitoring. It is already accepted that preferably two MRD-PCR targets should 
be used per patient. Furthermore, our data show that monoclonal targets should be 
chosen as first option. As previously suggested, monoclonal Kde rearrangements 
were characterized by the best stability (95% ), owing to their end-stage charac-
ter.24,30 In addition, approximately 85% of monoclonal IGH and TCRD gene 
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rearrangements remained stable at relapse (Table 2). In monoclonal VH-JH 
rearrangements, it is particularly attractive to position the patient-specific 
primers/probes at the VH-OH part of the junctional region, which is a preferred strat-
egy in current RQ-PCR based strategies.9·11 Identification of preferably two mono-
clonal MRO-PCR targets (IGH, IGK, and/or TCRD) was possible in 67 (77%) of 87 
patients. When applying these monoclonal targets, the detection of relapse would 
have been possible in 65 patients, but false-negative results would have been 
obtained in two patients: one with presumably secondary ALL and an infant case 
characterized by extensive clonal lg/TCR evolution. The second choice for target 
selection should concern oligoclonal IGH gene rearrangements. Although these 
rearrangements are particularly prone to ongoing and secondary recombination 
processes, they are the sole MRO-PCR targets in approximately 10% of childhood 
precursor-B-ALL patients4 6 In case of oligoclonal IGH targets, the patient-specific 
primers/probes should preferably be positioned at the 0-N-J junctions. Moreover, all 
identified clonal OH-JH stems should be followed because restriction to two targets 
would increase the risk of false-negative MRO results. In our series this approach 
could have been used in additional17 (20%) of 87 patients with available MRO-PCR 
targets and should have resulted in detection of relapse in 15 cases (false negativi-
ty in patients 2308 and 5978 with secondary IGH gene rearrangements). Finally, suc-
cessful MRO detection in the remaining three patients could have been accom-
plished by usage of TCRG gene rearrangements, which were sole MRO-PCR targets 
in these patients. One could argue for the preferred usage of TCRG gene rearrange-
ments instead of oligoclonal IGH targets. However, in at least two of our patients 
(4910, 5661) usage of common OH-JH stems would have been superior to Vy-Jy tar-
gets (Figure 4C). More importantly, TCRG gene rearrangements are generally less 
sensitive markers in RQ-PCR analyses, owing to their limited combinatorial diversi-
ty and the abundance of polyclonal Vy-Jy joinings in normal T-cells in postinduction 
follow-up samples47 Finally, our study clearly shows that oligoclonal V82-083 and 
082-083 rearrangements should not be used as MRO-PCR targets, because most 
of them (about 75%) would be modified through clonal evolution processes. The 
Southern blot and PCR-based strategy for MRO-PCR target selection (priority order. 
two monoclonal IGH, IGK, and/or TCRD targets, followed by OH-JH stems of oligo-
clonal IGH rearrangements, followed by TCRG targets with full exclusion of oligo-
clonal IGK and TCRD targets) would enable successful detection of relapse in 83 
(95%) of 87 patients with the currently available MRO-PCR targets (Figure 5). 
The above-presented strategy is based on combined Southern blot and PCR 
analyses for discrimination between monoclonal and oligoclonal lg/TCR gene con-
figuration. However, many MRO-PCR laboratories do not routinely perform Southern 
blotting, implying that they will underestimate the occurrence of oligoclonality in IGH 
(44% of patients in this series), TCRD (36%) and /GK (8%) genes. In an exclusively 
PCR-based strategy for MRO target selection, Kde rearrangements should be cho-
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sen as first option. When applying all available Kde targets the detection of relapse 
would have been possible in 37 patients in our series (43%), but false-negative 
results would have been obtained in two patients. The second choice for target 
selection should concern IGH gene rearrangements. Using all identified IGH gene 
rearrangements with patient-specific oligonucleotides positioned at the DH-JH stems 
should have resulted in detection of relapse in 43 cases (49%), with false-negative 
results in two patients. If the design of DH-JH oligonucleotides is not successful, one 
might decide to design VH-DH-JH oligonucleotides supplemented with the usage of 
PCR-based monoclonal TCRD targets. Finally, successful MRD detection in the 
remaining three patients could have been accomplished by usage of TCRG gene 
rearrangements (Figure 5). Similarly to the cornbined Southern blot/PCR-based 
approach, the exclusively PCR-based approach would enable successful detection 
of relapse in 95% of patients. Thus, the lack of Southern blot information for dis-
crimination between monoclonal and oligoclonal PCR targets might be compensat-
Figure 5. 
MRD-PCR target 
detection and identification 
Southern blotting and 
heteroduplex PCR 
of /GH, IGK, TCRD and TCRG 
Only heteroduplex PCR of 
/GK, IGH, TCRD, and TCRG 
1 always try to select 1 two MRD-PCR tarrg,;:e:=tsc.:_ ____ _ 
,...------=-----, 
at least one monoclonal IGH, 
IGK, and/or TCRD target 
(succesful in 75% of cases) 
if not at least one 1 
monoclonal 
MRD-PCR target 
(25% of cases) 
add all oligoclonal 
/GHtargets with focus 
on DH-JH stems 
(succesful in 20% of cases) 
if not yet succesful 1 
(5% of cases) 
try to add TCRG targets 
at least one /GKtarget 
(succesful in 40-45% of cases) 
1 if not at least one MRD-PCR target (55-60% of cases) 
add aii/GH targets 
with focus on DH-JH stems 
if DH-JH primers can not be 
designed, use VH-OH-JH 
primers supplemented with 
available PCR-based 
monoclonal TCRD targets 
I if not yet succesful 
~ (5-10% of cases) 
try to add TCRG targets 
Flow diagram for the stepwise selection of MRO-PCR targets, dependent on the choice of techniques for 
detection and identification of IGH, JGK, TCRD, and TCRG gene rearrangements. 
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ed by monitoring of a higher number of IGH and TCRD targets (Figure 5). 
Both described strategies for selection of MRD-PCR targets have their advan-
tages and limitations, which should be carefully weighed in the context of the facili-
ties and experience of each MRD-PCR laboratory. Nevertheless, each strategy 
would enable successful detection of relapse in 95% of patients. If one assumes that 
the actual relapse rate in childhood precursor-B-ALL is 25% to 30%, the current 
lg/TCR-based MRD-PCR methodology should be "effective" in 97% to 98% of cases 
with identifiable MRD-PCR targets at diagnosis. 
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ABSTRACT 
Twenty-eight children with T-ALL were subjected to detailed analyses ofT-cell 
receptor (TCR) and TAL1 genes at diagnosis and relapse using combined Southern 
blotting and PCR. 
A total of 120 clonal TCR and TAL 1 gene rearrangements were identified at diag-
nosis; in each patient at least two PCR targets for minimal residual disease (MRD) 
detection were found. In 16 patients (62%) all rearrangements and in 9 patients 
(35%) most (<:60%) rearrangements identified at diagnosis were preserved at 
relapse. In one T-ALL patient three clonal rearrangements were lost and only one 
rearrangement was preserved at relapse. Finally, two patients displayed completely 
different TCR gene rearrangement sequences between diagnosis and relapse and 
the rearrangement patterns were highly suggestive of secondary ALL. Strikingly, 
both patients experienced very late T-ALL recurrences, 6 and 10 years from diagno-
sis, respectively. This is in striking contrast to the remaining 26 patients, who 
relapsed within 37 months from diagnosis. 
Ninety-five (86%) of 111 clonal rearrangements identified at diagnosis in true 
relapsed T-ALL were preserved at relapse. The best stability was found for the 
TCRD gene rearrangements and SIL-TAL1 fusion genes (both 100%). Vy-Jy gene 
rearrangements identified in all 26 patients were generally stable targets (42/49, 
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86%). Finally, the stability of TCRB gene rearrangements approximated 80% (35/44). 
Based on the stability of TCR gene rearrangements and their sensitivity as MRD-
PCR targets, we propose a stepwise strategy for PCR target selection (TCRD + SJL-
TAL 1 -> TCRB --+ TCRG), which would enable successful detection of MRD in all 
(100%) T-ALL patients. 
INTRODUCTION 
Detection of low levels of malignant cells, known as minimal residual disease 
(MRD), is becoming a routine tool in diagnostics and management of various 
hematopoietic malignancies.1 MRD information is particularly valuable for childhood 
ALL patients as shown by several large multi-center prospective studies.2-6 MRD 
information on early response to induction treatment contributes to an improved def-
inition of remission in ALL, and therefore is currently being incorporated into stratifi-
cation of treatment protocols.7,8 MRD monitoring is particularly attractive in T-ALL 
patients, because it can be performed by analysis of peripheral blood without the 
need for repetitive traumatic bone marrow punctures.9 
In childhood ALL detection of MRD most frequently relies on patient-specific 
junctional regions of immunoglobulin (I g) and T-cell receptor (TCR) gene rearrange-
ments (reviewed in B). These leukemia-specific 'fingerprints' can be identified in vir-
tually all ALL patients and they enable routine MRD detection with sensitivities of 
1Q-4 to 10-5 (i.e. one malignant cell in the background of 104 to 105 normal cells). 
Clonal lg and TCR gene rearrangements are easily identified with molecular biology 
techniques including Southern blot, polymerase chain reaction (PCR) and sequenc-
ing methods, and the results are reproducible between laboratories as proven by 
international standardization.10 With the advent of real-time quantitative PCR (RQ-
PCR) analysis of lg and TCR gene junctional regions, precise quantification of MRD 
levels is routinely achievable.11-15 
One of the most important pitfalls of MRD detection using lg/TCR gene 
rearrangements is clonal evolution caused by the persistent activity of the V(D)J 
recombinase machinery in leukemic blasts (reviewed in 16). Ongoing or secondary 
rearrangements might lead to the loss of MRD-PCR targets and consequently to 
false negative results. Such clonal selection processes might even occur early dur-
ing induction treatment hampering reliable stratification into MRD-based risk 
groups.17 Our extensive study in precursor-B-ALL patients showed differences in 
lg/TCR gene rearrangement patterns between diagnosis and relapse in 62% of 
patients.18 However, based on the stability of the individual lg and TCR gene 
rearrangements, we proposed a stepwise strategy for selection of PCR targets 
enabling successful detection of MRD in the vast majority (95%) of precursor-B-ALL 
patients. 
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AlthOugh the presence of clonal evolution phenomena has also been reported in 
T-ALL, the studies comparing the TCR gene rearrangement patterns at diagnosis 
and relapse in T-ALL either did not compare junctional region sequences or were 
limited to TCR gamma (TCRG) and/or TCR delta (TCRO) gene loci.19-22 Therefore 
we studied the stability of the TCR gene rearrangements currently used for MRD 
monitoring in T-ALL, i.e. TCR beta (TCRB), TCRG, TCRD gene rearrangements and 
S/L-TAL 1 gene fusion in a series of 28 T-ALL patients. This information forms the 
basis for reliable selection of MRD-PCR targets in T-ALL patients with minimal 
chance of false-negative MRD results. 
PATIENTS, MATERIALS, AND METHODS 
Patients 
Bone marrow. peripheral blood samples or lymph node biopsy from 28 T-ALL patients were obtained 
at initial diagnosis and at relapse. The age distribution ranged from 2 years until 15.9 years. The diagno-
sis of T-ALL was made according to FAB and standard immunophenotypic criteria.23,24 
lmmunophenotyping of the T-ALL revealed that 18 (64%) were CD3- T-ALL. 8 (29%) were TCRa:~+ T-
ALL. and 2 (7%) were TCRyo+ T-ALL Three patients were studied at two subsequent leukemia relapses. 
The rationale. methodology and pitfalls of the stepwise molecular comparison of the lg/TCR gene 
rearrangements between diagnosis and relapse of precursor-B-ALL were described in detail previously.25 
Comparative Southern blot analysis 
Mononuclear cells (MNC) were separated from bone marrow or peripheral blood samples by Ficoll-
Paque centrifugation (density 1.077 g/cm3; Pharmacia, Uppsala. Sweden). DNA was isolated from frozen 
MNC, digested with the appropriate restriction enzymes. and blotted to nylon membranes as described 
previously.26 TCRB gene rearrangements were detected with TCRBJ1. TCRBJ2. and TCRBC probes 
(DAKO Corporation, Carpinteria. CA. USA) in EcoRI and Hindi II digests.27 The configuration of the TCRD 
genes was analyzed with the TCROJ1 probe (DAKO) in EcoRI and Hind Ill digests.28 The TCRG gene con-
figuration was studied using the TCRGJ13 probe (DAKO) in EcoRI digests together with either the 
TCRGJ21 probe (DAKO) in Pstl digests or a combination of the Jy2.1 probe in EcoRI digests and the Jy1.2 
probe in Bg/11 digests.29,30 The diagnosis and relapse samples of the 28 patients were always run in par-
allel lanes. The Southern blot configuration of the TCR genes in 14 patients at diagnosis and in 10 patients 
at relapse has been reported previously.19,27,28.31 
PCR amplification and comparative heteroduplex analysis of PCR products 
PCR analysis was performed on both diagnosis and relapse samples in all patients as described pre-
viously_10.32 The sequences of the oligonucleotides used for amplification of TCRG {four Vy family-specif-
ic forward primers, six Vyl member-specific forward primers, and three reverse Jy primers), TCRD (V01-
J01, V02-J01. V03-J01, D02-J01. V02-D03 and 002-003 primer pairs) and S/L-TAL 1 gene rearrangements 
were published before_1o In each 50 J.ll PCR reaction 50 ng DNA sample, 6.3 pmo! of the forward and 
reverse primers. and 0.5 U AmpliTaq Gold polymerase (PE Biosystems. Foster City, CA. USA) were used. 
PCR conditions were: initial denaturation for 10 min at 94°C, followed by 40 cycles of 45 sec at 92°C, 90 
sec at 60°C, and 2 min at 72°C using a Perkin-Elmer 480 thermal cycler (PE Biosystems). After the last 
cycle an additional extension step of 10 min at 72°C was performed. Appropriate positive and negative 
controls were included in all experiments.10 
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Identification of clonal TCRB gene rearrangements was based on multiplex strategy using 23 VI), 2 
0/), and 13 Jj3 primers as developed by BIOMED-2 Concerted Action ~peR-based clonality studies for 
early diagnosis of lymphoproliferative disorders" {Van Oongen et al. submitted for publication}. 
For heteroduplex analysis, the PCR products were denatured at 94°C for 5 min after the final cycle 
of amplification and subsequently cooled to 4°C for 60 min to induce duplex formation.33 Afterwards the 
duplexes were immediately loaded on 6% non-denaturing polyacrylamide gels in 0.5 x Tris-borate-EDTA 
(TBE) buffer, run at room temperature, and visualized by ethidium bromide staining.33 For identification of 
gene segments involved in clonal TCRB gene rearrangements, homoduplexes of appropriate size were 
excised from the polyacrylamide gel and eluted as described previously.34.35 The eluted PCR products 
were directly sequenced e·1ther with 0[3 or multiplex V[3 primers {Van Dong en et al. submitted for publica-
tion}. 
Relapse samples were at first analyzed with those primer combinations, which showed clonal PCR 
products at diagnosis. When the clonal PCR product was also found at relapse, its identity was subse-
quently compared with the PCR product found at diagnosis by means of mixed heteroduplex analysis, i.e. 
mixing of the diagnosis and relapse PCR products followed by heterodup!ex analysis (Figure 1 ).18.25 
When clonal PCR products found at diagnosis were undetectable at relapse, the relapse sample was then 
analyzed with additional primer combinations for the involved gene loci. 
Sequence analysis of lgfTCR gene rearrangements 
Clonal PCR products discordant between diagnosis and relapse of precursor-B-ALL as found by 
mixed heteroduplex analysis were directly sequenced. Sequenc·1ng was performed using the dye-termi-
nator cycle sequencing kit with AmpliTaq DNA polymerase FS on an ABI377 sequencer (PE Biosystems) 
as described before.35 V[3, 0[3, and J[3 segments were identified using ONAPLOT software (W. MUller, H-
H. Althaus, University of Cologne, Germany) by searching for homology with all known human germline 
Vp, Op, and Jp sequences obtained from the IMGT directory of human TCR genes 
(http://imgtcnusc.fr.8104).36 Vy, VO. DO, Jy, and JO gene segments were identified by comparison to 
germline TCRG and TCRD sequences as described before.37 
Figure 1. 
Examples of comparative heteroduplex PCR analysis. (A) Comparative heterodup!ex PCR analysis of 
TCRD gene rearrangements. Monoclonal homoduplexes (ho) in patients 6329, 6584, and 6787 found at 
diagnosis and at relapse were of the same size. Mixing of the PCR products of these disease phases fol-
lowed by heteroduplex PCR analysis demonstrated no heteroduplex (he) formation, proving that these 
gene rearrangements had identical junctional regions. (B) Comparative heteroduplex PCR analysis of 
TCRG gene rearrangements showed identical rearrangements at diagnosis and relapse in patients 4643 
and 6329. In patients 3025 and 6953 monoclonal homoduplexes found at diagnosis and at relapse slight-
ly differed ·m size. Mixing of the Vy-.Jy PCR products followed by heteroduplex PCR analysis demonstrat-
ed clear heteroduplex formation, proving that these Vy-Jy gene rearrangements had different junctional 
regions. (C) Comparative heterodup!ex PCR analysis of TCRB gene rearrangements. Patients 5370, and 
5550 with mono and biallelic rearrangements, respectively, had stable Vf3-JP rearrangements. In contrast, 
in patient 5598 with presumed secondary T-ALL, monoclonal DP1-J[31.2 homoduplexes found at diagno-
sis and at relapse had different junctional regions confirmed by heteroduplex formation after mixing of the 
PCR products. (D) Comparative heteroduplex PCR analysis of DP2-J[32.7 gene rearrangements. Patients 
3288 and 4564 with monoallelic rearrangements had stable D[32-J[32.7 rearrangements between diagno-
sis and relapse. In patient 5598 with presumed secondary T-ALL, D[32-J[32.7 joinings at diagnosis and 
relapse were different as shown by mixed heteroduplex analysis. Patient 3810 was negative for D[32-J[32.7 
rearrangement at diagnosis but had identical D[32-J[32.7 rearrangements in two subsequent relapse sam-
ples. 
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Statistical analysis 
Statistical analysis using the x2 test on a 2 x 2 table was performed to compare the frequencies of 
clonal evolution between different immunophenotypic subgroups of T-ALL. A value of p < 0.05 was regard-
ed to be statistica!!y significant. 
RESULTS 
PCR delectability of TCR gene rearrangements in relapsed T-All patients 
A total of 120 clonal PCR products of different TCR gene rearrangements and 
SIL-TAL 1 fusion gene were identified at diagnosis in the 28 T-ALl patients with an 
average of 4.3 per patient and a range from two to six rearrangements per patient. 
Consequently, in each T-ALL patient at least two MRD-PCR targets were available. 
TCR gene rearrangement patterns in two patients suspected of a secondary 
T-AlL 
Within the studied T-ALL group, two patients (3025 and 5598) displayed com-
pletely different TCR gene rearrangement sequences between diagnosis and pre-
sumed relapse (3 and 6 rearrangements lost, respectively) and the rearrangement 
patterns were highly suggestive of a secondary ALL (Table 1 ). Moreover, the emer-
gence of a new chromosome aberration, i.e. t(10;14), at relapse in patient 5598 indi-
cated the development of a secondary malignancy. Both patients experienced very 
Table 1. TCR gene rearrangement patterns in the two T-All patients suspected of secondary 
T-ALL 
Patient 3025 Patient 5598 
D"1agnosis Relapse Diagnosis Relapse 
TCRB R- Vp7.9- Jp2.5 R- Op2- Jp2.7 R • Vp2.2- J~2.7 R-VP20.1-J~1.2 
G R- not identified to J/32 R-0~1-J01.2 R-V06.1-J01.1 
R- V06.3 • J01.2 R • 002 • Jp2.7 RN • 0~1 - J01.2 
R- not identified to Jf31 RN- 002- J02.7 
TCRG R- Vy2 - Jy2.3 R • Vy7 • Jy2.3 R- Vy10- Jy2.3 R - Vy2 - Jy2.3 
R- Vy4 • Jy2.3 R • Vy9 • Jy2.3 R- Vy11 • Jy2.3 R - Vy4 • Jy2.3 
TCRD 0 R-Vo1-Jo1 R- V01 - J31 R-? t(10;14) 
0 R-002-0<33 0 G 
G, allele in germ line configuration; R, rearranged allel; D, deletion of the CO gene segment RN, rearrange-
ment using the same gene segments but with different junctional region as compared to rearrangement 
at diagnosis 
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late relapses at 6 and 10 years from initial diagnosis, respectively. This is in striking 
contrast to the remaining 26 patients, who relapsed within 37 months from diagnosis 
(mean: 14 months). Therefore, we concluded that these two patients developed a 
secondary T-ALL, and consequently they were excluded from further calculations on 
the stability of the rearrangements. 
Stability of gene rearrangements in T-ALL patients at relapse 
A total of 95 (86%) of 111 clonal TCR and S!L-TAL 1 gene rearrangements iden-
tified with heteroduplex PCR analysis at diagnosis in 26 T-ALL patients were pre-
served at relapse (Figure 1). This concerned 17 of 17 (100%) TCRD, 42 of49 (86%) 
TCRG, 35 of 44 (80%) TCRB gene rearrangements and a single S/L-TAL1 fusion 
gene (Table 2). 
In 16 patients all TCR gene rearrangements identified at diagnosis were pre-
served at relapse (Figure 2A). In 9 cases some targets (ranging from one to 40%) 
were lost during the disease course (Figure 28). Finally, in one patient (6953) only 
one TCRB rearrangement was common for both the diagnosis and relapse samples, 
whereas the other three TCR gene rearrangements were absent at relapse. 
Consequently, at least one rearrangement was preserved at relapse in all 26 T-ALL 
patients. 
Clonal evolution was observed in seven of 16 patients with CD3- T-ALL (44%), 
two of eight patients with TCRaV T-ALL (25%) and one of two TCRyo+ T-ALL 
(50%). CD3- group can be further subdivided based on TCRD gene configuration. 
Clonal evolution was more frequent in T-ALL with biallelic TCRD deletions (two of 
three cases; 67%) as compared with five of 13 T-ALL with at least one TCRD gene 
rearrangement (38%), but this difference did not reach statistical significance. 
It should be noted that in the eight TCRaV T-ALL at least one TCRB rearrange-
ment (in six patients all TCRB rearrangements) remained stable and that also in the 
two TCRyo+ T-ALL no changes were observed in the TCRG or TCRD gene 
rearrangements. Apparently, at least the expressed TCR alleles were not subjected 
to continuing rearrangements. 
Stability and patterns of clonal evolution of particular gene rearrangements 
in T-ALL patients 
Based on combined Southern blot, PCR, and sequence analysis, it was possible 
to follow the patterns of clonal evolution leading to the disappearance of rearrange-
ments, which were originally present at diagnosis. 
TCRD gene rearrangements 
A total of 17 clonal TCRD gene rearrangements (1 0 V81-J81, 4 D82-J81, 1 V82-
J81, 1 V83-J81 and 1 V82-D83) were identified by PCR in 13 T-ALL patients. All clon-
al rearrangements were preserved at relapse. In four additional patients PCR analy-
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Figure 2. 
TCR gene rearrangement stability patterns in 26 T-ALL patients subjected to comparative heterodupfex 
PCR analysis at diagnosis and relapse. Black squares represent complete rearrangements, while gray 
squares reflect incomplete rearrangements. A!! squares above the (upper) line represent stable MRD-
PCR targets, while all squares below the (lower) line represent TCR gene rearrangements lost owing to 
clonal evolution. p squares between the two Jines have common Dp-Jj3 stems shared by different TCRB 
rearrangements at d·1agnosis and at relapse. (A) 16 patients with all rearrangements identified at diagno-
sis preserved at relapse, {B) 9 cases with some TCR gene rearrangements (ranging from one to 40%) 
lost dur'mg the disease course and one patient (6953) with the majority of clonal markers absent at 
relapse. 
Abbreviations: ~. TCRB gene rearrangements; 3. TCRD gene rearrangements; y, Vy-Jy gene rearrange-
ments; T, SJL-TAL1 fusion gene. 
sis did not result in identification of clonal TCRD rearrangements, while Southern blot 
data showed rearrangements to the D83/J81 region, which could not be assigned to 
a particular Vo-Jo joining based on the size of the clonal bands. Identically 
rearranged bands, most probably representing Vo:-J81 rearrangements or transloca-
tions into the TCRD locus, were also present in these four patients at relapse. 
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Table 2. Stability of MRD-PCR targets in 26 T-ALL patients. 
STABILITY OF 
MRD-PCR TARGETS 
STABILITY 
IN PATIENTS 
245 
A!! targets preserved At least one target 
preserved 
TCRB 
V~-J~ 79% (23/29) 74% (17/23) 78% (18/23) 
D~-J~ 80% (12/15) 75% (9/12) 83% (10/12) 
all TCRB 80% (35/44) 76% (19/25) 92% (23/25) 
TCRG 
Vy-Jy 86% (42/49) 81% (21/26) 89% (23/26) 
TCRD 
V8-J8 or V0-08 100% (13/13) 1 00°/o (12/12) 100% (12/12) 
Do2.Jo1 or D02-D03 100% (4/4) 100% (3/3) 100% (3/3) 
all TCRD 100% (17/17) 100% (13/13) 100% (13/13) 
S!L-TAL1 100% (1/1) 100% (1/1) 100% (1/1) 
Clonal evolution in TCRG locus 
A total of 49 TCRG gene rearrangements were detected in 26 T-ALL patients at 
diagnosis and in 23 cases (89%) at least one TCRG gene rearrangement was pre-
served at relapse. Clonal evolution of TCRG gene rearrangements was observed in 
5 patients leading to loss of 7 MRD-PCR targets. In two patients (5775, 6584) this 
concerned "regression" of clonal rearrangements most probably to germline config-
uration. In one patient (4643) Southern blot data indicated the deletion of a second 
allele. In one patient (4564) the new rearrangements at relapse contained upstream 
Vy and downstream Jy segments as compared to the Vy-Jy rearrangements at diag-
nosis, which is suggestive of ongoing recombination with Vy-Jy replacement. Finally, 
in the fifth patient (6953) the sequence comparison of Vy-Jy rearrangements at diag-
nosis and at relapse excluded secondary rearrangements and indicated the emer-
gence of a clone related to the initial (pre)leukemic clone but different from the pre-
dominant clone at diagnosis. 
Clonal evolution in TCRB locus 
A total of 44 TCRB gene rearrangements were detected in 25 T-ALL patients at 
diagnosis and in 23 cases (92%) at least one MRD-PCR target was preserved at 
relapse. Clonal evolution of TCRB gene rearrangements was observed in 6 patients 
leading to loss of 9 MRD-PCR targets. In two patients (3288 and 6329) combined 
Southern blot and PCR information showed that subclones found at diagnosis dis-
appeared at relapse. In one patient (6090), the configuration at relapse refiected 
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ongoing V~ to D~2-J~2 joining, deleting the V~-J~1 rearrangement present at diag-
nosis (Figure 3). In two patients (3810 and 6953), the sequences of the V~-J~ 
rearrangements contained common D~-J~ stems, which confirms their origin from a 
common (pre)leukemic progenitor with such D~-J~ rearrangement (Figure 3). Finally, 
in one TCRyo+ T-ALL patient (5158), the sequences of the TCRB gene rearrange-
ments at diagnosis and at relapse were completely different but the TCRG and 
TCRD rearrangements were identical suggesting that the presumed leukemic pro-
genitor probably had germline TCRB genes. 
An additional example of clonal evolution in the TCRB genes was found at 
relapse of patient 5598. Two of the oligoclonal rearrangements at relapse (V~20.1-
J~1.2 and D~1-J~1.2) contained identical D~1-J~1.2 junctions, which is consistent 
with ongoing V~ to D~-J~ joining. 
DISCUSSION 
When compared to precursor-B-ALL, T-ALL are generally characterized by more 
high-risk clinical features at presentation and by a more aggressive clinical course.38 
This is also clearly visible in the MRD kinetics during the first year of treatment. The 
frequency of MRD-positive patients and the MRD levels are generally higher in T-
ALL than in precursor-B-ALL, refiecting the more frequent occurrence of resistant 
disease in T-ALL.6 This more aggressive disease kinetics is also associated with 
shorter progression free survival in T-ALL patients.6.39 In fact, the vast majority ofT-
ALL relapses occur within the first 2 to 3 years from diagnosis.39,40 
Surprisingly, two patients in our study with very late T-ALL relapses (6 and 10 
years from initial diagnosis, respectively) showed fully changed TCR gene configu-
rations, very much suggestive of a secondary leukemia (Table 1 ). This was in strik-
ing contrast to the other 26 patients, which showed moderate-to-high stability of iden-
tified MRD-PCR targets. The only alternative explanation for so different TCR gene 
rearrangement patterns would be the emergence of clones at diagnosis and relapse 
from a common progenitor with all TCR genes in germline configuration. The sec-
ondary character of one of the two T-ALL was further supported by the finding of a 
novel genetic aberration at relapse. 
Secondary ALL are rare, comprising only 5-10% of secondary leukemias and 
secondary T-ALL was previously described only anecdotally and never in associa-
tion with a primary T-ALL41-45 In fact, our hypothesis that a proportion of very late 
T-ALL recurrences represent secondary T-ALLs has never been put forward previ-
ously. In contrast, Lo Nigro and colleagues22 studied TCRD and TCRG gene config-
urations in two T-ALL patients relapsing 72 and 77 months from diagnosis and found 
in both patients at least one identical clonal TCR gene rearrangement at diagnosis 
and at relapse. Therefore, it would be of great importance to study more patients with 
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Examples of clonal evolution in TCRB locus. (A) On one TCRB allele in patient 3810, the V~20.1-J~2.3 
rearrangement at diagnosis and the V~4.1-Jf32.3 rearrangement at relapse had identical DJ3-Jf32.3 junc-
tions. The DJ32-Jf32.1 rearrangement at diagnosis and the D~2-Jf32.7 rearrangement at both relapses were 
not related. This indicates the origin of clones at diagnosis and at relapses from a common (pre)leukemic 
clone with a DJ3-JJ32.3 rearrangement on one allele and a second TCRB allele in germline configuration. 
(B) In patient 6953, the VJ329-J~1.3 rearrangement at diagnosis and the V~12.4-Jf31.3 rearrangement at 
relapse had identical DJ31-Jf31.3junctions. On the same allele, the D~2-J~2.1 rearrangement identified at 
diagnosis was preserved at relapse. This indicates the origin of clones at diagnosis and at relapses form 
a common (pre)leukemic clone with double DJ31-Jf31.3 and DJ32-Jf32.1 rearrangements on one allele. The 
second allele at diagnosis was in germline configuration. (C) Example of complex secondary rearrange-
ment and ongoing VJ3 to Jl3 joining in patient 6090. At diagnosis, two rearrangements were found on one 
allele: VJ37.4-J~1.6 and D~2-Jf32.3. Ongoing rearrangement of the VJ36.5 segment, located immediately 
upstream to the VJ37.4 segment, to 0132 resulted in a new VJ36.5-Jf32.3 rearrangement with a preserved 
D~2-J~2.3 stem at relapse. The configuration on the second TCRB allele (DJ31-Jf32.2 rearrangement) was 
identical at diagnosis and relapse. 
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very late T-ALL recurrences to address the question of secondary T-ALL in this 
group. In fact, such patients might have an inherited predisposition for T-ALL 
development. 
Our comparative Southern blot, PCR, and sequencing analyses ofT-ALL at diag-
nosis and relapse have provided detailed insight in the stability and changes of TCR 
and S/L-TAL 1 gene rearrangements during the disease course. This information is 
essential for reliable application of such clonal rearrangements as PCR targets in 
MRD studies in T-ALL. Our previous study in a large group of precursor-B-ALL 
patients demonstrated extreme clonal evolution in approximately 20% of patients, 
with all MRD-PCR targets lost in 7% of patients.18 In contrast, the loss of virtually all 
MRD-PCR targets was observed in only one T-ALL patient, in whom one of the four 
clonal TCR gene rearrangements was still present at relapse. Also the proportion of 
patients with all MRD-PCR targets preserved at relapse was markedly higher in T-
ALL (62%) compared with precursor-B-ALL (40%). 
DNA breakpoints of chromosome aberrations are ideal targets for MRD detec-
tion, since they are linked to the oncogenic process and are therefore stable through-
out the disease course46 However, such aberrations, namely TAL 1 deletion with 
SIL-TAL 1 gene fusion, can be identified in only 10-25% of T-ALL patients47,48 Only 
one T-ALL case in our study group had a TAL 1 deletion with an identical breakpoint 
sequence at diagnosis and at relapse. 
Analyzing the stability of particular MRD-PCR targets, TCRD gene rearrange-
ments were uniformly preserved at relapse in all T-ALL patients. Recombination of 
the TCRD locus is one of the presumably earliest events in T-cell development in the 
thymus. Oncogenic transformation in T-ALL, i.e. malignant proliferation of thymo-
cytes, usually (in 95% of patients) occurs when TCRD gene rearrangement is com-
pleted on at least one allele28 The TCRD gene rearrangements might be potential-
ly lost during the disease course via ongoing recombination in the TCRA locus, 
thereby deleting the TCRD genes49 Such clonal evolution at relapse has indeed 
been described in two patients, associated in one case with a phenotypic shift from 
CD3- T-ALL to TCRa~+ T-ALL.21 -22 Nevertheless, in concordance with our study, the 
vast majority of previously described T-ALL patients analyzed at diagnosis and 
relapse showed a fully stable TCRD configuration.19,21,22 
In contrast to TCRD gene rearrangements, which are detectable in only half of 
the T-ALL patients, TCRG gene rearrangements are present in more than 95% ofT-
ALL patients31 and accordingly could be identified in all patients in our study. In 81% 
of patients, the TCRG gene configuration was fully identical between diagnosis and 
relapse, and in 89% of patients at least one TCRG rearrangement was preserved. 
Such high stability might be anticipated from the finding that most of the TCRG gene 
recombinations are end-stage rearrangements involving either the most upstream 
Vy2 or the most downstream Jy2.3 gene segments.31 Nevertheless, in a subgroup of 
patients we and others20 observed clonal "regressions" to a less mature configura-
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lion, which in fact represented the outgrowth of different subclone at relapse. In these 
cases (patients 5775, 6584 and 6953), the oncogenic event most probably occurred 
before the TCRG gene rearrangement. Another potential disadvantage of using 
TCRG junctions as MRO-PCR targets might be their limited sensitivity owing to the 
abundant background of polyclonal TCRG gene rearrangements in normal 
T-cells.15·50 The currently used RQ-PCR techniques aim at sensitivities of o>10-4 , but 
in approximately one-third of TCRG gene rearrangements in T-ALL such sensitivity 
cannot easily be reached_15 
The development of multiplex approaches for detection of TCRB gene 
rearrangements, resulted in an additional PCR target for MRO detection (Van 
Oongen et al. submitted for publication). Clonal TCRB gene rearrangements were 
identified in all except one patient in our series. Although their general stability (80%) 
was inferior to TCRG and TCRD gene rearrangements, at least one TCRB PCR tar-
get was preserved at relapse in 92% of patients. Particularly, complete V~-J~ 
rearrangements are attractive MRD PCR targets because of their extensive junc-
tional regions, which guarantee good sensitivities in RQ-PCR analysis in virtually all 
patients (Bruggemann et al, submitted for publication). However, we observed sev-
eral examples of clonal evolution phenomena owing to continuing rearrangements 
as well as resulting from the selection of drug-resistant subclones with partly related 
or unrelated TCRB genes (Figure 3). In patients with extreme clonal evolution, the 
TCRB gene rearrangements might represent post-oncogenic events (see Figure 3), 
which might be related to the observation that TCRB gene rearrangements occur rel-
atively late during T-cell differentiation. 
Based on the comparative analysis of the TCR gene configuration at diagnosis 
and relapse of T-ALL, we propose a stepwise strategy for MRO-PCR target selec-
tion. In precursor-B-ALL, the molecular approach for MRO-PCR target identification 
significantly profits from Southern blot information, which distinguishes a subgroup of 
precursor-B-ALL patients with oligoclonal and generally unstable lg!TCR gene 
rearrangements.18 In contrast, the strategy developed for T-ALL can be exclusively 
based on PCR data, since TCR oligoclonality is rare ·,n T-ALL patients. In our study 
at least one MRO-PCR target was preserved in all patients, but we recommend that 
two MRO-PCR targets should be used per patient. TCRD and S/L-TAL1 gene 
rearrangements are highly stable targets and should be selected as the first choice 
(Figure 4 ). TCRB gene rearrangements are slightly more stable at the patient level 
than TCRG gene rearrangements (see Table 2) and therefore should be selected as 
the second choice. Ideally, patient-specific oligonucleotides should be positioned on 
0~-J~ juncf1ons to prevent false negative results owing to ongoing V~ to 0~-J~ 
rearrangements. Finally, TCRG gene rearrangements have a fair stability but are 
less sensitive RQ-PCR targets and should therefore be selected as third-choice 
MRD-PCR targets. In our study group, such stepwise strategy (TCRD + SIL-TAL 1 -> 
TCRB--> TCRG) would enable successful detection of MRD in all T-ALL patients. 
250 
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MRD-PCR target 
detection and identification 
only heteroduplex PCR of 
TCRB, TCRD, TCRG, and S/L-TAL1 
[ always try to select 
.J, two MRD-PCR targets 
at least one TCRD or SIL-TAL 1 target 
(succesful in 50% of all patients) 
[ if not at least one PCR 
.J, target (50% of cases) 
add one or two TCRB targets 
with the focus on Dj3-Jj3 stems 
I if not yet succesful 
.J, (25% of cases) 
try to add TCRG targets 
Flow diagram for the stepwise selection of PCR targets for MRD detection in T-ALL. 
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ABSTRACT 
Background 
Discrimination between late relapse of acute lymphoblastic leukemia (ALL) and 
secondary ALL might be clinically important, because the former might still respond 
favorably to chemotherapy and/or bone marrow transplantation, whereas secondary 
ALL is associated with poor prognosis. 
Procedure 
We present a pre-B-ALL patient in whom disease recurred two years after com-
pletion of treatment. Differences in cytomorphology and immunophenotyping raised 
a suspicion of secondary ALL. We performed detailed molecular studies of 
immunoglobulin and T-cell receptor genes for discrimination between relapsed and 
secondary ALL. 
Results 
Southern blot analysis showed an oligoclonal immunoglobulin heavy chain (/GH) 
gene configuration at diagnosis and a monoclonal configuration at relapse. The size 
of one of the rearranged bands at relapse was identical to one of the faint rearranged 
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bands at diagnosis. However, heteroduplex PCR analysis demonstrated that none of 
the clonal IGH gene rearrangements at diagnosis and at relapse was fully identical. 
Sequencing of several clonal PCR products revealed an identical DH6-13<-->JH6b 
junction shared by two different rearrangements at diagnosis and one rearrangement 
at relapse, thereby proving the clonal relationship between diagnosis and late 
relapse in this patient 
Conclusions 
We propose a stepwise molecular approach for discrimination between relapsed 
and secondary ALL based on the rapid and cheap heteroduplex PCR technique, 
including mixing of clonal (homoduplex) PCR products identified at diagnosis and at 
relapse. Direct sequencing and comparative sequence analysis of IGH gene 
rearrangements at diagnosis and at relapse should be regarded as an ultimate stan-
dard, but can be limited to the rare cases, in which no identical clonal PCR products 
at diagnosis and at relapse were detected with the mixed heteroduplex PCR analy-
ses. 
INTRODUCTION 
Despite major progress in the treatment of childhood acute lymphoblastic 
leukemia (ALL), approximately 25-30% of patients relapse after successful remission 
induction.1 ·2 In a proportion of cases there are obvious cytomorphological, 
immunophenotypic and/or cytogenetic differences between diagnosis and relapse of 
ALL3-5 Detailed Southern blot (SB) analysis of clonal immunoglobulin (I g) and T-cell 
receptor (TCR) gene rearrangements, showed one or more changes in the 
rearrangement patterns between diagnosis and relapse of ALL in approximately 70% 
of patients6 However, in 75% to 90% of ALLs at least one major lg heavy chain 
(IGH), TCR gamma (TCRG), or TCR delta (TCRD) gene rearrangement remained 
present at relapse.6 Subsequent PCR-based studies of clonal lg and TCR junction-
al regions demonstrated that the vast majority of changes between diagnosis and 
relapse resulted from ongoing rearrangementsl-10 In more than 90% of studied ALL 
cases, the junctional V-(D)-J sequences of at least one rearrangement were identi-
cal at diagnosis and at relapse.B-10 Thus, in 5-1 O% of cases no clonal relationship 
could be assessed between the leukemic clone at diagnosis and during recurrence 
of the disease, suggesting that in fact a secondary ALL might have emerged. 
Secondary acute leukemias comprise a substantial proportion of secondary 
malignancies as a side effect of intensive chemotherapy. In more than 90% of cases 
this concerns treatment-related acute myeloid leukemia (AML) characterized by an 
aggressive clinical course, the presence of MLL gene rearrangements, and an unfa-
vorable outcome.1 1 Prior usage of topoisomerase II inhibitor and/or alkylating agents 
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is significantly associated with the development of treatment-related AML.11,12 
Secondary ALL occurs less frequently, comprising only 5-10% of secondary 
leukemias. In several secondary ALL the presence of the t(4;11) translocation was 
demonstrated and the outcome was found to be generally unfavorable.13 
Discrimination between late relapse of ALL, usually still favorably responding to 
treatment, and secondary ALL might thus be of clinical importance. 
Here, we present an ALL patient in whom disease recurred two years after treat-
ment cessation. Based on differences in cytomorphology and immunophenotyping, 
secondary ALL was strongly suspected. However with a stepwise molecular diag-
nostic procedure for discrimination between relapsed and secondary ALL, we were 
able to show the clonal relationship between the leukemic cells at diagnosis and at 
relapse. 
MATERIALS AND METHODS 
Case report 
A 10-year-old child was admitted to the Beatrix Children's Hospital in Groningen with the suspicion 
of acute leukemia. Cytomorphology of FAB-L 1 and immunophenotype (CD19 ... /CD22 ... /CD10+ffdT+/ 
/HLA-DR ... /CD34+ with 36% of blasts expressing Cylg).l.) were compatible with pre-B-ALL. Based on the 
estimated leukemic cell mass at diagnosis, and the absence of the t(9;22) translocation and MLL gene 
rearrangements, the patient was stratified into the standard-risk treatment group of the Dutch Childhood 
Leukemia Study Group (DCLSG) ALL-8 protocol, which has a BFM {Berlin-Frankfurt-MOnster) back-
bone.14 Complete clinical remission was successfully induced and the patient received full standard-risk 
chemotherapy. Two years after treatment cessation, the child was readmitted to the hospital and relapse 
of ALL was assumed. However, the morphology of lymphoblasts differed from diagnosis (FAB-L2) and all 
cells co-expressed the CDS antigen, whereas the expression of C034 was lost. Virtually a!! TdT+ cells 
(>98%) were now expressing CylgJ.L Both the morphological and the immunological changes raised a sus-
picion of secondary ALL. 
Southern blot analysis 
Mononuclear cells {MNC) were isolated from bone marrow {BM) samples by Ficoii-Paque centrifu-
gation {density 1.077 g/cm3; Pharmacia, Uppsala, Sweden). DNA was isolated from fresh or frozen MNC 
fractions as described previously. 15 Fifteen micrograms of DNA was digested with the appropriate restric-
tion enzymes (Pharmacia), size-separated in 0.7% agarose gels and transferred to Nytran-13N nylon 
membranes (Schleicher and Schue!!, Dassel. Germany) as described.16 IGH and lg kappa light chain 
(IGK) gene configurations were analyzed with the !GHJ6, IGKJ5. IGKC and IGKDE probes (DAKO 
Corporation, Carpinteria, CA) in Bg/11 and BamHI/Hindlll digests, whereas the lg lambda light chain {IGL) 
gene configuration was analyzed with the lGLC3 probe in EcoR!!Hind!ll digest.17-19 The configuration of 
the TCRD genes was analyzed with the TCRDJ1 probe in Bg/11, EcoRI, and Hindi!! digests {DAK0).20 
Incomplete and complete TCRB gene rearrangements were detected with the TCRB01 U, TCRBD1, 
TCRBJ1, TCRBD2U, TCRBD2, TCRBJ2, and TCRBC probes (DAKO) in EcoRI and Hindlll digests21 
TCRG gene rearrangements were analyzed with the Jy1.2 probe in Bgll! digests and the TCRGJ13 and 
Jy2. 1 probes in EcoRI digests.22.23 
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PCR amplification and heteroduplex analysis of PCR products 
PCR was essentially performed as described previously.24·25 In each 50J..ll PCR reaction 50 ng DNA 
sample, 6.3 pmol of the 5' and 3" oligonucleotide primers, and 0.5 U AmpliTaq Gold™ polymerase (PE 
Biosystems. Foster City, CA) were used. The sequences of the oligonucleotides used for amplification of 
complete VH-JH and incomplete DH-JH gene rearrangements were published before.26,27 PCR conditions 
were: initial denaturation for 10 min at 94°C, followed by 35 cycles of 45 sec at 92°C, 90 sec at 60°C, and 
2 min at 72°C using a Perkin-Elmer 480 thermal cycler (PE Biosystems). After the last cycle, an addition-
al extension step of 10 min at 72°C was performed. Appropriate positive and negative controls were 
included in all experiments.25 
For heteroduplex analysis. the PCR products were denatured at 94°C for 5 min after the final cycle 
of amplification and subsequently cooled to 4°C for 60 min to induce duplex formation.28 Afterwards, the 
duplexes were immediately loaded on 6% non-denaturing polyacrylamide gels in 0.5 x Tris-borate-EDTA 
(TBE) buffer, run at room temperature, and visualized by ethidium bromide staining_zs A 1 00-bp DNA !ad-
der (Promega Corporation. Madison, WI) was used as size marker. Usage of heteroduplex analysis 
enables discrim·mation between PCR products derived from monoclonal and polyclonal lymphoid cell pop-
ulations, based on the presence of homoduplexes (PCR products with identical junctional regions) or a 
smear of heteroduplexes (derived from PCR products with heterogeneous junctional regions), respec-
tively. 
Sequence analysis of IGH gene rearrangements 
Clonal PCR products as found by heteroduplex analysis were directly sequenced. Sequencing was 
performed using the dye-terminator cycle sequencing kit with AmpliTaq<9 DNA polymerase FS on an ABI 
377 sequencer (PE Biosystems) as described before.27 VH, DH, and JH segments were identified using 
ONAPLOT software (W. MU!Ier. H-H. Althaus, University of Cologne, Germany) by searching for homolo-
gy with all known human germline VH, DH. and JH sequences obtained from the VBASE directory of 
human lg genes (http://www.mrc-cpe.cam.ac.uk!imt-doc/).29 
RESULTS 
Southern blot (SB) analysis 
SB analysis at diagnosis revealed an ollgoclonal pattern In the IGH gene locus 
with two major rearrangements and four to five minor rearrangements (Figure 1 ), 
whereas the IGK and IGL genes were In germllne configuration. SB analysis of the 
TCRD locus revealed a strong germllne band as well as two weak subclonal 
rearranged bands (V82-D83 and 082-083 rearrangements). The TCRG and TCRB 
genes were In germ line configuration. 
At relapse, SB analysis of IGH revealed a monoclonal pattern with two strong 
non-germllne bands of equal Intensity, corresponding to blallellc rearrangements 
(Figure 1 ). The size of one of the rearranged bands was identical to one of the minor 
rearrangements at diagnosis. The TCRD genes were now In germllne configuration. 
Heteroduplex PCR analysis 
Detailed heteroduplex PCR analysis of the IGH locus was performed with thlr-
Figure 1. 
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Southern blot analysis of the IGH gene in patient 5498. Control DNA and patient's DNA isolated from diag-
nosis (D) and relapse (R) BM samples were digested with Bg/!1 and BamH!/Hind!!l restriction enzymes. 
size separated, and blotted onto nylon membrane filters, which were hybridized with the 32P-1abeled 
IGHJ6 probe.17 At diagnosis multiple bands of different densities were found, reflecting IGH oligoclonali-
ty. In contrast, the relapse sample displayed a monoclonal pattern with biallelic IGH gene rearrangements. 
Based on the germline sequence and the restriction map of the IGH locus,30 rearrangements found by 
direct sequencing were assigned to corresponding bands on the Southern blot. The asterisk indicates the 
comigration of a faint rearranged band corresponding to the incomplete DH2-2<->DH6-1:X->JH6b 
rearrangement with a major non-identified rearranged band in the BamHI/Hindlll digest. 
teen primer combinations (six /GHframework-1 VH family-specific primers and seven 
family-specific DH primers in combination with one JH consensus primer). At diagno-
sis, monoclonal homoduplexes were found with the following primer combinations: 
VH5-JH, VH6-JH, 0H2-JH, and DH3-JH, whereas the VH1-JH, VH3-JH and VH4-JH PCR 
products were seemingly oligoclonal (Figure 2A). At relapse, monoclonal homodu-
plexes were found with both the VH2-JH and VH6-JH primer combinations_ The VH6-
JH monoclonal products at diagnosis and at relapse slightly differed in size. When 
mixed together and subjected to denaturation and renaturation they formed a het-
eroduplex band, confirming that the VH6-JH PCR products at diagnosis and relapse 
were not identical (Figure 28). 
Sequence analysis 
Four monoclonal PCR products found at diagnosis and two monoclonal PCR 
products found at relapse were sequenced resulting in identification of the involved 
Table 1. Junctional region sequences of different IGH gene rearrangements found in patient 5498 at diagnosis and at relapse of ALL.8 
Disease stage VH gene N-REGION VHIDH gene N-REGION DH gene N-REGION JH gene Reading frame 
segment segment segment segment 
Diagnosis 0H2-2 (-1) AAG (-7) 0H6-13 (0) CGGGGATG (-6) JH6b Not applicable 
VH6-1 (-6) GAGGGAGGG (-14) 0H2-2 (-1) AAG (-7) 0H6-13 (0) CGGGGATG (-6) JH6b (+) 
0H3-3 (-5) CCTAATCCCTCTIATAC (-7) 0H1-7 (0) CCACGAGA (-6) JH6b Not applicable 
VH5-51 (-2) GG (-5) 0H3-3 (-5) CCTAATCCCTCTTATAC (-7) DH1-7 (0) CCACGAGA (-6) JH6b (+) 
Relapse VH2-70 (-2) CCGCCG (-10) 0H6-13 (0) CGGGGATG (-6) JH6b (-) 
VH6-1 (0) ACGG (-1) 0H2-8 (-6) CCACCCCC (-7) JH6b (+) 
a Numbers in parentheses indicate the extent of nucleotide deletion by trimming of the 5' and 3' part of the involved gene segments. 
N 
m 
0 
0 
:;; 
-, 
iij 
"' 
"' 
... 
A 
bp 
1000-
900-
800-
700-
600-
500-
400-
300-
200-
Q; 
~ 
:;; 
E , 
::;: 
Figure 2. 
0: 0: 
7 7 
N 
0: 0: 
> > 
Molecular discrimination behNeen relapsed and secondary ALL 
5498 Diagnosis 
0: 0: 0: 0: 0: 0: 0: 0: 
7 7 7 7 7 ..., 7 7 
"' "' " "' "' 
N N 
r r 0: r 0: r 0: r 
> > > > a a > > 
5498 Relapse 
0: 0: 0: 0: 
7 7 7 7 
"' " "' "' r r 0: r > > > > 
0: 0: 
7 7 
N 
"' 0: r 
a a 
B 
bp 
1500-
1000-
900-
800-
700-
600-
500-
400-
j 
" E , 
:;; 
261 
VH6-JH 
e a: 
<= a a: 0 0 
"' "' "' 
u 
:±: "' "' "' " " "' 
"' "' "' 
ss 
he 
ho 
(A) Heteroduplex PCR analysis of !GH gene rearrangements at diagnosis and at relapse of the ALL clone 
in patient 5498. Several clonal PCR products were found at diagnosis. confirming IGH o!igoclonality. 
whereas the relapse sample revealed two major VH-JH gene rearrangements. 
(B) Heteroduplex PCR analysis of VH6-JH PCR products. Monoclonal homoduplexes (ho) found at diag-
nosis and at relapse slightly differed in size. Mixing of the VH6-JH PCR products followed by heterodup!ex 
PCR analysis demonstrated clear heteroduplex (he) formation, proving that these VH6-JH gene rearrange-
ments had different junctional regions. (ss) =single strands. 
gene segments and the junctional regions (Table 1 ). The four sequences at diagno-
sis were found to be derived from two different incomplete rearrangement stems: 
DH2-2<->DH6-13<->JH6b and DH3-3<->DH1-7<->JH6b, illustrating ongoing VH to D-J 
joining. The junctional region of the 0H6-13<->JH6b stem was also preserved in the 
VH2-70<->DH6-13<->JH6b rearrangement at relapse. The sequence of the VH6-
1<->DH2-8<->JH6b gene rearrangement found at relapse did not have any relationship 
with the sequences found at diagnosis, also not with the VH6-1<->DH2-2<->DH6-
13<->JH6b rearrangement at diagnosis (Table 1 ). 
Functionality of IGH gene rearrangements and its correlation with 
immunophenotype 
Based on the sequenced clonal IGH gene rearrangements at diagnosis and at 
relapse and the availability of the complete sequence of the human JGH locus,30 the 
sizes of restriction fragments containing the respective rearrangements were calcu-
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lated (Figure 1 ). At diagnosis the incomplete DH3-3BDH1-7<->JH6b rearrangement 
corresponded to a major rearranged band, whereas the DH2-2BDH6-13<->JH6b and 
VH6-1 +->DH2-2BDH6-13<->JH6b rearrangements represented faint bands. 
Based on the SB rearranged band density, the in-frame VH6-1<->DH2-2+->DH6-
13+->JH6b rearrangement was largely contributing to CylgJ.L expression found in 36% 
of leukemic cells at diagnosis, whereas the functional (in-frame) VH5-51BDH3-
3<->DH1-7BJH6b rearrangement (expected size of 1.3 kb in Bg/11 and 8.0 kb in 
BamHI/Hindlll) was not visible in the SB analyses, implying that this rearrangement 
was derived from a minor subclone (<5%). The two rearranged bands at relapse had 
sizes corresponding with the out-of-frame VH2-70+->DH6-13+->JH6b and the in-frame 
VH6-1BDH2-8<->JH6b rearrangements. The latter was consistent with the finding that 
virtually all blasts at relapse were expressing CylgJ.L. Curiously, the functional VH6-
1+->JH6b rearrangements at diagnosis and at relapse were completely different 
(Table 1 ). 
DISCUSSION 
SB analysis is considered to be the gold standard for detection of clonal lg and 
TCR gene rearrangements.16 This technique has also been used in a large compar-
ative study of leukemia-specific molecular markers between diagnosis and recur-
rence of ALL.6 The finding of identically rearranged bands at diagnosis and at 
relapse, however, only refiects usage of identical gene segments, but does not nec-
essarily imply identical junctional regions. For reliable proof of clonal identity, the 
identically sized rearranged bands should represent major gene rearrangements and 
preferably this should be found for multiple lg and TCR gene loci. This is particular-
ly important for patients with oligoclonal lg and TCR gene rearrangements. When the 
only indication for clonal relationship is based on the identity of a single band, com-
parative analysis of junctional regions is mandatory, like in our patient with a sub-
clone at diagnosis, which seemed to result in a major rearrangement at relapse. 
Such comparative junctional region analyses can be performed with the current 
PCR-based methods. 
Using multiple primer combinations followed by heteroduplex PCR analysis, we 
were able to detect several clonal IGH gene rearrangements at diagnosis and two at 
relapse, but only the VH6-JH primer combination resulted in clonal PCR products 
both at diagnosis and at relapse. However, the VH6-JH homoduplex PCR products 
slightly differed in size, whereas denaturation and renaturation of the mixed PCR 
products resulted in obvious heteroduplex formation (Figure 2B), confirming a differ-
ence in the junctional regions of the VH6<->JH gene rearrangements. Indeed in both 
rearrangements the same VH6-1 and JH6b gene segments were found, but the junc-
tional regions were completely different (Table 1 ). These two different VH6-1+->JH6b 
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gene rearrangements gave rise to identical bands in the diagnosis and relapse sam-
ples on SB analysis. Only after sequencing of several clonal PCR products, an iden-
tical 0H6-13<-+JH6b junction stem shared by two rearrangements at diagnosis and 
one at relapse was observed (Figure 3), finally confirming the clonal relationship 
between the diagnosis and late relapse of ALL, and excluding secondary malignan-
cy. Thus comparative sequence analysis of different IGH gene rearrangements at 
diagnosis and at relapse should be regarded as an ultimate standard for the dis-
crimination between the relapse of ALL and a secondary leukemia. 
Coincidentally, the two distinct VH6-1<-+JH6b gene rearrangements both encod-
ed for functional Cylgf.L chains. The fact that the VH6-1<-+JH6b rearrangement was 
only present as a minor rearrangement at diagnosis (Figure 1 ), explains that the 
Cylgf.L expression was found in only one-third of the leukemic blasts at diagnosis. 
The functional VH6-1<-+JH6b gene rearrangement at relapse characterized the total 
monoclonal population, which indeed uniformly expressed Cylgf.L. As explained 
above, the VH6-1<-+JH6b gene rearrangements at diagnosis and at relapse were 
derived from different chromosomes. This means that although both disease stages 
were classified as pre-B-ALL, the expressed Cylgf.l protein chains were different. The 
finding of a pre-B-ALL phenotype at diagnosis and at relapse is therefore pure coin-
cidence and illustrates that the absence of an immunophenotypic shift does not nec-
essarily mean that the leukemic cells at diagnosis and at relapse are identical. 
Clonal evolution in the JGH gene locus in our patient clearly demonstrates the pit-
falls of using IGH gene rearrangements as PCR targets for minimal residual disease 
(MRD) monitoring. Frequent IGH oligoclonality at diagnosis (at least 40% of precur-
sor-B-ALL cases) as well as ongoing and secondary gene rearrangements may 
hamper MRD detection resulting in false-negativity.7.31-33 Therefore, the initial large-
scale prospective MRD studies in childhood precursor-B-ALL included more stable 
although less frequently occurring TCR and /GK deletional element gene rearrange-
ments.34.35 Nevertheless, in 10-15% of precursor-B-ALL cases, including our 
patient, IGH gene rearrangements would be the only available PCR targets for MRD 
monitoring.36.37 Based on the common DH6-13<-+JH6b junction stem in our patient, 
we performed real-time quantitative PCR (RQ-PCR) analysis.38-4D This RQ-PCR 
common stom: DH6-13 JH6b 
Figure 3. 
Schematic representation of different IGH gene rearrangements at diagnosis (D) and at relapse (R) with 
the common DH6-13<->JH6b stem. 
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analysis revealed that the common junction stem, which was preserved at relapse 
could in principal have been used as RQ-PCR target for MRD monitoring (data not 
shown). This information is particularly important for patients with oligoclonal /GH 
gene rearrangements. Our findings also confirm the need to use at least two inde-
pendent molecular MRD targets,34 since in our patient the second common DH1-
7 <->JH6b junction stem found at diagnosis was not present at relapse. 
Using a stepwise molecular approach, we were able to prove the clonal relation-
ship between diagnosis and late relapse of ALL, thereby excluding the possibility of 
secondary leukemia. Such discrimination is relevant for tailoring the treatment strat-
egy and intensity. We also demonstrated the usefulness of mixed heteroduplex PCR 
analysis for rapid discrimination between identical or different clonal PCR products 
at diagnosis and at relapse. This technique was already proven to be a rapid and 
cheap alternative for the more laborious and time-consuming SB analysis to identify 
clonal lg and TCR gene rearrangements.28,36 Direct sequencing can be limited to 
those cases, in which non-identical clonal PCR products at diagnosis and at relapse 
are detected with mixed heteroduplex PCR analyses. 
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ABSTRACT 
Background 
Malignant hematopoietic proliferations might severely hamper the course of 
acute lymphoblastic leukemia (ALL) in patients with an otherwise good prognosis. It 
is important to distinguish whether such neoplastic proliferations represent an ALL 
relapse or secondary treatment-related malignancies. 
Procedure 
We present a precursor-B-ALL patient in whom maintenance treatment of ALL 
was complicated by an isolated ALL relapse in the brain, nodular lymphoprolifera-
tions in liver, and an isolated myelo-monocytic leukemia cutis. All these hemato-
oncologic malignancies occurred in the background of an iatrogenic immunodefi-
ciency 
Results and conclusions 
Using a stepwise molecular approach, we were able to demonstrate that the liver 
infiltrates were Epstein-Barr virus (EBV)-positive, contained monoclonal mature B-
cells with immunoglobulin heavy chain gene (IGH) gene rearrangements unrelated 
to the primary ALL, and thus represented a true secondary Non-Hodgkin's lym-
phoma (NHL). In contrast, the skin infiltrates consisted of myelo-monocytic cells with 
*Submitted 269 
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clonal /GH and T-cell receptor gamma gene rearrangements, identical to the pre-
cursor-B-ALL blasts at diagnosis. Thus, the disease course of the precursor-B-ALL 
patient was complicated by two different isolated extramedullary relapses and a sec-
ondary EBv+ B-NHL. 
INTRODUCTION 
Among acute hemato-oncologic complications of childhood acute lymphoblastic 
leukemia (ALL) relapse of the disease is the most frequent problem. Despite signifi-
cant progress in treatment of ALL in last decades 25-30% of ALL patients relapse 
and most children with an early relapse die of disease progression. 1.2 Another seri-
ous malignant side-effect of ALL treatment is acute myelogenous leukemia (AML) 
affecting approximately 4% of ALL patients.3 Most of these AML are secondary 
malignancies with translocations involving MLL gene on chromosome 11 q23, partic-
ularly developed after treatment with topoisomerase II inhibitors, such as 
epipodophyllotoxins or alkylating agents.3 Nevertheless, detailed molecular analyses 
of immunoglobulin (lg) and T-cell receptor (TCR) gene rearrangements revealed that 
a subset of presumed secondary AML represent in fact a phenotypic shift of the 
same leukemic clone4,5 
Epstein-Barr virus (EBV) related lymphoproliferative disorders and EBV-related 
non-Hodgkin's lymphomas (NHL) are rare acute complications of ALL treatment.6-12 
These disorders usually are associated with profound and prolonged immunosup-
pression such as in patients with severe combined immunodeficiency, recipients of 
organ or bone marrow transplants, and AIDS patients_13,1 4 
Here we present a child with precursor-B-ALL who suffered from several con-
secutive acute hemato-oncologic complications, namely isolated central nervous 
system involvement, multiple liver tumors, and skin infiltrations. The application of 
various molecular techniques could discriminate between ALL relapse and treat-
ment-related secondary malignancies. 
MATERIALS AND METHODS 
Case report 
An eleven-year-old, previously healthy girl (patient 4687) was admitted to the University Hospital in 
Nijmegen with a suspicion of acute leukemia. On physical examination she presented with generalized 
lymphadenopathy and prominent hepatosplenomegaly. More than 90% of bone marrow nucleated cells 
and peripheral blood leukocytes (WBC of 220 x 1 os/1) were lymphoblasts of FAB-L 1 morphology and com-
mon-ALL immunophenotype (CD19+/C010 ... /TdT ... /Cylgf..C). Cytogenetic analysis of leukemic blasts 
revealed a normal 46XX karyotype. The treatment was started according to the Dutch Childhood 
Leukemia Study Group (DCLSG) ALL-7 protocol.15·16 The response to steroid treatment was good and 
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cytomorphological remission was successfully induced already after two weeks. Further induction as well 
as consolidation treatment was well tolerated. 
During maintenance treatment she developed several periods of absolute neutropenia and hypogam-
maglobulinemia complicated by protracted infections. A year after initial diagnosis the child presented with 
headache, hesitant speech, and wordfinding difficulties, subsequently combined with periods of visual hal-
lucinations, confusion and vomiting without nausea. Neurological examination revealed a fronto-temporal 
dysfunction and a slight !eft-sided hearing disturbance. Ophtalmological and otolaryngological examina-
tions were normal. Lumbar puncture provided clear cerebrospinal fluid (CSF) with a normal cell count and 
slightly elevated protein concentration. Cytomorphology and immunophenotyping of CSF cells revealed 
only normal lymphocytes and macrophages. s·mce the neurological symptoms pers·1sted despite empir"1c 
broad-spectrum anti-bacterial/anti-mycotic treatment and computed tomography revealed multiple brain 
lesions a small brain cortex biopsy was performed. Histomorphology showed patchy necrosis and perivas-
cular cuffs of infiltrating leukemic lymphoblasts. This was consistent with the isolated central nervous sys-
tem ALL relapse. Taking into account the persistent iatrogenic immune deficiency the child was not 
exposed to an intensive systemic re-induction therapy. Instead cranial irradiation was administered to a 
total dose of 30 Gy combined with monthly intravenous L-asparaginase and intrathecal methotrexate 
injections in addition to the normal maintenance therapy. The neurological symptoms gradually resolved 
and follow-up by computed tomography scan demonstrated disappearance of the cerebral lesions. 
After subsequent two months, the child presented with the bouts of fever, while abdominal ultra-
sonography showed multiple liver lesions with a diameter of 2 - 5 em. The open liver biopsy procedure 
showed multiple round gray-yellowish tumors in both liver lobes. A good representative biopsy was 
obtained. The bacteriologic and mycological cultures were negative. Histopathologic investigation showed 
several areas of liver necrosis, surrounded by polymorphous lymphoid infiltration. lmmunophenotyping 
revealed a mixed population of both T and B-cells, and the staining pattern for immunoglobulin light chains 
was polyclonal. The overall picture was very much suggestive of polymorphic B-cell lymphoma, which is 
typically associated with Epstein-Barr virus (re-)infection in the background of immunodeficiency. Since 
the follow-up ultrasonography showed a steady increase of liver lesions, the whole liver was irradiated to 
a total dose of 21 Gy. Radiotherapy was well tolerated by the child and follow-up ultrasound investigation 
showed complete resolution of the lesions. 
Three months later the girl presented with multiple slightly elevated red-bluish skin lesions on the 
arms. The nodules were neither pruritic nor tender. The sections of the skin biopsy showed small nodular 
proliferations of cells with monocytic/histiocytic morphology infiltrating the dermis and subcutaneous fat, 
extending to periadnexal regions. Immunohistochemistry showed that the infiltrating cells were strongly 
positive for C014 and CD68, and negative forB-cell, T-cell, and epithelial markers. The histomorpholog-
ical picture was strongly suggestive of an aleukemic leukemia cutis ofmyelomonocytic subtype (AML-M4). 
Very shortly after the appearance of the skin lesions, the patient developed severe bronchopneumo-
nia, which progressed to overt cardio-respiratory insufficiency and child's death. The autopsy showed 
extensive necrotizing pneumonia with the presence of Aspergillus fumigatus and Pneumocystis carinii. 
Aspergillus infection was widely disseminated into heart, brain and large blood vessels. Remarkably, bone 
marrow, central nervous system and liver did not show any macroscopic or microscopic evidence for the 
persistence of malignant ce!ls. 
Southern blot analysis of !g and TCR gene rearrangements 
Mononuclear cells (MNC) were isolated from bone marrow (BM) sample at diagnosis by Ficoii-Paque 
centrifugation (density 1.077 g/cm3; Pharmacia, Uppsala, Sweden). DNA was isolated from frozen MNC 
and from snap-frozen tissue samples (liver and skin biopsies) after homogenization with a tissue grinder 
(Tamson, Zoeterrneer, The Netherlands) as described previously.17 Unfortunately, there was no materia! 
available for molecular analysis of the centra! nervous system infiltrate. Fifteen J.1g of DNA was digested 
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with the appropriate restriction enzymes {Pharmacia), size-separated in 0.7% agarose gels and trans-
ferred to Nytran-13N nylon membranes (Schleicher and Schue!!, Dassel, Germany) as described.17 For 
comparative analysis the diagnosis and biopsy-derived DNA samples were run in parallel lanes (Figure 
1}. lg heavy chain (/GH) and lg kappa light chain {IGK) gene configurations were analyzed with the IGHJ6, 
JGKJS, IGKC and JGKDE probes (DAKO Corporation. Carpinteria, CA) in Bg/11, Xbal and BamHJ/Hindlll 
digests, whereas the lg lambda light chain (IGL) gene configuration was analyzed with the IGLC3 probe 
in EcoRI/Hindlll digest18-20 The configuration of the TCR delta (TCRD) genes was analyzed with the VS2, 
TCRDJ1, J82, TCRDC4 probes in Bg/11, EcoRI, and Hindlll digests (DAK0).21 TCR beta (TCRB) gene 
rearrangements were detected with the TCRBJ1. TCRBJ2, and TCRBC probes (DAKO) in EcoRI and 
Hindi! I digests.22 TCR gamma (TCRG) gene rearrangements were analyzed with the Jy1.2 probe in Bg/11 
digests and the TCRGJ13 and Jy2.1 probes in EcoRI digests.2324 
Southern blot based detection of EBV genome 
The presence of clonal EBV DNA was analyzed with a 32p labeled Xhol probe. This probe is a 1.9 
kb fragment, which recognizes unique EBV-DNA sequences, adjacent to the repeat sequence at each ter-
minus.25-26 The DNA isolated from BM at diagnosis and from the liver and skin biopsies was analyzed with 
this probe in BamHI/Hindlll digests. 
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Southern blot analysis of the IGH genes in patient 4687. Control DNA and patient's DNA isolated from BM 
at diagnosis as well as from liver and skin biopsies were digested with Xbal and BamHI/HindiJI restriction 
enzymes, size separated, and blotted onto nylon membrane filters, which were hybridized with the 32p_ 
labeled IGHJ6 probe.18 At diagnosis as well as in the skin biopsy two bands of identical size were found, 
reflecting identical. monoclonal IGH gene rearrangements. In contrast, the liver biopsy displayed a 
germline band with two faint IGH gene rearrangements of different sizes as compared to BM at diagnosis 
and the skin infiltrate. This fits with a presence of a minor clonal population in an otherwise polyclonal 
EBV-related lymphoproliferation. Based on the germline sequence and the restriction map of the IGH 
locus,34 rearrangements found by direct sequencing could be assigned to the corresponding bands in the 
Southern blot. 
Unusual isolated extramedullary relapse of ALL 273 
PCR amplification and heteroduplex analysis of PCR products 
PCR was essentially performed as described previously.27·28 In each 50).1.1 PCR reaction 50 ng DNA 
sample, 6.3 pmol of the 5' and 3' oligonucleotide primers, and 0.5 U AmpliTaq Gold polymerase (PE 
Biosystems. Foster City, CA) were used. The sequences of the oligonucleotides used for amplification of 
complete VH-JH and incomplete DH-JH as well as Vy-Jy gene rearrangements were published before.28·29 
PCR conditions were: initial denaturation for 10 min at 94°C, followed by 35 cycles of 45 sec at 92°C, 90 
sec at 60°C, and 2 min at 72°C using a Perkin-Elmer 480 thermal cycler (PE Biosystems). After the last 
cycle an additional extension step of 10 min at 72°C was performed. Appropriate positive and negative 
controls were included in all experiments.28 
For heteroduplex analysis, the PCR products were denatured at 94°C for 5 min after the final cycle 
of amplification and subsequently cooled to 4°C for 60 min to induce duplex formation.30 Afterwards the 
duplexes were immediately loaded on 6% non-denaturing polyacrylamide gels in 0.5 x Tris-borate-EDTA 
(TBE) buffer, run at room temperature, and visualized by ethidium bromide staining.30 A 100-bp DNA lad-
der (Promega Corporation, Madison, USA) was used as size marker. Usage of heterodup!ex analysis 
enables discrimination between PCR products derived from monoclonal and polyclonallymphoid cell pop-
ulations, based on the presence of homoduplexes (PCR products with identical junctional regions) or a 
smear of heteroduplexes (derived from PCR products with heterogeneous junctional regions). respec-
tively. 
When a particular primer combination detected clonal PCR products in two different DNA samples, 
their identity was subsequently compared by means of mixed heteroduplex analysis, i.e. mixing of the 
PCR products followed by heteroduplex analysis (Figure 2).31 
Sequence analysis of JGH gene rearrangements 
Clonal PCR products as found by heteroduplex analysis were directly sequenced. Sequencing was 
performed using the dye-terminator cycle sequencing kit with AmpliTaq DNA polymerase FS on an ABI 
377 sequencer (PE Biosystems) as described before.32 VH, DH, and JH segments were identified using 
DNAPLOT software ryJ. MOller, H-H. Althaus, University of Cologne, Germany) by searching for homolo-
gy with all known human germline VH, DH. and JH sequences obtained from the VBASE directory of 
human lg genes (http:/I~;V~NW.mrc-cpe.cam.ac.uklimt-doc/).33 Based on the germline sequence and the 
restriction map of the IGH locus,34 rearrangements found by direct sequencing were assigned to corre-
sponding bands on the Southem blot as descr'1bed previously.31 Vy and Jy gene segments were identified 
by comparison to germline TCRG sequences as described before.35 
RESULTS 
Southern blot analysis 
Southern blot analysis at diagnosis of ALL demonstrated a monoclonal pattern in 
the /GH gene locus with two major rearrangements (Figure 1 ), whereas the IGK and 
IGL genes were in germline configuration. Southern blot analysis of the TCRD locus 
revealed a strong germ line band and a rearranged band of similar density; the size 
of this rearranged band did not correspond to any of the well-established TCRD gene 
rearrangements21 The TCRG locus showed two rearranged bands with the Jy2.1 
probe most probably reflecting biallelic rearrangements. The TCRB genes were in 
germline configuration. 
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Heteroduplex PCR analysis of IGH and TCRG gene rearrangements in BM at diagnosis of ALL as well as 
in liver and skin biopsies from patient 4687. In diagnosis BM and in the monocytic skin infiltrate identical 
clonal PCR products of two VH3-JH rearrangements and two Vyi-Jy1.1/2.1 were found. Mixing of these 
PCR products followed by heteroduplex PCR analysis (as exemplified for Vyi-Jy1.1/2.1 rearrangements) 
demonstrated no additional heteroduplex formation, thereby proving that these gene rearrangements had 
identical junctional regions. In contrast, PCR analysis of IGH rearrangements in liver proliferation showed 
clonal VHS-JH and DH2-JH joinings, not present in the ALL clone. No clonal TCRG gene rearrangements 
were demonstrated in the liver biopsy. Abbreviations: ss, single strands; he, heteroduplexes; ho. homod-
uplexes. 
In the liver biopsy two rearranged IGH gene bands and one rearranged IGK gene 
band were found, which differed completely from the pattern at diagnosis, while their 
density suggested a minor clonal component among otherwise polyclonal cells 
(Figure 1 ). All TCR genes were in germ line configuration. 
Curiously, the configuration of the lg and TCR genes in the skin monocytic infil-
trate was identical to the pattern identified at diagnosis, except for the presence of a 
monoallelic JK rearrangement; the size of this IGK band was different from the one 
identified in the liver biopsy. 
DNA samples from the diagnosis BM as well as from the liver and skin biopsies 
were examined for the presence of EBV genome. In the diagnosis and the skin biop-
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sy cell samples no EBV genome was found, whereas the liver cell sample showed a 
clonal EBV-DNA band. 
Heteroduplex PCR analysis 
Detailed heteroduplex PCR analysis of the IGH locus was performed with twelve 
primer combinations (five IGH framework-1 VH-family specific primers and seven 
family-specific DH primers in combination with one JH consensus primer). In diagno-
sis BM as well as in the skin biopsy, two monoclonal homoduplexes were found with 
the VH3-JH primer combination (Figure 2). When samples from both disease stages 
were mixed together and subjected to denaturation and renaturation they did not 
form any additional heteroduplex band, confirming that the VH3-JH PCR products at 
diagnosis and at skin relapse were identical (Figure 28). Similarly, identical biallelic 
Vyi-Jy1.1/2.1 gene rearrangements were characteristic both for ALL at diagnosis and 
for the skin infiltrate. 
In contrast, heteroduplex analysis of PCR products derived from the liver biopsy 
did not disclose any of the clonal PCR products found at diagnosis, while it showed 
monoclonal homoduplexes with the VH5-JH and 0H2-JH primer combinations. 
Sequence analysis 
Two monoclonai/GH PCR products found at diagnosis and two monoclonal PCR 
products found in liver biopsy sample were sequenced resulting in identification of 
the involved gene segments and the junctional regions. In the two IGH sequences at 
diagnosis (VH3-13e0H2-2.->DH6-13eJH4b and VH3-74e0H6-19<-+JH4b) the junc-
tional regions were completely unrelated to those found in liver biopsy (VH5-
51<-+JH6b and DH2-21<-+JH4b). The sequences of the VH3 gene segments in the VH-
OH-JH rearrangements at diagnosis were 100% concordant with the germ line, but the 
in-frame sequence of the VH5-51<-+JH6b gene rearrangement derived from the liver 
tumor contained 6% somatic mutations. 
Based on the sequenced clonal /GH gene rearrangements at diagnosis and at 
relapse and the availability of the complete sequence of the human IGH locus,34 the 
predicted sizes of restriction fragments containing the respective rearrangements 
were calculated (Figure 1 ), which confirmed the full concordance of Southern blot 
and PCR results. 
The sequence analysis of TCRG gene rearrangements at diagnosis revealed 
clonal Vy3-Jy1.1 and Vy8-Jy1.1 gene rearrangements. 
DISCUSSION 
We present an unusually complicated course of ALL in a child with initially high 
tumor mass but with an excellent response to the induction treatment and rapid 
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achievement of complete remission. Therefore, the early isolated cerebral relapse 
was highly unexpected, particularly because repetitive normal findings in cere-
brospinal fluid. One might speculate that the iatrogenic immunodeficiency during the 
maintenance treatment hampered the clearance of residual ALL cells from the cen-
tral nervous system. Shortly before the child died from a heavily disseminated 
Aspergillus infection and Pneumocystis carinii pneumonia, she presented with an 
aleukemic leukemia cutis of AML-M4 type. Using detailed molecular studies,31 we 
clearly proved that this was not a secondary malignancy, since we demonstrated 
identicai/GH and TCRG gene rearrangements in BM at diagnosis of ALL and in the 
skin infiltrate. It is not clear whether this unusual skin relapse is induced by the 
immunodeficiency status. 
EBV-relaled lymphoproliferative disorders are usually associated with congenital 
or acquired immunodeficiencies. Seven well-documented cases of such an acute 
hemato-oncologic complication were described in patients receiving ALL treatment6-
11 They were uniformly associated with (re)-activation of EBV infection, usually in the 
background of profound treatment-related immunodeficiency. The EBV-positive lym-
phoproliferation in our patient contained a monoclonal B-cell component in an other-
wise polymorphous tumor. The sequences of the clonal IGH gene rearrangements in 
the liver infiltrates were completely different from those found in the ALL clone. 
Moreover, the high frequency of somatic mutations in the VH gene sequences were 
compatible with a mature B-cell lymphoproliferation in contrast to the unmutated !GH 
genes in the precursor-B-ALL.36 Consequently, the EBV-related polymorphic Non-
Hodgkin's lymphoma represented a true secondary malignancy, unrelated to the pre-
ceding precursor-B-ALL 
In conclusion, the iatrogenic immunodeficiency status in a girl with ALL resulted 
in an unusually complex and fatal disease course with an early isolated central nerv-
ous system relapse, an EBV-related B-cell lymphoma in the liver, an isolated 
leukemia relapse in the skin with AML-M4 immunophenotype, and life-threatening 
disseminated infections. 
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CHAPTER 4.1 
SPECIFIC APPLICATIONS OF PCR-BASED DETECTION OF 
MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC 
LEUKEMIA 
Several minimal residual disease (MRD) studies used immunoglobulin (lg) and 
T-cell receptor (TCR) gene rearrangements as PCR targets, and demonstrated that 
evaluation of early treatment response has high predictive value for clinical outcome 
in childhood acute lymphoblastic leukemia (ALL).1·3 Therefore, MRD monitoring is 
currently being applied for treatment stratification in several front-line ALL treatment 
protocols. MRD information can also be relevant for specific ALL subsets, which are 
characterized by common features, like age, immunophenotype, or the presence of 
particular chromosomal aberrations. One such specific patient group that might prof-
it from MRD-based treatment modification is infant ALL. Chapter 4.2 exemplifies how 
currently available MRD techniques can provide insight into treatment effectiveness 
in infant ALL. 
In addition to the "classical" application of MRD-PCR techniques for evaluation 
of the kinetics of ALL cell disappearance, PCR studies can be applied for many other 
purposes (Table 1 ). For instance, lgfTCR gene rearrangements can be used as clon-
ality markers for confirmation or exclusion of the common origin of two phenotypically 
different malignancies (see Chapters 3.5 and 4.3). 
Early diagnosis of ALL in patients with smoldering leukemia 
Another specific application of MRD-PCR techniques is the early diagnosis of 
ALL in cases of 'smoldering' leukemia, i.e. in patients with initially hypoplastic bone 
marrow with less than 25% of lymphoblasts, who subsequently developed overt ALL. 
A few case reports demonstrated the presence of identical clonal cell populations 
during the hypoplastic phase, the subsequent recovery phase, and the overt 
leukemia phase using patient-specific lgfTCR gene rearrangements as PCR tar-
gets4-5 In contrast, monoclonal gene rearrangements could not be detected in 
patients with idiopathic hypoplastic anemia.s 
Assessment of central nervous system involvement in ALL 
MRD-PCR techniques can also be used for detection of central nervous system 
(CNS) involvement in ALL patients. One possibility is to screen for TdT+ or CD34+ 
cells, which normally are not found in cerebrospinal fiuid (CSF); consequently, their 
presence in CSF provides evidence for meningeal leukemic infiltration6 Monitoring 
of MRD in CSF samples of more than one hundred patients with a TdT+ malignan-
cy during a 5-year follow-up period showed the development of overt CNS involve-
283 
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Table 1. Application of MRD-PCR technology using lgrrCR gene rearrangements as targets. 
Classical applications of PCR-based MRO detection in All 
MRD based risk-group classification of ALL patients according to the kinetics of leukemia cell 
decrease (front-line treatment and relapse treatment); 
evaluation of added value of individual treatment blocks, particularly in high-risk patients; 
evaluation of treatment effectiveness in specific ALL subtypes, such as infant ALL and T-ALL; 
evaluation of the pre-transplant MRD levels and assessment of the effectiveness of post-transplant 
immunotherapy; 
Specific applications of PCR-based MRD detection in All 
assessment of common origin of two phenotypically different malignancies; 
early diagnosis of ALL in patients with smoldering leukemia, i.e. patients initially presenting with aplas-
tic bone marrow with low percentages of lymphoblasts: 
assessment of CNS involvement at diagnosis and monitoring of CSF during follow-up for prediction of 
CNS leukemia; 
detection of bone marrow involvement during 'isolated' extramedullary relapse of ALL 
evaluation of testicular biopsies, e.g. at the end of treatment or evaluation of the contralateral testis in 
case of testicular relapse; 
evaluation of autologous stem cell transplants, before and after purging; 
evaluation of cord blood and later blood samples for the presence oftransplacentally-migrated mater-
nal ALL cells; 
evaluation of Guthrie cards and blood samples of monozygotic twins in case of ALL diagnosis (early 
diagnosis of ALL in the second twin and proving of the clonal relationship between the ALL cells of 
both twins). 
men! in 70% of the patients with repeated finding of TdT+ cells in CSF, despite nor-
mal cell morphology_6 On the other hand, patients with CSF pleocytosis or "suspi-
cious" morphology but TdT negativity (probably indicative of activated lymphocytes) 
had no evidence of subsequent CNS disease_6.7 Also patient-specific TCRD 
rearrangements have been used as a MRD-PCR target for detection of CNS 
involvement in childhood precursor-B-ALL8 Identical rearrangements were found 
both in bone marrow and CSF in 43% of the analyzed patients, which confirms the 
clinical assumption that asymptomatic CNS involvement occurs much more fre-
quently than diagnosed on the basis of classical cytomorphological criteria.s 
Moreover, preliminary data indicate that the molecular finding of MRD in CSF during 
ALL treatment as assessed via patient-specific lg/TCR gene rearrangements is 
inevitably associated with subsequent CNS relapse.9 
Detection of bone marrow involvement during 'isolated' extramedullary 
relapse of ALL 
MRD techniques can be also employed for detection of bone marrow involve-
ment during 'isolated' extramedullary relapse of ALL (e.g. in CNS or testis). Such 
sub-microscopic bone marrow involvement is confirmed in most of ALL patients with 
isolated extramedullary relapse.10-12 This is in concordance with the clinical obser-
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vation that full systemic reinduction therapy is required in these patients to prevent 
hematological relapse. Nevertheless, some ALL patients with isolated CNS relapse 
did not have detectable MRD levels in BM.10.13 
Evaluation of testicular biopsies for the presence of leukemic infiltration 
MRD positivity of histologically normal end-of-treatment testicular biopsies was 
shown to be followed by overt testicular relapse.14 Moreover, PCR-based MRD 
assays at the time of a unilateral testicular relapse allowed reliable exclusion of 
occult leukemic blasts in the histologically normal contralateral testis.14Nevertheless, 
in some patients testicular relapse did occur despite MRD negativity in testicular 
biopsies.14 
Evaluation of autologous stem cell transplants, before and after purging 
Another attractive application of MRD detection is the evaluation of autologous 
stem cell grafts for contamination with leukemic blasts. Autologous purged stem cell 
transplantation following intensified chemotherapy is currently being evaluated as 
new treatment modality in high-risk ALL patients in second complete remission, who 
do not have a matched related donor. PCR studies showed that MRD-positivity of the 
autologous bone marrow graft before purging was the most predictive factor of treat-
ment failure in ALL, regardless of a seemingly successful purging procedure (MRD-
negative graft).15 In fact, the remission duration after autologous stem cell trans-
plantation significantly correlated with MRD levels before the purging procedure. On 
the other hand, infusion of MRD-negative purged grafts in patients with MRD-nega-
tive pre-transplantation bone marrow was associated with durable clinical remis-
sion.16 
Evaluation of cord blood and later blood samples for the presence of 
transplacental All cells 
Finally, we used PCR-based MRD studies for assessing the disappearance of 
transplacentally-migrated maternal ALL blasts from the blood of a newborn child (see 
Chapter 4.4). Transplacental migration of leukemic cells has also been observed in 
monozygotic twins with monochorionic placenta, developing ALL at different ages 
(reviewed by MF Greaves17). The finding of identical DNA sequences of lg/TCR 
gene rearrangements and identical translocation breakpoints has proven the prena-
tal origin of ALL in one of the twins with subsequent transplacental dissemination to 
the second twin. Using MRD-PCR techniques, it is also possible to detect or exclude 
the presence of ALL clone ·,n the unaffected monozygotic twin of the ALL patient.18 
Extensive MRD-PCR analyses of Guthrie cards of childhood ALL patients showed 
the presence of clonotypic ALL sequences already at birth in the vast majority of 
cases, confirming in utero origin of childhood ALL.17-19 
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CHAPTER 4.2 
INTENSIFIED THERAPY FOR INFANTS WITH ACUTE 
LYMPHOBLASTIC LEUKEMIA* 
Results from the Dana-Farber Cancer Institute Consortium 
Tomasz Szczepariski1, Marja J. Pongers-Willemse1, Karel Hahlen2, 
and Jacques J. M. van Dongen1 
1 Department of Immunology and 2 Department of Pediatrics, Erasmus MC, University Medical Center 
Rotterdam, Rotterdam, The Netherlands 
We read with great interest the report by Silverman et al.1 summarizing treatment 
outcome in 23 infants treated with Dana-Farber Cancer Institute Consortium proto-
cols. Intensified multidrug therapy resulted in significantly improved long term, event 
free survival in 54%± 11% of infants. This included at least three patients with MLL 
gene rearrangements, which are known to be associated with multidrug-resistant 
disease. 
The authors describe two infants in whom the blasts atthe time of recurrence dif-
fered phenotypically from those at diagnosis. They considered the possibility of sec-
ondary leukemia, but also speculated about recurrence of the leukemia with a phe-
notypic shift. In our opinion, the latter explanation appears most probable. In acute 
lymphoblastic leukemia (ALL) occurring in infants, particularly in cases with MLL 
gene rearrangements, leukemogenesis affects early progenitor cells. In such 
patients cross-lineage expression of myeloid antigens such as CD13, CD15, CD33, 
and CD65 frequently is observed,2 in a minority of cases even biphenotypic acute 
leukemia has been diagnosed based on simultaneous expression of lineage specif-
ic antigens.3 Using clone specific markers such as clonal immunoglobulin (lg) and T-
cell receptor (TCR) gene rearrangements, it is possible to distinguish between recur-
rence and secondary, therapy-related leukemia. We previously described a pre-B-
ALL patient who developed acute myeloid leukemia 17 months after diagnosis, sug-
gesting the development of secondary leukemia. However, the lg and TCR gene 
rearrangement pattern was identical between diagnosis and recurrence, implying 
cy1omorphologic and immunophenotypic evolution of the same clone4 
In contrast to previous reports,3 Silverman et al.1 clearly showed that infant ALL 
in principle can be cured. However, 50% of patients still recur. This implies that 
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analysis of specimens at diagnosis is not sufficient for predicting treatment response 
and that more insight is needed into in vivo effectiveness of treatment during the fol-
low-up. This is possible with the currently available standardized techniques for the 
detection of minimal residual disease (MRD).5 To exemplify this strategy we show 
the monitoring of MRD in a 1 0-month-old infant with common-ALL using a patient 
specific oligonucleotide probe to the junctional region of an IGK gene rearrangement 
(Figure 1 ).6 Despite cytomorphologic remission at the end of induction therapy, we 
still could detect low levels of malignant cells. The recurrence 14 month after diag-
nosis was predicted 3 months earlier with molecular MRD analysis. We believe that 
such prospective MRD monitoring can be used for the assessment of treatment 
response and can be applied toward individualization of therapy to improve the out-
come of infant leukemia further. 
100 bp junctional 
region Kde 
5' --------------------,1---- 3' 
Y---,-----~----------~~y-----------~------~----1'~·~--~z 
"--{ ___),-~-~---'---"'~~~>-~-· ·---+--1 ·=-"'-'------<111111.:::_· --'--"---'-"--'-----<1/-/ ~-.l_i ____,.$ 
I -------------VKVII primer -8 GAA 4 
~ 
Kde primer 
~ 
5' ATCCTGTGGAAGCTAATGATACT 3' 3' CACGGACTTCCCAGATACTTCCC 5' 
.... " 
•••• <II 
() 
z 
::;;: 
0 
:r:" 
dot blot hybridization with junctional region probe (GAGTAAGAATGAACCCTAGTGGC) 
Figure 1. 
VkVII and Kde primers were used for polymerase chain reaction (PCR) amplification of bone marrow DNA 
samples at d'1agnosis (D) as well as during fo!!ow-up. The PCR products were spotted onto a nylon mem-
brane, which was hybridized with the 32P-Iabeled junctional region probe. Tenfold dilution series of diag-
nosis DNA revealed a sensitivity of 10-4 (one acute lymphoblastic leukemia cell between 104 normal 
cells). During follow-up the bone marrow became negative after Week 15, but at Week 47 PCR positivity 
was found again (i.e. 3 months before clinical relapse [R]). bp: base pa'1rs: MNC: DNA from norma! 
mononuclear cells. 
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ABSTRACT 
A 12-year-old girl presented with a CD33+ precursor B-acute lymphoblastic 
leukemia (All) and seemed to respond well to ALL treatment. However, 2 weeks 
after diagnosis her leukocyte count rose rapidly with a predominance of myeloid 
blasts with M5b morphology and CD19+ myeloid immunophenotype. Acute myeloid 
leukemia (AML) treatment was started and remission was achieved after one course 
of chemotherapy; the AML treatment was continued for 6 months. Two months after 
cessation of chemotherapy, the patient developed a bone marrow relapse, this time 
with an undifferentiated blast morphology and a precursor B immunophenotype. 
Molecular analysis of the immunoglobulin and T-cell receptor genes showed sev-
eral clonal gene rearrangements at diagnosis: two IGH, two IGK and two TCRD gene 
rearrangements. All rearrangements were also detected during the AML phase of the 
disease, suggesting a phenotypic shift of the same leukemia. At relapse, 8 months 
later, all rearrangements were preserved except for one TCRD (V82-083) rearrange-
ment. 
The first phenotypic shift in the genotypically stable leukemia was remarkably 
fast. The most probable explanation for our observations is an oncogenic event in an 
undifferentiated hematopoetic progenitor clone, with a highly versatile phenotype. 
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INTRODUCTION 
In contrast to the vast majority of normallymphoblasts, a significant proportion of 
acute lymphoblastic leukemias (ALLs) co-express myeloid antigens, such as CD13, 
CD14, CD15, CD33, CD65 and/or CD66c at diagnosis.1-3 Also, several acute 
myeloid leukemias (AMLs) co-express lymphoid antigens such as C02, CD4, CD? 
and CD194 ·5 Rarely, acute leukemias co-express several antigens from two differ-
entiation lineages; if so, the diagnosis of acute biphenotypic leukemia is assumed.6 
lnterlineage switch of acute leukemia at relapse usually concerns a switch from 
ALL to AML and has been reported to occur in 5-7% of cases.7,8 Such phenotype 
switches generally occur late in the course of the disease and are most frequently 
assumed to represent therapy-induced secondary malignancies. However, in rare 
cases analysis of immunoglobulin (lg) and T-cell receptor (TCR) gene rearrange-
ments have suggested that both malignancies were derived from the same stem cell 
clone9 In contrast, an early lineage switch during induction chemotherapy is an 
extremely rare event Such an early phenotypic switch might be the result of aber-
rant differentiation of the malignant clonogenic cells or selection of a minor subtrac-
tion from a mixed population as the result of selective killing by chemotherapy. 
We present the clinical course and the immunophenotypic and immunogenotyp-
ic investigations in a case of childhood ALL showing an early phenotypic switch and 
a second later switch. 
PATIENT AND METHODS 
Clinical course 
A 12-year-old girl presented with a history of tiredness and easy bruising. Her hemoglobin was 6.77 
g/dl, platelets were 45 x 109/1 and the leukocyte count was 15 x 109/1 (with 18% blasts). Her bone mar-
row (BM) contained 96% lymphoblasts with a precursor-B-ALL phenotype and cross-lineage expression 
of CD33 and dimCD13 (Table 1)(Figure 1A). Her cerebrospinal flu"1d was free of blast cells. Cytogenetic 
analysis of BM did not show any abnormalities. She was started on the non-high-risk ALL-9 protocol of 
the Dutch Childhood Leukemia Study Group (DCLSG). 
Her initial chemotherapy consisted of dexamethasone, vincristin and intrathecal triple therapy. She 
responded well to this treatment in the first week and was discharged from the hospital on day 7. Two 
weeks after diagnosis, a rapidly rising leukocyte count (62 x 1 Q9fl) was found with the re-emergence of 
84% blast cells in her blood, but this time with a different morphology (Figure 1 B). BM cytomorphology 
revealed 65% blast cells with a phenotypic switch to AML (Table 1 ). Cytogenetic analysis again showed 
a normal karyotype. Her treatment was accordingly changed to the Medical Research Council (MRC) AML 
12/DCLSG ANLL 97 protocol and after one induction course she attained remission. She received a total 
of two ADE courses (cytosine-arabinoside/etoposide/daunorubicin), one MACE (cytosine-
arabinoside/etoposide/amsacrine) and one MidAc course (high-dose cytosine-arabinoside/mitoxantrone). 
Treatment was electively stopped after 6 months. 
The patient developed a BM relapse 8 months after the initial diagnosis. This time, the morphology 
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Figure 1. 
Morphology of blast cells at initial diagnosis (A}, 2 weeks later (B), and at relapse (C). (Magnification x 
1000). 
of the blast cells was undifferentiated (Figure 1 C), while the immunophenotype was of precursor-S-line-
age {common ALL) (Table 1). Cytogenetic investigation revealed a 46, XX, del {9) (p21) [9] /46, XX [23]; 
i.e. a mosaicism of normal cells and cells with a deletion of the short arm of chromosome 9. This deletion 
is seen in ALL-L 1 and ALL-L2. 
The patient was started on the DCLSG ALL-relapse protocol. Reinduction was with vincristin, dex-
amethasone, L-asparaginase, VM-26 and cytosine-arabinoside. After 6 weeks, her BM was again in 
remission. Six weeks after the newly attained remission. she was transplanted with CD34 selected 
(CiiniMACS, Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) blood stem cells from her father (one 
HLA-8 locus mismatch). Conditioning was with etoposide (cumulative dose 700 mg/m2 ), cyclophos-
phamide (cumulative dose 120 mg/kg) and total body irradiation (2 x 6 Gy). Anti-thymocyte globulin was 
used as serotherapy. She eng rafted in 21 days (neutrophil count > 0.5 x 1 09/J) and chimerism studies 
showed full donor chimerism. Cyclosporin A, used as graft-versus-host disease (GvHD) prophylaxis, was 
rapidly tapered. There was no sign of GvHD. She died in complete remission from liver failure of unknown 
cause 10 months after her allogeneic transplant. 
lmmunophenotypic analysis 
lmmunophenotypic studies at diagnosis and relapse were performed on lysed whole BM or blood 
samples by triple staining with directly conjugated monoclonal antibodies, as described previously.10·11 
The specificity and source of the monoclonal antibodies used in this study are summarized in Table 1. 
Measurements were performed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA, 
USA). For data acquisition, CELLQUEST software was used with the PAINT-A-GATE PRO program for data 
analysis (Becton Dickinson). The percentage of positivity for the various monoclonal antibodies was deter-
mined after gating of the blast populations as defined by their forward scatter and sideward scatter char-
acteristics. 
Southern blot analysis of lg and TCR gene rearrangements 
DNA was isolated from frozen mononuclear cell fractions as described previously.12 Fifteen micro-
grams of DNA was digested with the appropriate restriction enzymes. size-separated in 0.7% agarose 
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gels and transferred to Nytran-13N nylon membranes as described.13Jg heavy chain {IGH) and lg kappa 
light chain (IGK) gene configurations were analyzed after hybridization with the IGHJ6, IGKJ5, IGKC, and 
IGKDE probes in Bgill digests.14.15 The configuration of the TCR delta (TCRD) genes was analyzed with 
the TCRDJ1 and TCRVD2 probes in Bg/11 and EcoRJ digests.16 
Table 1. Morphological, cytochemical, immunophenotypic and immunogenotypic characteristics 
at different disease phases. 
Diagnosis AML (day 14) 
Cytomorphology (FAB) ALL-L 1 AML-M5b 
Blast percentage in 96 65 
bone marrow 
Cytochemistry 
Periodic-acid -Schiff (PAS) negative negative 
Peroxidase negative negative 
Alpha naphtyl-acetate esterase weak positive, positive spots positive 
Alpha naphtyl-acetate esterase not done inhibited 
+ Na F 
lmmunophenotype (% positivity within the gated blast cell population) 
TdT(HTdT6)a 91 0 
CD34 (HPCA-2)b 93 98 
HLA-DR (anti-HLA-DR)b 95 98 
CD10 (J5)" 
CD 19 (Leu-12)b 
CyCD79a (HM47)0 
CD22 (Leu-14 )b 
CD13 (My-7)C 
CD14 (RM052)c 
CD15 (Leu-M1 )b 
CD33 (D3HL60.251)0 
CD65 (VIM2)d 
MPO (MP0-7)e 
lmmunogenotype 
!GH gene 
IGKgene 
TCRD gene 
88 
93 
97 
96 
92 (dim) 
not done 
0 
86 
0 
0 
RJR 
VKI-JKIVKI-JK 
(+2 x intronRSS-Kde) 
Vo3-J31N32-D83 
a. Supertechs, Bethesda. MD, USA 
b. Becton Dickinson, San Jose, CA, USA 
c. Coulter/Jmmunotech, Westbrook, ME, USA 
d. Caltag, San Francisco, CA, USA 
e. DAKO, Glostrup, Denmark 
R, rearranged allele; D, deleted allele 
0 
91 
0 
0 
87 (dim) 
96 
19 
99 
24 
5 
RJR 
VKI-JKIVKI~JK 
(+2 x intronRSS-Kde) 
Vo3-Jo1No2-Do3 
Relapse (day 245) 
AUL 
30 
negative 
negative 
diffuse 
not done 
81 
85 
91 
81 
83 
78 
82 
92 (dim) 
0 
0 
79 
0 
0 
RJR 
VKI-JKIVKI-Jx: 
(+2 x intronRSS-Kde) 
Vo3-Jo1/D 
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Polymerase chain reaction (PCR) heteroduplex analysis of lg and TCR gene rearrangements 
PCR was essentially performed as described previously.17 In each 50)11 PCR reaction, a 50 ng DNA 
sample, 6.3 pmol of the 5' and 3' oligonucleotide primers, and 0.5 U of AmpliTaq Gold polymerase (PE 
Biosystems, Foster City, CA, USA) were used. The sequences of the oligonucleotides used for amplifica-
tion of IGK and TCRD gene rearrangements have been published.18 For heteroduplex analysis, the PCR 
products were denatured at 94°C for 5 min after the final cycle of amplification and subsequently cooled 
to 4°C for 60 min to induce duplex formation. 19 
RESULTS 
Cytomorphological and immunophenotypic characterization 
Cytomorphology and immunophenotyping at diagnosis showed an ALL with a 
CD1 0-positive precursor-B-ALL phenotype with co-expression of two myeloid mark-
ers (CD33 and CD13dim). Two weeks later, an acute leukemia of monocytic cell type 
could be seen with a.-naphthyl-acetate-esterase positivity inhibited by sodium fluo-
ride; this was supported by positivity for CD13 (dim), CD14 and CD33, but negativi-
ty for TdT and the B-cell markers CD10, CD22 and CD79a; only CD19 was 
expressed. At relapse, the morphology was undifferentiated and the original CD10-
positive precursor-B-ALL phenotype had reappeared again (Table 1 ). 
Morphologically, the size of the blast cells (twice the size of an erythrocyte) in com-
bination with a low nucleus/cytoplasm ratio, several large nucleoli and the absence 
of granulation and negative peroxidase reactivity, were suggestive of an undifferen-
tiated phenotype. 
Immunogenetic characterization of the disease phases 
Southern blot analysis at diagnosis revealed monoclonal IGH gene rearrange-
ments on both alleles. Also, in the IGK locus two monoclonal rearrangements were 
observed that both concerned VK-JK recombinations coupled to intron RSS to Kappa 
deleting element (Kde) recombinations on the same allele (Figure 2A). Southern blot 
analysis of the TCRD locus revealed a strong rearranged band corresponding to a 
V83-J81 recombination as well as a weak subclonal V82-D83 rearrangement. 
At the AML phase and at relapse, Southern blot analysis of IGH and IGK 
revealed exactly the same rearrangements (Figure 2A). The TCRD gene rearrange-
ments of the AML phase were identical to initial diagnosis, but at relapse the sub-
clonal V82-D83 rearrangement was lost while the V83-J81 rearrangement was pre-
served. 
Based on the Southern blot information, PCR heteroduplex analysis was per-
formed with V83-J81, V82-D83, VK-JK and intron RSS-Kde primer combinations. At 
all three disease phases, monoclonal V83-J81 homoduplexes of equal size were 
found. When mixed together and subjected to denaturation and renaturation, they 
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B patient 6543 patient 6543 patient 6543 
V03-J.S1 V82-D83 Jx-CK intron RSS-Kde 
(A) Southern blot analysis of the IGK gene. Control DNA and patient DNA at diagnosis {ALL D), AML 
phase (AML) and relapse (ALL R) were digested with the Bg!ll restriction enzyme, size separated and 
blotted onto nylon membrane filters, which were hybridized with the 32p_fabelled IGKDE probe. In all 
three disease phases. an identical monoclonal pattern with bialle!ic IGK gene rearrangements was iden-
tified. 
(B) Heteroduplex PCR analysis of V03-J81, V82-D83 and intron RSS-Kde PCR products. Monoclonal 
homoduplexes (ho) found at three disease phases were of the same size. Mixing of the PCR products of 
these disease phases fol!owed by heteroduplex PCR analysis demonstrated no heteroduplex (he) forma-
tion, proving that these gene rearrangements had identical junctional regions. ss, remaining single strand 
fragments. 
did not form any additional (heteroduplex) bands, confirming that the PCR products 
at diagnosis, at the AML phase and at relapse were identical (Figure 28). Similarly, 
identical V82-D83 homoduplexes were found at initial diagnosis and at AML phase, 
while repeated PCR analysis did not reveal clonal V82-D83 PCR products at the 
ALUacute undifferentiated leukemia (AUL) relapse. Finally, two VKI-JK and two 
intron RSS-Kde homoduplexes were found by PCR analysis, representing biallelic 
rearrangements that were identical at all three disease phases (Figure 28). 
DISCUSSION 
We describe a patient with three different phases of acute leukemia. A remark-
ably early switch was observed from a precursor-B-ALL, initially responding to stan-
dard ALL therapy, to AML5b 2 weeks after diagnosis. This switch was apparent both 
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morphologically and immunophenotypically. After completion of AML treatment. a 
relapse occurred. This third phase of the disease was morphologically AUL but had 
immunophenotypic characteristics of precursor-B-ALL. 
Biallelic IGH and IGK gene rearrangements were found at diagnosis. Also, two 
TCRD gene rearrangements were detected, a V83-J81 and a V82-Do3 rearrange-
ment, the latter being derived from a subclone. The finding of a complete V83-J81 
gene rearrangement was unusual for precursor-B-ALL, because complete TCRD 
gene rearrangements are characteristic ofT-lineage ALL and are rarely observed in 
precursor-B-ALL.16.2D lg/TCR gene rearrangements, including complete TCRD 
rearrangements, can be found in AML, albeit with low frequency (5-15%) and usual-
ly concerning single loci21.22 Multiple lg gene rearrangements particularly involving 
the IGK gene are almost exclusively observed in precursor-B-ALL. All identified lg 
and TCR gene rearrangements were stable throughout the disease course, except 
for the subclonal V82-D83 rearrangement, which was lost at relapse. These immuno-
genetic results prove the clonal relationship between the three disease phases in this 
leukemia patient. 
Sensitivity to chemotherapy was remarkably good at all three stages of the dis-
ease. There was no apparent development of drug resistance and, even at the time 
of relapse, conventional ALL-type chemotherapy was sufficient to obtain remission 
again. 
Two patients with a similar early ALL to AML switch have been described previ-
ously but without any proof for clonal relationship.23.24 There may be several mech-
anisms to explain the described phenomenon of phenotypic switch in a leukemic 
clone. Clearly, a 2-week period is too short for therapy-induced secondary leukemia. 
However, chemotherapy might have selected a therapy-insensitive myeloid sub-
clone, which represented a minority in the larger population of leukemic cells with a 
different (lymphoid) phenotype. Such a shift in lineage predominance rather than a 
true phenotypic change has been described previously in two infants with congenital 
leukemia2 5.26 Both patients had biphenotypic leukemias at diagnosis, with lymphoid 
and myeloid blasts sharing the same MLL gene abnormality and IGH gene 
rearrangement in the two disease phases. This is in contrast to our case, in which 
there was no cytomorphological and immunophenotypic evidence for the presence 
of phenotypically biclonal leukemia at diagnosis. An alternative explanation for the 
early phenotype switch would be reprogramming of a malignant pluripotent stem cell, 
capable of both lymphoid and myeloid differentiation. 
The dynamics of the phenotype switch in our patient- especially apparent in the 
first episode- is puzzling. Within days, chemotherapy was capable of killing the lym-
phoid leukemic cells, while the leukemic stem cell could change its program into a 
different (myeloid) direction, resistant to the chemotherapy used in that phase. The 
second shift, with the same immunogenotype, may have been the initial phenotype 
or alternatively a third phenotype. 
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We conclude that this case illustrates the rare potential of leukemic clones to 
adapt to chemotherapy by changing phenotype. This phenotype switch did not, how-
ever, lead to clinically apparent multidrug resistance. Cases like our patient may pro-
vide more insight into adaptive mechanisms in the behavior of leukemias. 
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ABSTRACT 
A 36-week pregnant woman was diagnosed with acute lymphoblastic leukemia. 
Delivery was initiated prematurely, and a healthy child was born. Cord blood and 
peripheral blood samples from the neonate (obtained at 6 weeks, 3 months and 6 
months) were analyzed for the presence of minimal residual disease by polymerase 
chain reaction analysis of a leukemia-specific IGH gene rearrangement and the E2A-
PBX1 fusion gene transcript. In the cord blood sample, a tumor load of z 4 x 1 o-4 
was found, whereas all later blood samples were negative. Our data indicate that the 
maternal leukemic cells did not engraft in the neonate. 
INTRODUCTION 
It has become widely accepted that the placenta is not an absolute barrier, but 
that single cells can pass from mother to child and vice versa.1·3 Recently, Catlin et 
af4 reported transplacental transmission of a maternal natural killer cell lymphoma 
and subsequent engraftment of these cells in the fetus, with fatal consequences for 
the infant. In addition, direct evidence has been obtained for intraplacental metasta-
sis of (pre)leukemic cells between monozygotic twins who developed concordant 
acute lymphoblastic leukemia (ALL) several years after birthS The clonal origin of the 
twin leukemias was proved by the presence of exactly the same clonotypic fusion 
"BrJ Haemato/2001; 114:104-106 303 
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sequence of a chromosome aberration and an identically rearranged !GH allele. 
Reports of patients with ALL during pregnancy are rare. In most cases reported 
so far. chemotherapy was given during pregnancy and a healthy child was born.6·7 
We report the presence of maternal ALL cells in cord blood (CB) of a neonate. born 
to a mother who was diagnosed with ALL during late pregnancy. 
MATERIALS AND METHODS 
Case report 
A previously healthy pregnant woman at 36 weeks' gestation presented with symptoms of abdomi-
nal pain, extensive night sweating and nose bleeding. She was referred to the St. Antonius Hospital 
(Nieuwegein, The Netherlands) and diagnosed with ALL of pre-B-ALL immunophenotype (TdT ... , CD10 ... , 
CD19 ... , CD22 ... , cytoplasmic CD79 ... , HLA-DR .... , and cytoplasmic lgJ..l+) with 90% blast cells in her periph-
eral blood (PB). Before the start of the cytotoxic treatment, delivery was initiated prematurely, and a 
healthy female child (2.72 kg) was born. No abnormalities were found upon physical exam·mation of the 
newborn. and her PB was normal by routine biochemical and cytomorphological analyses. The child 
developed normally, was released from the hospital 3 weeks after birth and has continued to do well for 
30 months. 
A CB sample was taken, and PB samples were obtained from the newborn at 6 weeks, 3 months and 
6 months after birth. Mononuclear cells (MNCs) were obtained by Ficoll density centrifugation and used 
for molecular investigations. 
Molecular analysis of blood samples from the newborn using lg/TCR gene rearrangements as 
targets 
To detect clonal immunoglobulin (lg) and T-cell receptor (TCR) gene rearrangements in the maternal 
ALL cells, DNA was extracted from MNCs obtained at diagnosis. Polymerase chain reaction (PCR) analy-
sis was performed using 26 d"1fferent pr-1mer combinations to detect rearrangements of the IGH, !GK, 
TCRD, and TCRG gene loci.S PCR products were denaturated and renatured (60 min at 4°C) for het-
eroduplex analysis to confirm the c!onality of the detected rearrangements. Monoclonal rearrangements 
were subjected to direct sequence analysis of the junctional regions. a 
The tumor load in the CB and PB samples from the child were analyzed by dot blotting followed by 
hybridization with a patient-specific junctional region probes,s and by real-time quantitative PCR (RQ-
PCR) analysis as described previously.10 Tenfold serial dilutions of ALL DNA into DNA from normal MNCs 
(1 o-1 - 1 o-6) were made to define the sensitivity of the two PCR techniques and for assessment of the 
tumor load. 
Molecular analysis of blood samples from the newborn using fusion gene transcripts as PCR 
target 
RNA was extracted from maternal MNCs at diagnosis, and eDNA was prepared. Reverse transcrip-
tion (RT)-PCR was performed to detect the most common chromosome aberrations in ALL. 11 RNA sam-
ples from CB and PB MNCs from the child were analyzed by a nested RT -PCR approach using E2A and 
PBX1 primers as described previously. 11 To check for the integrity of the RNA samples, an ABL RT-PCR 
was performed. In addition, RQ-PCR analysis was performed for the E2A-PBX1 fusion transcript The for-
ward primer (5"-GAC TCC TAC AGT GCT TCC CTG TTT AT-3") and TaqMan probe (AGC CCA GGA GGA 
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GGA ACC CAC AGA) were positioned in exon 13 of the E2A gene and the reverse primer (5'-CGC TAA 
GAG CAT GTT GTC CAG-3') was positioned in exon 2 of the PBX1 gene. Tenfold serial dilutions of ALL 
RNA into HL-60 RNA (10-1 -10-6) were made to define the sensitivity of the two PCR techniques and for 
assessment of the tumor load. 
RESULTS 
PCR heteroduplex analysis and subsequent sequencing revealed two clonai/GH 
gene rearrangements, of which a VH3-11-JH6c rearrangement was selected for this 
study. A junctional region-specific probe was developed for PCR dot-blot analysis 
reaching a sensitivity of 10·5 (Figure 1). Analysis of the CB sample showed the pres-
ence of maternal leukemic cells, with an estimated tumor load of 1 o-3 The PB sam-
ples taken at 6 weeks and 3 months were negative (Figure 1 ). RQ-PCR analysis of 
the VH3-11-JH6c rearrangement resulted in a sensitivity of 10-4. The calculated 
tumor load of the CB sample was 5 x 1 Q-4, whereas the later neonatal PB samples 
were negative. 
100 bp 
VH3 
junctional 
region 
JH 
VH3 ;ri~~~~ primer 1 -1 GGCAAAACCACCTTCCATA-17 1 
3' 
5' GGGGGTCCCTGAGACTCTC 3' 3' CCAGTGGCAGAGGAGTCCA 5' 
child 
'0 
mother 0 
"' 
"' 0 .c 2 :c "' 'E w 
b b "o b ~ ~ 
() ~ 'E 'E! "' 0 -0 0 0 z 0 0 " E :;;; 0 0 "' "' 
• • e • • • 
• • ~ • • • 
dot blot hybridization with junctional region probe (GGCAAAACCACCTTCCATACTC) 
Figure 1. 
Dot-blot hybridization after PCR amplification of the VH3-11-JH6c target. The PCR products obtained were 
hybridized with the patient-specific probe as indicated. This technique reached a sensitivity of 10-s. The 
CB MNCs were clearly positive, with an estimated tumor load of 1 o-3 based on comparison of the 
hybridization signals with those of the dilution series. The samples obtained from the child at 6 weeks and 
3 months of age were negative. 
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RT-PCR analysis of the diagnosis sample identified the E2A-PBX1 fusion tran-
script, characteristic for t(1 ;19) and in line with the pre-B-ALL immunophenotype. Via 
nested RT-PCR analysis, E2A-PBX1 fusion transcripts were found in the CB sam-
ple, whereas all neonatal PB samples were negative. RQ-PCR analysis of the E2A-
PBX1 fusion gene transcript resulted in a sensitivity of 5 x 1 o-s. The relative tumor 
load of the CB sample was 3 x 104 , whereas all PB samples were negative. 
DISCUSSION 
This is the first report on the presence of maternal ALL cells in the CB sample of 
a neonate. The occurrence of maternal leukemic cells in the CB sample and in the 
child's PB samples was determined by analysis of a clonal IGH rearrangement and 
E2A-PBX1 fusion gene transcripts via classical PCR approaches S.9. 11 as well as via 
the recently developed RQ-PCR technique. 10 Fully concordant results were obtained 
with the four different minimal residual disease (MRD) PCR techniques, and accu-
rate quantification of the leukemic load (" 4 x 1 04 ) was achieved by the RQ-PCR 
analyses. 
Formally, we cannot exclude the possibility that the CB sample has been con-
taminated with a minor amount of maternal PB during sampling, but we took all nec-
essary precautions to obtain uncontaminated CB. However, it is fair to assume that 
the maternal leukemic cells passed the placental barrier, like normal maternal leu-
cocytes 1-3 and natural killer cell lymphoma cells4 Consequently, we conclude that 
these maternal leukemic cells did not engraft in the fetus: within 6 weeks after birth, 
the leukemic cells became undetectable and were probably eliminated by the 
immune system. 
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ABSTRACT 
Immunoglobulin (lg) and T-cell receptor (TCR) gene rearrangements are 
assumed to be unique 'fingerprint-like' sequences for each acute lymphoblastic 
leukemia (ALL). Various clonal lg!TCR gene rearrangements can be identified at 
diagnosis in virtually all childhood ALL patients, representing molecular targets for 
detection of minimal residual disease (MRD) during follow-up analysis. The usage of 
at least two MRD-PCR targets per patient generally ensures high sensitivity (1 :104 
normal cells) and prevents false-negative results owing to ongoing or secondary 
rearrangements. 
MRD monitoring in childhood ALL employing lg!TCR gene rearrangements as 
PCR targets has significant prognostic value. This is particularly powerful for evalu-
ation of early treatment response and consequently can be used for improved ther-
apy stratification. Prolonged continuous MRD monitoring might be important for 
patients at intermediate or high risk of relapse. MRD monitoring in second complete 
remission identifies patients with excellent drug sensitivity and predicts outcome 
after stem cell transplantation. 
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INTRODUCTION 
Modern treatment protocols induce complete remission in virtually all (>95%) 
children with acute lymphoblastic leukemia (ALL), but approximately 20-30% of 
these patients relapse. 1 Apparently, chemotherapy regimens are not capable of 
killing all clonogenic malignant cells in these patients although they reached com-
plete remission according to clinical and morphOlogical criteria. The detection limit of 
morphological techniques in ALL is not lower than 1-5% of malignant lymphoblasts 
between normal bone marrow (BM) cells. Therefore, it was postulated that more sen-
sitive techniques would discern cases at high risk of relapse from patients with excel-
lent prognosis. In childhood ALL detection of malignant cells at low frequencies dur-
ing and after treatment, i.e. detection of minimal residual disease (MRD), most fre-
quently relies on patient-specific immunoglobulin (lg) and T-cell receptor (TCR) gene 
rearrangements as molecular markers for investigation. 
JUNCTIONAL REGIONS OF IG/TCR GENE REARRANGEMENTS AS PCR 
TARGETS FOR MRD DETECTION 
During early B- and T-cell differentiation the germline variable (V), diversity (D), 
and joining (J) gene segments of the lg and TCR gene complexes rearrange, and 
each lymphocy1e thereby obtains a particular combination of V-(D-)J segments2 -4 
Moreover, deletion of germline nucleotides by trimming the ends of the rearranging 
gene segments as well as insertion of nucleotides between the joined gene seg-
ments by terminal deoxynucleotidyl transferase (TdT) creates an enormous junc-
tional diversity (Figure 1 ). Therefore, the junctional regions of rearranged lg and TCR 
genes are unique 'fingerprint-like' sequences that are assumed to be different in 
each lymphoid precursor cell. Consequently, the junctional region can be considered 
as a 'DNA-fingerprinf of each particular ALL because ALL cells are clonal lymphoid 
precursor proliferations (Figure 1 )4 ·5 Several early studies have shown that junc-
tional regions indeed can be used as tumor-specific targets for MRD monitoring.6-8 
For this purpose, the various lg and/or TCR gene rearrangements have to be identi-
fied in each leukemia patient at initial diagnosis. 
Identification of junctional regions of lg and TCR gene rearrangements as 
MRD targets 
To identify leukemia-specific junctional region sequences precisely, clonallg and 
TCR gene rearrangements should first be amplified by PCR analysis, followed by 
sequencing of the PCR product obtained. PCR amplification is possible only when 
the lg or TCR gene segments are juxtaposed through rearrangement, as the dis-
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A 
r 
Germline VK3-20 sequence 
I.GI.C.~§_C.8_GTATQGTAGCTCACCTCC 
5142 TGTCAGCAGT 
5257 TGTCAGCAGTATGGTAGCTCACCTCC 
5346 TGTCAGCAGTATGGTAGCTCACCT 
5500 TGTCAGCAGTATGGTAGCTCACCTCC 
6229 TGTCAGCAGTATGGTAGCTCACC 
6364 TGTCAGCAGTATGGTAGCTCACCTCC 
6429 TGTCAGCAGTATGGTAGCTCACC 
7092 TGTCAGCAGTATGGTAGCTCACC 
7102A TGTCAGCAGTATGGTAGCTCACCTCC 
71028 TGTCAGCAGTATGGTAGCTCACCTCC 
B 
junctional region 
CCCGAAGGGA 
GGTTCCCAA 
ACCGAGAGA 
TCCCC 
CATCCCCGAGG 
cc 
CTC 
GGG 
AA 
junctional 
region Kde 
Germ line Kde sequence 
I§GAG..C..C_C.I~§_LG_G_C8§_C.CCAGGGCGACTCC 
AGGGCGACTCCT 
CAGGGCGACTCCT 
AGCCCTAGTGGCAGCCCAGGGCGACTCCT 
CCCTAGTGGCAGCCCAGGGCGACTCCT 
GCCCTAGTGGCAGCCCAGGGCGACTCCT 
GCCCTAGTGGCAGCCCAGGGCGACTCCT 
GGCAGCCCAGGGCGACTCCT 
CCTAGTGGCAGCCCAGGGCGACTCCT 
GAGCCCTAGTGGCAGCCCAGGGCGACTCCT 
AGCCCAGGGCGACTCCT 
junctional 
region 
VH DH JH r~ ____,~=:;::::;::::;::::;:::;;;:,~ ,;:;:2 ,;:;:; :;:::;::~:;:::;:::;:::;:::;:::;:::;:::;:::;:::;:::;:::;::=;•~· ...=;;,;.,;.;:;:. =:::::::;-1 __,( 
Germline VH6-1 sequence junctional region 
3963 CTGTGCAA w 
5161A CTGTGCAAGAG GACGAAACAGT AACT GC 
51618 CTGTGCAAGAG CCTCTCTCCACTGGGATGGGGGG 
5161C (-31) CG 
c::::::: 
Germline JH sequences 
~TTACTACTACTACTACG_G.I6I.G_G.8_C_GI.GI._G_§_ JHS 
6..CM.CI.G_GTI.C.G_8.ci._C_C_I_G_§_ JHS 
AC.IACTTTGACTACTGG JH4 
ATGCTTTTGATATCTG~ JH3 
CTACTTTGACTACTGG J<4 
CTACTACTACTACGGTATGGACGTCTGG J<6 
CTACTGG J<4 
CCTGG JH5 
5260 CTGTGCA c~GTAGTACCAGCTGCCCATACGATTTITGGAGTGGTTACCCCGACTGGG ACTACGGTATGGACGTCTGG J<6 
5357 CTGTGCAAGAG GACTITGG ATGCTTTTGATATCTGG J<3 
5561 CTGTGCAAGAG CAGCAGCTCGGCCCC CTTTGACTACTGG J<4 
5565A CTGTGCAAGAG GGGT A TT ATGA TT ACGTTTGGGGGAGTT ATCGTT ACTCCCTCAGACGCTCAAA TTTGACTACTGG J<4 
55658 CTGTGCAAGAG CGGGCTATGGTTCAGGGAGTTATGG CTACTACGGTATGGACGTCTGG JH6 
5582 CTGTGCAAGAG GGTGGGAGCTACTA GACTACTGG J<4 
5584 CTGTGCAAGAGA TCCGGGcAGCTCGTTT TGCTTTTGATATCTGG J<3 
5602 CTGTGCAAGAGA GATAGTATAGCAGCTCGT ACAACTGGTTCGACTCCTGG J<S 
5670 CTGTGCAAG GGTAGCTAJI..ti.C CTTTGACTACTGG J<4 
Figure 1. 
(A) Schematic diagram of the VK3-20 gene segment joined to the Kde gene segment via a junctional 
region. PCR-mediated amplification of the joined IGK gene segments and subsequent sequencing of the 
junctional region in the PCR products obtained can be performed. The junctional region sequences pre-
sented are derived from precursor-B-ALL patients and illustrate the deletion of nuc!eotides from the 
germrme sequences as well as the s·1ze and composition of the junct'1onal regions. 
(B) Schematic diagram of the VH6-1 gene segment joined to one of the JH gene segments via a junction-
al region. IGH junctional regions may contain one, or rarely, two DH gene segments. The IGH junctional 
region sequences presented illustrate that deletion and insertion of nucleotides are more extensive than 
in the case of IGK-Kde junctions. DH gene segments and inserted nucleotides are indicated by capital let-
ters and small capital letters, respectively. 
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lance between these gene segments in germline configuration is far too large for 
PCR amplification. Because most PCR studies on lg and TCR gene rearrangements 
in ALL are performed at the DNA level, the primers are complementary to exon 
and/or intron sequences of V, D and/or J gene segments, depending on the type and 
completeness of the rearrangement.S.6.8 lg heavy chain (!GH), TCR gamma 
(TCRG), and TCR delta (TCRD) gene rearrangements can be analyzed relatively 
easily with the PCR technique because the IGH gene complex contains only seven 
VH families, seven DH families, and six functional JH gene segments (recognized by 
five VH family-specific and seven DH family-specific primers in combination with one 
consensus JH primer) and because the TCRG and TCRD genes contain a limited 
number ofV, (D), and J gene segments.5.9-11 This implies that only a restricted num-
ber of oligonucleotide primers are needed.11 ·12 Also PCR analysis of lg kappa (/GK), 
lg lambda (!GL), TCR alfa (TCRA) and TCR beta (TCRB) gene rearrangements is 
possible, but this requires more primers, especially for the many different V and J 
gene segments in TCRA and TCRB gene complexes. 
The detection of (clonal) lg/TCR gene rearrangements by PCR analysis is limit-
ed by the choice of primers, raising the possibility of false-negative results. A more 
essential drawback is the risk of false-positive results owing to the fact that not only 
clonally rearranged lg and TCR genes are amplified but also lg and TCR rearrange-
ments from normal, polyclonal cells, which have rearranged the same gene seg-
ments. Discrimination between clonal (leukemia-derived) and polyclonal (reactive 
and normal lymphoid cell-derived) PCR products is virtually impossible by means of 
standard agarose gel electrophoresis. Therefore, PCR-amplified rearranged gene 
products need additional analysis for distinction between polyclonal and monoclonal 
PCR products. Methods that have been successfully applied for this purpose include 
direct sequencing of PCR products,13 single strand conformation polymorphism 
analysis, 14 denaturing gradient gel electrophoresis, 15 heteroduplex analysis,16.17 
temperature gradient gel electrophoresis, 18 high-resolution radioactive fingerprint-
ing19 and fluorescent gene scanning analysis.20 Of these, heteroduplex analysis is 
probably the simplest, fastest and most cost-effective. In the heteroduplex analysis, 
the double-strand PCR products are denatured at 94°C and subsequently renatured 
at 4°C to induce homoduplex formation (duplexes with identical, clonal junctions) or 
heteroduplex formation (duplexes with different junctional regions).17 Homoduplexes 
and heteroduplexes are subsequently separated from each other by polyacrylamide 
gel electrophoresis, which clearly discriminates between the presence of rapidly 
migrating homoduplex bands or slowly migrating heteroduplex smears. 17 
lg and TCR gene rearrangements in precursor-B-ALL 
Based on their immunophenotypic characteristics, precursor-B-ALL are general-
ly regarded as clonal malignant counterparts of normal precursor-B-cells. In line with 
this assumption, our studies indicate that >95% of childhood precursor-B-ALL have 
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IGH gene rearrangements and that most of them contain IGK gene rearrangements 
(30%) or deletions (50%); even 20% of precursor-B-ALL cases have JGL gene 
rearrangements (Table 1 ).21-24 The vast majority of JGH gene rearrangements rep-
resent complete VH-(DH)-JH joining. while incomplete DH-JH rearrangements could 
be identified in 22% of patients. being the sole IGH gene rearrangements in only 5% 
of patients. 11 Deletions in the IGK genes are predominantly mediated via the IGK 
deleting element (Kde) sequence, which implies that JGK gene deletions can be 
identified as Kde rearrangements. Kde rearranges either to a heptamer recombina-
tion signal sequence (RSS) in the JK-CK intron, thereby deleting the CK gene seg-
ment, or to a VK gene segment, thereby deleting a large part of the JGK gene, includ-
ing the JK and CK gene segments, or very rarely to one of the RSS flanking JK gene 
segments.25,26 /GK-Kde rearrangements occur on one allele or both alleles in 20% 
and 30% of precursor-B-ALL cases, respectively.22 
Cross-lineage TCR gene rearrangements occur at high frequency in childhood 
precursor-B-ALL: TCRB, TCRG and TCRD gene rearrangements and/or deletions 
are found in 35%, 60% and 90% of cases, respectively27.28 However, the spectrum 
of cross-lineage TCR gene rearrangements in precursor-B-ALL is very limited. TCRB 
gene rearrangements are restricted to the Jj32 region. This is in contrast to normal 
Table 1. Frequencies of identifiable !g and TCR gene rearrangements as MRD-PCR targets in 
childhood ALL.a 
Gene Rearrangement type Precursor-B-ALL T-ALL 
IGH VH-JH 93% 5% 
DH-JH 20% 23% 
totai/GH 98% 23% 
IGK VK-Kde 45% 0% 
intron RSS-Kde 25% 0% 
totai/GK-Kde 50% 0% 
TCRG Vy-Jy 55% 95% 
TCRD VO-J01 or DO-J01 <1% 50% 
Vo2-Do3 or Do2-Do3 40% 5% 
Total TCRD 40% 55% 
At least one PCR target >95%b >95%b 
At least two PCR targets -90%b -90%b 
At least three PCR targets -65% -50% 
a. The indicated frequencies refer solely to the presence of PCR-detectable rearrangements. 
b. When a high sensitivity of::>:; 10-4 is included as an extra criterion, the frequency of at least one sensi-
tive PCR target drops to 85-90% and the frequency of at least two sensitive PCR targets drops to 
approximately 80%. 
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T-cells and T-All, which employ both Jf31 and Jf32 gene regions. TCRG gene 
rearrangements in childhood precursor-B-All most frequently (-70%) concern 
rearrangements to Jy1 region gene segments. Curiously, 80% of TCRD gene 
rearrangements represent incomplete V82-D83 or 082-083 joinings, whereas com-
plete rearrangements to the J81 gene segment, characteristic for normal T-cells and 
T-All blasts (particularly TCRy8+)29 have been reported in precursor-B-All only 
anecdotally.30 Furthermore, V82-D83 rearrangements are prone to continuing 
rearrangements, particularly to Ja gene segments with concomitant deletion of the 
C8 exons and subsequent Va-Ja recombination.31 ,32 In fact, 40% of TCRD gene 
deletions in childhood precursor-B-All result from a V82-Ja recombination, while 
the remaining 60% of C8 deletions are caused most probably by Va-Ja rearrange-
ments.2• Interestingly, the occurrence of cross-lineage TCR gene rearrangements 
seems to be age-dependent.33,34 For example, the incidence of incomplete V82-D83 
gene rearrangements significantly decreases with patient age, while TCRG gene 
rearrangements are rarely found in patients below 2 years of age.33,34 
Junctional regions of IGH, IGK (especially /GK-Kde), TCRG, and TCRD gene 
rearrangements are convenient MRD-PCR targets because they can be identified wit 
only a limited number of PCR primer sets.11,12 Moreover, the vast majority (>95%) of 
precursor-B-All patients can be monitored by application of junctional regions of 
/GH, IGK, TCRG and/or TCRD gene rearrangements (Table 1 ).28,35 
TCR and lg gene rearrangements in T-ALL 
The immunophenotype of T-ALL is comparable to those of cortical thymocytes. 
Subclassification of T-ALL into CD3-, TCRy8+, and TCRaf3+ subgroups reveals 
major differences in TCR gene rearrangement patterns21 ,36 Although the frequency 
of TCR gene rearrangements in the total group of T-ALL is very high, approximately 
10% of CD3- T-ALL still have all TCR genes in germ line configuration;21 ,36 this con-
cerns mainly immature CD1-/CD3- T-ALL of the prothymocytic/pre-T-ALL subgroup. 
The TCRD genes in CD3- T-ALL are rearranged in most cases (approximately 80%) 
and contain biallelic deletions in approximately 10% of cases9·36 As expected, all 
TCRyo+ T-ALL have TCRG and TCRD gene rearrangements and the vast majority 
(approximately 95%) also contain TCRB gene rearrangements.9,29 All TCRaf3+ T-
ALL contain TCRB and TCRG gene rearrangements and have at least one deleted 
TCRD allele (TCRA rearrangement); the second TCRD allele is also deleted in two 
third of cases9 ·21 Analysis of the TCRG gene configuration in T-All showed that 
TCRyo+ T-ALL display a less mature TCRG immunogenotype as compared to 
TCRaf3+ and most CD3- cases.37 This is reflected by significantly more frequent 
usage of the more downstream Vy genes and the upstream Jy1 segments in TCRy8+ 
T-ALL.29,37 Despite the described immunobiological differences between the T-All 
subsets, in virtually all childhood T-ALL (>95%) TCRG and/or TCRD junctional 
regions are potentially suitable targets for MRD monitoring (Table 1).9,37 
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Cross-lineage lg gene rearrangements occur at relatively low frequency in T-ALL 
(approximately 20%) and involve virtually only IGH genes (Table 1 )21 Interestingly, 
cross-lineage IGH gene rearrangements occur more frequently in CD3- T-ALL 
(approximately 20%) and TCRyo+ T-ALL (approximately 50%) than in TCRaJ3+ T-
ALL (<5%).38 
Heteroduplex PCR analysis showed a high frequency (approximately 80%) of 
incomplete DH-JH rearrangements as well as preferential usage of DH6-19 and the 
most downstream DH7-27 gene segment together with the most upstream JH1 and 
JH2 gene segments. Complete VH-JH recombinations comprised only 18% of cross-
lineage IGH gene rearrangements in T-ALL patients.36 
Applicability of the junctional regions of lg/TCR gene rearrangements for MRD 
analysis 
The homoduplex PCR products can be used for direct sequencing of the junc-
tional regions of the clonal lg/TCR gene rearrangements. This sequence information 
allows the design of junctional region-specific oligonucleotides. These oligonu-
cleotides can be applied for detection of malignant cells among normal lymphoid 
cells in two different ways. One possibility is the use of the oligonucleotides as 
patient-specific junctional region probes in hybridization experiments to detect PCR 
products derived from the malignant cells. The other possibility is to use the junc-
tional region-specific oligonucleotide as primer in a PCR to amplify the rearrange-
ments of the malignant clone specifically. 
Sensitivity of MRD monitoring by PCR analysis of junctional regions 
Theoretically the detection limit of the PCR technique is approximately 1 o-6 if a 
DNA segment is used as PCR targetS This detection limit can indeed be reached, 
but generally varies between 10-4 and 1 o-6 5.39.40 The sensitivity of MRD-PCR 
analysis of junctional regions is dependent on the type of rearrangement and on the 
'background' of normal lymphoid cells with comparable lg or TCR gene rearrange-
ments. Junctional regions of complete V-D-J rearrangements are extensive, where-
as junctional regions of V-J rearrangements are generally three to four times small-
er. Normal cells can contain the same rearranged gene segments as the leukemic 
cells. For instance, V81-J81 rearrangements frequently occur in T-ALL, but also in a 
small fraction (0.1-2%) of normal peripheral blood (PB) T-cells; Vyi-Jy1.3 and Vyi-
Jy2.3 joinings comprise 50-60% TCRG gene rearrangements in ALL, but are also 
found in a large fraction (70-90%) of normal PB T-cells. This might significantly infiu-
ence sensitivity levels, particularly taking into account the abundance of polyclonal 
Vy-Jy joinings in normal T-cells in post-induction follow-up samples.41 Therefore, 
MRD-PCR analysis of long V81-J81 junctional regions in PB samples is generally 
more sensitive (1 0-4 to 1 o-6 ) than MRD-PCR analysis of short Vy-Jy junctional 
regions (1 o-3 to 1 o-5 ).12 Similarly, substantial expansions of normal precursor-S-
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cells with polyclonai/GH gene rearrangements in regenerating BM after cessation of 
maintenance therapy may affect sensitivity of MRD detection using lg gene 
rearrangements as PCR targets42.43 
lg/TCR gene rearrangements can be identified at diagnosis in more than 95% of 
patients, and at least two targets per patient are available for 90% of childhood 
ALL4D However, as explained above, not all lg/TCR targets can reach a sensitivity 
of ~1 o-4 Preliminary results of first 500 childhood ALL patients treated with current 
BFM (Berlin-Frankfurt-MOnster) Study Group treatment protocol indicate that it is 
generally possible to identify two sensitive MRD targets (~1 0-4) in approximately 
80% of patients (T. Flohr et al., unpublished results). 
Quantification of MRD levels detected by PCR analysis of junctional regions 
MRD quantification by PCR analysis of lg/TCR gene rearrangements is a com-
plex process, which is essential for reliable disease monitoring. First, the quality and 
amplifiability of isolated DNA should be ensured. Second, minor variations in primer 
annealing and primer extension may lead to major variations after 30-35 PCR cycles. 
100 bp junctional 
region 
Kde 
5, ---------------------Jt-- 3' T---~~~--------~-----v~--~~~~~----~~~·~·~--~z 
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() e 
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dot blot hybridization with junctional region probe (CAATTTCCC.C§...IAGCCCTAGT) 
Figure 2. 
A Vxii-Kde rearrangement of a precursor-B-ALL as sensitive MRD-PCR target. The patient-specific junc-
tional region prObe was designed according to the junctional region sequence with deletion of five 
nucleotides and insertion of only three nucleotides. Tenfold dilutions were made from DNA of the leukemic 
cells into DNA from mononuclear cells. PCR analysis with VKII and Kde primers was performed on the 
dilution samples. The PCR products were blotted in duplicate on a nylon membrane and hybridized with 
the junctional region probe. This specific MRD-PCR target reached a sensitivity of 1 a-s without back-
ground signals. despite the relatively short junctional region. 
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The disadvantages of PCR end-point quantification might (partly) be overcome by 
using serial dilutions of DNA isolated from the leukemic cell sample at diagnosis into 
DNA of normal mononuclear cells (Figure 2).12 The same dilution series of diagno-
sis DNA is generally used to determine the tumor load in a follow-up sample in a 
semi-quantitative manner by comparison of the hybridization signals. This approach 
gives an indication of the tumor burden in the follow-up sample. A more precise but 
also more laborious quantification method is based on limiting dilution of MRD posi-
tive remission samples44.45 To make this assay reliable, it is necessary to perform 
replicate experiments to determine the level of MRD positivity. Another less tedious 
strategy for quantitative PCR uses an internal standard that is co-amplified with the 
target of interest. Quantification by competitive PCR is performed by comparing the 
PCR signal of the specific target DNA with that of known concentrations of an inter-
nal standard, the competitor46 
Recently, a novel technology has become available, the 'real-time' quantitative 
PCR (RQ-PCR)47-48 In contrast to the above-described PCR end-point quantifica-
tion techniques, RQ-PCR permits accurate quantification during exponential PCR 
amplification. The first available RQ-PCR technique was based on TaqMan technol-
ogy (Figure 3). This assay explotts the 5' --+3' nuclease activity of the Taq polymerase 
to detect and quantify specific PCR products as the reaction proceeds4 9 Upon 
amplification, an internal target-specific TaqMan probe (hydrolysis probe) conjugat-
ed with a reporter and a quencher dye is degraded, resulting in emission of a fluo-
rescent signal by the reporter dye that accumulates during the consecutive PCR 
cycles. Because of the real-time detection, the method has a very large dynamic 
detection range over five orders of magnitude, thereby eliminating the need for per-
forming serial dilutions of follow-up samples (Figure 3). Quantitative data can be 
obtained in a short period of time because post-PCR processing is not necessary. 
Several groups have shown that RQ-PCR via the TaqMan technology can be used 
for the quantitative detection of MRD in childhood ALL using junctional regions of 
lg/TCR gene rearrangements as leukemia-specific PCR targets .S0-52 Another type of 
RQ-PCR technology exploits hybridization probes via fluorescence resonance ener-
gy transfer (FRET) technology, which is usually performed using rapid-cycle RQ-
PCR (UghtCycler) technology. This method requires two hybridization probes com-
plementary to neighboring sequences, one labeled with a fluorescent dye at the 3' 
end and the other carrying a fluorochrome at the 5' end. One dye is a donor fluo-
rochrome, whereas the other fluorochrome (acceptor) emits light if it is positioned 
close to the donor dye. Fluorescence is measured during each annealing step, when 
both probes hybridize to adjacent target sequences on the same strand47-53 Also in 
this hybridization probe-based RQ-PCR analysis, the fluorescent signal is exponen-
tially increasing during the consecutive cycles, in line with the amount of PCR prod-
uct formed. A third possibility for RQ-PCR is detection of SYBR green I (DNA-inter-
calating dye) fluorescence during PCR employing patient-specific primers (Figure 
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4 )47·54 The SYBR Green I dye binds to the minor groove of double-stranded DNA, 
which greatly enhances its fluorescence. During the consecutive PCR cycles, the 
amount of double-stranded PCR product will increase, and therefore more SYBR 
Green I dye can bind to DNA and emit its fluorescence. Maximal SYBR Green I dye 
binding will occur at the end of each elongation phase. This approach is most cost-
effective and is sufficiently sensitive for MRD detection.S4 Several studies are in 
progress to assess whether SYBR green !-based detection of PCR products ensures 
satisfactory specificity; the first results look very promising (T. Flohr et al., unpub-
lished results). 
Oligoclonality and stability of lg and TCR gene rearrangements 
lg and TCR gene rearrangements in precursor-B-ALL and T-ALL might be prone 
to subclone formation owing to continuing rearrangements or secondary rearrange-
ments mediated via the active recombinase enzyme system in these immature lym-
phoid malignancies (reviewed in ref. 55). Several studies have shown that newly 
diagnosed childhood precursor-B-ALL are frequently oligoclonal because they con-
tain multiple IGH gene rearrangements (30% to 40% of cases) and even multiple 
/GK gene rearrangements (5% to 10% of cases)23.56 These multiple lg gene 
rearrangements can resultfrom both continuing rearrangement processes (e.g., con-
tinuing VH to DH-JH joining) as well as secondary rearrangements (e.g., DH-JH 
replacements, VH-JH replacements, and VK-JK replacements), which result in one or 
more subclones.S6-58 /GH gene rearrangement patterns might even differ between 
BM and PB in the same patient. 59 Furthermore, oligoclonality in the /GH locus is also 
found in 27% of T-ALL patients with rearranged /GH genes.36 
The problem of oligoclonality at diagnosis is the uncertainty as to which clone is 
going to emerge at relapse and which should therefore be monitored with MRD-PCR 
techniques. Secondary and ongoing IGH gene rearrangements might also occur in 
the time period between diagnosis and relapse, resulting in loss of leukemia-specif-
ic MRD targets.S6,60 These continuing or secondary IGH gene rearrangements in 
ALL frequently represent VH to DH-JH rearrangements or VH replacements, respec-
tiveJy.38,5? During these two types of rearrangements the DH-JH junctional region 
remains unaffected, leading to the concept of designing the primers around the rei-
Figure 3. 
Real-time quantitative PCR analysis by use of the TaqMan technique. (A) The TaqMan probe contains a 
reporter dye (R) and a quencher dye (0). which prevents emission of the reporter dye as long as the 
reporter dye and the quencher dye are closely linked. During the extension phase of each PCR cycle, the 
annealed TaqMan probe is hydrolyzed by the 5'~>3' exonuclease activity of the Taq polymerase, thereby 
separating the reporter dye from the quencher dye. This results in a fluorescent signal (delta Rn). which 
further increases during each subsequent PCR cycle. 
(B) Example of an RQ-PCR analysis using the TaqMan approach. Tenfold dilutions of a diagnostic sam-
ple in normal mononuclear cell DNA were analyzed using an IGH rearrangement and a junctional region-
specific primer. 
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atively stable OH-JH region in order to prevent false-negative PCR results.S7 
TCR gene oligoclonality is rarely seen at diagnosis in T-ALL.21.37,60 However, 
combined Southern blot and PCR data show that the frequency of oligoclonality in 
the cross-lineage TCR gene rearrangements of precursor-B-ALL is approximately 
20%, which is slightly less than in the IGH gene2 8 Initially, subclone formation at 
diagnosis was thought to be less frequent for the TCRD gene complex, as suggest-
ed by Southern blotting9 However, heteroduplex PCR analysis and sequencing 
have shown that V82-083 and 082-083 rearrangements in newly diagnosed precur-
sor-B-ALL are oligoclonal in 30-40% of cases.28,33,61 V82-0i53 rearrangements are 
also prone to continuing rearrangements, particularly to Ja gene segments with con-
comitant deletion of the Co exons. 32.61 
Monoclonal MRO-PCR targets in childhood precursor-B-ALL are characterized 
by high stability, with approximately 90% of all targets detectable at relapse. In con-
trast, only 40% of the oligoclonal MRO-PCR targets are preserved at relapse 
(T. Szczepanski et al., unpublished observations). Therefore, it is probably important 
to discriminate between monoclonal and oligoclonal lg/TCR rearrangements; this 
requires a combined Southern blot and PCR approach. Southern blotting is particu-
larly informative for detection of oligoclonality in IGH and IGK gene rearrange-
ments,21·23 whereas heteroduplex PCR analysis in combination with Southern blot-
ting is informative for detection of oligoclonal TCRD gene rearrangements28.61 
False-negative results due to clonal evolution are a major drawback of using 
lg/TCR gene rearrangements as PCR targets for MRO detection. Changes in /GH 
gene rearrangement patterns at relapse occur at high frequency in childhood pre-
cursor-B-ALL, particularly when subclone formation is already present at diagno-
sis60 Changes in TCRG and TCRD gene rearrangements at relapse are found in 
both precursor-B-ALL and T-ALL, but generally concern only one allete.S8,60,62 At 
present, the /GK-Kde gene rearrangements are considered to be the most stable 
MRO-PCR targets, probably because they are rarely oligoclonal and represent end-
stage rearrangements, which do not allow continuing or secondary rearrangements 
(VanderVelden et al., unpublished observations). The risk of changes in rearrange-
ment patterns was suggested to increase with time (i.e. with remission duration).60 
However, clonal selection processes can occur already during early treatment phas-
es,63 whereas clonal identity was frequently reported between diagnosis and very 
late relapse of precursor-B-ALL.64 Moreover, in relapse patients further clonal evo-
Figure 4. 
RQ-PCR based MRD analysis using the Light Cycler technology and SYBR green l detection format. (A) 
Schematic representation of the allele-specific oligonucleotide (ASO) PCR strategy. For TCRG gene 
rearrangement. first-round PCR was performed using the Vyl family-specific primer and the Jy1.3/2.3 con-
sensus primer. An inner Vyl member-specific primer (Vy4-3') and an ASO were used for ASO-PCR. (B) 
ASO-PCR results after 25 PCR cycles at 62"C, including five initial touch-down cycles with a decrease in 
temperature of 1 oc per cycle from 67°C to 62"C on a block thermocycler and gel electrophoresis. (C) 
Amplification profile. (D) Melting curve analysis. (E) Calibration graph (see reference 54 for details). 
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lution is generally not observed at second or third relapse.32,60 Despite the high fre-
quency of immunogenotypic changes in childhood ALL at relapse, at least one 
rearranged !GH, TCRG and/or TCRD allele remains stable in 75-90% of precursor-
B-ALL and in 90% ofT-ALL.58.60.62,65 More importantly, in most ALL patients at least 
two suitable PCR-targets are available (Table 1 ). Therefore, it is now generally 
accepted that MRD-PCR studies should preferably employ at least two lg/TCR tar-
gets per patient. Such approach should result in a major reduction of false-negative 
MRD results. 
CLINICAL VALUE OF MRD IN CHILDHOOD All 
Assessment of early treatment response 
The initial retrospective and small prospective studies with relatively short follow-
up indicated that the detection of MRD in ALL in childhood has potent clinical value, 
although the results of these clinical studies were not fully concordant8.46.66-79 This 
was attributed to differences in MRD methods and particularly differences in sensi-
tivities of MRD monitoring as well as to differences in intensity of cytotoxic treatment 
protocols. Several recent large prospective studies confirmed the clinical value of 
MRD monitoring, justifying incorporation of the MRD information to refine risk assign-
ment in current childhood ALL treatment protocols.65,80-84 
The most significant application of MRD monitoring in childhood ALL is the esti-
mation of the initial response to chemotherapy. Traditionally, good clinical response 
with blast count in PB less than 1 000/1"1 after a week of single agent steroid therapy 
or absence of circulating blasts after 7 days of multi-agent induction chemotherapy 
were found to be important prognostic factors85 As a logical continuation of these 
clinical findings, low levels or absence of MRD after completion of induction therapy 
seems to predict good outcome, as found by PCR-based MRD stud-
ies.65,68.72.77,78,80,82 Meta-analysis of published MRD studies showed that approxi-
mately 50% of children with ALL are MRD positive at the end of induction treatment 
and approximately 45% of these MRD-positive patients will ultimately relapse.86 The 
risk of relapse is proportional to the detected MRD levels.65.72,77,80 The level of 
MRD-PCR positivity after induction therapy is the most powerful prognostic factor. 
Multivariate analyses showed that this prognostic value is independent of other clin-
ically relevant risk factors, including age, blast count at diagnosis, immunophenotype 
at diagnosis, presence of chromosome aberrations, response to prednisone, and 
classical clinical risk group assignment, provided that accurate MRD quantification 
on adequate BM samples is performed.65,80,82 
The meaning of MRD positivity differs in cytogenetic subgroup of ALL. 
Philadelphia-positive (Ph+) ALL with t(9;22) is characterized by high drug-resistance 
and a very poor prognosis87 This leukemia subtype is also associated with an 
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increased percentage of MRD positive patients and increased MRD levels at the end 
of induction treatment.88 Chemotherapy can lower the degree of MRD by only 2 to 3 
logs in most Ph+ ALL patients, which is not enough for prolonged hematological 
remission. Nevertheless, in some patients with favorable prognostic features (e.g., 
low initial leukocyte count or good prednisone response) the disease can be con-
trolled with intensive chemotherapyS7 MRD monitoring might identify this small drug-
sensitive subgroup of Ph+ patients. However, due to the poor prognosis of ALL with 
t(9;22) and the very low frequency of complete cure in this patient group, this hypoth-
esis should be confirmed by large multi-center studies. The same holds true for other 
cytogenetic ALL subgroups with increased risk of relapse- as, for instance, precur-
sor-B-ALL with t(4;11). It is possible to identify a small subgroup of t(4;11)-positive 
patients with rapid achievement of molecular remission after intensive chemothera-
PY and/or allogeneic BM transplantation (BMT) and persistent PeR-negativity in 
long-term complete remissionS9 Therefore, prospective MRD monitoring can be 
used for assessment of treatment response and can be applied for individualization 
of therapy in order further to improve the outcome of high-risk t(4;11) positive 
leukemia, including infant ALL patients9 0 MRD studies in patients with the prognos-
tically favorable TEL-AML 1 aberration suggest that the MRD levels at the end of 
induction therapy are generally below the threshold associated with bad outcome.S1 
Nevertheless, using quantitative MRD analysis of early treatment response, it is pos-
sible to identify the subgroup of TEL-AML 1 positive patients at high risk of leukemia 
relapse 91 
The results from the large prospective MRD study of the International BFM Study 
Group (1-BFM-SG) indicated that analysis of MRD at a single time point is not suffi-
cient for recognition of patients with poor prognosis as well as patients with good 
prognosis.65 In contrast, combined information on the kinetics of tumor load 
decrease at the end of induction treatment and before consolidation treatment 
appeared to be highly informative. This combined MRD information distinguishes 
patients at low-risk with MRD negativity at both time points (5-year relapse rate of 
2%); patients at high risk with an intermediate (1 o-3) or high (;:,10-2 ) degree of MRD 
at both time points (5-year relapse rate of 80%); and the remaining patients at inter-
mediate risk (5-year relapse rate of 22%) (Figure 5).65 The MRD-based low-risk 
patients make up a group of a substantial size (approximately 45%), comparable to 
the frequency of survivors of childhood ALL before treatment intensification was 
introduced92 Within the MRD-based low-risk group, half of the patients have already 
low (:>10-4) or undetectable MRD levels after two weeks of treatment.83 This group 
might particularly profit from treatment reduction. On the other hand, the group of 
patients at MRD-based high risk is larger than any previously identified high-risk 
group (approximately 15%) and has an unprecedented high 5-year relapse rate of 
80%. This group might benefit from further intensification of treatment protocols 
including BMT during first remission or novel treatment modalities -for instance the 
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Figure 5. 
Relapse-free survival of the three MRD-based risk groups of children treated for ALL according to proto-
cols of the International BFM Study Group. The three risk groups were defined by combined MRD infor-
mation at the end of induction treatment {time point 1) and before consolidation treatment {time point 2).65 
Patients in the low-risk group have MRO negativity at both time points (43% of patients). patients in the 
high-risk group have MRO degrees of :?:10-3 at both time points (15% of patients), and the remaining 
patients form the MRD-based intermediate-risk group (43% of patients). 
inclusion of antibodies conjugated with immunotoxins or tyrosine kinase inhibitors. It 
is important to bear in mind that optimal time-points and sensitivities for determina-
tion of early treatment response ('MRD window') should be determined as per ALL 
treatment protocol. Modifications in chemotherapy regimens and the corresponding 
BM sampling time points might result in the loss of clinical significance of MRD infor-
mation if the MRD window is not simultaneously adjusted.93 
The predictive value of MRD monitoring is particularly clear after first 
relapse.73,94 This can be perceived as assessment of early treatment response after 
second induction treatment. The BFM group demonstrated the high prognostic value 
of MRD detection at day 42 of the ALL-REZ treatment protocol. Patients with MRD 
levels below 10-3 had a probability of relapse-free survival of 88%, whereas MRD 
levels 2 1 o-3 were uniformly predictive of dismal outcome (probability of relapse-free 
survival of 0%).94 
The MRD data from a single study suggest slower kinetics of leukemia clearance 
in T-All as compared to precursor-B-ALL patients.76 Virtually all (16 of 17) patients 
were found to be MRD-positive at the end of induction treatment, while a later time 
point at the beginning of maintenance treatment carried the most significant prog-
nostic information. All but one (seven of eight) MRD-positive patients at this late time 
point subsequently relapsed, while all eight MRD-negative patients remained in con-
tinuous complete remission.76 This is in contrast to the MRD study of the 1-BFM-SG, 
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which showed that PCR-based measurement of early treatment response at two 
consecutive time points after induction treatment and before consolidation treatment 
results in highly prognostic MRD information: -25% low-risk patients with 0% relaps-
es, -50% intermediate-risk patients with 25% relapses, and -25% high-risk patients 
with 100% relapses (M. J. Willemse et al., unpublished observations). 
The value of continuous MRD monitoring in childhood All 
Continuous MRD monitoring in childhood ALL has shown that a steady decrease 
of MRD levels to negative PCR results during treatment is associated with favorable 
prognosis,71 whereas persistence of high MRD levels or a steady increase of MRD 
levels generally leads to clinical relapse.65-6?.69.?8 Therefore, persisting MRD levels 
during treatment can be regarded as the best indicator of resistance to treatment. 
PCR-based MRD monitoring was shown to be able to select the group of 'poor-
responders' with early relapse during maintenance treatment.46,65,80,82 Sequential 
sampling generally shows positive MRD-PCR results prior to clinical relapse. 
However, the time span between the re-appearance of MRD positivity and overt 
hematological relapse might be too short for earlier implementation of re-induction 
treatment.69 Real false-negative results might be obtained due to continuing or sec-
ondary lg or TCR gene rearrangements (clonal evolution). Such false-negative 
results can generally be prevented by using two lg/TCR targets per patient (see 
above).65 
Low levels of MRD after therapy might be associated with late development of 
relapse, but absence of MRD at the end of treatment is not sufficient to assure that 
the patient is cured.65.70.78 Despite the high sensitivity of most MRD techniques, it 
should be noted that MRD negativity does not exclude the presence of leukemic cells 
in the patient because each MRD test only screens a minor fraction of all BM and PB 
leukocytes. Curiously, one report claims that multiple PCR analyses (testing a high-
er number of cells) gave evidence for residual leukemia at very low levels in -90% 
(15/17) of patients remaining in long-term clinical remission.75 In 7 out of these 15 
patients this PCR result was confirmed in a blast colony assay. So far these data 
have not been confirmed by other investigators, even by using extremely sensitive 
1 0-fold PCR analyses (sensitivities: 1 o-6 to 1 o-7 ).65 In contrast, large prospective 
studies showed 0 to 1 0% of patients being positive at the end of treatment, with the 
majority of these MRD positive patients relapsing later on.65-78 
The value of MRD monitoring in childhood All patients undergoing BMT 
MRD monitoring is particularly informative for ALL patients undergoing BMT. 
High levels of MRD positivity (1 o-2 to 1 o-3) before allogeneic BMT are invariably 
associated with relapse after transplantation, while 2-year event-free survival in 
patients with low-level MRD positivity (1 o-3 to 1 o-5) approximated 35%.95 This is 
particularly true for patients receiving T-cell-depleted grafts, while a strong graft-ver-
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sus-leukemia effect associated with non-depleted grafts might even overcome high 
levels of MRD positivity in selected cases.96 In contrast, MRD-negativity before allo-
geneic transplantation significantly correlated with better outcome and a 2-year 
event-free survival of 73%95 Therefore, patients with a high MRD burden prior to 
BMT might be offered alternative treatment (e.g. further cytoreduction before BMT, 
intensified conditioning, and/or early post-BMT immunotherapy) in order to improve 
their generally poor outcome.95.97 
MRD-PCR positivity in ALL patients after BMT is suggestive of impending 
relapse. 9 s This is true both for high-risk patients transplanted in first remission and 
patients subjected to BMT in second remission after leukemia relapse. MRD was 
shown to occur in post-BMT samples in 88% of patients who subsequently relapsed, 
while only 22% of patients in long-term complete remission showed MRD at any time 
after BMT, mostly at low levels.98 The patients with persistent MRD positivity after 
BMT may be candidates for early treatment with immunotherapy, including donor 
lymphocyte infusions to increase graft-versus leukemia effects.98 
Potential usage of peripheral blood for MRD monitoring in childhood ALL 
One of the serious limitations of continuous MRD monitoring is the need of mul-
tiple traumatic BM aspirations. Replacement of BM sampling by PB sampling has 
been a topic of debate in MRD studies for the last 15 years. The data from a single 
PCR study showed 11.7 difference between BM and PB during induction treatment 
of precursor-B-ALL patients.99 This implies that MRD techniques need to be at least 
tenfold more sensitive (i.e. :>10-5), when PB samples are monitored.65 The differ-
ence between BM and PB might be lower in Ph+ precursor-B-ALL, most probably 
because of a generally higher degree of MRD as compared to other ALL subtypes. 
Undoubtedly, the differences in MRD levels between BM and PB are additionally 
influenced by the degree of dilution of BM aspirates with PB. This is suggested by 
the finding of 4.1-fold greater mean MRD level in the trephine BM biopsies as com-
pared to the BM aspirates.10° Nevertheless, more information is needed to decide 
whether or not, and to what extent, the more traumatic BM sampling can be replaced 
by PB sampling. 
SUMMARY 
Antigen receptor gene rearrangements are reliable patient-specific targets for 
PCR-based MRD monitoring in childhood ALL. Such lg/TCR rearrangements can be 
identified at diagnosis in more than 95% of patients through relatively easy and cost-
effective approaches such as heteroduplex PCR analysis or fluorescent gene scan-
ning. This should result in MRD-PCR targets, which are at least two orders of mag-
nitude more sensitive than conventional cytomorphological techniques. Usage of at 
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least two sensitive targets per patient (available for approximately 80% of ALL) is 
strongly advised to prevent false-negative results owing to target loss via secondary 
or ongoing recombination throughout the course of the disease. With currently avail-
able RQ-PCR methods, MRD monitoring via lg/TCR gene rearrangements is quan-
titative and highly reproducible between laboratories. 
Several studies have demonstrated that MRD monitoring in childhood ALL apply-
ing lg/TCR gene rearrangements as PCR targets significantly predicts clinical out-
come. This is particularly useful for evaluation of early treatment response, which 
distinguishes high-risk patients with poor prognosis from low-risk patients with excel-
lent prognosis. Similarly, high MRD positivity before stem cell transplantation is 
strongly prognostic of relapse after transplantation. Prolonged continuous MRD 
monitoring might be important for patients at high risk of relapse and for patients at 
intermediate risk of relapse, i.e. patients with a relatively slow early response to treat-
ment. 
As detection of MRD has proven to be of clinical importance, it is currently being 
incorporated into stratification of childhood ALL treatment protocols. Further studies 
should prove whether MRD-based individualization of therapy improves treatment 
outcome in high-risk ALL patients and prevents unnecessary treatment-related toxi-
city in low-risk ALL patients. 
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PRACTICE POINTS 
junctional regions of lg and TCR gene rearrangements are 'fingerprint-like' 
sequences which are unique for each acute lymphoblastic leukemia. They can 
therefore be used as PCR targets for sensitive detection of low frequencies of 
leukemic cells, i.e. minimal residual disease (MRD) 
it is possible to identify clonal immunoglobulin and T-cell receptor gene 
rearrangements in virtually all childhood precursor-B-ALL and T-ALL patients 
using immunoglobulin and T-cell receptor gene rearrangements, it is possible to 
monitor quantitatively minimal residual disease with high specificity and high sen-
sitivity, at least 1 00-fold more sensitive than with routine morphology 
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MRD monitoring in childhood ALL employing lgffCR gene rearrangements as 
PCR targets has significant predictive value superior to that of other clinically rel-
evant prognostic factors 
evaluation of early treatment response via MRD monitoring results in an unprece-
dentedly accurate MRD-based risk group classification which can be used for 
treatment stratification in childhood ALL 
prolonged continuous MRD monitoring might be important for patients at inter-
mediate risk or high risk of relapse for assessment of long-term response to more 
aggressive treatment 
MRD monitoring in second complete remission identifies patients with excellent 
drug-sensitivity and predicts outcome after stem cell transplantation 
RESEARCH AGENDA 
for a subgroup of childhood ALL patients there is still the requirement to identify 
new sensitive MRD-PCR targets. This might be accomplished by further charac-
terization of lgffCR gene rearrangement patterns with subsequent identification 
of new PCR targets 
further standardization of RQ-PCR techniques should provide rapid and quantita-
tive MRD information, which is essential for clinical decision-making. 
ongoing prospective multi-center studies should answer the question: does MRD-
based intensification of ALL treatment improve the outcome in MRD-based high-
risk ALL patients? 
future treatment protocols should show whether less intensive chemotherapy in 
MRD-based low-risk ALL patients (40 ± 45% of childhood ALL) decreases treat-
ment-related toxicity and does not result in an increase in the rate of relapse 
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CHAPTER 5.2 
CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
Several studies have proven that minimal residual disease (MRD) monitoring in 
acute lymphoblastic leukemia (ALL) patients has significant prognostic value, which 
can be used for improved therapy stratification. At present such clinically relevant 
MRD information can be obtained with three different techniques (reviewed in 
ref. 1-3): 
- fiow cytometric immunophenotyping using aberrant or "leukemia-associated" phe-
notypes; 
PCR techniques using chromosome aberrations that result in fusion gene tran-
scripts or aberrant expression of transcripts; 
PCR techniques using patient-specific junctional regions of rearranged 
immunoglobulin (lg) and T-cell receptor (TCR) genes. 
The characteristics of the three currently used MRD techniques in ALL are sum-
marized in Table 1. Each of the three MRD techniques has specific advantages and 
disadvantages, which should be weighed against each other when plannings are 
made for large-scale clinical MRD studies. Particularly, the required sensitivity and 
the applicability will play an important role, because these two characteristics deter-
mine which patients can actually be monitored. 
Flow cytometric MRD detection 
The immunophenotypic "targets" in fiow cytometric MRD detection mainly con-
cern aberrant or "leukemia-associated" immunophenotypes, which are rare (or 
sometimes absent) in normal bone marrow (BM) and peripheral blood (PB) 
(reviewed in. ref. 2.4). Current triple and quadruple labelings allow detection of such 
leukemia-associated phenotypes in the majority (60-98%) of precursor-B-ALL and in 
virtually all T-ALL.5-8 lmmunophenotypic shifts during the disease course do occur, 
although their reported frequency is variable, mainly because different definitions are 
used for phenotypic shifts.2.9 Nevertheless, most groups agree that preferably two 
different leukemia-associated phenotypes should be monitored per patient to prevent 
false-negative results. 2,4 
The sensitivity of fiow cytometric MRD detection remains unclear. Flow cytomet-
ric evaluation of 106 cells is technically not a problem, but detection of 50 to 100 
malignant precursor-S-cells between 10,000 to 50,000 normal precursor-S-cells in 
BM is not easy, particularly in regenerating BM during or after therapy.10 However, 
this is essential to reach sensitivities of 1Q-4. Some experienced centers claim that 
a detection limit of 1 Q-4 can be reached routinely in virtually all ALL patients, but 
other centers agree that the detection limit varies between w-3 and 1 Q-4 for most 
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Table 1. Characteristics of the techniques currently employed for MRD detection in ALL. 
Sensitivity 
Applicability 
- Precursor-B-ALL 
-T-ALL 
Advantages 
Disadvantages 
Flow cytometric 
immunophenotyping 
10-3-1o-4 
60-98% 
90-95% 
applicable for most patients 
relatively cheap 
rapid: 1-2 days 
limited sensitivity 
need for preferably two 
aberrant immunophenotypes 
per patient, because of chance 
of immunophenotypic shifts 
PCR analysis of chromosome 
aberrations (mainly detection 
of fusion gene transcripts) 
1o-4-1o-6 
40-45%* 
15-35%** 
relatively easy and cheap 
sensitive and leukemia-specific 
stable target during disease course 
rapid: 2-3 days 
suitable for monitoring of uniform patient 
groups (e.g., Ph+ All) 
useful in only a minority of patients 
cross-contamination of PCR products 
leading to false-positive results 
(even at diagnosis) 
* In childhood ALL this particularly concerns 1(12;21 )(TEL-AML 1) and in adult ALL particularly t(9;22)(BCR-ABL) 
PCR analysis of lgfTCR 
genes Uunctional region 
specific approach) 
10-4-10-5 
90-95% 
90-95%· 
applicable for virtually all patients 
if IGH, IGK-Kde, TCRG, and 
TCRD gene rearrangements are 
used as targets 
sensitive and patient-specific 
rapid during follow-up: 2-3 days 
(if junctional region is identified 
and if RQ-PCR is used) 
lime-consuming at diagnosis: 
identification of the junctional 
regions and sensitivity testing 
relatively expensive 
need for preferably two PCR 
targets per patient, because 
of chance of clonal evolution 
** This mainly concerns del(1 )(p32 p32) with S/L- TAL 1 fusion and 1(5;14) v.rilh aberrant HOX11L2 expression, together occurring in 25-35% of childhood 
T-ALL and in 15-20% of adult ALL.11,12 
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precursor-B-ALL, while in virtually all T-ALL a detection limit of 10-4 can indeed be 
reached, because of their specific thymocytic phenotype. 
PCR analysis of chromosome aberrations 
Structural chromosome aberrations are ideal leukemia-specific PCR targets, 
which remain stable during the disease course and can reach excellent sensitivities 
of 10-4 to 10-6. In ALL, these PCR targets mainly concern fusion gene transcripts 
(e.g. TEL-AML1, BCR-ABL, and SIL-TAL1) or aberrantly expressed specific tran-
scripts (e.g., HOX11L2 and WT1), which can be detected via reverse transcriptase 
(RT) PCR analysis.3.11-13 
Two main disadvantages limit the application of chromosome aberrations as 
MRD-PCR targets: applicability in only a minority of ALL patients and the chance of 
false-positive results via cross-contamination of PCR products. 
PCR analysis of lg and TCR gene rearrangements 
The junctional regions of rearranged lg and TCR genes are fingerprint-like 
sequences, which differ in length and composition per lymphocyte or lymphocyte 
clone and consequently also per each lymphoid malignancy, such as ALL.14 These 
patient-specific MRD-PCR targets can be detected in the vast majority of precursor-
B-ALL and T-ALL (Table 2) and generally reach sensitivities of 10-4 to 1Q-S.1.15-17 
These high sensitivities require the precise identification of the junctional region 
sequences of lg and TCR genes in each ALL, because these sequences are need-
Table 2. Frequencies and stability of MRD-PCR targets in childhood precursor-B-ALL 
PCR target 
/GH 
- VH-JH 
- DH-JH 
IGK-Kde 
- Vx-Kde 
- intron-Kde 
TCRG (Vy-Jy) 
TCRD 
-Vo2-Do3 
-Do2-Do3 
-
see ref.15-17 
** see ref.20 
NT not tested 
Frequency" 
at diagnosis 
95% 
95% 
20% 
50% 
45% 
25% 
55% 
40% 
35% 
7% 
Monoclonality 
at diagnosis"" 
60-70% 
90% 
60-65% 
60% 
monoclonal 
85% 
88% 
57% 
95% 
95% 
86% 
NT 
86% 
81% 
100% 
Stability at relapse--
oligoc!onal 
44% 
47% 
38% 
40% 
40% 
0 
NT 
26% 
31% 
14% 
total 
64% 
69% 
43% 
90% 
91% 
87% 
75% 
63% 
63% 
63% 
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ed to design patient-specific oligonucleotides. Subsequently, sensitivity testing has 
to be performed via serial dilution of DNA obtained at diagnosis in order to assess 
whether the required sensitivity can indeed be reached. 
If only sensitivities of 1 o-2 to 1 o-3 are required, it is possible to skip the sequenc-
ing of the junctional regions and focus on differences in length of the junctional 
regions, which can be evaluated by PCR product length assessment via fluorescent 
GeneScanning. An internal competitor containing the same type of rearrangement 
can be used for quantification of the lg/TCR gene target.18 
The main disadvantage of using lg/TCR gene rearrangements as MRD-PCR tar-
gets in ALL is the occurrence of continuing rearrangements during the disease 
course as has been identified by comparing the lg/TCR gene rearrangement pat-
terns at diagnosis and relapse.19.20 Such changes in rearrangement patterns will 
lead to false-negative PCR results. 
In precursor-B-ALL, changes at relapse were particularly observed in patients 
with more than one leukemic subclone (oligoclonality) at diagnosis.zo The occur-
rence of subclones differs per type of lg/TCR gene rearrangement and consequent-
ly also the stability differs per type of rearrangement (Table 2). For example, /GK 
gene rearrangements involving the so-called kappa deleting element (Kde) are more 
stable than IGH, TCRG, and TCRD gene rearrangements.zo 
In T-ALL, the changes in TCR gene rearrangement patterns at relapse are more 
limited, probably related to the fact that T-ALL rarely contains oligoclonal TCR gene 
rearrangement patterns.16,19 Nevertheless, it is now generally accepted that prefer-
ably two lg/TCR gene targets should be used for reliable and sensitive M RD detec-
tion in ALL patients. 
Real-time quantitative PCR techniques 
PCR-based MRD methodologies are increasingly achievable thanks to the 
development of real-time quantitative (RQ-) PCR techniques (reviewed in ref. 21 ). 
Fusion gene transcripts from chromosome aberrations or aberrantly expressed 
transcripts are excellent RQ-PCR targets for the detection of MRD in ALL.22.23 Copy 
numbers of the relevant transcript in BM or PB follow-up samples can be calculated 
via a dilution curve of known amounts of plasmids containing the fusion gene 
sequences. A standardized approach has been developed for the most frequent 
fusion gene transcripts in ALL via the Europe Against Cancer program.Z4 
Several studies have proven that RQ-PCR can be effectively used for quantita-
tive detection of MRD using junctional regions of lg and TCR gene rearrangements 
as PCR targets. Uniform approaches with a junctional region-specific primer in com-
bination with a germline TaqMan probe and primer have been developed for the clas-
sical lg/TCR targets: IGH, /GK-Kde, TCRG and TCR0.25-28 Introduction of new 
MRD-PCR targets like TCRB gene rearrangements is currently a subject of an 
European BIOMED-2 Concerted Action.29 
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PROGNOSTIC VALUE OF MRD DETECTION IN All 
Early retrospective and small prospective studies with relatively short follow-up 
indicated that the detection of MRD in childhood ALL predicts treatment outcome, 
although the results of these clinical studies were not fully concordant (reviewed in 
ref. 1 ). This was attributed to differences in sensitivities of MRD monitoring as well as 
to differences in intensity of cytotoxic treatment protocols. Several recent large-scale 
prospective studies confirmed the clinical value of MRD monitoring, justifying incor-
poration of MRD information in current childhood ALL treatment protocols to refine 
risk assignment.5.8,3D-33 
Significance of MRD detection during front-line treatment of childhood ALL 
The most significant application of MRD monitoring for front-line treatment of ALL 
is the evaluation of the initial response to cytotoxic therapy. Low levels or absence of 
MRD in BM after completion of induction therapy appears to predict good out-
come_5.8,3D-34 Depending on the treatment protocol and the end-of-induction sam-
pling time point, MRD-negativity is associated with overall relapse rates of only 
2-10% (Figure 1 and Table 3)5,8,30-33 Moreover, sensitive MRD detection during the 
induction phase seems capable of identifying 20% of childhood ALL patients with a 
very rapid leukemia clearance and long-term relapse-free surviva1_35 On the other 
A B 
low risk group (n=SS) 
__ ~b_s~12c_o of MRD (n=89) 
MRD<10"' (11,119) 
Intermediate risk group (n=SS) 
MRD~10~ (n=12) 
high risk group (n,19) 10 
years years 
Figure 1. 
(A) Relapse-free survival of the three MRD-based risk groups of children treated for ALL according to pro-
tocols of the International BFM Study Group. The three risk groups were defined by combined MRD infor-
mation at the end of induction treatment and before consolidation treatment (see3° for details). (B) 
Relapse-free survival according to the qualitative (presence or absence) and quantitative detection of 
MRD after the completion of induction therapy in EORTC trial 58881 (with courtesy to Dr. H. Cave and 
Prof. E. Vilmer)_32,36 
Table 3. Comparison between large prospective MRO studies In pediatric ALL* 
Study group 
Treatment protocol 
Induction intensity 
before MRD sampling 
Number of patients 
Relapse rate 
Technique 
Standardization 
MRD time point at 
the end of induclion 
treatment 
MRD status at 
the end of induction 
treatment 
MRD-negalive 
MRD ~ 104 
MRD, 10·3 
MRD 2. 10·2 
1-BFM-SG 
ALL-BFM 90! AEIOP ALL91 
/DCLSG - ALLB 
Standard (PRED + MIX l.th. 
t VCR+ DAUNO t l-ASP) 
169 
27% at 5 years 
lgfTCR PCR 
multi-center 
5 weeks 
Distribution Relapse rate 
%(No.) %{No.) 
42% (71) 3% (2) 
20% (33) 24% (8) 
22% (38) 39% (15) 
16% {27) 74% (20) 
BFM-Austria NOPHO EORTC 
AlL-BFM 95 NOPHO ALL MRD 95 EORTC protocol 58881 
Standard (PRED t MIX Uh. Standard (PRED t MIX l.th. Standard (PRED + Mtx i.th. 
VCR t DAUNO t L-ASP) VCR +DOXO t L-ASP) VCR +DOXO t L-ASP) 
98 100 151 
12% at 3.5 years 15% at 4 years 21% at 3 years 
Flow cylometry lgfTCR PCR lgfTCR PCR 
single-center single-center multi-center 
5 weeks 4 weeks 5 weeks 
Distribution Relapse rate Distribution Relapse rate Distribution Relapse rate 
%{No.) %(No.) %(No.) %-{No.) %(No.) %{No.) 
----
60% (59) 7% (4) -- J 53% 2% 66% {88) 8% (7) 
5% (5) 20% (1) -- (53) (1) 23% (30) 17% (5) 
32% (31) 6% (5) 32% (32) 28% (9) ·~ 11% 73% 
3% (3) 100% (3) 15% (15) 33% (5)-- (15) (11) 
~ 
St-Juda 
Total Therapy Study 
Xl!IA and XI liB 
Intensive (MIX t PRED 
t VCR t Dauno t l-ASP 
+ VP-16 + Ara-C +triple i.th.) 
165 0 
16.3% ± 3.5% at 4 years ?;; lJ 
Flow cytometry ill 
single-center 
'" 6 weeks !-" 
"' 
Distribution Relapse rate 
%(No.) %{No.) 
75% (123) 7% (9) 
12% (19)1 '30% 
8% (14) 
5% (9) 72%± 21% 
Continued Table 3. 
Risk group dassiflcation 
MRD-based LRG 
MRD-based IRG 
MRD-based HRG 
• see ref.5,8.3iH2 
Combined two time points Combined two time points Single lima point 
Distribution Relapse rata Distribution Relapse rate Distribution Relapse rate 
----
43% (55) 2% (1)---90% 3% 40% (40) 0% 
43% (55) 24% (13)--· I (94) (3) ~60% 25% 
15% (19) 84% (16) 10% (10) 100% (10) (60) (15) 
Single time point 
Distribution Relapse rate 
:::J 89% 10% 
(118) (12) 
11% (15) 73% (11) 
Combined two time 
points 
Distribution Relapse rata 
79% (123) 7% (9) 
9% (14) 7% (1) 
12% (18) 56% (10) 
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Figure 2. 
(A) Probability of event-free survival according to the MRD levels after the second block of the ALL-REZ 
BFM treatment protocols {with courtesy to Or. C. Eckert and Prof. G. Henze).38 (8) Probability of event-
free survival after allogeneic BMT according to the MRD levels in pre-BMT BM samples (with courtesy to 
Dr. P. Bader).42 
hand, several studies proved that high MRD levels at the end of induction treatment 
are associated with high relapse rates of?0-100% (Figure 1 and Table 3).5.8.30.32.36 
Statistical analyses have shown that the MRD status after induction therapy is the 
most significant prognostic factor, independent of other clinically relevant risk factors, 
such as age, blast count, immunophenotype, presence of chromosome aberrations 
at diagnosis, and response to prednisone.30.32,37 
Clinical value of MRD during treatment of relapsed ALL 
The predictive value of MRD monitoring is particularly clear after ALL relapse, as 
shown by the BFM group.38 This can be perceived as assessment of early treatment 
response after second induction treatment. Low MRD levels (<10-3 ) were associat-
ed with a probability of relapse-free survival of 86%, whereas MRD levels ;o:1 o-3 were 
uniformly predictive of dismal outcome (probability of relapse-free survival of 0%; see 
Figure 2).38 Apparently, MRD information also has a high predictive value in relapsed 
ALL. However, the patient numbers are still small and the results need further con-
frrmation.38 
Clinical value of MRD detection before bone marrow transplantation in 
childhood ALL 
MRD monitoring was shown to be very informative for ALL patients undergoing 
bone marrow transplantation (BMT).39-43 In patients receiving T-cell depleted grafts, 
high levels of MRD-PCR positivity (1 o-2 to 1 o-3) before allogeneic BMT were invari-
ably associated with relapse after transplantation.39.42.43 The 2-year event-free sur-
vival in patients with low level of MRD positivity (1 o-3 to 10-5) was 35 to 50%, irre-
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spective of graft manipulation.39.42.43 It has been suggested that significant graft-ver-
sus-host disease associated with non-depleted grafts might overcome MRD positiv-
ity, even high MRD levels.42.43 In contrast, MRD-negativity before allogeneic trans-
plantation significantly correlated with better outcome and 2-year event-free survival 
higher than 70% (Figure 2).39-43 Therefore, patients with a high MRD burden prior to 
BMT might be offered alternative treatment (e.g. further cytoreduction before BMT, 
intensified conditioning, and/or early post-BMT immunotherapy) in order to improve 
their generally poor outcome.39.41 
Clinical value of MRD detection in adult All 
The preliminary results of MRD studies in adult ALL showed molecular response 
to chemotherapy similar to childhood ALL, but with higher frequencies of persistent 
MRD positivity in adults.44.45 Not only the frequencies of MRD positivity, but also the 
MRD levels in adult patients were significantly higher than in comparably treated chil-
dren, which is consistent with a higher in-vivo drug-resistance of adult ALL.44.45 A 
single prospective MRD study in t(9;22) negative adult precursor-B-ALL patients 
demonstrated the strong predictive value of MRD information at all investigated time 
points within two years of treatment, particularly 3-5 months after remission induction 
and beyond.46 
Recognition of MRD-based risk groups 
The results of the large prospective MRD studies in childhood ALL indicate that 
MRD analysis at a single time point gives highly significant prognostic information, 
but a single time point is not sufficiently precise for defining MRD-based low-risk and 
high-risk groups.5.8,30-32 Depending on the MRD study, the end-of-induction MRD 
status either identifies only patients at low risk of relapse30,31 or more frequently 
identifies exclusively high-risk patients (Table 3).32,37 In contrast, information on the 
kinetics of tumor load decrease, e.g., at the end of induction treatment and before 
consolidation treatment, appeared to be highly reliable for the recognition of all clin-
ically relevant risk groups.30,33 As shown by the International BFM Study Group (1-
BFM-SG), this combined MRD information distinguished patients at low-risk with 
MRD negativity at both time points (5-year relapse rate of 2%); patients at high risk 
with intermediate (1 o-3 ) or high (<:1 o-2 ) MRD levels at both time points (5-year 
relapse rate of 84%); and the remaining patients at intermediate risk (5-year relapse 
rate of 24%) (Figure 1 ).30 The group of MRD-based high-risk patients was larger 
than any previously identified high-risk group (approximately 15%) and had an 
unprecedentedly high 5-year relapse rate of 84%. On the other hand, the MRD-
based low-risk patients made up a group of a substantial size (approximately 45%), 
comparable to the frequency of survivors of childhood ALL in the 1970s before treat-
ment intensification was introduced.47 Such a precise MRD-based risk stratification 
has not yet been demonstrated for adult ALL. 
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CAN WE COMPARE THE MRD RESULTS OF DIFFERENT CLINICAL All 
TRIALS? 
The prognostic value of MRD detection during the early treatment phases of 
childhood and adult ALL has been established. In fact, every published study has 
confirmed the high prognostic value of MRD data obtained at the end of induction 
treatment.5.8.30-32 Nevertheless, the reported large-scale MRD studies show remark-
able differences in the meaning of MRD level information at the end of induction 
(Table 3). Also the MRD-based risk groups are defined differently, resulting in differ-
ent distributions of the patients over the risk groups and different relapse rates 
(Table 3). 
The major differences in risk group definition and corresponding relapse rates 
might be related to the type of treatment protocol, the timing of the follow-up sam-
ples, or the applied MRD technique (e.g., sensitivity and/or stability of the applied tar-
gets). Consequently, it will be impossible to extrapolate data from one clinical treat-
ment protocol to another. This implies that for each treatment protocol the "MRD win-
dow" has to be defined precisely: sampling time points versus required sensitivity. In 
practice, this means that MRD-based treatment intervention should always be 
designed according to earlier-obtained MRD results from the same treatment proto-
col. 
HOW TO TRANSLATE MRD INFORMATION INTO NEW CLINICAL TREATMENT 
PROTOCOLS? 
When MRD information from existing treatment protocols is translated into new 
clinical treatment protocols, several MRD-related aspects will influence the imple-
mentation of the new protocol: 
MRD-based stratification can only be introduced in the protocol after the actual 
MRD measurements, i.e., 6 to 13 weeks after start of treatment. 
The treatment blocks before the MRD sampling time points cannot be changed, 
because this would directly change the prognostic value of the MRD results. 
Preferably at least two early MRD sampling time points should be used, because 
this results in a more accurate definition of MRD-based risk groups. 
MRD-based high-risk and low-risk patients 
Protocol Committees will choose for specific MRD-based aims in new protocols, 
depending on the results of the preceding clinical MRD studies (Table 3). MRD-
based high-risk patients (with relapse rates of 75 to 100%) might profit from further 
treatment intensification including stem cell transplantation or new treatment modal-
ities. For example, this was a logical choice for the ongoing MRD-based BFM-AIEOP 
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and EORTC studies (Figure 1 ). 
MRD-based low-risk patients (with relapse rates 0-2%) represent a group of sub-
stantial size in childhood ALL and might profit from treatment de-intensification, e.g., 
reduction of re-intensification treatment, as aimed for by the current BFM-AIEOP pro-
tocol (M. Schrappe, personal communication). It should be emphasized that truly 
low-risk patients can only be identified if the applied MRD technique is sufficiently 
sensitive (:0:1 0-4). 
MRD-based intermediate-risk patients 
The group of MRD-based intermediate-risk patients (relapse rate of 20 to 30%) 
comprises ALL patients, who are MRD-positive at the end of induction treatment and 
are MRD-negative or positive at low levels (i.e. :0:1 0-4) before consolidation treat-
ment_3D,33 This group can have a substantial size and would need further treatment 
intensification, but this would imply that -75% of patients in this group are overtreat-
ed. The 1-BFM-SG has shown that MRD information at later time points (e.g. at one 
year) has added value for the MRD-based intermediate-risk patients: MRD-positive 
patients (generally with low MRD levels) have a high chance of relapse (65%), 
whereas MRD-negative patients have a low chance of relapse (-10%).30 
The vast majority of relapses (-90%) in the MRD-based intermediate-risk group 
occur after one year of treatment (see Figure 1A).3D.33 Consequently, the MRD infor-
mation at one year can potentially be used for treatment modification in MRD-posi-
tive intermediate-risk patients only. 
MRD-based stratification of relapsed All patients 
As suggested by the results of BFM study group,38there is a subset of relapsed 
ALL patients with a good molecular response tore-induction chemotherapy. For such 
patients, BMT might not be required, which should be proven in a prospective treat-
menttrial. 
MRD-based stratification of All patients undergoing BMT 
Based on available data,39-42 MRD information should play an important role in 
the clinical BMT setting. It is generally accepted that BMT should be performed with-
in the first half a year of remission, but patients with high MRD levels (<:1 o-3) at this 
time point are at very high risk of relapse post BMT. Future prospective trials should 
answer the question, whether further pre-transplant tumor load reduction can be 
achieved with intensified chemotherapy or post-transplant immunotherapy and 
whether this would improve post-BMT survival. 
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CHOICE OF MRD TECHNIQUES 
The three different MRD techniques differ in their sensitivity and applicability. 
Consequently, the choice of MRD techniques is dependent on the requirements of 
the clinical MRD study and vice-versa the applied MRD technique determines the 
possibilities for MRD-based treatment intervention (see Table 3). 
If only high-risk patients need to be identified, GeneScanning of lg/TCR gene 
rearrangements and fiow cytometric MRD detection are well-suited (cheap and 
rapid) methods. If the clinical MRD study is focusing on the recognition of high-risk 
and low-risk patients within a specific subgroup of ALL, a sensitive MRD technique 
can be selected for that specific subgroup. For example, flow cytometry in case of a 
clinical MRD study in T-ALL or RT-PCR analysis of BCR-ABL fusion gene transcripts 
in case of a clinical MRD study focusing on Ph+ ALL. 
Usage of different MRD techniques for different patients within the same treat-
ment protocol should be avoided, unless full proof is provided that the obtained MRD 
results are fully identical, as has been demonstrated for RQ-PCR analysis of patient-
specific lg/TCR gene rearrangements and TEL-AML 1 transcripts48 Small single-
center studies showed that results of MRD detection by fiow cytometry and quanti-
tative PCR of patient-specific lg/TCR gene rearrangements are largely compara-
ble.49,50 However, differences have been found in follow-up samples with low MRD 
levels (around 10-4 ), which are essential for recognition of low-risk patients.49.50 
These discrepancies are probably caused by differences in cell sample processing, 
sensitivity, and expression of MRD results. So, harmonization of these topics is 
essential before MRD data obtained with different techniques become interchange-
able. 
Thus far, RQ-PCR detection of patient-specific lg/TCR gene rearrangements is 
the most broadly applicable(> 90%) and sufficiently sensitive (s 10-4) MRD tech-
nique in ALL, which has proven to be realizable in multi-center clinical MRD stud-
ies.30.33,38 This probably explains why most European MRD studies in ALL use RQ-
PCR analysis of lg/TCR genes. 
CONCLUSIONS 
Sensitive and quantitative MRD detection has proven to be clinically relevant in 
childhood ALL patients. Particularly the evaluation of early treatment response has 
high prognostic value, because this allows identification of low-risk and high-risk 
patients, which may profit from treatment reduction or treatment intensification, 
respectively. Also the pre-BMT MRD status has predictive value for post-BMT 
relapse-free survival. Comparable results are currently being obtained in adult ALL 
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MRD studies, albeit that the relative sizes of the MRD-based risk groups differ from 
those in childhood ALL. 
Although the prognostic value of MRD has been established, the reported MRD 
studies show remarkable differences in MRD-based risk group definition and the cor-
responding relapse-free survival rates. This might be related to the type of treatment 
protocol, the timing of the follow-up samples, or the applied MRD technique (partic-
ularly its sensitivity). Consequently, the precise prognostic value of MRD information 
has to be assessed carefully for each treatment protocol before MRD-based inter-
vention can be implemented. Furthermore, standardization of MRD techniques and 
quality control of MRD results are essential for multi-center clinical MRD studies that 
aim for MRD-based treatment intervention. 
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ABBREVIATIONS 
ALL 
AML 
APL 
ASO 
AUL 
BFM-SG 
BM 
BMT 
CB 
CD 
CDR 
C gene segment 
CLL 
CML 
CNS 
CSF 
Cy 
DCLSG 
D gene segment 
DGGE 
EBV 
EFS 
FR 
FRET 
lg 
IGH 
IGK 
IGL 
J gene segment 
Kde 
LGL 
MNC 
MRD 
NHL 
PAGE 
PB 
PCR 
precursor-B-ALL 
RAG 
acute lymphoblastic leukemia 
acute myeloid leukemia 
acute promyelocytic leukemia 
allele-specific oligonucleotide 
acute undifferentiated leukemia 
Berlin-Frankfurt-MOnster Study Group 
bone marrow 
bone marrow transplantation 
cord blood 
cluster of differentiation 
complementarity-determining region 
constant gene segment 
chronic lymphocytic leukemia 
chronic myeloid leukemia 
central nervous system 
cerebro-spinal fluid 
cytoplasmic 
Dutch Childhood Leukemia Study Group 
diversity gene segment 
denaturing gradient gel electrophoresis 
Epstein-Barr virus 
event-free survival 
framework 
fluorescence resonance energy transfer 
immunoglobulin 
immunoglobulin heavy chain gene 
immunoglobulin kappa light chain gene 
immunoglobulin lambda light chain gene 
joining gene segment 
immunoglobulin kappa deleting element 
large granular lymphocytes 
mononuclear cells 
minimal residual disease 
non-Hodgkin's lymphoma 
polyacrylamide gel electrophoresis 
peripheral blood 
polymerase chain reaction 
precursor-S-cell acute lymphoblastic leukemia 
recombination-activating gene 
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RQ-PCR 
RSS 
RT 
SB 
SCT 
Sm 
SSCP 
T-ALL 
TCR 
TCRA 
TCRB 
TCRD 
TCRG 
TdT 
TGGE 
V gene segment 
real-time quantitative polymerase chain reaction 
recombination signal sequence 
reverse transcriptase 
Southern blotting 
stem cell transplantation 
surface membrane 
single-strand conformation polymorphism 
T-cell acute lymphoblastic leukemia 
T-cell receptor 
T-cell receptor alpha gene 
T-cell receptor beta gene 
T-cell receptor delta gene 
T-cell receptor gamma gene 
terminal deoxynucleotidyl transferase 
temperature gradient gel electrophoresis 
variable gene segment 
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SUMMARY 
Acute lymphoblastic leukemia (ALL) represents the most frequent malignancy in 
childhood. Last decades brought enormous progress in ALL treatment and in the 
understanding of ALL biology (see Chapter 1.1 ), but still 20 to 30% of children suffer 
from relapse and many of them will ultimately die of disease progression. The cur-
rently used cytomorphological (microscopic) techniques can only detect 1 to 5% of 
malignant cells, which is not sufficiently sensitive for identification of patients who are 
prone to relapse and who might be rescued by treatment intensification. During the 
past 15 years several approaches have been developed for detection of much lower 
numbers of malignant cells, i.e. for detection of minimal residual disease (MRD) in 
various hematopoietic malignancies (see Chapter 1.2). Monitoring of MRD with sen-
sitivities of 1 Q-4 to 1 o-6 (i.e. one malignant cell within the background of 104 to 106 
normal cells) has significantly higher prognostic value than conventional cytomor-
phological techniques and other clinical parameters at diagnosis and is therefore cur-
rently implemented into clinical practice in several hematopoietic malignancies, 
including ALL. 
In childhood ALL, detection of MRD most frequently relies on patient-specific 
immunoglobulin (lg) and T-cell receptor (TCR) gene rearrangements as molecular 
markers for PCR studies. The junctional regions of rearranged lg and TCR genes are 
unique "fingerprint-like" sequences, which are assumed to be different in each lym-
phoid cell and thus also in each lymphoid malignancy. They can be easily identified 
and characterized for instance by using heteroduplex PCR analysis (see Chapter 
2.2) and direct sequencing. 
This thesis aimed at detailed evaluation of lg and TCR gene rearrangements in 
ALL with regard to the following aspects: 
-characterization of lg/TCR gene rearrangements patterns in precursor-B-
ALL and T-ALL; 
- immunobiological differences between malignant and normal lymphoid cells; 
-stability of clonal lg/TCR gene rearrangements at relapse of ALL; 
-applicability of lg/TCR gene rearrangements as PCR targets for detection of 
MRD. 
Virtually all precursor-B-ALL (96%) have rearranged lg heavy chain (/GH) genes. 
In most cases (80-90%) this concerns complete VH-DH-JH rearrangements on at 
least one allele. Incomplete DH-JH rearrangements could be identified in 22% of 
patients, being the sole /GH gene rearrangements in only 5% of patients (see 
Chapter 2.3). Most precursor-B-ALL contain lg kappa (/GK) light chain gene 
rearrangements (30%) or deletions (50%); 20% of precursor-B-ALL cases even have 
lg lambda (IGL) gene rearrangements. Deletions in the IGK genes are predominant-
ly mediated via the IGK deleting element (Kde) sequence. Such Kde rearrangements 
occur in 50% of precursor-B-ALL cases. 
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Cross-lineage TCR gene rearrangements occur at high frequency in childhood 
precursor-B-ALL: TCR beta (TCRB), TCR gamma (TCRG), and TCR delta (TCRD) 
gene rearrangements and/or deletions were found in 35%, 60%, and 90% of cases, 
respectively (see Chapter 2.4). Moreover, in approximately 40% of childhood pre-
cursor-B-ALL patients V82-Ja gene rearrangements could be identified, which might 
serve as principal MRD-PCR targets in approximately 25% of precursor-B-ALL (see 
Chapter 2.5). Interestingly, the occurrence of cross-lineage TCR gene rearrange-
ments seems to be age-dependent For example, the incidence of incomplete TCRD 
gene rearrangements significantly decreases with the age of the patient, while TCRG 
gene rearrangements are rarely found in patients below 2 years of age. Alltogether, 
analysis of lg and TCR gene rearrangement patterns suggests that the lg and TCR 
genotype of adult precursor-B-ALL is less mature than in childhood precursor-B-ALL 
(see Chapter 2.8). 
Analysis of the TCRG gene configuration in T-ALL showed that TCRyo+ T-ALL 
display a less mature TCRG immunogenotype as compared to TCRa~+ and most 
CD3- cases. This is reflected by significantly higher usage of the more downstream 
Vy genes and the more upstream Jy1 segments in TCRyo+ T-ALL (see Chapter 2.6). 
Despite immunobiological differences between the T-ALL subsets, in virtually all 
childhood T-ALL (>95%) TCRG and/or TCRD junctional regions are potentially suit-
able targets for MRD monitoring. Cross-lineage lg gene rearrangements occur at rel-
atively low frequency in T-ALL (approximately 20%) and almost exclusively involve 
IGH genes. Interestingly, cross-lineage IGH gene rearrangements occur more fre-
quently in CD3- T-ALL (approximately 20%) and TCRyo+ T-ALL (approximately 50%) 
than in TCRa~+ T-ALL (<5%). Heteroduplex PCR analysis showed a high frequency 
(approximately 80%) of incomplete DH-JH rearrangements as well as preferential 
usage of DH6-19 and the most downstream DH7-27 gene segment together with the 
most upstream JH1 and JH2 gene segments (see Chapter 2.7). 
lg and TCR gene rearrangements in precursor-B-ALL and T-ALL might be prone 
to continuing rearrangements or secondary rearrangements mediated via the active 
recombinase enzyme system, resulting in subclone formation in these immature 
lymphoid malignancies (reviewed in Chapter 2.9). This might lead to loss of lg/TCR 
gene rearrangements during the disease course and thereby to false-negative MRD 
results. Chapter 3 contains several reports on detailed comparative analysis of lg 
and TCR gene rearrangements at diagnosis and relapse of precursor-B-ALL and T-
ALL. Despite the high frequency of immunogenotypic changes in childhood ALL at 
relapse, at least one rearranged IGH, /GK-Kde, TCRG and/or TCRD allele remained 
stable in > 90% of precursor-B-ALL and in > 95% of T-ALL. Based on these data, we 
proposed strategies for MRD-PCR target selection in order to minimize the risk of 
false-negative results (Chapter 3). 
In childhood ALL, MRD monitoring is particularly powerful for evaluation of early 
response during the first months of treatment and consequently allows identification 
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of low-risk and high-risk patients, who may profit from treatment reduction or treat-
ment intensification, respectively (see Chapters 5.1 and 5.2). MRD monitoring at 
later time points might be important for patients at intermediate or high risk of 
relapse. MRD information is therefore highly valuable in ALL subgroups with 
increased risk of relapse such as infant ALL (see Chapter 4.2) or t(9;22)-positive 
ALL. MRD monitoring after relapse can identify patients with a good therapy 
response, who probably do not need bone marrow transplantation (BMT) but who 
might be cured with cytotoxic treatment. Also the MRD status before BMT has pre-
dictive value for post-BMT relapse-free survival. Moreover, techniques for MRD 
detection can be further applied for several specific purposes, e.g., detection of cen-
tral nervous system involvement, assessment of the common clonal origin of two 
phenotypically different malignancies, early detection of smoldering leukemia in 
patients with aplastic bone marrow, detection of residual leukemic cells in autologous 
stem cell grafts, etc. (see Chapters 4.1, 4.3 and 4.4). 
In conclusion, lg and/or TCR gene rearrangements can be identified at diagno-
sis in more than 95% of patients, comprising at least two MRD targets per patient in 
90% of childhood ALL. Moreover, when knowledge about clonal evolution is 
employed in the process of MRD-PCR target selection, MRD monitoring should 
enable successful detection of relapse in the majority of patients. Nevertheless, two 
sensitive (:>1 Q-4) lg/TCR targets, required for recognition of low risk patients, are only 
available in approximately 80% of patients. Thus, future studies should focus on 
improvement of currently available MRD-PCR targets and introduction of new sensi-
tive MRD markers, such as TCRB gene rearrangements in precursor-B-ALL and T-
ALL and DNA breakpoint fusion regions of MLL gene rearrangements in infant ALL. 
The results of our studies contribute to the immunobiological knowledge of lg and 
TCR gene rearrangements in ALL, which is essential for performing reliable PCR-
based MRD studies in ALL patients. Careful assessment of the prognostic value of 
MRD information in each treatment protocol will enable MRD-based treatment inter-
vention with treatment intensification and treatment reduction (see Chapter 5.2). The 
ultimate goal is to improve overall outcome in childhood ALL with concomitant 
increase of quality of life and reduction of long-term sequelae. 
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SAMENVATTING 
Acute lymfatische leukemie (ALL) is de meest voorkomende maligniteit op de 
kinderleeftijd. De afgelopen jaren is een enorme vooruitgang geboekt in de behan-
deling van ALL en in het beg rip random de biologie van ALL (zie Hoofdstuk 1 ). 
Desondanks krijgt 20 a 30% van de kinderen met ALL een recidief, van wie uitein-
delijk een groat deel zal overlijden aan de ziekte. Met de huidige cytomorfologische 
(microscopische) technieken kan slechts 1 tot 5% maligne cellen worden gede-
tecteerd, wat niet voldoende gevoelig is voor het herkennen van patienten die een 
grate kans hebben op het krijgen van een recidief en die mogelijk zouden kunnen 
worden genezen met een intensievere behandeling. De afgelopen 15 jaar zijn 
diverse technieken ontwikkeld voor de detectie van zeer kleine aantallen maligne 
cellen bij patienten met een hematopo"ietische maligniteit, d.w.z. de detectie van 
"minimale restziekte" ofwel "minimal residual disease" (MRD) (zie Hoofdstuk 1.2). 
Het vervolgen van MRD met gevoeligheden tussen 104 en 1 o-6 (d.w.z. een maligne 
eel tussen 104 -106 normale cellen) heeft een zeer grote prognostische waarde 
vergeleken met conventionele cytomorfologische technieken en andere klinische 
parameters bij diagnose. Daarom word! MRD diagnostiek op dit moment ge"imple-
menteerd in therapieprotocollen voor verschillende typen hematopo"ietische malig-
niteiten, waaronder ALL. 
Detectie van MRD bij kinderen met ALL is meestal gebaseerd op patient-speci-
fieke immunoglobuline (lg) en T-celreceptor (TCR) genherschikkingen, die worden 
gebruikt als moleculaire markers voor PCR studies. De "junctional regions" van her-
schikte lg en TCR genen zijn unieke sequenties ("DNA vingerafdruk"), waarvan 
word! verondersteld dat ze verschillend zijn in elke lymfatische eel en dus ook in elke 
lymfatische maligniteit. Deze junctional regions kunnen op eenvoudige wijze worden 
ge"identificeerd en gekarakteriseerd door bijvoorbeeld heteroduplex PCR analyse 
(zie Hoofdstuk 2.2) en direct sequencen. 
Het onderzoek in dit proefschrift was gericht op gedetailleerde analyse van lg en 
TCR genherschikkingen bij ALL met speciale aandacht voor: 
- karakterisering van de lgffCR genherschikkingspatronen bij precursor-B-ALL en T-
ALL; 
- immunobiologische verschillen tussen maligne en normale lymfatische eel len; 
- stabiliteit van lgffCR genherschikkingen bij recidieven van ALL; 
- toepasbaarheid van lgffCR genherschikkingen als PCR targets voor MRD diag-
nostiek. 
Vrijwel aile precursor-B-ALL patienten (96%) hebben herschikte lg zware keten 
(IGH) genen in hun leukemiecellen. In de meeste gevallen (80-90%) betreft dit com-
plete VH-DH-JH herschikkingen op tenminste een allel. Incomplete DH-JH her-
schikkingen konden worden ge"identificeerd in 22% van de leukemieen en waren de 
enige IGH genherschikkingen bij 5% van de leukemieen (zie Hoofdstuk 2.3). De 
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meeste precursor-B-ALL bevatten lg kappa (IGK) Iichte keten genherschikkingen 
(30%) of deleties (50%); 20% van de precursor-B-ALL hebben zelfs lg lambda (IGL) 
genherschikkingen. Deleties in de IGK genen worden voornamelijk gemedieerd via 
het IGK deletie element (Kde). Dergelijke /GK-Kde herschikkingen komen voor bij 
50% van de precursor-B-ALL. 
"Cross-lineage'' TCR genherschikkingen komen zeer frequent voor in kinder pre-
cursor-B-ALL: TCR beta (TCRB), TCR gamma (TCRG) en TCR delta (TCRD) gen-
herschikkingen en/of deleties werden gevonden bij respectievelijk 35%, 60% en 90% 
van de patienten (zie Hoofdstuk 2.4). Tevens worden bij ongeveer 40% van de pre-
cursor-B-ALL op de kinderleeftijd V82-Ja genherschikkingen ge'identificeerd, die bij 
ongeveer 25% van de precursor-B-ALL het meest belangrijke MRD-PCR target vor-
men (zie Hoofdstuk 2.5). Het voorkomen van cross-lineage TCR genherschikkingen 
lijkt bovendien gerelateerd te zijn aan de leeftijd. De incidentie van incomplete TCRD 
genherschikkingen daalt bijvoorbeeld significant met de leeftijd van de patient, terwijl 
TCRG genherschikkingen nauwelijks worden gevonden bij voorloper-B-ALL patien-
ten jonger dan 2 jaar. Analyse van lg en TCR genherschikkingspatronen suggereert 
in aile opzichten dat het lg en TCR genotype van precursor-B-ALL bij volwassenen 
minder rijp is dan bij kinder precursor-B-ALL (zie Hoofdstuk 2.8). 
Analyse van de TCRG genconfiguratie bij T-ALL liet zien dat TCRy8+ T-ALL een 
minder rijp TCRG immunogenotype vertonen vergeleken met TCRa~+ T-ALL en de 
meeste Co3- T-ALL. Oil blijkt uit een significant groter gebruik van de meer down-
stream gelegen Vy genen en de meer upstream gelegen Jy1 segmenten in TCRy8+ 
T-ALL (zie Hoofdstuk 2.6). Ondanks de immunobiologische verschillen tussen de 
drie T-ALL subgroepen, zijn TCRG en/of TCRD junctional regions bij vrijwel aile 
kinder T-ALL patienten (>95%) bruikbare targets voor MRD monitoring. 
Cross-lineage lg genherschikkingen komen in relatief lage frequentie voor bij T-ALL 
(ongeveer 20%) en betreffen met name /GH genen. lnteressant is daarbij dat cross-
lineage IGH genherschikkingen frequenter voorkomen bij CD3- T-ALL (ongeveer 
20%) en TCRy8+ T-ALL (ongeveer 50%) dan bij TCRa~+ T-ALL (<5%). 
Heteroduplex PCR analyse toonde een hoge frequentie (ongeveer 80%) van incom-
plete DH-JH herschikkingen aan en tevens een preferentieel gebruik van DH6-19 en 
het meest downstream gelegen DH7-27 gensegment samen met de meest upstream 
gelegen JH1 en JH2 gensegmenten (zie Hoofdstuk 2.7). 
lg en TCR genherschikkingen bij precursor-B-ALL en T-ALL kunnen gevoelig zijn 
voor doorgaande herschikkingen of secundaire herschikkingen, die gemedieerd wor-
den via het actieve recombinase enzymsysteem en resulteren in het ontstaan van 
subklonen (samengevat in Hoofdstuk 2.9). Dit kan leiden tot een verlies van lg/TCR 
genherschikkingen gedurende het ziekteproces en op deze wijze resulteren in vals-
negatieve MRD resultaten. Hoofdstuk 3 bevat verscheidene studies over vergelij-
kende analyses van lg en TCR genherschikkingen bij diagnose en recidief van pre-
cursor-B-ALL en T-ALL patienten. Ondanks de hoge frequentie van immunogeno-
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typische veranderingen in kinder ALL bij recidief blijft tenminste een herschikt !GH, 
/GK-Kde, TCRG en/of TCRD allel stabiel in >90% van de precursor-B-ALL en >95% 
van T-ALL. Op basis van deze data hebben we strategieen voorgesteld voor de 
selectie van MRD-PCR targets om de kans op vals-negative resultaten te mini-
maliseren (Hoofdstuk 3). 
Bij ALL op de kinderleeftijd is MRD monitoring vooral belangrijk voor de evalu-
atie van de vroege therapierespons tijdens de eerste maanden van de behandeling, 
waarbij het mogelijk is om laag-risico en hoog-risico groepen te definieren, die 
profijt kunnen hebben van respectievelijk een reductie of intensivering van de behan-
deling (zie Hoofstukken 5.1 en 5.2). MRD monitoring op latere tijdstippen kan belan-
grijk zijn voor patienten met een intermediair of hoog risico op het krijgen van een 
recidief. MRD onderzoek blijkt bijzonder waardevol te zijn bij hoog-risico ALL sub-
groepen, zoals ALL bij zuigelingen (zie Hoofdstuk 4.2) en t(9;22)-positieve ALL. 
MRD monitoring bij kinderen met een recidief kan patienten herkennen met een 
hoge gevoeligheid voor medicijnen, die waarschijnlijk geen beenmergtransplantatie 
(BMT) nodig hebben, maar kunnen worden genezen met een cytotoxische behan-
deling. Daarnaast heeft de MRD status v66r BMT voorspellende waarde voor de 
recidief-vrije overleving na BMT. Tenslotte kunnen MRD technieken worden 
toegepast voor verschillende specifieke doeleinden, zoals aantonen van uitbreiding 
naar het centrale zenuwstelsel, vaststellen of uitsluiten van de gemeenschappelijke 
klonale afkomst van twee fenotypisch verschillende maligniteiten, vroege detectie 
van sluimerende leukemie bij patienten met aplastisch beenmerg, detectie van 
resterende leukemiecellen in autologe stamceltransplantaten, etc. (zie Hoofdstukken 
4.1, 4.3 en 4.4). 
Concluderend kan worden gesteld dat lg en/of TCR genherschikkingen bij diag-
nose kunnen worden ge"identificeerd bij meer dan 95% van de patienten, waarbij in 
90% van de kinder ALL tenminste twee MRD targets per patient worden gevonden. 
lndien bovendien kennis over klonale evolutie wordt gebruikt tijdens het proces van 
MRD-PCR target selectie, zal MRD monitoring de succesvolle detectie van recidi-
vering mogelijk maken in de meerderheid van de patienten. Desondanks zijn twee 
gevoelige (:>1 0-4) lg/TCR targets, die noodzakelijk zijn voor de herkenning van laag-
risico patienten, slechts beschikbaar in ongeveer 80% van de patienten. Daarom 
zouden vervolgstudies gericht moeten zijn op het verbeteren van de huidig beschik-
bare MRD-PCR targets en de introductie van nieuwe gevoelige MRD-PCR targets, 
zoals TCRB genherschikkingen in precursor-B-ALL en T-ALL en DNA breukpunt 
fusiegen gebieden van MLL genherschikkingen in ALL bij zuigelingen. 
De resultaten van onze studies dragen bij aan de immunobiologische kennis van 
lg en TCR genherschikkingen in ALL, die essentieel is voor het uitvoeren van 
betrouwbare PCR-gebaseerde MRD studies bij ALL patienten. Zorgvuldige 
beoordeling van de prognostische waarde van MRD informatie voor ieder behande-
lingsprotocol zal MRD-gebaseerde behandelingsinterventie mogelijk maken met 
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zowel intensivering als reductie van behandeling (zie Hoofdstuk 5.2). Het uitein-
delijke doel is om de kans op genezing van kinderen met ALL te verhogen. parallel 
aan een verbetering van de kwaliteit van Ieven en een reductie van de lange 
termijn effecten. 
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